parent_name,parent_smiles,metabolite_name,metabolite_smiles,enzymes,reaction_type,fingerprint_similarity
acetaminophen,CC(O)=NC1=CC=C(O)C=C1,N-Acetyl-p-benzoquinone,CC(=O)N=C1C=CC(=O)C=C1,CYP1A2; CYP2E1; CYP3A4; CYP2A6; CYP2C9; CYP2D6; CYP1A1,Oxidation of p-substituted anilides,0.06
acetaminophen,CC(O)=NC1=CC=C(O)C=C1,3-Hydroxyacetaminophen,CC(O)=NC1=CC=C(O)C(O)=C1,CYP2A6 (major); CYP2E1; CYP1A2; CYP2C8; CYP2C9; CYP3A4,Hydroxylation of benzene on carbon orhto to a strongly electron donating group,0.7
pinoline,COC1=CC=C2NC3=C(CCNC3)C2=C1,"1H,2H,3H,4H,9H‐pyrido[3,4‐b]indol‐6‐ol",OC1=CC=C2NC3=C(CCNC3)C2=C1,CYP2D6,O-aryl demethylation,0.95
1-(3-Trifluoromethylphenyl)piperazine,FC(F)(F)C1=CC=CC(N2CCNCC2)=C1,HO-TFMPP,OC1=CC=C(N2CCNCC2)C=C1C(F)(F)F,CYP2D6; CYP1A2; CYP3A4,Aromatic Hydroxylation,0.77
"2-Amino-3-methylimidazo(4,5-F)quinoline",CN1C(=N)NC2=C3C=CC=NC3=CC=C21,"N-OH-2-amino-3-methylimidazo[4,5-f]quinoline (N-OH-IQ)",CN1C(NO)=NC2=C3C=CC=NC3=CC=C21,CYP1A2; CYP1A1,N-Hydroxylation,0.65
"5-Methoxy-N,N-diisopropyltryptamine",COC1=CC=C2NC=C(CCN(C(C)C)C(C)C)C2=C1,5-OH-DIPT,CC(C)N(CCC1=CNC2=CC=C(O)C=C12)C(C)C,CYP2D6,O-Demethylation,0.92
"5-Methoxy-N,N-diisopropyltryptamine",COC1=CC=C2NC=C(CCN(C(C)C)C(C)C)C2=C1,5-MeO-IPT,COC1=CC=C2NC=C(CCNC(C)C)C2=C1,CYP1A2;CYP3A4;CYP2C9;CYP2C19,N-deisopropylation,0.95
(R)-halothane,FC(F)(F)C(Cl)Br,trifluoroacetic acid,O=C(O)C(F)(F)F,CYP2E1,Oxidation of halotrifluoroethane,0.19
(R)-halothane,FC(F)(F)C(Cl)Br,"1-chloro-2,2,2-trifluoroethanide",FC(F)(F)[CH-]Cl,CYP2A6; CYP3A4; CYP2B6; CYP2C9; CYP2D6,Reduction of terminal aliphatic trihalide,0.55
"(R)-3,4-Methylenedioxymethamphetamine",CNC(C)CC1=CC=C2OCOC2=C1,"N-Methyl-3,4- dihydroxyamphetamine",CNC(C)CC1=CC=C(O)C(O)=C1,CYP1A2; CYP2D6,Methylenedioxy ring opening,0.69
"(R)-3,4-Methylenedioxymethamphetamine",CNC(C)CC1=CC=C2OCOC2=C1,"3,4-Methylenedioxymethamphetamine",CC(N)CC1=CC=C2OCOC2=C1,CYP2D6 (major); CYP1A2; CYP2B6; CYP3A4,N-dealkylation of acyclic secondary amine,0.95
"(4R)-5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid",COC(=O)C1=C(C)NC(C)=C(C(=O)O)C1C1=CC=CC([N+](=O)[O-])=C1,OPC-13463,COC(=O)C1=C(C)N=C(C)C(C(=O)O)=C1C1=CC=CC([N+](=O)[O-])=C1,CYP2C19;CYP2D6;CYP2E1;CYP3A4,Dehydrogenation,0.32
Homo-Tienilic Alcohol,O=C(C1=CC=CS1)C1=CC=C(OCCCO)C(Cl)=C1Cl,,O=C(C1=CC=C(O)S1)C1=CC=C(OCCCO)C(Cl)=C1Cl,CYP2C8;CYP2C9;CYP2C19,Aliphatic Hydroxylation,0.93
Homo-Tienilic Alcohol,O=C(C1=CC=CS1)C1=CC=C(OCCCO)C(Cl)=C1Cl,,O=C(C1=CC=CS1)C1=CC=C(O)C(Cl)=C1Cl,CYP2C8;CYP2C9;CYP2C19,O-Demethylation,0.86
(R)-1-(4-Methoxyphenyl)propan-2-amine,COC1=CC=C(CC(C)N)C=C1,,CC(N)CC1=CC=C(O)C=C1,CYP2D6,O-Demethylation,0.83
"1-Methyl-10-alpha-methoxy-9,10-dihydrolysergol",COC12CC(CO)CN(C)C1CC1=CN(C)C3=CC=CC2=C13,MDL,COC12CC(CO)CN(C)C1CC1=CNC3=CC=CC2=C13,CYP2D6,N-Demethylation,0.94
"(S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid",COC1=CC=CC(OC)=C1C1=CC=C(CC(N=C(O)C2=C(Cl)C=CC=C2Cl)C(=O)O)C=C1,,COC1=CC=CC(O)=C1C1=CC=C(CC(N=C(O)C2=C(Cl)C=CC=C2Cl)C(=O)O)C=C1,CYP2C9,O-Desmethylation,0.99
Rabeprazole (rabeprazole_thioether),COCCCOC1=CC=NC(CSC2=NC3=CC=CC=C3N2)=C1C,Rabeprazole,COCCCOC1=CC=NC(CS(=O)C2=NC3=CC=CC=C3N2)=C1C,CYP1A2;CYP2A6;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,S-OXIDATION,0.86
Rabeprazole (rabeprazole_thioether),COCCCOC1=CC=NC(CSC2=NC3=CC=CC=C3N2)=C1C,Desmethylrabeprazole-thioether,CC1=C(OCCCO)C=CN=C1CSC1=NC2=CC=CC=C2N1,CYP1A2;CYP2A6;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,O-Desmethylation,0.99
Dehydroxyzyleuton,CC(NC(=N)O)C1=CC2=CC=CC=C2S1,Dehydroxyzyleuton sulfoxide,CC(NC(=N)O)C1=CC2=CC=CC=C2S1=O,CYP3A4,Thiohene S-oxidation,0.2
Dehydroxyzyleuton,CC(NC(=N)O)C1=CC2=CC=CC=C2S1,(1S)â€1â€(6â€hydroxyâ€1â€benzothiophenâ€2â€yl)ethylurea,CC(NC(=N)O)C1=CC2=CC=C(O)C=C2S1,CYP1A2; CYP2C9,Aromatic hydroxylation of fused benzene ring,0.86
"(2R,3S)-2-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholine",CC(OC1OCCNC1C1=CC=C(F)C=C1)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1,aprepitant_M2,CC(OC1OCC=NC1C1=CC=C(F)C=C1)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1,CYP3A4,Dehydrogenation,0.72
2-Methoxy-5-trifluoromethoxybenzylamine,COC1=CC=C(OC(F)(F)F)C=C1CN,"CP-919,230",NCC1=CC(OC(F)(F)F)=CC=C1O,CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,O-Demethylation,0.93
"3-(furan-2-ylmethyl)-1,7,8-trimethylpurine-2,6-dione",CC1=NC2=C(C(=O)N(C)C(=O)N2CC2=CC=CO2)N1C,,CC1=NC2=C(C(=O)N(C)C(=O)N2CC2=CC(O)=CO2)N1C,CYP1A2,Aliphatic Hydroxylation,0.98
"3-(furan-2-ylmethyl)-1,7,8-trimethylpurine-2,6-dione",CC1=NC2=C(C(=O)N(C)C(=O)N2CC2=CC=CO2)N1C,,CC1=NC2=C(C(=O)N(C)C(=O)N2CC2=C(O)C=CO2)N1C,CYP1A2,Aliphatic Hydroxylation,0.96
"3-(furan-2-ylmethyl)-1,7,8-trimethylpurine-2,6-dione",CC1=NC2=C(C(=O)N(C)C(=O)N2CC2=CC=CO2)N1C,,CC1=NC2=C(C(=O)N(C)C(=O)N2CC2=CC=C(O)O2)N1C,CYP1A2,Aliphatic Hydroxylation,0.96
"3-(furan-2-ylmethyl)-1,7,8-trimethylpurine-2,6-dione",CC1=NC2=C(C(=O)N(C)C(=O)N2CC2=CC=CO2)N1C,,CN1C(=O)C2=C(N=C(CO)N2C)N(CC2=CC=CO2)C1=O,CYP1A2,Aliphatic Hydroxylation,0.96
"3-(cyclohexylmethyl)-1,7,8-trimethylpurine-2,6-dione",CC1=NC2=C(C(=O)N(C)C(=O)N2CC2CCCCC2)N1C,,CC1=NC2=C(C(=O)N(C)C(=O)N2CC2CCCC(O)C2)N1C,CYP1A2,Aliphatic Hydroxylation,0.97
"3-(cyclohexylmethyl)-1,7,8-trimethylpurine-2,6-dione",CC1=NC2=C(C(=O)N(C)C(=O)N2CC2CCCCC2)N1C,,CC1=NC2=C(C(=O)N(C)C(=O)N2CC2CCCCC2)N1CO,CYP1A2,Aliphatic Hydroxylation,0.95
"3-(cyclohexylmethyl)-1,7,8-trimethylpurine-2,6-dione",CC1=NC2=C(C(=O)N(C)C(=O)N2CC2CCCCC2)N1C,,CN1C(=O)C2=C(N=C(CO)N2C)N(CC2CCCCC2)C1=O,CYP1A2,Aliphatic Hydroxylation,0.96
(-)-ethosuximide,CCC1(C)CC(O)=NC1=O,,CC(O)C1(C)CC(O)=NC1=O,CYP2E1;CYP3A4,Alphatic Hydroxylation,0.69
(-)-etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(=O)O,6-Hydroxyetodolac,CCC1=CC(O)=CC2=C1NC1=C2CCOC1(CC)CC(=O)O,CYP2C9,Aromatic hydroxylation of fused benzene ring,0.94
(-)-etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(=O)O,7-Hydroxyetodolac,CCC1=C(O)C=CC2=C1NC1=C2CCOC1(CC)CC(=O)O,CYP2C9,Aromatic hydroxylation of fused benzene ring,0.93
(-)-limonene,C=C(C)C1CC=C(C)CC1,Carveol,C=C(C)C1CC=C(C)C(O)C1,CYP2C9; CYP2C19,Allylic hydroxylation,0.58
(-)-limonene,C=C(C)C1CC=C(C)CC1,Perillyl alcohol,C=C(C)C1CC=C(CO)CC1,CYP2C9; CYP2C19; CYP3A4,Allylic hydroxylation,0.76
(-)-pseudococaine,COC(=O)C1C(OC(=O)C2=CC=CC=C2)CC2CCC1N2C,Norcocaine,COC(=O)C1C2CCC(CC1OC(=O)C1=CC=CC=C1)N2,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.94
(-)-thalidomide,O=C1N=C(O)CCC1N1C(=O)C2=CC=CC=C2C1=O,"cis, trans-5'-OH-thalidomide",O=C1N=C(O)C(N2C(=O)C3=CC=CC=C3C2=O)CC1O,CYP2C19,Alpha hydroxylation of carbonyl group,0.62
(-)-thalidomide,O=C1N=C(O)CCC1N1C(=O)C2=CC=CC=C2C1=O,5-OH-thalidomide,O=C1N=C(O)CCC1N1C(=O)C2=CC=C(O)C=C2C1=O,CYP2C19,Aromatic hydroxylation of fused benzene ring,0.9
(-)-thalidomide,O=C1N=C(O)CCC1N1C(=O)C2=CC=CC=C2C1=O,(-)-thalidomide arene oxide,O=C1N=C(O)CCC1N1C(=O)C2=CC3OC3C=C2C1=O,CYP1A1; CYP1A2; CYP2C19; CYP2E1,ARENE_EPOXIDATION,0.44
(-)-zileuton,CC(C1=CC2=CC=CC=C2S1)N(O)C(=N)O,Zileuton sulfoxide,CC(C1=CC2=CC=CC=C2S1=O)N(O)C(=N)O,CYP3A4,Thiohene S-oxidation,0.25
(-)-zileuton,CC(C1=CC2=CC=CC=C2S1)N(O)C(=N)O,Hydroxyzileuton,CC(C1=CC2=CC=C(O)C=C2S1)N(O)C(=N)O,CYP1A2; CYP2C9,Aromatic hydroxylation of fused benzene ring,0.89
Perhexiline,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,cis-hydroxyperhexilline,OC1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,CYP2D6,Hydroxylation of alicyclic secondary carbon,0.8
Perhexiline,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,trans-hydroxyperhexilline,OC1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,CYP2D6,Hydroxylation of alicyclic secondary carbon,0.8
(+)-3-carene,CC1=CCC2C(C1)C2(C)C,3-Caren-10-ol,CC1(C)C2CC=C(CO)CC21,CYP2B6; CYP2C19; CYP2D6,Hydroxlation of methyl carbon adjacent to an aliphatic ring,0.78
(+)-3-carene,CC1=CCC2C(C1)C2(C)C,Carene epoxide,CC12CC3C(CC1O2)C3(C)C,CYP1A2,EPOXIDATION_OF_112_TRISUBSTITUTED_ALKLENE,0.24
(+)-bisoprolol,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,"(+)-bisoprolol, O-deisopropyl",CC(C)NCC(O)COC1=CC=C(COCCO)C=C1,CYP2D6; CYP3A4,O-deisopropylation,0.94
(+)-fipronil,N#CC1=NN(C2=C(Cl)C=C(C(F)(F)F)C=C2Cl)C(N)=C1S(=O)C(F)(F)F,f ipronil sulfone,N#CC1=NN(C2=C(Cl)C=C(C(F)(F)F)C=C2Cl)C(N)=C1S(=O)(=O)C(F)(F)F,CYP3A4,S-oxidation of sulfoxide to sulfone,0.96
(+)-halofantrine,CCCCN(CCCC)CCC(O)C1=CC2=C(Cl)C=C(Cl)C=C2C2=CC(C(F)(F)F)=CC=C12,"(+)-halofantrine, N-desbutyl",CCCCNCCC(O)C1=CC2=C(Cl)C=C(Cl)C=C2C2=CC(C(F)(F)F)=CC=C12,CYP3A4,N-dealkylation of acyclic tertiary amine,0.96
(+)-isothujone,CC1C(=O)CC2(C(C)C)CC12,4-hydroxy-isothujone,CC(C)C12CC(=O)C(C)(O)C1C2,CYP2A6; CYP2B6; CYP2D6; CYP3A4,Hydroxylation of penultimate aliphatic tertiary carbon,0.55
(+)-isothujone,CC1C(=O)CC2(C(C)C)CC12,7-hydroxy-isothujone,CC1C(=O)CC2(C(C)(C)O)CC12,CYP2A6; CYP2B6; CYP2D6; CYP3A4,Hydroxylation of penultimate aliphatic tertiary carbon,0.61
"(13alpha)-3-methoxy-estra-1,3,5(10)-triene-17alpha-ol",COC1=CC=C2C(=C1)CCC1C2CCC2(C)C(O)CCC12,Estradiol,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2O,CYP2C19(major);CYP2C9;CYP1A2;CYP3A4,O-Demethylation,0.94
(2r)-1-(2-methoxyphenyl)propan-2-amine,COC1=CC=CC=C1CC(C)N,,CC(N)CC1=CC=CC=C1O,CYP2D6,O-Demethylation,0.77
(2r)-1-(2-methoxyphenyl)propan-2-amine,COC1=CC=CC=C1CC(C)N,,COC1=C(O)C=CC=C1CC(C)N,CYP2D6,Aromatic Hydroxylation,0.76
(2r)-1-(2-methoxyphenyl)propan-2-amine,COC1=CC=CC=C1CC(C)N,,COC1CCC(O)CC1CC(C)N,CYP2D6,Aromatic Hydroxylation,0.08
(2r)-2-[4-(3-methylthiophen-2-yl)phenyl]propanoic acid,CC1=C(C2=CC=C(C(C)C(=O)O)C=C2)SC=C1,,CC1=C(C2=CC=C(C(C)C(=O)O)C=C2)SC(=O)C1,CYP2C9,C-Oxidation,0.3
"(2s,5s)-troglitazone",CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)N=C4O)C=C3)O2)C(C)=C1O,"(2S)â€3â€(4â€{[(2S)â€6â€hydroxyâ€2,5,7,8â€tetramethylâ€3,4â€dihydroâ€1â€benzopyranâ€2â€yl]methoxy}phenyl)â€2â€(hydroxysulfanyl)propanecarbonyl isocyanate",CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC(SO)C(=O)N=C=O)C=C3)O2)C(C)=C1O,CYP3A4,"2,4-thiazolidinedione ring opening",0.73
"(2s,5s)-troglitazone",CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)N=C4O)C=C3)O2)C(C)=C1O,"(1S)-1-(formylcarbamoyl)-2-(4-{[(2S)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl]methoxy}phenyl)ethane-1-sulfinic acid",CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC(C(=O)N=CO)S(=O)O)C=C3)O2)C(C)=C1O,CYP3A4,"2,4-thiazolidinedione ring opening",0.71
Saquinavir,CC(C)(C)N=C(O)C1CC2CCCCC2CN1CC(O)C(CC1=CC=CC=C1)N=C(O)C(CC(=N)O)NC(=O)C1=CC=C2C=CC=CC2=N1,"(2S)-N-[(2S,3R)-4-[(3S,4aR,8aS)-3-(tert-butylcarbamoyl)-6-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide",CC(C)(C)N=C(O)C1CC2CC(O)CCC2CN1CC(O)C(CC1=CC=CC=C1)N=C(O)C(CC(=N)O)NC(=O)C1=CC=C2C=CC=CC2=N1,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.99
Saquinavir,CC(C)(C)N=C(O)C1CC2CCCCC2CN1CC(O)C(CC1=CC=CC=C1)N=C(O)C(CC(=N)O)NC(=O)C1=CC=C2C=CC=CC2=N1,"(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-7-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide",CC(C)(C)N=C(O)C1CC2CCC(O)CC2CN1CC(O)C(CC1=CC=CC=C1)N=C(O)C(CC(=N)O)NC(=O)C1=CC=C2C=CC=CC2=N1,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.98
"(3z)-5-[(1alpha,4alpha)-3beta-[(phenylsulfonyl)amino]bicyclo[2.2.1]heptan-2alpha-yl]-3-pentenoic acid",O=C(O)CC=CCC1C2CCC(C2)C1NS(=O)(=O)C1=CC=CC=C1,(3Z)â€5â€{3â€benzenesulfonamidoâ€6â€hydroxybicyclo[2.2.1]heptanâ€2â€yl}pentâ€3â€enoic acid,O=C(O)CC=CCC1C2CC(CC2O)C1NS(=O)(=O)C1=CC=CC=C1,CYP2C9;CYP3A4,Aliphatic Hydroxylation,0.85
"(3z)-5-[(1alpha,4alpha)-3beta-[(phenylsulfonyl)amino]bicyclo[2.2.1]heptan-2alpha-yl]-3-pentenoic acid",O=C(O)CC=CCC1C2CCC(C2)C1NS(=O)(=O)C1=CC=CC=C1,(3Z)â€5â€{3â€benzenesulfonamidoâ€5â€hydroxybicyclo[2.2.1]heptanâ€2â€yl}pentâ€3â€enoic acid,O=C(O)CC=CCC1C2CC(O)C(C2)C1NS(=O)(=O)C1=CC=CC=C1,CYP3A4,Aliphatic Hydroxylation,0.82
(r)-(+)-felodipine,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl,Dehydrofelodipine,CCOC(=O)C1=C(C)N=C(C)C(C(=O)OC)=C1C1=CC=CC(Cl)=C1Cl,CYP3A4,"Dehydrogenation of 4-aryl substituted 1,4-dihydropyridine",0.33
(R)-(-)-Mexiletine,CC1=CC=CC(C)=C1OCC(C)N,"(R)-(-)-Mexiletine, p-hydroxyl",CC1=CC(O)=CC(C)=C1OCC(C)N,CYP1A2 (minor); CYP2D6 (major),HYDROXYLATION_OF_AROMATIC_CARBON; HYDROXYLATION_OF_BENZENE_PARA_TO_EDG,0.85
(R)-(-)-Mexiletine,CC1=CC=CC(C)=C1OCC(C)N,"(R)-(-)-Mexiletine, m-hydroxyl",CC1=CC=C(O)C(C)=C1OCC(C)N,CYP1A2 (minor); CYP2D6 (major),HYDROXYLATION_OF_AROMATIC_CARBON; HYDROXYLATION_OF_BENZENE_ORTHO_TO_EDG,0.78
(R)-(-)-Mexiletine,CC1=CC=CC(C)=C1OCC(C)N,"(R)-(-)-Mexiletine, 2-OH-hydroxymethyl",CC1=CC=CC(CO)=C1OCC(C)N,CYP1A2 (minor); CYP2D6 (major),Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.77
(R)-(-)-Mexiletine,CC1=CC=CC(C)=C1OCC(C)N,"(R)-(-)-Mexiletine, N-hydroxy",CC1=CC=CC(C)=C1OCC(C)NO,CYP1A2 (major); CYP2B6; CYP2E1,N-hydroxylation of primary or secondary aliphatic amine,0.91
(r)-azelastine,CN1CCCC(N2N=C(CC3=CC=C(Cl)C=C3)C3=CC=CC=C3C2=O)CC1,"(r)-azelastine, N-desmethyl",O=C1C2=CC=CC=C2C(CC2=CC=C(Cl)C=C2)=NN1C1CCCNCC1,CYP3A4; CYP2D6; CYP1A2 (minor),N-dealkylation of alicyclic tertiary amine,0.98
(r)-bupropion,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,(2R)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one,CC(NC(C)(C)CO)C(=O)C1=CC=CC(Cl)=C1,CYP2B6; CYP3A4,Hydroxylation of terminal methyl,0.92
(r)-bupropion,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,(2R)-2-(tert-butylamino)-1-(3-chlorophenyl)-3-hydroxypropan-1-one,CC(C)(C)NC(CO)C(=O)C1=CC=CC(Cl)=C1,CYP2C19,Hydroxylation of terminal methyl,0.86
(r)-bupropion,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,(2R)-2-(tert-butylamino)-1-(3-chloro-4-hydroxyphenyl)propan-1-one,CC(NC(C)(C)C)C(=O)C1=CC=C(O)C(Cl)=C1,CYP2B6;CYP2C19; CYP2E1,Hydroxylation of aromatic carbon ortho to halide group,0.82
(r)-bupropion,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,(2R)â€2â€(tertâ€butylamino)â€1â€(3â€chloroâ€5â€hydroxyphenyl)propanâ€1â€one,CC(NC(C)(C)C)C(=O)C1=CC(O)=CC(Cl)=C1,CYP2B6;CYP2C19; CYP2E1,Hydroxylation of aromatic carbon meta to halide group,0.78
(r)-chloroquine,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,"(r)-chloroquine, N-desethyl",CCNCCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,CYP2C8; CYP2D6; CYP3A4; CYP3A5,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES,0.97
(r)-enflurane,FC(F)OC(F)(F)C(F)Cl,"2-(difluoromethoxy)-2,2-difluoroacetyl fluoride",O=C(F)C(F)(F)OC(F)F,CYP2E1,Oxidation of halotrifluoroethane,0.45
(r)-ketamine,CNC1(C2=CC=CC=C2Cl)CCCCC1=O,Norketamine,NC1(C2=CC=CC=C2Cl)CCCCC1=O,CYP2C9; CYP2B6; CYP3A4 ,N-dealkylation of acyclic secondary amine,0.84
(r)-mda,CC(N)CC1=CC=C2OCOC2=C1,Alpha-methyldopamine,CC(N)CC1=CC=C(O)C(O)=C1,CYP2D6;CYP3A4,O-Demethylation,0.66
(r)-metoprolol,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,alpha-Hydroxymetoprolol,COCC(O)C1=CC=C(OCC(O)CNC(C)C)C=C1,CYP2D6,Hydroxylation of non-terminal aliphatic carbon adjacent to aromatic ring,0.83
(r)-metoprolol,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,O-Demethylmetoprolol,CC(C)NCC(O)COC1=CC=C(CCO)C=C1,CYP2D6; CYP3A4,O-dealkylation of dialkylether,0.96
(r)-metoprolol,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,N_DEISOPROPYLATION,COCCC1=CC=C(OCC(O)CN)C=C1,CYP2C19,N-deisopropylation,0.87
(r)-trimipramine,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C21,,CNCC(C)CN1C2=CC=CC=C2CCC2=CC=CC=C21,CYP2C19,N-demethylation,0.98
(r)-trimipramine,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C21,,CC(CN(C)C)CN1C2=CC=CC=C2CC(O)C2=CC=CC=C21,CYP2D6,Aliphatic Hydroxylation,0.76
(r)-trimipramine,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C21,,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC(O)=CC=C21,CYP2D6,Aliphatic Hydroxylation,0.87
(s)-(-)-carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,4'-OH-carvedilol,COC1=CC(O)=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,CYP2D6 (major); CYP2E1 (minor); CYP2C9 (minor); CYP3A4 (minor),Hydroxylation of benzene on carbon para to a strongly electron donating group,0.94
(s)-(-)-carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,O-Desmethylcarvedilol,OC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,CYP2C9 (major); CYP2D6 (minor); CYP1A2 (minor); CYP2E1 (minor),O-aryl demethylation,0.98
(s)-(-)-carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,5'-OH-carvedilol,COC1=CC=C(O)C=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,CYP2D6 (major); CYP2E1 (minor); CYP2C9 (minor); CYP3A4 (minor),Hydroxylation of benzene on carbon para to a strongly electron donating group,0.93
(s)-(-)-carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,8-OH-carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC(O)=C1N2,CYP1A2 (major); CYP3A4 (minor); CYP1A1 (minor),Aromatic hydroxylation of fused benzene ring,0.91
(s)-(+)-ibuprofen,CC(C)CC1=CC=C(C(C)C(=O)O)C=C1,2-Hydroxyibuprofen,CC(C(=O)O)C1=CC=C(CC(C)(C)O)C=C1,CYP2C9; CYP2C8,Hydroxylation of penultimate aliphatic tertiary carbon,0.91
(s)-(+)-ibuprofen,CC(C)CC1=CC=C(C(C)C(=O)O)C=C1,3-Hydroxyibuprofen,CC(CO)CC1=CC=C(C(C)C(=O)O)C=C1,CYP2C9; CYP2C8,Hydroxylation of terminal methyl,0.92
(s)-fluoxetine,CNCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,(s)-Norfluoxetine,NCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,CYP2C9 (major); CYP2D6; CYP2C19; CYP3A4; CYP3A5,N-dealkylation of acyclic secondary amine,0.95
(s)-fluoxetine,CNCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,p-Trifluoromethyl phenol,OC1=CC=C(C(F)(F)F)C=C1,CYP2C19; CYP3A4,O-dealkylation,0.32
(s)-fluoxetine,CNCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,3-(methylamino)-1-phenylpropan-1-one,CNCCC(=O)C1=CC=CC=C1,CYP2C19; CYP3A4,O-dealkylation,0.27
(s)-flurbiprofen,CC(C(=O)O)C1=CC=C(C2=CC=CC=C2)C(F)=C1,4-OH-S-flurbiprofen,CC(C(=O)O)C1=CC=C(C2=CC=C(O)C=C2)C(F)=C1,CYP2C9,p-Hydroxylation of monosubstituted benzene,0.92
(s)-hexobarbital,CN1C(=O)N=C(O)C(C)(C2=CCCCC2)C1=O,3'-OH-(S)-hexobarbital,CN1C(=O)N=C(O)C(C)(C2=CC(O)CCC2)C1=O,CYP2C9; CYP2C19,Allylic hydroxylation,0.95
(s)-mephobarbital,CCC1(C2=CC=CC=C2)C(=O)N(C)C(=O)N=C1O,4-hydroxymephobarbital,CCC1(C2=CC=C(O)C=C2)C(=O)N(C)C(=O)N=C1O,CYP2C19,Aromatic Hydroxylation,0.97
(s)-mephobarbital,CCC1(C2=CC=CC=C2)C(=O)N(C)C(=O)N=C1O,phenobarbital,CCC1(C2=CC=CC=C2)C(O)=NC(=O)N=C1O,CYP2B6,N-demethylation,0.46
(s)-norfenfluramine,CC(N)CC1=CC=CC(C(F)(F)F)=C1,,NCCC1=CC=CC(C(F)(F)F)=C1,CYP1A2,C-DEALKLYATION,0.83
(s)-oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1=CC=CC=C1)C1CCCCC1,2-cyclohexyl-2-phenylglycolic acid,O=C(O)C(O)(C1=CC=CC=C1)C1CCCCC1,CYP3A4,HYDROLYSIS_OF_CARBOXYLIC_ESTER,0.76
(s)-oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1=CC=CC=C1)C1CCCCC1,4-(diethylamino)but-2-yn-1-ol,CCN(CC)CC#CCO,CYP3A4,HYDROLYSIS_OF_CARBOXYLIC_ESTER,0.08
(s)-oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1=CC=CC=C1)C1CCCCC1,N-desethyloxybutynin,CCNCC#CCOC(=O)C(O)(C1=CC=CC=C1)C1CCCCC1,CYP3A4,N-dealkylation of acyclic tertiary amine,0.99
(s)-propafenone,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,(S)-5-Hydroxypropafenone,CCCNCC(O)COC1=CC=C(O)C=C1C(=O)CCC1=CC=CC=C1,CYP2D6,Hydroxylation of benzene on carbon para to a strongly electron donating group,0.9
(s)-propafenone,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,(S)-N-Despropylpropafenone,NCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,CYP1A2; CYP3A4,N-dealkylation of acyclic secondary amine,0.94
(s)-propafenone,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,(S)-4'-Hydroxypropafenone,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=C(O)C=C1,CYP2D6 (implied),p-Hydroxylation of monosubstituted benzene,0.98
(s)-tomoxetine,CNCCC(OC1=CC=CC=C1C)C1=CC=CC=C1,4-Hydroxy-(s)-tomoxetine,CNCCC(OC1=CC=C(O)C=C1C)C1=CC=CC=C1,CYP2D6; CYP2A6; CYP2B6; CYP2C9; CYP2C19; CYP2E1; CYP3A4,Hydroxylation of benzene on carbon para to a strongly electron donating group,0.93
(s)-tomoxetine,CNCCC(OC1=CC=CC=C1C)C1=CC=CC=C1,N-Desmethyl-(s)-tomoxetine,CNCCC(OC1=CC=CC=C1CO)C1=CC=CC=C1,CYP2D6; CYP2C19 (major),N-dealkylation of acyclic secondary amine,0.93
(s)-tomoxetine,CNCCC(OC1=CC=CC=C1C)C1=CC=CC=C1,2-Hydroxy-(s)-tomoxetine,CC1=CC=CC=C1OC(CCNCO)C1=CC=CC=C1,CYP2D6; CYP2B6; CYP2C19,Aliphatic hydroxylation of carbon alpha to secondary or tertiary alkyl-N,0.97
(s)-venlafaxine,COC1=CC=C(C(CN(C)C)C2(O)CCCCC2)C=C1,N-Desmethylvenlafaxine,CNCC(C1=CC=C(OC)C=C1)C1(O)CCCCC1,CYP2C19 (major); CYP3A4 (minor); CYP2C9 (minor),N-dealkylation of acyclic tertiary amine,0.95
(s)-venlafaxine,COC1=CC=C(C(CN(C)C)C2(O)CCCCC2)C=C1,O-Desmethylvenlafaxine,CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1,CYP2D6,O-aryl demethylation,0.96
[2-methyl-4-(o-tolylazo)phenyl]amine,CC1=CC(N=NC2=CC=CC=C2C)=CC=C1N,4'-hydroxy-o-aminoazotoJuene,CC1=CC(N=NC2=CC=C(O)C=C2C)=CC=C1N,CYP1A2,AROMATIC HYDROXYLATION,0.77
[2-methyl-4-(o-tolylazo)phenyl]amine,CC1=CC(N=NC2=CC=CC=C2C)=CC=C1N,2'-hydroxymethyl-3-raethyl-4-aminoazoberizene,CC1=CC(N=NC2=CC=CC=C2CO)=CC=C1N,CYP1A2,ALIPHATIC HYDROXYLATION,0.81
[2-methyl-4-(o-tolylazo)phenyl]amine,CC1=CC(N=NC2=CC=CC=C2C)=CC=C1N,N-hydroxy-oaminoazotohiene,CC1=CC=CC=C1N=NC1=CC=C(NO)C(C)=C1,CYP1A2,N-HYDROXYLATION,0.83
1_4_cineole,CC(C)C12CCC(C)(CC1)O2,,CC(C)C12CCC(C)(O1)C(O)C2,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.59
1_8_cineole,CC12CCC(CC1)C(C)(C)O2,"2alpha-hydroxy-1,8-cineole",CC1(C)OC2(C)CCC1CC2O,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.67
1_8_cineole,CC12CCC(CC1)C(C)(C)O2,"3alpha-hydroxy-1,8-cineole",CC12CCC(C(O)C1)C(C)(C)O2,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.71
1-(3-chlorophenyl)piperazine,ClC1=CC=CC(N2CCNCC2)=C1,2‐chloro‐4‐(piperazin‐1‐yl)phenol,OC1=CC=C(N2CCNCC2)C=C1Cl,CYP2D6,Hydroxylation of aromatic carbon ortho to halide group,0.77
1-(4-methoxyphenyl)piperazine,COC1=CC=C(N2CCNCC2)C=C1,1-(4-hydroxyphenyl)piperazine,OC1=CC=C(N2CCNCC2)C=C1,CYP2D6,O-aryl dealkylation not adjacent to substituted carbon,0.87
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",CN1CC=C(C2=CC=CC=C2)CC1,1-methyl-4-phenylpyridin-1-ium,C[N+]1=CC=C(C2=CC=CC=C2)C=C1,CYP2D6,N_DEHYDROGENATION_OF_ALICYCLIC_TERTIARY_AMINES_PATTERN1,0.08
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",CN1CC=C(C2=CC=CC=C2)CC1,pOH-MPTP,CN1CC=C(C2=CC=C(O)C=C2)CC1,CYP2D6,Aromatic Hydroxylation,0.87
1-nitropyrene,O=[N+]([O-])C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,3-OH-1-nitropyrene,O=[N+]([O-])C1=CC(O)=C2C=CC3=CC=CC4=CC=C1C2=C34,CYP3A4,HYDROXYLATION_OF_AROMATIC_CARBON,0.66
1-nitropyrene,O=[N+]([O-])C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,"trans-4,5- Dihydrodiol- 1-nitropyrene",O=[N+]([O-])C1=CC=C2C3=C1C=CC1=CC=CC(=C13)C1OC21,CYP3A4,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.39
1-nitropyrene,O=[N+]([O-])C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,6-OH-1- nitropyrene,O=[N+]([O-])C1=CC=C2C=CC3=C(O)C=CC4=CC=C1C2=C43,CYP3A4; CYP1A2,HYDROXYLATION_OF_AROMATIC_CARBON,0.78
1-nitropyrene,O=[N+]([O-])C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,8-OH-1-nitropyrene,O=[N+]([O-])C1=CC=C2C=CC3=CC=C(O)C4=CC=C1C2=C34,CYP1A2,HYDROXYLATION_OF_AROMATIC_CARBON,0.78
"1-propanol, 3-[3-(1-piperidinylmethyl)phenoxy]-",OCCCOC1=CC=CC(CN2CCCCC2)=C1,,OC1=CC=CC(CN2CCCCC2)=C1,CYP2D6,O-dealkylation,0.74
"1-propanol, 3-[3-(1-piperidinylmethyl)phenoxy]-",OCCCOC1=CC=CC(CN2CCCCC2)=C1,,OCCCOC1=CC=CC(CN2CCCCC2O)=C1,CYP2D6,Aliphatic Hydroxylation,0.78
"1,2-dichlorobenzene",ClC1=CC=CC=C1Cl,"2,3-dichlorophenol",OC1=CC=CC(Cl)=C1Cl,CYP1A1; CYP1A2; CYP2E1 (major); CYP3A4,Hydroxylation of aromatic carbon ortho to halide group,0.42
"1,2-dichlorobenzene",ClC1=CC=CC=C1Cl,"3,4-dichlorophenol",OC1=CC=C(Cl)C(Cl)=C1,CYP1A1; CYP1A2; CYP2E1 (major); CYP3A4,Hydroxylation of aromatic carbon para to halide group,0.47
"1,2,4-trichlorobenzene",ClC1=CC=C(Cl)C(Cl)=C1,"2,3,5-trichlorophenol",OC1=CC(Cl)=CC(Cl)=C1Cl,CYP2E1 (major),Hydroxylation of aromatic carbon ortho to halide group,0.48
"1,2,4-trichlorobenzene",ClC1=CC=C(Cl)C(Cl)=C1,"2,3,6-trichlorophenol",OC1=C(Cl)C=CC(Cl)=C1Cl,CYP3A4 (major),Hydroxylation of aromatic carbon ortho to halide group,0.47
"1,2,4-trichlorobenzene",ClC1=CC=C(Cl)C(Cl)=C1,"2,4,5-trichlorophenol",OC1=CC(Cl)=C(Cl)C=C1Cl,CYP2E1 (major); CYP1A1,Hydroxylation of aromatic carbon ortho to halide group,0.48
1'-nitrosonornicotine,O=NN1CCCC1C1=CC=CN=C1,,O=NN1C(O)CCC1C1=CC=CN=C1,CYP2A6;CYP2D6;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.79
1'-nitrosonornicotine,O=NN1CCCC1C1=CC=CN=C1,,O=NN1CCCC1(O)C1=CC=CN=C1,CYP2A6;CYP2D6;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.67
11_oxo_delta8_tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CC=C(C=O)CC21,,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CC=C(C(=O)O)CC21,CYP2C8;CYP2C9;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.95
2-(1-piperazinyl)pyrimidine,C1=CN=C(N2CCNCC2)N=C1,,OC1=CN=C(N2CCNCC2)N=C1,CYP2D6,Aromatic Hydroxylation,0.82
2-acetamidofluorene,CC(O)=NC1=CC=C2C(=C1)CC1=CC=CC=C12,N-Hydroxy-2-acetamidofluorene,CC(=O)N(O)C1=CC=C2C(=C1)CC1=CC=CC=C12,CYP1A2,N-hydroxylation of secondary arylamide,0.59
2-acetamidofluorene,CC(O)=NC1=CC=C2C(=C1)CC1=CC=CC=C12,1-OH-AFF,CC(O)=NC1=CC=C2C(=C1)CC1=CC=CC(O)=C12,CYP1A2,Aromatic Hydroxylation,0.77
2-acetamidofluorene,CC(O)=NC1=CC=C2C(=C1)CC1=CC=CC=C12,5-OH-AFF,CC(O)=NC1=CC=C2C3=CC=CCC3(O)CC2=C1,CYP1A2,Aromatic Hydroxylation,0.3
2-acetamidofluorene,CC(O)=NC1=CC=C2C(=C1)CC1=CC=CC=C12,N-Hydroxy-2-acetamidofluorene,CC(=O)N(O)C1=CC=C2C(=C1)CC1=CC=CC=C12,CYP1A2,Aromatic Hydroxylation,0.59
2-acetylbenzothiophene,CC(=O)C1=CC2=CC=CC=C2S1,,CC(O)C1CC2CCCCC2S1=O,CYP1A2;CYP2B6;CYP2E1;CYP3A4,S-Oxidation,0.09
"2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide",N=C(O)C1=C2CCCCN2C(C2=CC=CN=C2)=C1Cl,rac-RPR 127025,N=C(O)C1=C2C(O)CCCN2C(C2=CC=CN=C2)=C1Cl,CYP1A2;CYP2C8;CYP2C9;CYP3A4,Aliphatic Hydroxylation,0.92
"2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide",N=C(O)C1=C2CCCCN2C(C2=CC=CN=C2)=C1Cl,RPR 122701,N=C(O)C1=C2CCCCN2C(C2=CC=C[N+]([O-])=C2)=C1Cl,CYP2C8,N-Oxidation,0.97
2-naphthylamine,NC1=CC=C2C=CC=CC2=C1,N-Hydroxy-2-naphthalenamine,ONC1=CC=C2C=CC=CC2=C1,CYP1A2,N-hydroxylation of primary arylamine,0.75
2-nitropyrene,O=[N+]([O-])C1=CC2=CC=C3C=CC=C4C=CC(=C1)C2=C34,2-aminopyrene,NC1=CC2=CC=C3C=CC=C4C=CC(=C1)C2=C34,CYP1A1; CYP1A2,REDUCTION_OF_NITRO_TO_AMINE,0.56
2-oxoquazepam,O=C1CN=C(C2=CC=CC=C2F)C2=CC(Cl)=CC=C2N1CC(F)(F)F,3-Hydroxy-2-oxoquazepam,O=C1C(O)N=C(C2=CC=CC=C2F)C2=CC(Cl)=CC=C2N1CC(F)(F)F,CYP3A4; CYP2C9,"3-Hydroxylation of 5-aryl-1,4-benzodiazepine",0.9
2-oxoquazepam,O=C1CN=C(C2=CC=CC=C2F)C2=CC(Cl)=CC=C2N1CC(F)(F)F,N-Desalkyl-2-oxoquazepam,OC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2F)=NC1,CYP3A4; CYP2C9,N-dealkylation of tertiary carboxamide,0.55
2-phenylphenol,OC1=CC=CC=C1C1=CC=CC=C1,"2,5-dihydroxybiphenyl",OC1=CC=C(O)C(C2=CC=CC=C2)=C1,CYP1A2; CYP2B6; CYP2D6; CYP2E1; CYP3A4,Hydroxylation of benzene on carbon para to a strongly electron donating group,0.81
2-propylquinoline,CCCC1=CC=C2C=CC=CC2=N1,,CCCC1=CC=C2C(=N1)C=CC1OC21,CYP2C9;CYP2E1;CYP3A4,Epoxidation,0.22
2-propylquinoline,CCCC1=CC=C2C=CC=CC2=N1,,CCCC1=CC=C2C=CC3OC3C2=N1,CYP2C9;CYP2E1;CYP3A4,Epoxidation,0.24
2-propylquinoline,CCCC1=CC=C2C=CC=CC2=N1,,OCCCC1=CC=C2C=CC=CC2=N1,CYP2A6;CYP2C9;CYP2C19;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.94
2-propylquinoline,CCCC1=CC=C2C=CC=CC2=N1,,CCC(O)C1=CC=C2C=CC=CC2=N1,CYP2A6;CYP2C9;CYP2C19;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.77
"2,2',4,5,5'-pentachlorobiphenyl",ClC1=CC=C(Cl)C(C2=CC(Cl)=C(Cl)C=C2Cl)=C1,"2,2',4',5,5'-pentachloro-[1,1'-biphenyl]-4-ol",OC1=CC(Cl)=C(C2=CC(Cl)=C(Cl)C=C2Cl)C=C1Cl,CYP2A6; CYP3A4; CYP2C18,Hydroxylation of aromatic carbon meta to halide group,0.74
"2,2',4,5,5'-pentachlorobiphenyl",ClC1=CC=C(Cl)C(C2=CC(Cl)=C(Cl)C=C2Cl)=C1,"2,2',4',5,5'-pentachloro-[1,1'-biphenyl]-4-ol",OC1=CC(Cl)=C(C2=CC(Cl)=C(Cl)C=C2Cl)C=C1Cl,CYP2A6; CYP3A4; CYP2C18,Hydroxylation of aromatic carbon ortho to halide group,0.74
"2,6-dichlorobenzonitrile",N#CC1=C(Cl)C=CC=C1Cl,,N#CC1=C(Cl)C2OC2C=C1Cl,CYP2A6,Epoxidation,0.06
"2,6-dichlorobenzonitrile",N#CC1=C(Cl)C=CC=C1Cl,,N#CC1C(Cl)=CC=C2OC21Cl,CYP2A6,Epoxidation,0.06
2'-methoxyacetophenone,COC1=CC=CC=C1C(C)=O,2'-Hydroxyacetophenone,CC(=O)C1=CC=CC=C1O,CYP2A6,O-Demethylation,0.75
"2h-1-benzopyran-2-one, 4-(chloromethyl)-7-ethoxy-",CCOC1=CC=C2C(CCl)=CC(=O)OC2=C1,4-(Chloromethyl)-7-hydroxychromen-2-one,O=C1C=C(CCl)C2=CC=C(O)C=C2O1,CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C19;CYP2D6;CYP2E1;CYP3A4,O-Deethylation,0.89
"2h-1-benzopyran-2-one, 7-(pentyloxy)-",CCCCCOC1=CC=C2C=CC(=O)OC2=C1,,CCC(O)CCOC1=CC=C2C=CC(=O)OC2=C1,CYP3A4,Aliphatic Hydroxylation,0.96
"2h-1-benzopyran-2-one, 7-(pentyloxy)-",CCCCCOC1=CC=C2C=CC(=O)OC2=C1,,CC(O)CCCOC1=CC=C2C=CC(=O)OC2=C1,CYP3A4,Aliphatic Hydroxylation,0.97
"2h-1-benzopyran-2-one, 7-(pentyloxy)-",CCCCCOC1=CC=C2C=CC(=O)OC2=C1,,CCCCC(O)OC1=CC=C2C=CC(=O)OC2=C1,CYP3A4,Aliphatic Hydroxylation,0.9
3-cyano-7-ethoxycoumarin,CCOC1=CC=C2C=C(C#N)C(=O)OC2=C1,3-Cyano-7-hydroxycoumarin,N#CC1=CC2=CC=C(O)C=C2OC1=O,"CYP1A2;CYP2A6;CYP2B6;CYP2C9;CYP2C19,CYP2D6;CYP2E1",O-Demethylation,0.89
3-cyano-7-methoxycoumarin,COC1=CC=C2C=C(C#N)C(=O)OC2=C1,3-Cyano-7-hydroxycoumarin,N#CC1=CC2=CC=C(O)C=C2OC1=O,CYP1A2;CYP2B6;CYP2C19;CYP2E1,O-Demethylation,0.92
3-methylindole,CC1=CNC2=CC=CC=C12,3-methyleneindolenine,C=C1C=[NH+]C2=CC=CC=C12,CYP2F1,Terminal desaturation,0.11
3-methylindole,CC1=CNC2=CC=CC=C12,"3-methylindole-2,3-epoxide",CC12OC1NC1=CC=CC=C12,CYP2F1; CYP2A6; CYP3A4; CYP2C8,PYRROLE_EPOXIDATION,0.13
"3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (4r)-",CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+](=O)[O-])=C1,,CCOC(=O)C1=C(C)N=C(C)C(C(=O)OC)=C1C1=CC=CC([N+](=O)[O-])=C1,CYP3A4 ,Dehydrogenation,0.32
"3alpha,12beta-dihydroxy-5alpha-cholan-24-oic acid",CC(CCC(=O)O)C1CCC2C3CCC4CC(O)CCC4(C)C3CC(O)C12C,hyocholic acid (HCA),CC(CCC(=O)O)C1CCC2C3C(O)C(O)C4CC(O)CCC4(C)C3CC(O)C12C,CYP3A4 ,Aliphatic Hydroxylation,0.8
"3alpha,7beta,12beta-trihydroxy-5alpha-cholan-24-oic acid",CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(=O)CCC4(C)C3CC(O)C12C,CYP3A4,Dehydrogenation,0.85
3s14s-ochratoxin a,CC1CC2=C(Cl)C=C(C(O)=NC(CC3=CC=CC=C3)C(=O)O)C(O)=C2C(=O)O1,,CC1OC(=O)C2=C(O)C(C(O)=NC(CC3=CC=CC=C3)C(=O)O)=CC(Cl)=C2C1O,CYP1A2;CYP2C9;CYP3A4,ALIPHATIC HYDROXYLATION,0.9
4_demethyl_olanzapine,CC1=CC2=C(NC3=CC=CC=C3N=C2N2CCNCC2)S1,,CC1=CC2=C(NC3=CC=CC=C3N=C2N2CCNCC2O)S1,CYP2D6,Aliphatic Hydroxylation,0.92
4-(butylaminomethyl)-7-methoxycoumarin,CCCCNCC1=CC(=O)OC2=CC(OC)=CC=C12,BHAMC,CCCCNCC1=CC(=O)OC2=CC(O)=CC=C12,CYP1A2;CYP2C9;CYP2C19;CYP2D6,O-Demethylation,0.94
4-(butylaminomethyl)-7-methoxycoumarin,CCCCNCC1=CC(=O)OC2=CC(OC)=CC=C12,,COC1=CC=C2C(CN)=CC(=O)OC2=C1,CYP1A2,N-Demethylation,0.89
4-(ethylaminomethyl)-7-methoxycoumarin,CCNCC1=CC(=O)OC2=CC(OC)=CC=C12,EHAMC,CCNCC1=CC(=O)OC2=CC(O)=CC=C12,CYP1A2;CYP2C19;CYP2D6,O-Demethylation,0.93
4-(ethylaminomethyl)-7-methoxycoumarin,CCNCC1=CC(=O)OC2=CC(OC)=CC=C12,MAMC,COC1=CC=C2C(CN)=CC(=O)OC2=C1,CYP1A2,N-Dealkylation,0.92
"4-(trifluoromethyl)-7-[2,5-bis(trifluoromethyl)benzyloxy]coumarin",O=C1C=C(C(F)(F)F)C2=CC=C(OCC3=CC(C(F)(F)F)=CC=C3C(F)(F)F)C=C2O1,HFC,O=C1C=C(C(F)(F)F)C2=CC=C(O)C=C2O1,CYP3A4,O-Dealklyation,0.72
"4-[(s)-alpha-(trichloromethyl)-4-methoxybenzyl]-1,2-benzenediol",COC1=CC=C(C(C2=CC=C(O)C(O)=C2)C(Cl)(Cl)Cl)C=C1,Tris-OH-M methoxychlor,OC1=CC=C(C(C2=CC=C(O)C(O)=C2)C(Cl)(Cl)Cl)C=C1,CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP3A4,O-demethylation,0.92
4-aminobiphenyl,NC1=CC=C(C2=CC=CC=C2)C=C1,"4-aminobiphenyl, N-oxide",ONC1=CC=C(C2=CC=CC=C2)C=C1,CYP1A2,N-hydroxylation of primary arylamine,0.78
4-Hydroxytamoxifen,CCC(=C(C1=CC=C(O)C=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,Endoxifen,CCC(=C(C1=CC=C(O)C=C1)C1=CC=C(OCCNC)C=C1)C1=CC=CC=C1,CYP3A4; CYP3A5,N-dealkylation of acyclic tertiary amine,0.98
4-Hydroxytamoxifen,CCC(=C(C1=CC=C(O)C=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,"3,4-Dihydroxy-Tamoxifen",CCC(=C(C1=CC=C(OCCN(C)C)C=C1)C1=CC=C(O)C(O)=C1)C1=CC=CC=C1,CYP3A4,Aromatic Hydroxylation,0.86
4-methylaminomethyl-7-methoxycoumarin,CNCC1=CC(=O)OC2=CC(OC)=CC=C12,N-methyl 7-hydroxy-4-(aminomethyl)-coumarin,CNCC1=CC(=O)OC2=CC(O)=CC=C12,CYP1A2;CYP2D6,N-Dealkylation,0.93
4-nitro-3-(trifluoromethyl)aniline,NC1=CC=C([N+](=O)[O-])C(C(F)(F)F)=C1,2-amino5-nitro-4-(trifluoromethyl)phenol,NC1=CC(C(F)(F)F)=C([N+](=O)[O-])C=C1O,CYP1A2;CYP2A6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,Aromatic Hydroxylation,0.75
4-nitro-3-(trifluoromethyl)aniline,NC1=CC=C([N+](=O)[O-])C(C(F)(F)F)=C1,N-[4-nitro-3-(trifluoromethyl)phenyl]-acetamide,C[NH+]([O-])C1=CC=C([N+](=O)[O-])C(C(F)(F)F)=C1,CYP1A2;CYP2A6;CYP2C9;CYP3A4,N-Hydroxylation; N-Oxidation,0.8
4-nitroanisole,COC1=CC=C([N+](=O)[O-])C=C1,P-Nitrophenol,O=[N+]([O-])C1=CC=C(O)C=C1,CYP1A2;CYP2A6;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,O-Demethylation,0.83
4-nitropyrene,O=[N+]([O-])C1=CC2=CC=CC3=CC=C4C=CC=C1C4=C32,4-aminopyrene,NC1=CC2=CC=CC3=CC=C4C=CC=C1C4=C32,CYP1A2; CYP3A4,REDUCTION_OF_NITRO_TO_AMINE,0.53
4-nitropyrene,O=[N+]([O-])C1=CC2=CC=CC3=CC=C4C=CC=C1C4=C32,,O=[N+]([O-])C1=CC2=CC=CC3=C2C2=C(C=CC=C12)C(O)C3O,CYP1A2,Epoxidation of arene,0.41
"4,4'-methylenebis(2-chloroaniline)",NC1=CC=C(CC2=CC=C(N)C(Cl)=C2)C=C1Cl,,NC1=CC=C(CC2=CC=C(N[O-])C(Cl)=C2)C=C1Cl,CYP2A6;CYP3A4,N-Oxidation,0.84
"4'-hydroxy-5,6,7,8-tetramethoxyflavone (tangeretin_T27)",COC1=C(OC)C(OC)=C2C(=O)C=C(C3=CC=C(O)C=C3)OC2=C1OC,OROBOL,COC1=C(OC)C(OC)=C2C(=O)C=C(C3=CC=C(O)C(O)=C3)OC2=C1OC,CYP1A2;CYP3A4,Aromatic Hydroxylation,0.97
5-hydroxydiclofenac,O=C(O)CC1=CC(O)=CC=C1NC1=C(Cl)C=CC=C1Cl,"4',5-Dihydroxydiclofenac",O=C(O)CC1=CC(O)=CC=C1NC1=C(Cl)C=C(O)C=C1Cl,CYP2C9,Aromatic Hydroxylation,0.94
5-methoxytryptamine,COC1=CC=C2NC=C(CCN)C2=C1,Serotonin,NCCC1=CNC2=CC=C(O)C=C12,CYP2D6,O-demethylation,0.91
5-methylchrysene,CC1=CC2=CC=CC=C2C2=CC=C3C=CC=CC3=C12,"5-Methyl-1,2-dihydrochrysene-1,2-diol",CC1=CC2=CC=CC=C2C2=CC=C3C(=C12)C=CC(O)C3O,CYP1A2;CYP2D6;CYP2E1;CYP3A4,Aromatic Hydroxylation,0.19
58c80,CC(C)(C)C1CCC(C2=C(O)C(=O)C3=CC=CC=C3C2=O)CC1,298C84,CC(C)(CO)C1CCC(C2=C(O)C(=O)C3=CC=CC=C3C2=O)CC1,CYP2C9,Hydroxylation of terminal methyl,0.98
6-chrysenamine,NC1=CC2=C3C=CC=CC3=CC=C2C2=CC=CC=C12,"6-MeC-1,2-diol",NC1=CC2=C3C=CC(O)C(O)C3=CC=C2C2=CC=CC=C12,CYP1A2;CYP2A6;CYP2B6;CYP2D6;CYP3A4,Aromatic Hydroxylation,0.19
6-methylchrysene,CC1=CC2=C3C=CC=CC3=CC=C2C2=CC=CC=C12,"6-MeC-1,2-diol",CC1=CC2=C3C=CC(O)C(O)C3=CC=C2C2=CC=CC=C12,CYP1A2;CYP2D6;CYP2E1;CYP3A4,Epoxidation,0.2
6-nitrochrysene,O=[N+]([O-])C1=CC2=C3C=CC=CC3=CC=C2C2=CC=CC=C12,N-hydroxy-6-AC,O[NH2+]C1=CC2=C3C=CC=CC3=CC=C2C2=CC=CC=C12,CYP1A2;CYP3A4,Aromatic Hydroxylation,0.71
6-nitrochrysene,O=[N+]([O-])C1=CC2=C3C=CC=CC3=CC=C2C2=CC=CC=C12,"1,2-DHD-6-NC ",O=[N+]([O-])C1=CC2=C3C=CC(O)C(O)C3=CC=C2C2=CC=CC=C12,CYP2E1;CYP3A4,Reduction,0.32
7-benzyloxy-4-trifluoromethylcoumarin,O=C1C=C(C(F)(F)F)C2=CC=C(OCC3=CC=CC=C3)C=C2O1,7-hydroxy-4-triuoromethylcoumarin (HFC),O=C1C=C(C(F)(F)F)C2=CC=C(O)C=C2O1,CYP2A6;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP2E1,O-Deethylation,0.85
7-benzyloxyquinoline,C1=CC=C(COC2=CC=C3C=CC=NC3=C2)C=C1,7-Hydroxyquinoline,O=C1C=CC2=CC=CN=C2C1,CYP1A2;CYP3A4,O-dealkylation,0.17
7-butoxy-2h-chromen-2-one,CCCCOC1=CC=C2C=CC(=O)OC2=C1,,CCCC(O)OC1CCC2CCC(O)OC2C1,CYP3A4,Aliphatic Hydroxylation,0.09
7-butoxy-2h-chromen-2-one,CCCCOC1=CC=C2C=CC(=O)OC2=C1,,CC(O)CCOC1CCC2CCC(O)OC2C1,CYP3A4,Aliphatic Hydroxylation,0.09
7-butoxy-2h-chromen-2-one,CCCCOC1=CC=C2C=CC(=O)OC2=C1,,OCCCCOC1CCC2CCC(O)OC2C1,CYP3A4,Aliphatic Hydroxylation,0.09
7-ethoxycoumarin,CCOC1=CC=C2C=CC(=O)OC2=C1,Umbelliferone,O=C1C=CC2=CC=C(O)C=C2O1,CYP1A1 (major); CYP2B6; CYP2E1; CYP1A2; CYP2A6; CYP3A7; CYP2C9; CYP2C19,O-aryl dealkylation not adjacent to substituted carbon,0.82
7-ethoxycoumarin,CCOC1=CC=C2C=CC(=O)OC2=C1,,CCOC1=CC=C2C(O)=CC(=O)OC2=C1,CYP1A1 (major); CYP2B6; CYP2E1; CYP1A2; CYP2A6; CYP3A7; CYP2C9; CYP2C19,Aromatic Hydroxylation,0.87
7-ethoxyresorufin,CCOC1=CC=C2N=C3C=CC(=O)C=C3OC2=C1,Resorufin,O=C1C=CC2=NC3=CC=C(O)C=C3OC2=C1,CYP1A2; CYP1A1,O-aryl dealkylation not adjacent to substituted carbon,0.93
7-methoxycoumarin,COC1=CC=C2C=CC(=O)OC2=C1,Umbelliferone,O=C1C=CC2=CC=C(O)C=C2O1,CYP1A2;CYP2A6,O-dealkylation,0.87
7-methoxycoumarin,COC1=CC=C2C=CC(=O)OC2=C1,4-Hydroxy-7-methoxycoumarin,COC1=CC=C2C(O)=CC(=O)OC2=C1,CYP1A2;CYP2A6,Aromatic Hydroxylation,0.86
7-methylbenz(c)acridine,CC1=C2C=CC=CC2=NC2=C1C=CC1=CC=CC=C12,,CC1=C2C(=NC3=C1C=CC1=CC=CC=C13)C=CC(O)C2O,CYP1A2;CYP3A4,Aromatic Hydroxylation,0.31
7-methylbenz(c)acridine,CC1=C2C=CC=CC2=NC2=C1C=CC1=CC=CC=C12,,CC1=C2C=CC=CC2=NC2=C1C(O)=C(O)C1=CC=CC=C12,CYP1A2;CYP3A4,Aromatic Hydroxylation,0.58
7-methylbenz(c)acridine,CC1=C2C=CC=CC2=NC2=C1C=CC1=CC=CC=C12,,CC1=C2C=CC=CC2=NC2=C1C=CC1=C(O)C(O)=CC=C12,CYP1A2;CYP3A4,Aromatic Hydroxylation,0.73
7-methylbenz(c)acridine,CC1=C2C=CC=CC2=NC2=C1C=CC1=CC=CC=C12,,OCC1=C2C=CC=CC2=NC2=C1C=CC1=CC=CC=C12,CYP1A2;CYP3A4,Aliphatic Hydroxylation,0.84
8-hydroxyefavirenz,OC1=NC2=C(O)C=C(Cl)C=C2C(C#CC2CC2)(C(F)(F)F)O1,"8,14-diOH-efavirenz",OC1=NC2=C(O)C=C(Cl)C=C2C(C#CC2(O)CC2)(C(F)(F)F)O1,CYP2B6,HYDROXYLATION_OF_ALICYCLIC_SECONDARY_CARBON; HYDROXYLATION_OF_ALICYCLIC_SECONDARY_CARBON_PATTERN1,0.97
9-anthraldehyde,O=CC1=C2C=CC=CC2=CC2=CC=CC=C12,,O=C(O)C1=C2C=CC=CC2=CC2=CC=CC=C12,CYP2A6;CYP2B6;CYP2C19;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.71
9-cis-retinal,CC(C=CC=C(C)C=CC1=C(C)CCCC1(C)C)=CC=O,4-hydroxy-9-cis-retinals,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,CYP1A2;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.9
"Lopinavir, D-valine diastereomer-",CC1=CC=CC(C)=C1OCC(O)=NC(CC1=CC=CC=C1)C(O)CC(CC1=CC=CC=C1)N=C(O)C(C(C)C)N1CCCN=C1O,,CC1=CC=CC(C)=C1OCC(O)=NC(CC1=CC=CC=C1)C(O)CC(CC1=CC=CC=C1)N=C(O)C(C(C)C)N1CCC(O)N=C1O,CYP3A4,Aliphatic Hydroxylation,0.95
abt_378,CC1=CC=CC(C)=C1OCC(O)=NC(CC1=CC=CC=C1)C(O)CC(CC1=CC=CC=C1)N=C(O)C(C(C)C)N1CCCN=C1O,,CC1=CC=CC(C)=C1OCC(O)=NC(CC1=CC=CC=C1)C(O)CC(CC1=CC=CC=C1)N=C(O)C(C(C)C)N1CCC(O)=NC1=O,CYP3A4,C-Oxidation,0.75
1â€[(2S)â€4â€(5â€benzylthiophenâ€2â€yl)butâ€3â€ynâ€2â€yl]â€1â€hydroxyurea,CC(C#CC1=CC=C(CC2=CC=CC=C2)S1)N(O)C(=N)O,ABT-515,CC(C#CC1=CC=C(C(O)C2=CC=CC=C2)S1)N(O)C(=N)O,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.81
"1-[Amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine",CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C(Cl)=C1,,CC(C)(O)NC(=N)NC(=N)NC1=CC=C(Cl)C(Cl)=C1,CYP2C19;,Aliphatic Hydroxylation,0.88
ac1ldic9,COC(=O)C(C1=CC=CC=C1Cl)N1CCC2=C(C=CS2)C1,2-oxo-clopidogrel,COC(=O)C(C1=CC=CC=C1Cl)N1CCC2=C(CC(=O)S2)C1,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2D6;CYP2C1;CYP3A4,C-Oxidation,0.54
ac1mip3e,CCN(CC)CC#CC(C)(C)OC(=O)C(O)(C1=CC=CC=C1)C1CCCCC1,N-deethylated  ac1mip3e,CCNCC#CC(C)(C)OC(=O)C(O)(C1=CC=CC=C1)C1CCCCC1,CYP3A4,N-deethylation,0.99
[5-(Diethylamino)-2-methylpent-3-yn-2-yl] (2S)-2-cyclohexyl-2-hydroxy-2-phenylacetate,CCN(CC)CC#CC(C)(C)OC(=O)C(O)(C1=CC=CC=C1)C1CCCCC1,4-cis-OH ac1mip3e,CCN(CC)CC#CC(C)(C)OC(=O)C(O)(C1=CC=CC=C1)C1CCC(O)CC1,CYP3A4,Aliphatic Hydroxylation,0.98
ac1ocg1j,CNC(C)CC1=CC=CC=C1OC,,CNC(C)CC1=CC=CC=C1O,CYP2D6,O-demethylation,0.79
ac1ocg1j,CNC(C)CC1=CC=CC=C1OC,,CNC(C)CC1=CC(O)=CC=C1OC,CYP2D6,Aromatic Hydroxylation,0.86
pimobendan,COC1=CC=C(C2=NC3=CC(C4=NN=C(O)CC4C)=CC=C3N2)C=C1,,CC1CC(O)=NN=C1C1=CC=C2NC(C3=CC=C(O)C=C3)=NC2=C1,CYP1A2;CYP3A4,N-demethylation,0.98
aceclofenac,O=C(O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,4'-OH-aceclofenac,O=C(O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=C(O)C=C1Cl,CYP2C9,Hydroxylation of aromatic carbon meta to halide group,0.89
aceclofenac,O=C(O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,5-OH-aceclofenac,O=C(O)COC(=O)CC1=CC(O)=CC=C1NC1=C(Cl)C=CC=C1Cl,CYP2C9,HYDROXYLATION_OF_AROMATIC_CARBON; HYDROXYLATION_OF_BENZENE_PARA_TO_EDG,0.87
aceclofenac,O=C(O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Diclofenac,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,CYP2C9,HYDROLYSIS_OF_CARBOXYLIC_ESTER,0.85
acetanilide,CC(O)=NC1=CC=CC=C1,Acetaminophen,CC(O)=NC1=CC=C(O)C=C1,CYP1A2; CYP2E1,p-Hydroxylation of anilide,0.73
acetanilide,CC(O)=NC1=CC=CC=C1,N-Hydroxy-N-phenylacetamide,CC(=O)N(O)C1=CC=CC=C1,CYP2E1,N-hydroxylation of anilide,0.16
adinazolam,CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N21,N-demethyladinazolam,CNCC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N21,CYP2C19;CYP3A4,N-demethylation,0.98
aflatoxin b1,COC1=CC2=C(C3=C1C1=C(C(=O)CC1)C(=O)O3)C1C=COC1O2," Aflatoxin B1- exo-8,9-oxide ",COC1=CC2=C(C3=C1C1=C(C(=O)CC1)C(=O)O3)C1C(O2)OC2OC21,CYP1A2; CYP3A5; CYP3A4; CYP2A13 ,Epoxidation of vinyl ether,0.88
aflatoxin b1,COC1=CC2=C(C3=C1C1=C(C(=O)CC1)C(=O)O3)C1C=COC1O2,Aflatoxin M1 ,COC1=CC2=C(C3=C1C1=C(C(=O)CC1)C(=O)O3)C1(O)C=COC1O2,CYP1A2 ,Allylic hydroxylation,0.92
aflatoxin b1,COC1=CC2=C(C3=C1C1=C(C(=O)CC1)C(=O)O3)C1C=COC1O2,Aflatoxin Q1 ,COC1=CC2=C(C3=C1C1=C(C(=O)CC1O)C(=O)O3)C1C=COC1O2,CYP3A4 ,Allylic hydroxylation,0.95
albendazole,CCCSC1=CC=C2N=C(N=C(O)OC)NC2=C1,,CCCS(=O)C1=CC=C2N=C(N=C(O)OC)NC2=C1,CYP1A2;CYP3A4,S-Oxidation,0.85
alfentanil,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCN2N=NN(CC)C2=O)CC1,N-phenylpropionamide,CCC(O)=NC1=CC=CC=C1,CYP3A4,N-dealkylation of tertiary carboxamide,0.09
alfentanil,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCN2N=NN(CC)C2=O)CC1,Noralfentanil,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCNCC1,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.73
alfentanil,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCN2N=NN(CC)C2=O)CC1,"2‐(4‐ethyl‐5‐oxo‐1,2,3,4‐tetrazol‐1‐yl)acetaldehyde",CCN1N=NN(CC=O)C1=O,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.25
alilusem,CC1=CC=CC=C1C(=O)N1CCC(=NOS(=O)(=O)O)C2=CC=C(Cl)C=C21,,O=C(C1=CC=CC=C1CO)N1CCC(=NOS(=O)(=O)O)C2=CC=C(Cl)C=C21,CYP2C9;CYP3A4,Aliphatic Hydroxylation,0.97
almotriptan,CN(C)CCC1=CNC2=CC=C(CS(=O)(=O)N3CCCC3)C=C12,2-OH-almotriptan,CN(C)CCC1=CNC2=CC=C(CS(=O)(=O)N3CCCC3O)C=C12,CYP2D6; CYP3A4,Hydroxylation of heteroalicyclic secondary carbon,0.87
almotriptan,CN(C)CCC1=CNC2=CC=C(CS(=O)(=O)N3CCCC3)C=C12,methyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine,CNCCC1=CNC2=CC=C(CS(=O)(=O)N3CCCC3)C=C12,CYP1A2; CYP2C8; CYP2E1; CYP2D6; CYP3A4,N-dealkylation of acyclic tertiary amine,0.99
alpha_dihydroergocryptine,CC(C)C1(N=C(O)C2CC3C4=CC=CC5=C4C(=CN5)CC3N(C)C2)OC2(O)C3CCCN3C(=O)CN2C1=O,,CC(C)C1(N=C(O)C2CC3C4=CC=CC5=C4C(=CN5)CC3N(C)C2)OC2(O)C3CCC(O)N3C(=O)CN2C1=O,CYP3A4,Aliphatic Hydroxylation,0.99
alpha-thujone,CC1C(=O)CC2(C(C)C)CC12,4-hydroxy-alpha-thujone,CC(C)C12CC(=O)C(C)(O)C1C2,CYP2A6; CYP2B6; CYP2D6; CYP3A4,Hydroxylation of penultimate aliphatic tertiary carbon,0.55
alpha-thujone,CC1C(=O)CC2(C(C)C)CC12,7-hydroxy-alpha-thujone,CC1C(=O)CC2(C(C)(C)O)CC12,CYP2A6; CYP2B6; CYP2D6; CYP3A4,Hydroxylation of penultimate aliphatic tertiary carbon,0.61
alphacetylmethadol,CCC(OC(C)=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,norLAAM,CCC(OC(C)=O)C(CC(C)NC)(C1=CC=CC=C1)C1=CC=CC=C1,CYP2B6;CYP2C8;CYP2C19;CYP3A4,N-DEMETHYLATION,0.97
alprazolam,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12,4-Hydroxyalprazolam,CC1=NN=C2C(O)N=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12,CYP3A4 (major); CYP2C9 (minor),Hydroxylation of heteroalicyclic secondary carbon,0.87
alprazolam,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12,Beta-Hydroxyalprazolam,OCC1=NN=C2C(O)N=C(C3=CC=CC=C3)C3=CC=CC=C3N12,CYP2C9 (minor); CYP2C19 (minor); CYP3A4 (minor),Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.8
ambroxol,NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1,"4-Aminocyclohexanol, cis-",NC1CCC(O)CC1,CYP3A4,N-dealkylation of acyclic secondary amine,0.17
ambroxol,NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1,"2-Amino-3,5-dibromobenzaldehyde",NC1=C(Br)C=C(Br)C=C1C=O,CYP3A4,N-dealkylation of acyclic secondary amine,0.46
Ametryn,CCN=C1N=C(SC)NC(=NC(C)C)N1,,CSC1=NC(=N)NC(=NC(C)C)N1,CYP1A1; CYP1A2; CYP2C19; CYP3A4,N-dealkylation of secondary arylalkylamine,0.98
Ametryn,CCN=C1N=C(SC)NC(=NC(C)C)N1,,CCN=C1NC(SC)=NC(=N)N1,CYP1A1; CYP1A2; CYP2C8; CYP2C9; CYP2C19; CYP3A4,N-deisopropylation,0.91
aminopyrine,CN(C)C1=CN(C)N(C2=CC=CC=C2)C1=O,"4-(Dimethylamino)-5-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one",CN(C)C1=CNN(C2=CC=CC=C2)C1=O,CYP2C19; CYP2C8; CYP2D6; CYP2C18; CYP1A2,N-dealkylation of hydrazide,0.76
aminopyrine,CN(C)C1=CN(C)N(C2=CC=CC=C2)C1=O,N-Desmethylaminopyrine,CNC1=CN(C)N(C2=CC=CC=C2)C1=O,CYP1A2; CYP3A4; CYP2C18; CYP2C19; CYP2C8; CYP2C9; CYP2D6,N-dealkylation of acyclic tertiary amine,0.95
amiodarone,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,N-Desethylamiodarone,CCCCC1=C(C(=O)C2=CC(I)=C(OCCNCC)C(I)=C2)C2=CC=CC=C2O1,CYP3A4; CYP2C8; CYP2C9; CYP1A2; CYP2D6,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES,0.99
amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,Nortriptyline,CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,CYP2C19; CYP3A4; CYP2C9; CYP1A2,N-dealkylation of acyclic tertiary amine,0.99
amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,E-10-OH-amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CC(O)C2=CC=CC=C12,CYP2D6,Hydroxylation of alicyclic secondary carbon,0.73
androstenedione,CC12CCC3C(CCC4=CC(=O)CCC43C)C1CCC2=O,6beta-hydroxy-androstenedione,CC12CCC3C(CC(O)C4=CC(=O)CCC43C)C1CCC2=O,CYP3A4,Hydroxylation of carbon gamma to conjugated carbonyl,0.73
antipyrine,CC1=CC(=O)N(C2=CC=CC=C2)N1C,Norantipyrine,CC1=CC(=O)N(C2=CC=CC=C2)N1,CYP2C8; CYP2C19; CYP2C9; CYP1A2,N-dealkylation of hydrazine,0.71
antipyrine,CC1=CC(=O)N(C2=CC=CC=C2)N1C,3-OH-methylantipyrine,CN1C(CO)=CC(=O)N1C1=CC=CC=C1,CYP1A2 ; CYP2C9,Hydroxylation of carbon gamma to conjugated carbonyl,0.87
antipyrine,CC1=CC(=O)N(C2=CC=CC=C2)N1C,4-OH-antipyrine,CC1=C(O)C(=O)N(C2=CC=CC=C2)N1C,CYP3A4 (major); CYP1A2 (minor),Hydroxylation of carbon alpha to conjugated carbonyl,0.78
aprepitant,CC(OC1OCCN(CC2=NC(O)=NN2)C1C1=CC=C(F)C=C1)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1,"5‐oxo‐1,4‐dihydro‐1,2,4‐triazole‐3‐carbaldehyde",O=CC1=NNC(O)=N1,CYP3A4; CYP3A5; CYP1A2; CYP2C19,N-dealkylation of alicyclic tertiary amine,0.13
aprepitant,CC(OC1OCCN(CC2=NC(O)=NN2)C1C1=CC=C(F)C=C1)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1,"(2R,3S)‐2‐[(1R)‐1‐[3,5‐bis(trifluoromethyl)phenyl]ethoxy]‐3‐(4‐fluorophenyl)morpholine",CC(OC1OCCNC1C1=CC=C(F)C=C1)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1,CYP3A4; CYP3A5; CYP1A2; CYP2C19,N-dealkylation of alicyclic tertiary amine,0.74
aprepitant,CC(OC1OCCN(CC2=NC(O)=NN2)C1C1=CC=C(F)C=C1)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1,"1‐[3,5‐bis(trifluoromethyl)phenyl]ethanone",CC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1,CYP3A4; CYP3A5; CYP1A2; CYP2C19,O-dealkylation of dialkylether,0.21
aprepitant,CC(OC1OCCN(CC2=NC(O)=NN2)C1C1=CC=C(F)C=C1)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1,"5‐{[(2S,3S)‐3‐(4‐fluorophenyl)‐2‐hydroxymorpholin‐4‐yl]methyl}‐2,4‐dihydro‐1,2,4‐triazol‐3‐one",OC1=NNC(CN2CCOC(O)C2C2=CC=C(F)C=C2)=N1,CYP3A4; CYP3A5; CYP1A2; CYP2C19,O-dealkylation of dialkylether,0.75
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,5-HETE,CCCCCC=CCC=CCC=CC=CC(O)CCCC(=O)O,CYP1A1; CYP1A2; CYP2C8; CYP2C9,"Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene",0.51
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,7-HETE,CCCCCC=CCC=CCC=CC(O)C=CCCCC(=O)O,CYP1A2; CYP3A4,Bisallylic hydroxylation,0.74
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,10-HETE,CCCCCC=CCC=CC(O)C=CCC=CCCCC(=O)O,CYP1A2; CYP2C8; CYP3A4,Bisallylic hydroxylation,0.77
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,13-HETE,CCCCCC=CC(O)C=CCC=CCC=CCCCC(=O)O,CYP1A2; CYP2C8; CYP2C9; CYP3A4,Bisallylic hydroxylation,0.74
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,20-HETE,O=C(O)CCCC=CCC=CCC=CCC=CCCCCCO,CYP1A1; CYP1A2; CYP2A6,Hydroxylation of terminal methyl,0.96
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,19-HETE,CC(O)CCCC=CCC=CCC=CCC=CCCCC(=O)O,CYP1A1; CYP1A2; CYP2C8; CYP2C9; CYP2C19; CYP2E1,Hydroxylation of penultimate aliphatic secondary carbon,0.89
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,18-HETE,CCC(O)CCC=CCC=CCC=CCC=CCCCC(=O)O,CYP1A1; CYP1A2; CYP2E1,Hydroxylation of acyclic aliphatic secondary carbon,0.81
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,17-HETE,CCCC(O)CC=CCC=CCC=CCC=CCCCC(=O)O,CYP1A1; CYP1A2,Hydroxylation of acyclic aliphatic secondary carbon,0.75
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,16-HETE,CCCCC(O)C=CCC=CCC=CCC=CCCCC(=O)O,CYP1A1; CYP1A2,Allylic hydroxylation,0.72
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,"14,15-EET",CCCCCC1OC1CC=CCC=CCC=CCCCC(=O)O,CYP1A1; CYP1A2; CYP2B6 (minor); CYP2D6,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.47
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,"11,12-EET",CCCCCC=CCC1OC1CC=CCC=CCCCC(=O)O,CYP1A1; CYP1A2; CYP2B6 (minor); CYP2D6,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.53
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,"8,9-EET",CCCCCC=CCC=CCC1OC1CC=CCCCC(=O)O,CYP1A1; CYP1A2; CYP2B6 (minor); CYP2D6,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.53
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,"5,6-EET",CCCCCC=CCC=CCC=CCC1OC1CCCC(=O)O,CYP1A1; CYP1A2; CYP2B6 (minor); CYP2D6,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.38
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,15-HETE,CCCCCC(O)C=CC=CCC=CCC=CCCCC(=O)O,CYP1A1; CYP1A2; CYP2C8,"Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene",0.62
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,12-HETE,CCCCCC=CCC(O)C=CC=CCC=CCCCC(=O)O,CYP1A1; CYP1A2; CYP2C9,"Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene",0.62
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,11-HETE,CCCCCC=CC=CC(O)CC=CCC=CCCCC(=O)O,CYP1A1; CYP1A2; CYP2C8,"Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene",0.63
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,9-HETE,CCCCCC=CCC=CCC(O)C=CC=CCCCC(=O)O,CYP1A2; CYP2C8; CYP2C9,"Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene",0.63
arachidonic acid,CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,8-HETE,CCCCCC=CCC=CC=CC(O)CC=CCCCC(=O)O,CYP1A1; CYP1A2; CYP2C8; CYP2C9,"Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene",0.62
aripiprazole,OC1=NC2=CC(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=CC=C2CC1,dehydro-aripiprazole,OC1=CC=C2C=CC(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=CC2=N1,CYP3A4,"Dehydrogenation of alpha,beta-unsaturated amide",0.54
aripiprazole,OC1=NC2=CC(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=CC=C2CC1,4-Hydroxyaripiprazole,OC1=NC2=CC(OCCCCN3CCN(C4=CC=C(O)C(Cl)=C4Cl)CC3)=CC=C2CC1,CYP2D6,Hydroxylation of aromatic carbon ortho to halide group,0.94
aripiprazole,OC1=NC2=CC(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=CC=C2CC1,"2,3‐dichlorophenylpiperazine",ClC1=CC=CC(N2CCNCC2)=C1Cl,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.41
aripiprazole,OC1=NC2=CC(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=CC=C2CC1,"4‐[(2‐oxo‐3,4‐dihydro‐1H‐quinolin‐7‐yl)oxy]butanal",O=CCCCOC1=CC=C2CCC(O)=NC2=C1,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.66
arverapamil,COC1=CC=C(CCNCCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,"(2R)-5-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-(3-methoxyphenyl)-2-(propan-2-yl)pentanenitrile",COC1=CC=CC(C(C#N)(CCCNCCC2=CC=C(OC)C(OC)=C2)C(C)C)=C1,CYP2C8; CYP3A4; CYP2D6,O-aryl dealkylation adjacent to substituted carbon,0.99
arverapamil,COC1=CC=C(CCNCCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,(2R)-5-amino-2-(3-methoxyphenyl)-2-(propan-2-yl)pentanenitrile,COC1=CC=CC(C(C#N)(CCCN)C(C)C)=C1,CYP2C8; CYP3A4; CYP2D6,N-dealkylation of acyclic secondary amine,0.79
arverapamil,COC1=CC=C(CCNCCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,"2-(3,4-dimethoxyphenyl)acetaldehyde",COC1=CC=C(CC=O)C=C1OC,CYP2C8; CYP3A4; CYP2D6,N-dealkylation of acyclic secondary amine,0.41
astemizole,COC1=CC=C(CCN2CCC(N=C3NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)CC2)C=C1,6-Hydroxyastemizole,COC1=CC=C(CCN2CCC(N=C3NC4=CC=C(O)C=C4N3CC3=CC=C(F)C=C3)CC2)C=C1,CYP2D6; CYP3A4 (minor),Aromatic hydroxylation of fused benzene ring,0.93
astemizole,COC1=CC=C(CCN2CCC(N=C3NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)CC2)C=C1,6-desmethylastermizole,OC1=CC=C(CCN2CCC(N=C3NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)CC2)C=C1,CYP2D6,O-aryl dealkylation not adjacent to substituted carbon,0.98
astemizole,COC1=CC=C(CCN2CCC(N=C3NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)CC2)C=C1,norastemizole,FC1=CC=C(CN2C(=NC3CCNCC3)NC3=CC=CC=C32)C=C1,CYP3A4 (minor),N-dealkylation of alicyclic tertiary amine,0.85
astemizole,COC1=CC=C(CCN2CCC(N=C3NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)CC2)C=C1,2-(4-hydroxyphenyl)acetaldehyde,O=CCC1=CC=C(O)C=C1,CYP3A4 (minor),N-dealkylation of alicyclic tertiary amine,0.13
atorvastatin,CC(C)C1=C(C(O)=NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CCC(O)CC(O)CC(=O)O,,CC(C)C1=C(C(O)=NC2=CC=CC=C2O)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CCC(O)CC(O)CC(=O)O,CYP3A4,Aromatic Hydroxylation,0.99
atorvastatin,CC(C)C1=C(C(O)=NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CCC(O)CC(O)CC(=O)O,,CC(C)C1=C(C(=O)NC2=CC=C(O)C=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CCC(O)CC(O)CC(=O)O,CYP3A4,Aromatic Hydroxylation,0.78
barnidipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCN(CC3=CC=CC=C3)C2)C1C1=CC=CC([N+](=O)[O-])=C1,,COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCNC2)C1C1=CC=CC([N+](=O)[O-])=C1,CYP2A6;CYP2D6;CYP3A4,N-dealkylation,0.93
barnidipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCN(CC3=CC=CC=C3)C2)C1C1=CC=CC([N+](=O)[O-])=C1,,COC(=O)C1=C(C)NC(C)=C(C(=O)O)C1C1=CC=CC([N+](=O)[O-])=C1,CYP2A6;CYP2D6;CYP3A4,O-dealkylation,0.83
barnidipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCN(CC3=CC=CC=C3)C2)C1C1=CC=CC([N+](=O)[O-])=C1,,COC(=O)C1=C(C)N=C(C)C(C(=O)OC2CCN(CC3=CC=CC=C3)C2)=C1C1=CC=CC([N+](=O)[O-])=C1,CYP2A6;CYP2D6;CYP3A4,Dehydrogenation,0.45
"benzeneethanol, 2-[(2,6-dichlorophenyl)amino]- (reduced_diclofenac)",OCCC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,,OCCC1=CC(O)=CC=C1NC1=C(Cl)C=CC=C1Cl,CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4,Aromatic Hydroxylation,0.84
"benzo(a)pyrene-7,8-diol",OC1=CC=C2C(=C1O)C=C1C=CC3=CC=CC4=CC=C2C1=C34,,OC1=C(O)C2=C(O2)C2=C1C=C1C=CC3=CC=CC4=CC=C2C1=C34,CYP1A2,Epoxidation,0.36
bergapten,COC1=C2C=COC2=CC2=C1C=CC(=O)O2,,COC1=C2C(=CC3=C1C=CC(=O)O3)OC1OC21,CYP2D6,Epoxidation,0.44
beta_arteether,CCOC1OC2OC3(C)CCCC4C(C)CCC(C1C)C24OO3,DIHYDROQINGHAOSU,CC1CCC2C(C)C(O)OC3OC4(C)CCCC1C32OO4,CYP2B6;CYP3A4,O-dealkylation,0.99
beta-artelinic acid,CC1CCC2C(C)C(OCC3=CC=C(C(=O)O)C=C3)OC3OC4(C)CCC1C32OO4,Dihydroqinghaosu (DQHS),CC1CCC2C(C)C(O)OC3OC4(C)CCC1C32OO4,CYP3A4,O-Debenzylation,0.81
beta-methylstyrene,CC=CC1=CC=CC=C1,2-methyl-3-phenyloxirane,CC1OC1C1=CC=CC=C1,CYP1A2;CYP2E1;CYP3A4,Epoxidation,0.18
beta-methylstyrene,CC=CC1=CC=CC=C1,,OCC=CC1=CC=CC=C1,CYP1A2;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.83
biochanin a,COC1=CC=C(C2=COC3=CC(O)=CC(O)=C3C2=O)C=C1,,O=C1C(C2=CC=C(O)C=C2)=COC2=CC(O)=CC(O)=C12,CYP1A2;CYP2C9;CYP2C19; CYP2D6; CYP2E1,O-Demethylation,0.96
bms_275183,COC(=O)OC12COC1CC(O)C1(C)C(=O)C(OC(C)=O)C3=C(C)C(OC(=O)C(O)C(N=C(O)OC(C)(C)C)C(C)(C)C)CC(O)(C(OC(=O)C4=CC=CC=C4)C21)C3(C)C,,COC(=O)OC12COC1CC(O)C1(C)C(=O)C(OC(C)=O)C3=C(C)C(OC(=O)C(O)C(N=C(O)OC(C)(C)C)C(C)(C)CO)CC(O)(C(OC(=O)C4=CC=CC=C4)C21)C3(C)C,CYP3A4,Aliphatic Hydroxylation,0.99
bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(C2=NC=CC=N2)N=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1,"4-(2-hydroxy-1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2Ã¢â‚¬â„¢]bipyrimidinyl-4-yl]-benzenesulfonamide",COC1=CC=CC=C1OC1=C(OCCO)N=C(C2=NC=CC=N2)N=C1NS(=O)(=O)C1=CC=C(C(C)(C)CO)C=C1,CYP3A4 (major); CYP2C9 (minor),Hydroxylation of terminal methyl,0.98
bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(C2=NC=CC=N2)N=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1,"4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-[2,2Ã¢â‚¬â„¢]bipyrimidinyl-4-yl]-benzenesulfonamide",CC(C)(C)C1=CC=C(S(=O)(=O)NC2=NC(C3=NC=CC=N3)=NC(OCCO)=C2OC2=CC=CC=C2O)C=C1,CYP3A4 (major); CYP2C9 (minor),O-aryl demethylation,0.99
brn 4201400,CC1=NC2=C(N1)N(CC1CCCCC1)C(=O)N(C)C2=O,,CN1C(=O)C2=C(NC(CO)=N2)N(CC2CCCCC2)C1=O,CYP1A2,Aliphatic Hydroxylation,0.96
brofaromine,COC1=CC(Br)=C2OC(C3CCNCC3)=CC2=C1,O-desmethyl-brofaromine,OC1=CC(Br)=C2OC(C3CCNCC3)=CC2=C1,CYP2D6,O-aryl demethylation,0.95
bromocriptine,CC(C)CC1C(=O)N2CCCC2C2(O)OC(N=C(O)C3C=C4C5=CC=CC6=C5C(=C(Br)N6)CC4N(C)C3)(C(C)C)C(=O)N12,,CC(C)CC1C(=O)N2CC(O)CC2C2(O)OC(N=C(O)C3C=C4C5=CC=CC6=C5C(=C(Br)N6)CC4N(C)C3)(C(C)C)C(=O)N12,CYP3A4,Aliphatic Hydroxylation,0.99
bropirimine,N=C1N=C(O)C(Br)=C(C2=CC=CC=C2)N1,m-hydroxybropirimine,N=C1N=C(O)C(Br)=C(C2=CC=CC(O)=C2)N1,CYP1A2,m-Hydroxylation of monosubstituted benzene,0.88
bropirimine,N=C1N=C(O)C(Br)=C(C2=CC=CC=C2)N1,p-hydroxybropirimine,N=C1NC(C2=CC=C(O)C=C2)=C(Br)C(=O)N1,CYP1A2,p-Hydroxylation of monosubstituted benzene,0.61
brotizolam,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(SC(Br)=C3)N12,alpha-OH-BRT,OCC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(SC(Br)=C3)N12,CYP3A4,Aliphatic Hydroxylation,0.95
brotizolam,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(SC(Br)=C3)N12,6-OH-BRT,CC1=NN=C2C(O)N=C(C3=CC=CC=C3Cl)C3=C(SC(Br)=C3)N12,CYP3A4,Aliphatic Hydroxylation,0.91
caffeine,CN1C(=O)C2=C(N=CN2C)N(C)C1=O,Paraxanthine,CN1C(O)=NC2=C(C1=O)N(C)C=N2,CYP1A2,N-dealkylation of N-acylurea,0.62
caffeine,CN1C(=O)C2=C(N=CN2C)N(C)C1=O,Theobromine,CC1C(O)=NC(=O)C2=C1N=CN2C,CYP1A2 (major); CYP2E1 (minor),N-dealkylation of N-acylurea,0.27
caffeine,CN1C(=O)C2=C(N=CN2C)N(C)C1=O,Theophylline,CN1C(=O)C2=C(NC=N2)N(C)C1=O,CYP1A2 (major); CYP2C8 (minor); CYP2C9 (minor); CYP3A4 (minor); CYP2E1 (minor),N-dealkylation of mixed tertiary amine,0.91
caffeine,CN1C(=O)C2=C(N=CN2C)N(C)C1=O,"1,3,7-Trimethyluric acid",CN1C(=O)C2=C(N=C(O)N2C)N(C)C1=O,CYP1A2 (major); CYP2C8 (minor); CYP2C9 (minor); CYP3A4 (minor); CYP2E1 (minor),HYDROXYLATION_OF_AROMATIC_CARBON_ADJACENT_TO_N,0.85
carbamazepine,N=C(O)N1C2=CC=CC=C2C=CC2=CC=CC=C21," Carbamazepine 10,11-epoxide ",N=C(O)N1C2=CC=CC=C2C2OC2C2=CC=CC=C21,CYP3A4; CYP2C8 ,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.51
carbamazepine,N=C(O)N1C2=CC=CC=C2C=CC2=CC=CC=C21,2-Hydroxycarbamazepine ,N=C(O)N1C2=CC=CC=C2C=CC2=CC(O)=CC=C21,CYP3A4; CYP2C8,Aromatic hydroxylation of fused benzene ring,0.87
carbamazepine,N=C(O)N1C2=CC=CC=C2C=CC2=CC=CC=C21,3-Hydroxycarbamazepine ,N=C(O)N1C2=CC=CC=C2C=CC2=CC=C(O)C=C21,CYP3A4; CYP2C8 ,Aromatic hydroxylation of fused benzene ring,0.85
carbamazepine,N=C(O)N1C2=CC=CC=C2C=CC2=CC=CC=C21,9-Hydroxycarbamazepine ,N=C(O)N1C2=CC=CC=C2C=CC2=C(O)C=CC=C21,CYP3A4; CYP2C8 ,Aromatic hydroxylation of fused benzene ring,0.78
carbaryl,CN=C(O)OC1=CC=CC2=CC=CC=C12,4-hydroxycarbaryl,CN=C(O)OC1=CC=CC2=C(O)C=CC=C12,CYP1A2;CYP2B6;CYP2C19;CYP3A4,Aromatic Hydroxylation,0.91
carbaryl,CN=C(O)OC1=CC=CC2=CC=CC=C12,5-hydroxycarbaryl,CN=C(O)OC1=CC=C(O)C2=CC=CC=C12,CYP1A2;CYP2B6;CYP2C19;CYP3A4,Aromatic Hydroxylation,0.92
carbaryl,CN=C(O)OC1=CC=CC2=CC=CC=C12,carbaryl methylol,OCN=C(O)OC1=CC=CC2=CC=CC=C12,CYP1A2;CYP2B6;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.93
Carbofuran,CN=C(O)OC1=CC=CC2=C1OC(C)(C)C2,e-hydroxy-carbofuran,CN=C(O)OC1=CC=CC2=C1OC(C)(C)C2O,CYP1A2; CYP2C19; CYP3A4,Hydroxylation of alicyclic secondary carbon,0.79
celecoxib,CC1=CC=C(C2=CC(C(F)(F)F)=NN2C2=CC=C(S(N)(=O)=O)C=C2)C=C1,Hydroxy celecoxib,NS(=O)(=O)C1=CC=C(N2N=C(C(F)(F)F)C=C2C2=CC=C(CO)C=C2)C=C1,CYP2C9 (major); CYP3A4 (minor); CYP2C19 (minor),Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.98
cerivastatin,COCC1=C(C(C)C)N=C(C(C)C)C(C=CC(O)CC(O)CC(=O)O)=C1C1=CC=C(F)C=C1,,CC(C)C1=NC(C(C)C)=C(CO)C(C2=CC=C(F)C=C2)=C1C=CC(O)CC(O)CC(=O)O,CYP2C8;CYP3A4,O-Demethylation ,0.96
cerivastatin,COCC1=C(C(C)C)N=C(C(C)C)C(C=CC(O)CC(O)CC(=O)O)=C1C1=CC=C(F)C=C1,,COCC1=C(C(C)CO)N=C(C(C)C)C(C=CC(O)CC(O)CC(=O)O)=C1C1=CC=C(F)C=C1,CYP2C8,Aliphatic Hydroxylation,0.95
cevimeline,CC1OC2(CS1)CN1CCC2CC1,,CC1OC2(CN3CCC2CC3)CS1=O,CYP2C19;CYP2D6;CYP3A4;CYP1A2;CYP2A6;CYP2E1,S-Oxidation,0.82
(R)-colchicine,COC1=CC2=C(C3=CC=C(OC)C(=O)C=C3C(N=C(C)O)CC2)C(OC)=C1OC,2-demethyicolchicine,COC1=CC2=C(C3=CC=C(OC)C(=O)C=C3C(N=C(C)O)CC2)C(OC)=C1O,CYP3A4,O-demethylation ,0.99
(R)-colchicine,COC1=CC2=C(C3=CC=C(OC)C(=O)C=C3C(N=C(C)O)CC2)C(OC)=C1OC,Colchiceine,COC1=CC2=C(C3=CC=C(O)C(=O)C=C3C(N=C(C)O)CC2)C(OC)=C1OC,CYP3A4,O-demethylation ,0.99
{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine,CSC1=NC(C2=CC=C(F)C=C2)=C(C2=CC=NC(NC(C)C3=CC=CC=C3)=C2)N1,,CC(NC1=CC(C2=C(C3=CC=C(F)C=C3)N=C(S(C)(=O)=O)N2)=CC=N1)C1=CC=CC=C1,CYP1A2;CYP2C19;CYP2D6;CYP3A4,S-OXIDATION,0.92
{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine,CSC1=NC(C2=CC=C(F)C=C2)=C(C2=CC=NC(NC(C)C3=CC=CC=C3)=C2)N1,,CS(=O)C1=NC(C2=CC=C(F)C=C2)=C(C2=CC(=N)NC=C2)N1,CYP3A4,N-dealkylation,0.57
{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine,CSC1=NC(C2=CC=C(F)C=C2)=C(C2=CC=NC(NC(C)C3=CC=CC=C3)=C2)N1,,CC(NC1=CC(C2=C(C3=CC=C(F)C=C3)N=C(S(C)=O)N2)=CC=[N+]1O)C1=CC=CC=C1,CYP3A4,N-oxidation,0.86
reduced_haloperidol,OC(CCCN1CCC(O)(C2=CC=C(Cl)C=C2)CC1)C1=CC=C(F)C=C1,CPHP,OC1(C2=CC=C(Cl)C=C2)CCNCC1,CYP3A4,N-Demethylation,0.72
reduced_haloperidol,OC(CCCN1CCC(O)(C2=CC=C(Cl)C=C2)CC1)C1=CC=C(F)C=C1,haloperidol,O=C(CCCN1CCC(O)(C2=CC=C(Cl)C=C2)CC1)C1=CC=C(F)C=C1,CYP3A4,Dehydrogenation,0.84
DRF_4367,COC1=CC=C(C2=CC(C(F)(F)F)=NN2C2=CC=C(S(N)(=O)=O)C(CO)=C2)C=C1,,NS(=O)(=O)C1=CC=C(N2N=C(C(F)(F)F)C=C2C2=CC=C(O)C=C2)C=C1CO,CYP2C19;CYP2D6,O-demethylation,0.99
benzodioxolyl-butanamine (BDB),CCC(N)CC1=CC=C2OCOC2=C1,DHABB,CCC(N)CC1=CC=C(O)C(O)=C1,CYP2C19;CYP2D6;CYP3A4,O-demethylenation,0.69
itraconazole,CCC(C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OCC5COC(CN6C=NC=N6)(C6=CC=C(Cl)C=C6Cl)O5)C=C4)CC3)C=C2)C1=O,Hydroxy-iteraconazole,CC(O)C(C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OCC5COC(CN6C=NC=N6)(C6=CC=C(Cl)C=C6Cl)O5)C=C4)CC3)C=C2)C1=O,CYP3A4,Aliphatic Hydroxylation,0.98
itraconazole,CCC(C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OCC5COC(CN6C=NC=N6)(C6=CC=C(Cl)C=C6Cl)O5)C=C4)CC3)C=C2)C1=O,keto-iteraconazole ,CC(=O)C(C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OCC5COC(CN6C=NC=N6)(C6=CC=C(Cl)C=C6Cl)O5)C=C4)CC3)C=C2)C1=O,CYP3A4,C-Oxidation,0.97
itraconazole,CCC(C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OCC5COC(CN6C=NC=N6)(C6=CC=C(Cl)C=C6Cl)O5)C=C4)CC3)C=C2)C1=O,N-Desalkyl-iteraconazole,OC1=NN=CN1C1=CC=C(N2CCN(C3=CC=C(OCC4COC(CN5C=NC=N5)(C5=CC=C(Cl)C=C5Cl)O4)C=C3)CC2)C=C1,CYP3A4,N-Desalkylation,0.85
Mequitazine,C1=CC=C2C(=C1)SC1=CC=CC=C1N2CC12CCN(CC1)CC2,,OC1=CC=C2C(=C1)SC1=CC=CC=C1N2CC12CCN(CC1)CC2,CYP2D6,Aromatic Hydroxylation,0.89
Mequitazine,C1=CC=C2C(=C1)SC1=CC=CC=C1N2CC12CCN(CC1)CC2,,O=S1C2=CC=CC=C2N(CC23CCN(CC2)CC3)C2=CC=CC=C21,CYP2D6,S-Oxidation,0.85
NE-100,CCCN(CCC)CCC1=CC=C(OC)C(OCCC2=CC=CC=C2)=C1,,CCCN(CCC)CCC1=CC=C(OC)C(OCCC2=CC=CC(O)=C2)=C1,CYP2D6;CYP3A4,Aromatic Hydroxylation,0.98
NE-100,CCCN(CCC)CCC1=CC=C(OC)C(OCCC2=CC=CC=C2)=C1,,CCCNCCC1=CC=C(OC)C(OCCC2=CC=CC=C2)=C1,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4,N-DEMETHYLATION,0.93
NE-100,CCCN(CCC)CCC1=CC=C(OC)C(OCCC2=CC=CC=C2)=C1,,CCCN(CCC)CCC1=CC=C(O)C(OCCC2=CC=CC=C2)=C1,CYP2C9;CYP2C19;CYP2D6,O-DEMETHYLATION,0.96
(R)-m-Methoxyamphetamine,COC1=CC=CC(CC(C)N)=C1,,CC(N)CC1=CC=CC(O)=C1,CYP2D6,O-DEMETHYLATION,0.8
(R)-m-Methoxyamphetamine,COC1=CC=CC(CC(C)N)=C1,,COC1=CC(CC(C)N)=CC=C1O,CYP2D6,Aromatic Hydroxylation,0.8
(R)-phenprocoumon,CCC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,,CCC(C1=CC=C(O)C=C1)C1=C(O)C2=CC=CC=C2OC1=O,CYP2C8;CYP2C9;CYP2C19;CYP3A4,Aromatic Hydroxylation,0.98
(R)-phenprocoumon,CCC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,,CCC(C1=CC=CC=C1)C1=C(O)C2=CC(O)=CC=C2OC1=O,CYP2C9;CYP2C19;CYP3A4,Aromatic Hydroxylation,0.96
(R)-phenprocoumon,CCC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,,CCC(C1=CC=CC=C1)C1=C(O)C2=CC=C(O)C=C2OC1=O,CYP2C9;CYP2C19;CYP3A4,Aromatic Hydroxylation,0.98
pantoprazole,COC1=CC=NC(CS(=O)C2=NC3=CC=C(OC(F)F)C=C3N2)=C1OC,,COC1=C(OCO)C=CN=C1CS(=O)C1=NC2=CC=C(OC(F)F)C=C2N1,CYP2C19,Aliphatic Hydroxylation,0.98
"2Ã¢â‚¬Â[(S)Ã¢â‚¬Â[4Ã¢â‚¬Â(cyclopropylmethoxy)pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl]methanesulfinyl]Ã¢â‚¬Â5Ã¢â‚¬ÂfluoroÃ¢â‚¬Â1HÃ¢â‚¬Â1,3Ã¢â‚¬Âbenzodiazole",O=S(CC1=CC(OCC2CC2)=CC=N1)C1=NC2=CC=C(F)C=C2N1,Sulphone,O=S(=O)(CC1=CC(OCC2CC2)=CC=N1)C1=NC2=CC=C(F)C=C2N1,CYP1A2;CYP2C9;CYP3A4,S-Oxidation,0.93
"2Ã¢â‚¬Â[(S)Ã¢â‚¬Â[4Ã¢â‚¬Â(cyclopropylmethoxy)pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl]methanesulfinyl]Ã¢â‚¬Â5Ã¢â‚¬ÂfluoroÃ¢â‚¬Â1HÃ¢â‚¬Â1,3Ã¢â‚¬Âbenzodiazole",O=S(CC1=CC(OCC2CC2)=CC=N1)C1=NC2=CC=C(F)C=C2N1,,O=S(CC1=CC(OCC2CC2)=CC=N1)C1=NC2=CC(O)=C(F)C=C2N1,CYP1A2;CYP2C9;CYP2C19;CYP3A4,Aromatic Hydroxylation,0.9
"2Ã¢â‚¬Â[(S)Ã¢â‚¬Â[4Ã¢â‚¬Â(cyclopropylmethoxy)pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl]methanesulfinyl]Ã¢â‚¬Â5Ã¢â‚¬ÂfluoroÃ¢â‚¬Â1HÃ¢â‚¬Â1,3Ã¢â‚¬Âbenzodiazole",O=S(CC1=CC(OCC2CC2)=CC=N1)C1=NC2=CC=C(F)C=C2N1,Pyridone,O=C1C=CNC(CSC2=NC3=CC(O)=C(F)C=C3N2)=C1,CYP1A2;CYP2C9;CYP2C19;CYP3A4,O-dealkylation,0.61
"(2S,3R)-3-(4-Hydroxy-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-2,3-dihydro-benzo[1,4]oxathiin-6-ol",OC1=CC=C(C2SC3=CC(O)=CC=C3OC2C2=CC=C(OCCN3CCCCC3)C=C2)C=C1,,O=S1C2=CC(O)=CC=C2OC(C2=CC=C(OCCN3CCCCC3)C=C2)C1C1=CC=C(O)C=C1,CYP3A4,S-Oxidation,0.84
"(2S,3R)-3-(4-Hydroxy-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-2,3-dihydro-benzo[1,4]oxathiin-6-ol",OC1=CC=C(C2SC3=CC(O)=CC=C3OC2C2=CC=C(OCCN3CCCCC3)C=C2)C=C1,,CCCCCNCCOC1=CC=C(C2OC3=CC=C(O)C=C3SC2C2=CC=C(O)C=C2)C=C1,CYP3A4,S-Dealkylation,0.98
PNU-96391,CCCN1CCCC(C2=CC=CC(S(C)(=O)=O)=C2)C1,,CS(=O)(=O)C1=CC=CC(C2CCCNC2)=C1,CYP1A2;CYP2C19;CYP2D6;CYP3A4,N-dealkylation,0.9
4Ã¢â‚¬Â[(dimethylamino)methyl]Ã¢â‚¬Â7Ã¢â‚¬ÂmethoxychromenÃ¢â‚¬Â2Ã¢â‚¬Âone,COC1=CC=C2C(CN(C)C)=CC(=O)OC2=C1,,CNCC1=CC(=O)OC2=CC(OC)=CC=C12,CYP1A2,N-dealkylation,0.98
4Ã¢â‚¬Â[(dimethylamino)methyl]Ã¢â‚¬Â7Ã¢â‚¬ÂmethoxychromenÃ¢â‚¬Â2Ã¢â‚¬Âone,COC1=CC=C2C(CN(C)C)=CC(=O)OC2=C1,,CN(C)CC1=CC(=O)OC2=CC(O)=CC=C12,CYP1A2;CYP2C19;CYP2D6,N-dealkylation,0.93
bpr-0L075,COC1=CC=C2C(C(=O)C3=CC(OC)=C(OC)C(OC)=C3)=CNC2=C1,,COC1=CC(C(=O)C2=CNC3=CC(O)=CC=C23)=CC(O)=C1OC,CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,O-Demethylation,0.98
bpr-0L075,COC1=CC=C2C(C(=O)C3=CC(OC)=C(OC)C(OC)=C3)=CNC2=C1,,COC1=CC(C(=O)C2=CNC3=CC(O)=CC=C23)=CC(O)=C1OC,CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,O-Demethylation,0.98
bpr-0L075,COC1=CC=C2C(C(=O)C3=CC(OC)=C(OC)C(OC)=C3)=CNC2=C1,,COC1=CC=C2C(C(=O)C3=CC(OC)=C(O)C(OC)=C3)=CNC2=C1,CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,O-Demethylation,0.98
bpr-0L075,COC1=CC=C2C(C(=O)C3=CC(OC)=C(OC)C(OC)=C3)=CNC2=C1,,COC1=CC(C(=O)C2=CNC3=CC(O)=CC=C23)=CC(OC)=C1OC,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,O-Demethylation,0.98
"(6-methoxy-1H-indol-3-yl)-(3,4,5-trimethoxyphenyl)methanone",COC1=CC=C2C(C(=O)C3=CC(OC)=C(OC)C(OC)=C3)=CNC2=C1,,COC1=CC(C(=O)C2=CNC3=C(O)C(OC)=CC=C23)=CC(OC)=C1OC,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.9
"(6-methoxy-1H-indol-3-yl)-(3,4,5-trimethoxyphenyl)methanone",COC1=CC=C2C(C(=O)C3=CC(OC)=C(OC)C(OC)=C3)=CNC2=C1,,COC1=CC2=C(C=C1O)C(C(=O)C1=CC(OC)=C(OC)C(OC)=C1)=CN2,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.95
KR-33028,N#CC1=CC=CC2=C1C=C(C(=O)NC(=N)N)S2,5-hydroxy-KR-33028,N#CC1=C(O)C=CC2=C1C=C(C(=O)NC(=N)N)S2,CYP3A4,Aromatic Hydroxylation,0.87
KR-33028,N#CC1=CC=CC2=C1C=C(C(=O)NC(=N)N)S2,7-hydroxy-KR-33028,N#CC1=CC=C(O)C2=C1C=C(C(=O)NC(=N)N)S2,CYP3A4;CYP1A2,Aromatic Hydroxylation,0.84
CTK0G1203,CC(NC(=NC#N)N=C1C=CNC=C1)C(C)(C)C,,CC(NC(=NC#N)NC1=CC=[N+]([O-])C=C1)C(C)(C)C,CYP3A4,N-Oxidation,0.39
CTK0G1203,CC(NC(=NC#N)N=C1C=CNC=C1)C(C)(C)C,,CC(N=C(N=C1C=CNC=C1)NC(=N)O)C(C)(C)C,CYP3A4,C-Oxidation,0.52
N-(1-Phenyl-1H-pyrazole-5-yl)-p-toluenesulfonamide,CC1=CC=C(S(=O)(=O)NC2=CC=NN2C2=CC=CC=C2)C=C1,,O=S(=O)(NC1=CC=NN1C1=CC=CC=C1)C1=CC=C(CO)C=C1,CYP2C8;CYP2C9;CYP2C19,Aliphatic Hydroxylation,0.97
N-(1-Phenyl-1H-pyrazole-5-yl)-p-toluenesulfonamide,CC1=CC=C(S(=O)(=O)NC2=CC=NN2C2=CC=CC=C2)C=C1,,CC1=CC=C(S(=O)(=O)NC2=CC=NN2C2=CC=C(O)C=C2)C=C1,CYP2C8;CYP2C19,Aliphatic Hydroxylation,0.95
terfenadine,CC(C)(C)C1=CC=C(C(O)CCCN2CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1,hydroxyterfenadine,CC(C)(CO)C1=CC=C(C(O)CCCN2CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1,CYP2D6;CYP3A4,Aliphatic Hydroxylation,0.93
terfenadine,CC(C)(C)C1=CC=C(C(O)CCCN2CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1,azacyclonol,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C1CCNCC1,CYP3A4,N-Dealkylation,0.86
2prime_hydroxy_indomethacin_phenethylamide,COC1=CC=C2C(=C1)C(CC(O)=NCC(O)C1=CC=CC=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,,CC1=C(CC(O)=NCC(O)C2=CC=CC=C2)C2=CC(O)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1,CYP2C19;CYP2D6,O-Demethylation,0.98
2prime_hydroxy_indomethacin_phenethylamide,COC1=CC=C2C(=C1)C(CC(O)=NCC(O)C1=CC=CC=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,,COC1=CC=C2C(=C1)C(CC(O)=NCC(=O)C1=CC=CC=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,CYP3A4,Dehydrogenation,0.95
"(2S)-1-(1,3-Benzodioxol-5-yl)-N-methyl-2-butanamine",CCC(CC1=CC=C2OCOC2=C1)NC,,CCC(N)CC1=CC=C2OCOC2=C1,CYP1A2;CYP2B6;CYP2C19;CYP2D6;CYP3A4,N-Demethylation,0.94
"(2S)-1-(1,3-Benzodioxol-5-yl)-N-methyl-2-butanamine",CCC(CC1=CC=C2OCOC2=C1)NC,,CCC(CC1=CC=C(O)C(O)=C1)NC,CYP1A2;CYP2B6;CYP2C19;CYP2D6;CYP3A4,O-Demethylation,0.71
Seratrodast,CC1=C(C)C(=O)C(C(CCCCCC(=O)O)C2=CC=CC=C2)=C(C)C1=O,5-OH-seratrodast,CC1=C(CO)C(=O)C(C)=C(C(CCCCCC(=O)O)C2=CC=CC=C2)C1=O,CYP2C19; CYP2C9; CYP2C8; CYP3A4; CYP2B6,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.91
Seratrodast,CC1=C(C)C(=O)C(C(CCCCCC(=O)O)C2=CC=CC=C2)=C(C)C1=O,4'-OH-seratrodast,CC1=C(C)C(=O)C(C(CCCCCC(=O)O)C2=CC=C(O)C=C2)=C(C)C1=O,CYP2C19; CYP2C9; CYP2C8,p-Hydroxylation of monosubstituted benzene,0.95
chlorpromazine,CN(C)CCCN1C2=CC=CC=C2SC2=CC=C(Cl)C=C21,7-Hydroxychlorpromazine,CN(C)CCCN1C2=CC=C(O)C=C2SC2=CC=C(Cl)C=C21,CYP2D6; CYP1A2,Aromatic hydroxylation of fused benzene ring,0.89
chlorpromazine,CN(C)CCCN1C2=CC=CC=C2SC2=CC=C(Cl)C=C21,Chlorpromazine S-oxide,CN(C)CCCN1C2=CC=CC=C2S(=O)C2=CC=C(Cl)C=C21,CYP3A4,S-oxidation of diarylthioether to sulfoxide,0.84
chlorpromazine,CN(C)CCCN1C2=CC=CC=C2SC2=CC=C(Cl)C=C21,"Chlorpromazine, N-desmethyl",CNCCCN1C2=CC=CC=C2SC2=CC=C(Cl)C=C21,CYP1A2,N-dealkylation of acyclic tertiary amine,0.99
chlorpropamide,CCCN=C(O)NS(=O)(=O)C1=CC=C(Cl)C=C1,2-OH-chlorpropamide,CCCN=C(O)NS(=O)(=O)C1=CC=C(Cl)C=C1O,CYP2C9 (major); CYP2C19 (minor); CYP2C8 (minor); CYP1A2 (minor); CYP3A4 (minor),Hydroxylation of benzene on carbon ortho to an electron donating group,0.72
chlorpropamide,CCCN=C(O)NS(=O)(=O)C1=CC=C(Cl)C=C1,3-OH-chlorpropamide,CCCN=C(O)NS(=O)(=O)C1=CC=C(Cl)C(O)=C1,CYP2D6,Hydroxylation of aromatic carbon ortho to halide group,0.77
chlorpropamide,CCCN=C(O)NS(=O)(=O)C1=CC=C(Cl)C=C1,p-Chlorobenzene sulfonylurea,N=C(O)NS(=O)(=O)C1=CC=C(Cl)C=C1,CYP2D6,N-dealkylation of urea,0.81
Chlorpyrifos,CCOP(=S)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl,"3,5,6-Trichloro-2-pyridinol",OC1=NC(Cl)=C(Cl)C=C1Cl,CYP2C19; CYP2B6; CYP3A4,Dearylation of organphosphosulfur compound,0.47
Chlorpyrifos,CCOP(=S)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl,Diethyl phosphorothioate,CCOP(=O)(O)OCC,CYP2C19; CYP2B6; CYP3A4,Dearylation of organphosphosulfur compound,0.07
Chlorpyrifos,CCOP(=S)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl,Chlorpyrifos-oxon,CCOP(=O)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl,CYP1A2; CYP2B6; CYP2C8; CYP2C9; CYP2C19; CYP2D6; CYP3A4,Desulfuration of organophosphothioates,0.71
chlorzoxazone,OC1=NC2=CC(Cl)=CC=C2O1,6-Hydroxychlorzoxazone,OC1=NC2=CC(Cl)=C(O)C=C2O1,CYP2E1; CYP1A2; CYP1A1; CYP2A6; CYP2D6; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.77
cilostazol,O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C2N1,OPC-13326,OC1=NC2=CC=C(OCCCCC3=NN=NN3C3CCCCC3)C=C2C(O)C1,CYP1A2;CYP2D6;CYP3A4,Aliphatic Hydroxylation,0.67
cilostazol,O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C2N1,OPC-13217,O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCC(O)CC3)=CC=C2N1,CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.96
cinnarizine,C(=CC1=CC=CC=C1)CN1CCN(C(C2=CC=CC=C2)C2=CC=CC=C2)CC1,4-{phenyl[4-(3-phenylprop-2-en-1-yl)piperazin-1-yl]methyl}phenol,OC1=CC=C(C(C2=CC=CC=C2)N2CCN(CC=CC3=CC=CC=C3)CC2)C=C1,CYP2B6,p-Hydroxylation of monosubstituted benzene,0.89
cinnarizine,C(=CC1=CC=CC=C1)CN1CCN(C(C2=CC=CC=C2)C2=CC=CC=C2)CC1,4-{3-[4-(diphenylmethyl)piperazin-1-yl]prop-1-en-1-yl}phenol,OC1=CC=C(C=CCN2CCN(C(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1,CYP2D6,p-Hydroxylation of monosubstituted benzene,0.9
cinnarizine,C(=CC1=CC=CC=C1)CN1CCN(C(C2=CC=CC=C2)C2=CC=CC=C2)CC1,1-Benzhydrylpiperazine,C1=CC=C(C(C2=CC=CC=C2)N2CCNCC2)C=C1,CYP2C9; CYP1A2; CYP2A6,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1,0.76
cinnarizine,C(=CC1=CC=CC=C1)CN1CCN(C(C2=CC=CC=C2)C2=CC=CC=C2)CC1,Cinnamaldehyde,O=CC=CC1=CC=CC=C1,CYP2C9; CYP1A2; CYP2A6,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1,0.22
cinnarizine,C(=CC1=CC=CC=C1)CN1CCN(C(C2=CC=CC=C2)C2=CC=CC=C2)CC1,Benzophenone,O=C(C1=CC=CC=C1)C1=CC=CC=C1,CYP2C9; CYP1A2; CYP2A6,OXIDATIVE_DEAMINATION_OF_TERTIARY_AMINES; N_DEALKYLATION_OF_ALICYCLIC_TERTIARY_AMINES_PATTERN1,0.21
cinnarizine,C(=CC1=CC=CC=C1)CN1CCN(C(C2=CC=CC=C2)C2=CC=CC=C2)CC1,1-Cinnamylpiperazine,C(=CC1=CC=CC=C1)CN1CCNCC1,CYP2C9; CYP1A2; CYP2A6,OXIDATIVE_DEAMINATION_OF_TERTIARY_AMINES; N_DEALKYLATION_OF_ALICYCLIC_TERTIARY_AMINES_PATTERN1,0.45
cisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(F)C=C2)CC1OC,Norcisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCNCC1OC,CYP3A4; CYP2C8; CYP2B6,N-dealkylation of alicyclic tertiary amine,0.9
cisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(F)C=C2)CC1OC,3-(4-fluorophenoxy)propanal,O=CCCOC1=CC=C(F)C=C1,CYP3A4; CYP2C8; CYP2B6,N-dealkylation of alicyclic tertiary amine,0.17
cisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(F)C=C2)CC1OC,3-Fluoro-4-hydroxycisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(O)C(F)=C2)CC1OC,CYP2C8,Hydroxylation of benzene on carbon para to an electron donating group,0.94
cisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(F)C=C2)CC1OC,4-Fluoro-2- hydroxycisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(F)C=C2O)CC1OC,CYP3A4,Hydroxylation of benzene on carbon ortho to an electron donating group,0.95
(+-)-Cisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(F)C=C2)CC1OC,Norcisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCNCC1OC,CYP3A4; CYP2C8; CYP2B6 ,N-dealkylation of mixed tertiary amine,0.9
(+-)-Cisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(F)C=C2)CC1OC,3-Fluoro-4-hydroxycisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(O)C(F)=C2)CC1OC,CYP2C8,HYDROXYLATION_OF_AROMATIC_CARBON,0.94
(+-)-Cisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(F)C=C2)CC1OC,4-Fluoro-2-hydroxycisapride,COC1=CC(N)=C(Cl)C=C1C(O)=NC1CCN(CCCOC2=CC=C(F)C=C2O)CC1OC,CYP3A4,"2-Hydroxylation of 1,4-disubstituted benzene",0.95
"(2R,3S)â€2â€(diphenylmethyl)â€Nâ€{[2â€methoxyâ€5â€(propâ€1â€enâ€2â€yl)phenyl]methyl}â€1â€azabicyclo[2.2.2]octanâ€3â€amine",C=C(C)C1=CC=C(OC)C(CNC2C3CCN(CC3)C2C(C2=CC=CC=C2)C2=CC=CC=C2)=C1,"CP-611,781",COC1=CC=C(C(C)CO)C=C1CNC1C2CCN(CC2)C1C(C1=CC=CC=C1)C1=CC=CC=C1,CYP2D6;CYP3A4,Aliphatic Hydroxylation,0.92
"(2R,3S)â€2â€(diphenylmethyl)â€Nâ€{[2â€methoxyâ€5â€(propâ€1â€enâ€2â€yl)phenyl]methyl}â€1â€azabicyclo[2.2.2]octanâ€3â€amine",C=C(C)C1=CC=C(OC)C(CNC2C3CCN(CC3)C2C(C2=CC=CC=C2)C2=CC=CC=C2)=C1,"CP-616,762",COC1=CC=C(C(C)(O)CO)C=C1CNC1C2CCN(CC2)C1C(C1=CC=CC=C1)C1=CC=CC=C1,CYP2D6;CYP3A4,Aliphatic Hydroxylation,0.86
clarithromycin,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C(O)C1(C)O,N-desmethyl-CLAR,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(NC)C2O)C(C)(OC)CC(C)C(=O)C(C)C(O)C1(C)O,CYP3A4,N-demethylation,0.97
clindamycin,CCCC1CC(C(O)=NC(C(C)Cl)C2OC(SC)C(O)C(O)C2O)N(C)C1,N-desmethyclindamycin,CCCC1CNC(C(O)=NC(C(C)Cl)C2OC(SC)C(O)C(O)C2O)C1,CYP3A4,N-Dealkylation,0.97
clindamycin,CCCC1CC(C(O)=NC(C(C)Cl)C2OC(SC)C(O)C(O)C2O)N(C)C1,clindamycin sulfoxide,CCCC1CC(C(O)=NC(C(C)Cl)C2OC(S(C)=O)C(O)C(O)C2O)N(C)C1,CYP3A4,S-Oxidation,0.94
clobazam,CN1C(=O)CC(=O)N(C2=CC=CC=C2)C2=CC(Cl)=CC=C21,N-desmethylclobazam,O=C1CC(O)=NC2=CC=C(Cl)C=C2N1C1=CC=CC=C1,CYP2C9;CYP2C19,N-desmethylation,0.58
clobazam,CN1C(=O)CC(=O)N(C2=CC=CC=C2)C2=CC(Cl)=CC=C21,4-Hydroxyclobazam,CN1C(=O)CC(=O)N(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP3A4,Aromatic Hydroxylation,0.95
clomethiazole,CC1=C(CCCl)SC=N1,NLA-715,CC1=C(C(O)CCl)SC=N1,CYP2A6,Aliphatic Hydroxylation,0.64
clomipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C21,2-OH-clomipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC(O)=C(Cl)C=C21,CYP2D6,Aromatic hydroxylation of fused benzene ring,0.85
clomipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C21,8-OH-clomipramine,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C(O)C=CC=C21,CYP2D6,Aromatic hydroxylation of fused benzene ring,0.81
clomipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C21,N-Desmethylclomipramine,CNCCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C21,CYP2C19; CYP3A4; CYP1A2,N-dealkylation of acyclic tertiary amine,0.99
clomipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C21,10-OH-clomipramine,CN(C)CCCN1C2=CC(Cl)=CC=C2CC(O)C2=CC=CC=C21,CYP2D6,Hydroxylation of heteroalicyclic secondary carbon,0.79
clotiazepam,CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl,Hydroxy-clotiazepam,CC(O)C1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl,CYP2B6;CYP3A4;CYP2C18;CYP2C19,Aliphatic Hydroxylation,0.94
clotiazepam,CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl,desmethyl-clotiazepam,CCC1=CC2=C(N=C(O)CN=C2C2=CC=CC=C2Cl)S1,CYP2B6;CYP3A4;CYP2C18;CYP2C19,N-desmethylation,0.65
clozapine,CN1CCN(C2=NC3=CC(Cl)=CC=C3NC3=CC=CC=C23)CC1,Clozapine-N-oxide,C[N+]1([O-])CCN(C2=NC3=CC(Cl)=CC=C3NC3=CC=CC=C23)CC1,CYP3A4; CYP1A2; CYP2C8; CYP2C19; CYP3A5,N-oxidation of alicyclic tertiary amine,0.95
codeine,COC1=CC=C2CC3C4C=CC(O)C5OC1=C2C45CCN3C,morphine,CN1CCC23C4=C5C=CC(O)=C4OC2C(O)C=CC3C1C5,CYP2D6,O-aryl demethylation,0.99
codeine,COC1=CC=C2CC3C4C=CC(O)C5OC1=C2C45CCN3C,norcodeine,COC1=CC=C2CC3NCCC45C2=C1OC4C(O)C=CC35,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.98
compound_1,O=S(=O)(NC1=CC=C(CCNCC(O)C2=CC=CN=C2)C=C1)C1=CC=C(C2=NC(C3=CC=C(C(F)(F)F)C=C3)=CC2)C=C1,M2,O=S(=O)(NC1=CC=C(CCNCC(O)C2=CC=C[N+]([O-])=C2)C=C1)C1=CC=C(C2=NC(C3=CC=C(C(F)(F)F)C=C3)=CC2)C=C1,CYP3A4,N-Oxidation,0.95
compound_1,O=S(=O)(NC1=CC=C(CCNCC(O)C2=CC=CN=C2)C=C1)C1=CC=C(C2=NC(C3=CC=C(C(F)(F)F)C=C3)=CC2)C=C1,M4,NCCC1=CC=C(NS(=O)(=O)C2=CC=C(C3=NC(C4=CC=C(C(F)(F)F)C=C4)=CC3)C=C2)C=C1,CYP3A4,N-Dealkylation,0.86
cotinine,CN1C(=O)CCC1C1=CC=CN=C1,trans-3'-hydroxycotinine,CN1C(=O)C(O)CC1C1=CC=CN=C1,CYP2A6,Hydroxylation of heteroalicyclic secondary carbon,0.8
cotinine,CN1C(=O)CCC1C1=CC=CN=C1,Norcotinine,OC1=NC(C2=CC=CN=C2)CC1,CYP2A6,N-dealkylation of tertiary carboxamide,0.4
cotinine,CN1C(=O)CCC1C1=CC=CN=C1,5'-hydroxycotinine,CN1C(=O)CCC1(O)C1=CC=CN=C1,CYP2A6,Hydroxylation of  carbon next to amide,0.69
coumarin,O=C1C=CC2=CC=CC=C2O1,7-Hydroxycoumarin,O=C1C=CC2=CC=C(O)C=C2O1,CYP2A6; CYP2B6; CYP1A1; CYP1A2,7-Hydroxylation of coumarin,0.73
coumarin,O=C1C=CC2=CC=CC=C2O1,3-Hydroxycoumarin,O=C1OC2=CC=CC=C2C=C1O,CYP3A4,7-Hydroxylation of coumarin,0.65
coumarin,O=C1C=CC2=CC=CC=C2O1,"Coumarin 3,4-epoxide",O=C1OC2=CC=CC=C2C2OC12,CYP1A1; CYP1A2; CYP2E1,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.13
cp_122_721,COC1=CC=C(OC(F)(F)F)C=C1CNC1CCCNC1C1=CC=CC=C1,,OC1=CC=C(OC(F)(F)F)C=C1CNC1CCCNC1C1=CC=CC=C1,CYP2D6,O-Demethylation,0.97
cp_122_721,COC1=CC=C(OC(F)(F)F)C=C1CNC1CCCNC1C1=CC=CC=C1,,COC1=CC=C(OC(F)(F)F)C=C1CN,CYP3A4,N-Dealkylation,0.42
cp_125_611,OC1=CC=C(OC(F)(F)F)C=C1CNC1CCCNC1C1=CC=CC=C1,"CP-919,230",NCC1=CC(OC(F)(F)F)=CC=C1O,CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,N-Dealkylation,0.41
cp_125_611,OC1=CC=C(OC(F)(F)F)C=C1CNC1CCCNC1C1=CC=CC=C1,quinone,O=C1CC=C(O)C=C1CNC1CCCNC1C1=CC=CC=C1,CYP1A2;CYP3A4,O-Detrifluoromethylation,0.53
cp-199331,COC1=CC=C(NS(=O)(=O)C(F)(F)F)C=C1CC1COC2=CC=C(OCC3=NC4=CC(F)=C(F)C=C4S3)C=C2C1O,,O=S(=O)(NC1=CC=C(O)C(CC2COC3=CC=C(OCC4=NC5=CC(F)=C(F)C=C5S4)C=C3C2O)=C1)C(F)(F)F,CYP3A4,O-Demethylation,0.99
cyclobenzaprine,CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12,N-Desmethylcyclobenzaprine,CNCCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12,CYP1A2 (major); CYP3A4 (major); CYP2D6 (minor),N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES,0.98
"cyclohexene, 4-ethenyl-, (s)-",C=CC1CC=CCC1,,C1=CCC(C2CO2)CC1,CYP2B6;CYP2E1,Epoxidation,0.28
"cyclohexene, 4-ethenyl-, (s)-",C=CC1CC=CCC1,,C=CC1CCC2OC2C1,CYP2B6;CYP2E1,Epoxidation,0.22
dacarbazine,CN(C)NN=C1N=CN=C1C(N)=O,MTIC,CNNN=C1N=CN=C1C(N)=O,CYP1A2;CYP2E1,N-demethylation,0.96
dapsone,NC1=CC=C(S(=O)(=O)C2=CC=C(N)C=C2)C=C1,N-Hydroxydapsone,NC1=CC=C(S(=O)(=O)C2=CC=C(NO)C=C2)C=C1,CYP2E1; CYP3A4; CYP2C9; CYP2C8,N-hydroxylation of aniline to hydroxylamine,0.87
debrisoquine,N=C(N)N1CCC2=CC=CC=C2C1,4-Hydroxydebrisoquine,N=C(N)N1CC2=CC=CC=C2C(O)C1,CYP2D6,Hydroxylation of heteroalicyclic secondary carbon,0.74
decursinol angelate,CC=C(C)C(=O)OC1CC2=CC3=C(C=C2OC1(C)C)OC(=O)C=C3,,CC1OC1(C)C(=O)OC1CC2=CC3=C(C=C2OC1(C)C)OC(=O)C=C3,CYP2A6,Epoxidation,0.86
dehydroepiandrosterone,CC12CCC3C(CC=C4CC(O)CCC43C)C1CCC2=O,,CC12CCC3C(CC=C4CC(O)CCC43C)C1CC(O)C2=O,CYP3A4,Aliphatic Hydroxylation,0.88
dehydroepiandrosterone,CC12CCC3C(CC=C4CC(O)CCC43C)C1CCC2=O,,CC12CCC3C(C(O)C=C4CC(O)CCC43C)C1CCC2=O,CYP3A4,Aliphatic Hydroxylation,0.85
delavirdine,CC(C)NC1=CC=CN=C1N1CCN(C(=O)C2=CC3=CC(NS(C)(=O)=O)=CC=C3N2)CC1,,CC(C)NC1=CC=C(O)N=C1N1CCN(C(=O)C2=CC3=CC(NS(C)(=O)=O)=CC=C3N2)CC1,CYP3A4,Aromatic Hydroxylation,0.94
delavirdine,CC(C)NC1=CC=CN=C1N1CCN(C(=O)C2=CC3=CC(NS(C)(=O)=O)=CC=C3N2)CC1,,CS(=O)(=O)NC1=CC=C2NC(C(=O)N3CCN(C4=NC=CC=C4N)CC3)=CC2=C1,CYP2D6;CYP3A4,N-desalkylation,0.93
deoxypodophyllotoxin,COC1=CC(C2C3=CC4=C(C=C3CC3COC(=O)C32)OCO4)=CC(OC)=C1OC,,COC1=CC(C2C3=CC(O)=C(O)C=C3CC3COC(=O)C32)=CC(OC)=C1OC,CYP2C19;CYP3A4,O-Demethylation,0.96
deoxypodophyllotoxin,COC1=CC(C2C3=CC4=C(C=C3CC3COC(=O)C32)OCO4)=CC(OC)=C1OC,,COC1=CC(C2C3=CC4=C(C=C3C(O)C3COC(=O)C23)OCO4)=CC(OC)=C1OC,CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.84
deoxypodophyllotoxin,COC1=CC(C2C3=CC4=C(C=C3CC3COC(=O)C32)OCO4)=CC(OC)=C1OC,,COC1=CC(C2C3=CC4=C(C=C3CC3COC(=O)C32)OCO4)=CC(OC)=C1O,CYP3A4,O-Demethylation,0.99
deramciclane,CN(C)CCOC1(C2=CC=CC=C2)CC2CCC1(C)C2(C)C,,CNCCOC1(C2=CC=CC=C2)CC2CCC1(C)C2(C)C,CYP3A4,N-demethylation,0.99
desmethylcitalopram,CNCCCC1(C2=CC=C(F)C=C2)OCC2=CC(C#N)=CC=C21,"N,N-Didesmethylcitalopram",N#CC1=CC=C2C(=C1)COC2(CCCN)C1=CC=C(F)C=C1,CYP2D6,N-dealkylation of acyclic secondary amine,0.99
desogestrel,C#CC1(O)CCC2C3CCC4=CCCCC4C3C(=C)CC21CC,3-alpha-OH-desogestrel,C#CC1(O)CCC2C3CCC4=CC(O)CCC4C3C(=C)CC21CC,CYP2C9; CYP2C19,Allylic hydroxylation,0.9
desogestrel,C#CC1(O)CCC2C3CCC4=CCCCC4C3C(=C)CC21CC,3-beta-OH-desogestrel,C#CC1(O)CCC2C3CCC4=CC(O)CCC4C3C(=C)CC21CC,CYP2C9; CYP2C19,Allylic hydroxylation,0.9
dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,6-alpha-OH DEXAMETHASONE,CC1CC2C3CC(O)C4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,CYP3A4,Hydroxylation of carbon gamma to conjugated carbonyl,0.9
dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,6-beta-OH DEXAMETHASONE,CC1CC2C3CC(O)C4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,CYP3A4,Hydroxylation of carbon gamma to conjugated carbonyl,0.9
dexfenfluramine,CCNC(C)CC1=CC=CC(C(F)(F)F)=C1,nordexfenfluramine,CC(N)CC1=CC=CC(C(F)(F)F)=C1,CYP1A2;CYP2D6,N-dealkylation,0.88
dexloxiglumide,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)N=C(O)C1=CC=C(Cl)C(Cl)=C1,,CCCCCN(CCCO)C(=O)C(CCC(=O)O)N=C(O)C1=CC=C(Cl)C(Cl)=C1,CYP2B6;CYP2C8;CYP2C9;CYP3A4,O-demethylation,0.98
dexpropranolol (propranolol),CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12,,NCC(O)COC1=CC=CC2=CC=CC=C12,CYP1A2;CYP2D6,N-DESISOPROPYLATION,0.86
dexpropranolol (propranolol),CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12,,CC(C)NCC(O)COC1=CC=CC2=C(O)C=CC=C12,CYP1A2;CYP2D6,AROMATIC HYDROXYLATION,0.93
dexpropranolol (propranolol),CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12,,CC(C)NCC(O)COC1=CC=C(O)C2=CC=CC=C12,CYP1A2;CYP2D6,AROMATIC HYDROXYLATION,0.94
dextromethorphan,COC1=CC=C2CC3C4CCCCC4(CCN3C)C2=C1,Dextrorphan,CN1CCC23CCCCC2C1CC1=CC=C(O)C=C13,CYP2D6 (major); CYP2C9 (minor); CYP3A4 (minor),O-dealkylation,0.96
dextromethorphan,COC1=CC=C2CC3C4CCCCC4(CCN3C)C2=C1,3-methoxymorphinan,COC1=CC=C2CC3NCCC4(CCCCC34)C2=C1,CYP3A4 (major); CYP2D6 (minor); CYP2C9 (minor); CYP2B6 (minor); CYP2C19 (minor),N-dealkylation of alicyclic tertiary amine,0.94
dextropropoxyphene,CCC(=O)OC(CC1=CC=CC=C1)(C1=CC=CC=C1)C(C)CN(C)C,Nordextropropoxyphene,CCC(=O)OC(CC1=CC=CC=C1)(C1=CC=CC=C1)C(C)CNC,CYP3A4,N-demethylation,0.98
dexverapamil,COC1=CC=C(CCN(C)CCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,"dexverapamil, N-demethyl",COC1=CC=C(CCNCCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,CYP2C8; CYP1A2; CYP3A4; CYP3A5,N-dealkylation of acyclic tertiary amine,0.95
dexverapamil,COC1=CC=C(CCN(C)CCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,"2-(3,4-dimethoxyphenyl)acetaldehyde",COC1=CC=C(CC=O)C=C1OC,CYP2C8; CYP3A4; CYP1A2,N-dealkylation of acyclic secondary amine,0.39
dexverapamil,COC1=CC=C(CCN(C)CCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,(R)-D-617,CNCCCC(C#N)(C1=CC=C(OC)C(OC)=C1)C(C)C,CYP2C8; CYP3A4; CYP1A2,N-dealkylation of acyclic secondary amine,0.88
diallyl disulfide,C=CCSSCC=C,DADSO,C=CCSS(=O)CC=C,CYP2A6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1,S-Oxidation,0.46
diazepam,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C21,Nordiazepam,OC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=NC1,CYP2B6; CYP3A4; CYP3A5; CYP2C19; CYP2C8; CYP2C9; CYP2C18,N-dealkylation of secondary carboxamide,0.5
diazepam,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C21,Temazepam,CN1C(=O)C(O)N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C21,CYP3A4; CYP3A5; CYP2C19 (minor),"3-Hydroxylation of 5-aryl-1,4-benzodiazepine",0.87
Diazinon,CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1,Pyrimidinol,CC1=CC(O)=NC(C(C)C)=N1,CYP2C19,Dearylation of organphosphosulfur compound,0.48
Diazinon,CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1,Diethyl thiophosphate,CCOP(O)(=S)OCC,CYP2C19,Dearylation of organphosphosulfur compound,0.11
Diazinon,CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1,Diazoxon,CCOP(=O)(OCC)OC1=CC(C)=NC(C(C)C)=N1,CYP1A2; CYP2A6; CYP2B6; CYP2C8; CYP2C9; CYP2C19; CYP2D6; CYP3A4,Desulfuration of organophosphothioates,0.71
"dibenzo[a,l]pyrene",C1=CC=C2C(=C1)C=C1C=CC3=CC=CC4=C5C=CC=CC5=C2C1=C34,,C1=CC=C2C(=C1)C1=CC=CC3=CC=C4C=C5C(=C2C4=C31)C=CC1=C5O1,CYP1A2;CYP2B6;CYP2C9;CYP3A4,Epoxidation,0.28
dibenzylfluorescein,O=C(OCC1=CC=CC=C1)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC(OCC3=CC=CC=C3)=CC=C12,Fluorescein benzyl ester,O=C(OCC1=CC=CC=C1)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC(O)=CC=C12,CYP2C8; CYP2C9; CYP2C19; CYP3A4,O-aryl dealkylation not adjacent to substituted carbon,0.95
dibenzylfluorescein,O=C(OCC1=CC=CC=C1)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC(OCC3=CC=CC=C3)=CC=C12,2-[6-(benzyloxy)-3-oxo-3H-xanthen-9-yl]benzoic acid,O=C(O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC(OCC3=CC=CC=C3)=CC=C12,CYP2C8; CYP2C9; CYP2C19; CYP3A4,HYDROLYSIS_OF_CARBOXYLIC_ESTER,0.95
diclofenac,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,4'-OH-diclofenac,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=C(O)C=C1Cl,CYP2C9,Hydroxylation of benzene on carbon para to a strongly electron donating group,0.87
diclofenac,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,5-OH-diclofenac,O=C(O)CC1=CC(O)=CC=C1NC1=C(Cl)C=CC=C1Cl,CYP2B6; CYP2C8; CYP2C19; CYP3A4,Hydroxylation of benzene on carbon para to a strongly electron donating group,0.85
digitoxin,CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CCC5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O,Digoxigenin Bisdigitoxoside,CC1OC(OC2C(O)CC(OC3CCC4(C)C(CCC5C4CC(O)C4(C)C(C6=CC(=O)OC6)CCC54O)C3)OC2C)CC(O)C1O,CYP3A4,O-dealkylation,0.97
dihydrocodeine,COC1=CC=C2CC3C4CCC(O)C5OC1=C2C45CCN3C,,CN1CCC23C4=C5C=CC(O)=C4OC2C(O)CCC3C1C5,CYP2D6,O-dementhylation,0.99
dihydrocodeine,COC1=CC=C2CC3C4CCC(O)C5OC1=C2C45CCN3C,,COC1=CC=C2CC3NCCC45C2=C1OC4C(O)CCC35,CYP3A4,N-dementhylation,0.98
diltiazem,COC1=CC=C(C2SC3=CC=CC=C3N(CCN(C)C)C(=O)C2OC(C)=O)C=C1,N-Demethyldiltiazem,CNCCN1C(=O)C(OC(C)=O)C(C2=CC=C(OC)C=C2)SC2=CC=CC=C21,CYP3A4 (major); CYP2C8 (minor); CYP2C9 (minor),N-dealkylation of acyclic tertiary amine,0.99
diltiazem,COC1=CC=C(C2SC3=CC=CC=C3N(CCN(C)C)C(=O)C2OC(C)=O)C=C1,O-Demethyldiltiazem,CC(=O)OC1C(=O)N(CCN(C)C)C2=CC=CC=C2SC1C1=CC=C(O)C=C1,CYP2D6,O-aryl dealkylation not adjacent to substituted carbon,0.98
diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,N-Desmethyldiphenhydramine,CNCCOC(C1=CC=CC=C1)C1=CC=CC=C1,CYP2D6; CYP1A2; CYP2C9; CYP2C19; CYP2B6,N-dealkylation of acyclic tertiary amine,0.96
disopiramide,CC(C)N(CCC(C(=N)O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C,mono-N-desalkyldisopyramide,CC(C)NCCC(C(=N)O)(C1=CC=CC=C1)C1=CC=CC=N1,CYP3A4,N-desalkylation,0.97
domitroban,O=C(O)CCCC=CCC1C2CCC(C2)C1NS(=O)(=O)C1=CC=CC=C1,,O=C(O)CCCC=CCC1C2CC(CC2O)C1NS(=O)(=O)C1=CC=CC=C1,CYP2C9,Aliphatic Hydroxylation,0.86
domitroban,O=C(O)CCCC=CCC1C2CCC(C2)C1NS(=O)(=O)C1=CC=CC=C1,,O=C(O)CCCC=CCC1C2CC(O)C(C2)C1NS(=O)(=O)C1=CC=CC=C1,CYP3A4,Aliphatic Hydroxylation,0.82
domperidone,OC1=NC2=CC=CC=C2N1CCCN1CCC(N2C(O)=NC3=CC(Cl)=CC=C32)CC1,,OC1=CC=C2C(=C1)N=C(O)N2CCCN1CCC(N2C(O)=NC3=CC(Cl)=CC=C32)CC1,CYP1A2;CYP2B6;CYP2C8;CYP2D6;CYP3A4,Aromatic Hydroxylation,0.9
domperidone,OC1=NC2=CC=CC=C2N1CCCN1CCC(N2C(O)=NC3=CC(Cl)=CC=C32)CC1,,OC1=NC2=CC(Cl)=CC=C2N1C1CCNCC1,CYP3A4,N-dealkylation,0.96
domperidone,OC1=NC2=CC=CC=C2N1CCCN1CCC(N2C(O)=NC3=CC(Cl)=CC=C32)CC1,,CCCN1C(O)=NC2=CC=CC=C21,CYP3A4,N-dealkylation,0.65
doxepin,CN(C)CCC=C1C2=CC=CC=C2COC2=CC=CC=C12,nordoxepin,CNCCC=C1C2=CC=CC=C2COC2=CC=CC=C12,CYP2C19,N-dealkylation of acyclic tertiary amine,0.99
doxepin,CN(C)CCC=C1C2=CC=CC=C2COC2=CC=CC=C12,2-OH-doxepin,CN(C)CCC=C1C2=CC(O)=CC=C2COC2=CC=CC=C12,CYP2D6,Aromatic hydroxylation of fused benzene ring,0.93
ebastine,CC(C)(C)C1=CC=C(C(=O)CCCN2CCC(OC(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1,Deslakylebastine,CC(C)(C)C1=CC=C(C(=O)CCC=O)C=C1,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.42
ebastine,CC(C)(C)C1=CC=C(C(=O)CCCN2CCC(OC(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1,4-(4-tert-butylphenyl)-4-oxobutanal,C1=CC=C(C(OC2CCNCC2)C2=CC=CC=C2)C=C1,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.59
ecabapide,CN=C(O)C1=CC=CC(NCC(O)=NCCC2=CC=C(OC)C(OC)=C2)=C1,6-hydroxy-ecabapide,CN=C(O)C1=CC(NCC(O)=NCCC2=CC=C(OC)C(OC)=C2)=CC=C1O,CYP3A4,Hydroxylation of benzene on carbon orhto to a strongly electron donating group,0.86
ecabapide,CN=C(O)C1=CC=CC(NCC(O)=NCCC2=CC=C(OC)C(OC)=C2)=C1,5-amino-2-hydroxy-N-methylbenzamide,CN=C(O)C1=CC(N)=CC=C1O,CYP3A4,N-dealkylation of secondary arylalkylamine,0.4
ecabapide,CN=C(O)C1=CC=CC(NCC(O)=NCCC2=CC=C(OC)C(OC)=C2)=C1,"N-[2-(3,4-dimethoxyphenyl)ethyl]-2-oxoacetamide",COC1=CC=C(CCNC(=O)C=O)C=C1OC,CYP3A4,N-dealkylation of secondary arylalkylamine,0.44
efavirenz,OC1=NC2=CC=C(Cl)C=C2C(C#CC2CC2)(C(F)(F)F)O1,8-OH-efavirenz,OC1=NC2=C(O)C=C(Cl)C=C2C(C#CC2CC2)(C(F)(F)F)O1,CYP2B6; CYP1A2; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.89
eicosapentaenoic acid,CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O,,CCC=CCC=CCC=CCCCCC=CCCCC(=O)O,CYP2C8;CYP2C9;CYP2C11;CYP2C23,Epoxidation,0.93
eletriptan,CN1CCCC1CC1CNC2=CC=C(CCS(=O)(=O)C3=CC=CC=C3)C=C21,N-Desmethyleletriptan,O=S(=O)(CCC1=CC=C2NCC(CC3CCCN3)C2=C1)C1=CC=CC=C1,CYP2D6 (major); CYP3A4 (major); CYP2C9 (minor); CYP2C19 (minor); CYP1A2 (minor); CYP2C8 (minor),N-dealkylation of acyclic tertiary amine,0.97
eplerenone,COC(=O)C1CC2=CC(=O)CCC2(C)C23OC2CC2(C)C(CCC24CCC(=O)O4)C13,6beta-hydroxyeplerenone,COC(=O)C1C(O)C2=CC(=O)CCC2(C)C23OC2CC2(C)C(CCC24CCC(=O)O4)C13,CYP3A4,Hydroxylation of carbon gamma to conjugated carbonyl,0.9
eplerenone,COC(=O)C1CC2=CC(=O)CCC2(C)C23OC2CC2(C)C(CCC24CCC(=O)O4)C13,21-hydroxyeplerenone,COC(=O)C1CC2=CC(=O)CCC2(C)C23OC2CC2(C)C(CCC24CC(O)C(=O)O4)C13,CYP3A4,Alpha hydroxylation of carbonyl group,0.94
erythromycin,CCC1OCC(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CC(C)C(O)C1(C)O,N-Desmethylerythromycin,CCC1OCC(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(NC)C2O)C(C)(O)CC(C)CC(C)C(O)C1(C)O,CYP3A4; CYP2B6,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1,0.97
esomeprazole,COC1=CC=C2N=C(S(=O)CC3=NC=C(C)C(OC)=C3C)NC2=C1,5-Hydroxyomeprazole ,COC1=CC=C2N=C(S(=O)CC3=NC=C(CO)C(OC)=C3C)NC2=C1,CYP2C19 ,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.94
esomeprazole,COC1=CC=C2N=C(S(=O)CC3=NC=C(C)C(OC)=C3C)NC2=C1,Omeprazole sulfone ,COC1=CC=C2N=C(S(=O)(=O)CC3=NC=C(C)C(OC)=C3C)NC2=C1,CYP3A4 ,S-oxidation of sulfoxide to sulfone,0.94
esomeprazole,COC1=CC=C2N=C(S(=O)CC3=NC=C(C)C(OC)=C3C)NC2=C1,5-O-Desmethylomeprazole ,COC1=C(C)C=NC(CS(=O)C2=NC3=CC=C(O)C=C3N2)=C1C,CYP2C19 ,O-aryl dealkylation not adjacent to substituted carbon,0.98
estazolam,ClC1=CC=C2C(=C1)C(C1=CC=CC=C1)=NCC1=NN=CN21,4-hydroxyestazolam,OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2N2C=NN=C12,CYP3A4,Hydroxylation of heteroalicyclic secondary carbon,0.88
estradiol,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2O,2-Hydroxyestradiol,CC12CCC3C4=CC(O)=C(O)C=C4CCC3C1CCC2O,CYP1A2; CYP3A4; CYP1A1,Aromatic hydroxylation of fused benzene ring,0.96
estradiol,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2O,4-Hydroxyestradiol ,CC12CCC3C4=CC=C(O)C(O)=C4CCC3C1CCC2O,CYP1B1 ,Aromatic hydroxylation of fused benzene ring,0.85
estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2=O,2-OH-estrone,CC12CCC3C4=CC(O)=C(O)C=C4CCC3C1CCC2=O,CYP3A4; CYP3A5; CYP3A7; CYP1A2; CYP2B6; CYP2C8; CYP2C9; CYP2C19; CYP2D6,Aromatic hydroxylation of fused benzene ring,0.96
estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2=O,4-OH-estrone,CC12CCC3C4=CC=C(O)C(O)=C4CCC3C1CCC2=O,CYP1A1; CYP1A2; CYP2C9; CYP3A4; CYP3A5; CYP3A7,Aromatic hydroxylation of fused benzene ring,0.85
estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2=O,6alpha-OH-estrone,CC12CCC3C4=CC=C(O)C=C4C(O)CC3C1CCC2=O,CYP1A1; CYP3A4; CYP3A5; CYP3A7,Hydroxylation of alicyclic secondary carbon,0.78
estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2=O,6beta-estrone,CC12CCC3C4=CC=C(O)C=C4C(O)CC3C1CCC2=O,CYP3A4; CYP3A5; CYP3A7,Hydroxylation of alicyclic secondary carbon,0.78
estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2=O,7alpha-OH-estrone,CC12CCC3C4=CC=C(O)C=C4CC(O)C3C1CCC2=O,CYP1A1,Hydroxylation of alicyclic secondary carbon,0.77
estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2=O,15alpha-OH-estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1C(O)CC2=O,CYP1A1; CYP3A7,Hydroxylation of alicyclic secondary carbon,0.84
estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2=O,16alpha-OH-estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CC(O)C2=O,CYP1A1; CYP2C8; CYP3A4; CYP3A5; CYP3A7,Alpha hydroxylation of carbonyl group,0.89
estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2=O,16beta-OH-estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CC(O)C2=O,CYP2C8; CYP3A4; CYP3A5,Alpha hydroxylation of carbonyl group,0.89
eszopiclone,CN1CCN(C(=O)OC2C3=NC=CN=C3C(=O)N2C2=CC=C(Cl)C=N2)CC1,N-oxide-zopiclone,C[N+]1([O-])CCN(C(=O)OC2C3=NC=CN=C3C(=O)N2C2=CC=C(Cl)C=N2)CC1,CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4,N-Oxidation,0.98
ethiprole,CCS(=O)C1=C(N)N(C2=C(Cl)C=C(C(F)(F)F)C=C2Cl)N=C1C#N,Ethiprole Sulfone,CCS(=O)(=O)C1=C(N)N(C2=C(Cl)C=C(C(F)(F)F)C=C2Cl)N=C1C#N,CYP3A4,S-oxidation of sulfoxide to sulfone,0.96
ethylmorphine,CCOC1=CC=C2CC3C4C=CC(O)C5OC1=C2C45CCN3C,Norethylmorphine,CCOC1=CC=C2CC3NCCC45C2=C1OC4C(O)C=CC35,CYP2D6,N-Demethylation,0.98
ethylmorphine,CCOC1=CC=C2CC3C4C=CC(O)C5OC1=C2C45CCN3C,Morphine,CN1CCC23C4=C5C=CC(O)=C4OC2C(O)C=CC3C1C5,CYP3A4,O-dealkylation,0.99
etizolam,CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl,,CCC1=CC2=C(S1)N1C(C)=NN=C1C(O)N=C2C1=CC=CC=C1Cl,CYP2B6;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.91
etizolam,CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl,,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(SC(C(C)O)=C3)N12,CYP2B6;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.96
etoperidone,CCC1=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C(=O)N1CC,,CCCN1N=C(CC)N(CC)C1=O,CYP3A4,N-Dealkylation,0.69
etoperidone,CCC1=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C(=O)N1CC,,ClC1=CC=CC(N2CCNCC2)=C1,CYP3A4,N-Dealkylation,0.29
etoperidone,CCC1=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C(=O)N1CC,,CCC1=NN(CCCN2CCN(C3=CC=C(O)C(Cl)=C3)CC2)C(=O)N1CC,CYP3A4,Aromatic Hydroxylation,0.94
etoperidone,CCC1=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C(=O)N1CC,,CCN1C(C(C)O)=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C1=O,CYP3A4,Aliphatic Hydroxylation,0.9
etoricoxib,CC1=CC=C(C2=NC=C(Cl)C=C2C2=CC=C(S(C)(=O)=O)C=C2)C=N1,6-Hydroxymethyletoricoxib,CS(=O)(=O)C1=CC=C(C2=CC(Cl)=CN=C2C2=CC=C(CO)N=C2)C=C1,CYP3A4 (major); CYP2C9 (minor); CYP2D6 (minor); CYP1A2 (minor),Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.95
etoricoxib,CC1=CC=C(C2=NC=C(Cl)C=C2C2=CC=C(S(C)(=O)=O)C=C2)C=N1,Etoricoxib 1'-N'-oxide,CC1=CC=C(C2=NC=C(Cl)C=C2C2=CC=C(S(C)(=O)=O)C=C2)C=[N+]1[O-],CYP3A4 (major); CYP2C9 (minor); CYP2D6 (minor); CYP1A2 (minor),Pyridine N-oxidation,0.89
eugenol,C=CCC1=CC=C(O)C(OC)=C1,Hydroxychavicol,C=CCC1=CC=C(O)C(O)=C1,CYP1A2;CYP2C9;CYP2D6;CYP2E1,O-demethylation,0.76
eupatilin,COC1=CC=C(C2=CC(=O)C3=C(O)C(OC)=C(O)C=C3O2)C=C1OC,Jaceosidine,COC1=CC(C2=CC(=O)C3=C(O)C(OC)=C(O)C=C3O2)=CC=C1O,CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1,O-demethylation,0.99
everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,CYP3A4,N-Dealkylation,0.99
ezlopitant,COC1=CC=C(C(C)C)C=C1CNC1C2CCN(CC2)C1C(C1=CC=CC=C1)C1=CC=CC=C1,,C=C(C)C1=CC=C(OC)C(CNC2C3CCN(CC3)C2C(C2=CC=CC=C2)C2=CC=CC=C2)=C1,CYP2D6;CYP3A4,Dehydrogenation,0.94
ezlopitant,COC1=CC=C(C(C)C)C=C1CNC1C2CCN(CC2)C1C(C1=CC=CC=C1)C1=CC=CC=C1,,COC1=CC=C(C(C)(C)O)C=C1CNC1C2CCN(CC2)C1C(C1=CC=CC=C1)C1=CC=CC=C1,CYP2D6;CYP3A4,Dehydrogenation,0.94
fentanyl,CCC(=O)N(C1=CC=CC=C1)C1CCN(CCC2=CC=CC=C2)CC1,Norfentanyl,CCC(=O)N(C1=CC=CC=C1)C1CCNCC1,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.78
fentanyl,CCC(=O)N(C1=CC=CC=C1)C1CCN(CCC2=CC=CC=C2)CC1,Phenylacetaldehyde,O=CCC1=CC=CC=C1,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.13
finasteride,CC(C)(C)N=C(O)C1CCC2C3CCC4N=C(O)C=CC4(C)C3CCC12C,,CC(C)(CO)N=C(O)C1CCC2C3CCC4N=C(O)C=CC4(C)C3CCC12C,CYP3A4,Alipathic Hydroxylation,0.98
flosequinan,CN1C=C(S(C)=O)C(=O)C2=CC=C(F)C=C21,flosequinan sulfone,CN1C=C(S(C)(=O)=O)C(=O)C2=CC=C(F)C=C21,CYP3A4,S-oxidation of sulfoxide to sulfone,0.95
flucloxacillin,CC1=C(C(O)=NC2C(=O)N3C2SC(C)(C)C3C(=O)O)C(C2=C(F)C=CC=C2Cl)=NO1,,CC1(C)SC2C(N=C(O)C3=C(CO)ON=C3C3=C(F)C=CC=C3Cl)C(=O)N2C1C(=O)O,CYP3A4,Aliphatic Hydroxylation,0.99
flunarizine,FC1=CC=C(C(C2=CC=C(F)C=C2)N2CCN(CC=CC3=CC=CC=C3)CC2)C=C1,1Ã¢â‚¬Â[bis(4Ã¢â‚¬Âfluorophenyl)methyl]piperazine,FC1=CC=C(C(C2=CC=C(F)C=C2)N2CCNCC2)C=C1,CYP1A2; CYP2C9,N-dealkylation of alicyclic tertiary amine,0.79
flunarizine,FC1=CC=C(C(C2=CC=C(F)C=C2)N2CCN(CC=CC3=CC=CC=C3)CC2)C=C1,p-Hydroxyflunarizine,OC1=CC=C(C=CCN2CCN(C(C3=CC=C(F)C=C3)C3=CC=C(F)C=C3)CC2)C=C1,CYP2D6,p-Hydroxylation of monosubstituted benzene,0.91
flunarizine,FC1=CC=C(C(C2=CC=C(F)C=C2)N2CCN(CC=CC3=CC=CC=C3)CC2)C=C1,bis(4Ã¢â‚¬Âfluorophenyl)methanone,O=C(C1=CC=C(F)C=C1)C1=CC=C(F)C=C1,CYP2C9; CYP1A1,N-dealkylation of alicyclic tertiary amine,0.28
fluphenazine,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C(F)(F)F)C=C32)CC1,10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-2-(trifluoromethyl)-10H-5ÃŽÂ»Ã¢ÂÂ´-phenothiazin-5-one,O=S1C2=CC=CC=C2N(CCCN2CCN(CCO)CC2)C2=CC(C(F)(F)F)=CC=C21,CYP2D6,S-oxidation of diarylthioether to sulfoxide,0.87
flunitrazepam,CN1C(=O)CN=C(C2=CC=CC=C2F)C2=CC([N+](=O)[O-])=CC=C21,desmethylflunitrazepam,O=[N+]([O-])C1=CC=C2N=C(O)CN=C(C3=CC=CC=C3F)C2=C1,CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4,N-DEMETHYLATION ,0.62
flunitrazepam,CN1C(=O)CN=C(C2=CC=CC=C2F)C2=CC([N+](=O)[O-])=CC=C21,3-hydroxyflunitrazepam,CN1C(=O)C(O)N=C(C2=CC=CC=C2F)C2=CC([N+](=O)[O-])=CC=C21,CYP2A6;CYP3A4,Aliphatic Hydroxylation,0.91
flutamide,CC(C)C(O)=NC1=CC=C([N+](=O)[O-])C(C(F)(F)F)=C1,2-OH-flutamide,CC(C)(O)C(O)=NC1=CC=C([N+](=O)[O-])C(C(F)(F)F)=C1,CYP1A2; CYP1B1,Alpha hydroxylation of carbonyl group,0.92
fluvastatin,CC(C)N1C(C=CC(O)CC(O)CC(=O)O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21,6-OH-fluvastatin,CC(C)N1C(C=CC(O)CC(O)CC(=O)O)=C(C2=CC=C(F)C=C2)C2=CC=C(O)C=C21,CYP2C9,Aromatic hydroxylation of fused benzene ring,0.95
fluvastatin,CC(C)N1C(C=CC(O)CC(O)CC(=O)O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21,N-Deisopropyl-fluvastatin,O=C(O)CC(O)CC(O)C=CC1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N1,CYP2C9,N-deisopropylation,0.77
fluvastatin,CC(C)N1C(C=CC(O)CC(O)CC(=O)O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21,5-OH-fluvastatin,CC(C)N1C(C=CC(O)CC(O)CC(=O)O)=C(C2=CC=C(F)C=C2)C2=CC(O)=CC=C21,CYP2C9 (major); CYP2C8 (minor); CYP2D6 (minor); CYP3A4 (minor),Aromatic hydroxylation of fused benzene ring,0.95
fluvoxamine,COCCCCC(=NOCCN)C1=CC=C(C(F)(F)F)C=C1,Fluvoxamino alcohol,NCCON=C(CCCCO)C1=CC=C(C(F)(F)F)C=C1,CYP2D6 (major); CYP1A2 (minor),O-dealkylation of dialkylether,0.97
formononetin,COC1=CC=C(C2=COC3=CC(O)=CC=C3C2=O)C=C1,Daidzein,O=C1C(C2=CC=C(O)C=C2)=COC2=CC(O)=CC=C12,CYP1A2,O-aryl dealkylation not adjacent to substituted carbon,0.96
furafylline,CC1=NC2=C(N1)N(CC1=CC=CO1)C(=O)N(C)C2=O,"3-[(furan-2-yl)methyl]-8-hydroxy-1-methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione   ",CN1C(=O)C2=C(NC(CO)=N2)N(CC2=CC=CO2)C1=O,CYP1A2,ALKYL_HYDROXYLATION,0.97
galangin,O=C1C(O)=C(C2=CC=CC=C2)OC2=CC(O)=CC(O)=C12,4'-OH-galangin,O=C1C(O)=C(C2=CC=C(O)C=C2)OC2=CC(O)=CC(O)=C12,CYP1A2 ; CYP2C9,p-Hydroxylation of monosubstituted benzene,0.98
galantamine,COC1=CC=C2CN(C)CCC34C=CC(O)CC3OC1=C24,O-Desmethylgalantamine,CN1CCC23C=CC(O)CC2OC2=C(O)C=CC(=C23)C1,CYP2D6,O-aryl dealkylation not adjacent to substituted carbon,0.99
galantamine,COC1=CC=C2CN(C)CCC34C=CC(O)CC3OC1=C24,Galantamine N-oxide,COC1=CC=C2C[N+](C)([O-])CCC34C=CC(O)CC3OC1=C24,CYP3A4,N-oxidation of alicyclic tertiary amine,0.96
galantamine,COC1=CC=C2CN(C)CCC34C=CC(O)CC3OC1=C24,N-desmethylgalantamine,COC1=CC=C2CNCCC34C=CC(O)CC3OC1=C24,CYP2D6,N-dealkylation of alicyclic tertiary amine,0.98
gefitinib,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCOCC1,,OC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCOCC1,CYP2D6,O-dementhylation,0.97
gefitinib,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCOCC1,,COC1=CC2=NC=NC(NC3=CC=C(O)C(Cl)=C3)=C2C=C1OCCCN1CCOCC1,CYP3A4,oxidative defluorination,0.91
genistein,O=C1C(C2=CC=C(O)C=C2)=COC2=CC(O)=CC(O)=C12,Orobol,O=C1C(C2=CC=C(O)C(O)=C2)=COC2=CC(O)=CC(O)=C12,CYP1A2;CYP2E1,Aromatic Hydroxylation,0.94
genistein,O=C1C(C2=CC=C(O)C=C2)=COC2=CC(O)=CC(O)=C12,,O=C1C(C2=CC=C(O)C(O)=C2)=COC2=CC(O)=CC(O)=C12,CYP1A2,Aromatic Hydroxylation,0.94
gepirone,CC1(C)CC(=O)N(CCCCN2CCN(C3=NC=CC=N3)CC2)C(=O)C1,,CC1(C)CC(=O)N(CCCCN2CCN(C3=NC=C(O)C=N3)CC2)C(=O)C1O,CYP3A4,Hydroxylation,0.69
gepirone,CC1(C)CC(=O)N(CCCCN2CCN(C3=NC=CC=N3)CC2)C(=O)C1,,CC1(C)CC(=O)N(CCCCN2CCN(C3=NC=C(O)C=N3)CC2)C(=O)C1,CYP3A4,Aromatic Hydroxylation,0.91
gepirone,CC1(C)CC(=O)N(CCCCN2CCN(C3=NC=CC=N3)CC2)C(=O)C1,,CC1(C)CC(=O)N(CCCCN2CCN(C3=NC=CC=N3)CC2)C(=O)C1O,CYP3A4,Aliphatic Hydroxylation,0.74
gepirone,CC1(C)CC(=O)N(CCCCN2CCN(C3=NC=CC=N3)CC2)C(=O)C1,1-(2-pyrimidinyl)-piperazine (1-PP),C1=CN=C(N2CCNCC2)N=C1,CYP3A4,N-Dealkylation,0.46
granisetron,CN1C2CCCC1CC(NC(=O)C1=NN(C)C3=CC=CC=C13)C2,7-Hydroxygranisetron,CN1C2CCCC1CC(NC(=O)C1=NN(C)C3=CC=CC(O)=C13)C2,CYP1A1,HYDROXYLATION_OF_AROMATIC_CARBON,0.86
granisetron,CN1C2CCCC1CC(NC(=O)C1=NN(C)C3=CC=CC=C13)C2,9'-Desmethylgranisetron,CN1C2CCCC1CC(NC(=O)C1=NNC3=CC=CC=C13)C2,CYP3A4 (major); CYP1A1; CYP2D6; CYP3A5,N-dealkylation of alicyclic tertiary amine,0.85
gts-21,COC1=CC=C(C=C2CCCN=C2C2=CC=CN=C2)C(OC)=C1,4-OH-GTS-21,COC1=CC(O)=CC=C1C=C1CCCN=C1C1=CC=CN=C1,CYP1A2;CYP2E1;CYP3A4,O-Demethylation,0.99
gts-21,COC1=CC=C(C=C2CCCN=C2C2=CC=CN=C2)C(OC)=C1,2-OH-GTS-21,COC1=CC=C(C=C2CCCN=C2C2=CC=CN=C2)C(O)=C1,CYP1A2;CYP2E1;CYP3A4,O-Demethylation,0.97
guanabenz,N=C(N)NN=CC1=C(Cl)C=CC=C1Cl,Guanoxabenz,N=C(NO)NN=CC1=C(Cl)C=CC=C1Cl,CYP1A2,N-hyroxylation of guanidine or aminohydrazone,0.93
haloperidol,O=C(CCCN1CCC(O)(C2=CC=C(Cl)C=C2)CC1)C1=CC=C(F)C=C1,p-Fluorobenzoylpropionic acid and 4-(4-chlorophenyl)-4-hydroxypiperidine,O=C(O)CCC(=O)C1=CC=C(F)C=C1,CYP3A4; CYP2D6,N-dealkylation of alicyclic tertiary amine,0.4
haloperidol,O=C(CCCN1CCC(O)(C2=CC=C(Cl)C=C2)CC1)C1=CC=C(F)C=C1,Haloperidol pyridinium,O=C(CCCN1C=CC(=C2C=CC(=[Cl+])C=C2)C=C1)C1=CC=C(F)C=C1,CYP3A4,Formation of pyridinium from 4-substituted piperidine,0.42
harmaline,COC1=CC=C2C3=C(NC2=C1)C(C)=NCC3,Harmalol,CC1=NCCC2=C1NC1=CC(O)=CC=C21,CYP2D6 (major); CYP1A2 (minor),O-aryl demethylation,0.96
harmine,COC1=CC=C2C(=C1)NC1=C(C)N=CC=C12,Harmol,COC1=CC2=C(C=C1O)C1=CC=NC(C)=C1N2,CYP2D6 (major); CYP2C9 (minor); CYP2C19 (minor); CYP1A2 (minor),Aromatic hydroxylation of fused benzene ring,0.91
harmine,COC1=CC=C2C(=C1)NC1=C(C)N=CC=C12,6-OH-harmaline,CC1=NC=CC2=C1NC1=CC(O)=CC=C12,CYP2D6,O-aryl demethylation,0.93
hydrocodone,COC1=CC=C2CC3C4CCC(=O)C5OC1=C2C54CCN3C,Hydromorphone,CN1CCC23C4=C5C=CC(O)=C4OC2C(=O)CCC3C1C5,CYP2D6,O-dementhylation,0.99
hydrocodone,COC1=CC=C2CC3C4CCC(=O)C5OC1=C2C54CCN3C,Norhydromorphone,COC1=CC=C2CC3NCCC45C2=C1OC4C(=O)CCC35,CYP3A4,N-dementhylation,0.98
ibrolipim,CCOP(=O)(CC1=CC=C(C(O)=NC2=CC=C(Br)C=C2C#N)C=C1)OCC,,CCOP(=O)(O)CC1=CC=C(C(O)=NC2=CC=C(Br)C=C2C#N)C=C1,CYP2C8;CYP3A4,O-DEETHYLATION,0.96
iloperidone,COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C2=NOC3=CC(F)=CC=C23)CC1,"4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-a-methylbenzene methanol",COC1=CC(C(C)O)=CC=C1OCCCN1CCC(C2=NOC3=CC(F)=CC=C23)CC1,CYP1A2;CYP2E1;CYP3A4,Reduction ,0.91
iloperidone,COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C2=NOC3=CC(F)=CC=C23)CC1,"1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]- propoxy]-3-hydroxyphenyl]ethanone",CC(=O)C1=CC=C(OCCCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(O)=C1,CYP3A4,O-Demethylation,0.97
iloperidone,COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C2=NOC3=CC(F)=CC=C23)CC1,"1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-2-hydroxyethanone",COC1=CC(C(=O)CO)=CC=C1OCCCN1CCC(C2=NOC3=CC(F)=CC=C23)CC1,CYP2D6,Aliphatic Hydroxylation,0.97
imidacloprid,O=[N+]([O-])NC1=NCCN1CC1=CC=C(Cl)N=C1,5-hydroxy-imidacloprid,O=[N+]([O-])NC1=NCC(O)N1CC1=CC=C(Cl)N=C1,CYP3A4,Aliphatic Hydroxylation,0.82
imidacloprid,O=[N+]([O-])NC1=NCCN1CC1=CC=C(Cl)N=C1,olefin,O=[N+]([O-])NC1=NC=CN1CC1=CC=C(Cl)N=C1,CYP3A4,Dehydrogenation,0.27
imipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C21,2-Hydroxyimipramine ,CN(C)CCCN1C2=CC=CC=C2CCC2=CC(O)=CC=C21,CYP2C19 (major); CYP2D6 ,Aromatic hydroxylation of fused benzene ring,0.86
imipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C21,Desimipramine ,CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C21,CYP2C19; CYP2C18; CYP2D6; CYP1A2 ,N-dealkylation of acyclic tertiary amine,0.99
indinavir,CC(C)(C)N=C(O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(O)=NC1C2=CC=CC=C2CC1O,,CC(C)(C)N=C(O)C1CN(CC2=CC=C[N+]([O-])=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(O)=NC1C2=CC=CC=C2CC1O,CYP3A4,N-Oxidation,0.98
indinavir,CC(C)(C)N=C(O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(O)=NC1C2=CC=CC=C2CC1O,,CC(C)(C)N=C(O)C1CNCCN1CC(O)CC(CC1=CC=CC=C1)C(O)=NC1C2=CC=CC=C2CC1O,CYP3A4,N-Dealkylation,0.91
indinavir,CC(C)(C)N=C(O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(O)=NC1C2=CC=CC=C2CC1O,,CC(C)(C)N=C(O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=C(O)C=C1)C(O)=NC1C2=CC=CC=C2CC1O,CYP3A4,Aromatic Hydroxylation,0.98
indinavir,CC(C)(C)N=C(O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(O)=NC1C2=CC=CC=C2CC1O,,CC(C)(C)N=C(O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(O)=NC1C2=CC=CC=C2C(O)C1O,CYP3A4,Aliphatic Hydroxylation,0.92
indiplon,CC(=O)N(C)C1=CC=CC(C2=CC=NC3=C(C(=O)C4=CC=CS4)C=NN23)=C1,N-Desmethylindiplon,CC(O)=NC1=CC=CC(C2=CC=NC3=C(C(=O)C4=CC=CS4)C=NN23)=C1,CYP3A4; CYP1A2,N-dealkylation of tertiary carboxamide,0.9
indole,C1=CC=C2NC=CC2=C1,,OC1=CNC2=CC=CC=C12,CYP2A6;CYP2C19;CYP2E1,Aliphatic Hydroxylation,0.57
indole,C1=CC=C2NC=CC2=C1,,OC1=NC2=CC=CC=C2C1,CYP2A6;CYP2C19;CYP2E1,C-Oxidation,0.06
indole,C1=CC=C2NC=CC2=C1,,OC1=CC=C2C=CNC2=C1,CYP2A6;CYP2C19;CYP2E1,Aromatic Hydroxylation,0.64
indomethacin,COC1=CC=C2C(=C1)C(CC(=O)O)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,O-Desmethylindomethacin,CC1=C(CC(=O)O)C2=CC(O)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1,CYP2C9 (major); CYP2C19 (minor); CYP2D6 (minor); CYP1A2 (minor),O-aryl demethylation,0.97
"invega, invega sustenna, 9-hydroxyrisperidone, paliperidone",CC1=C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(=O)N2CCCC(O)C2=N1,,CC1=C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(=O)N2CC(O)CC(O)C2=N1,CYP2D6,Aliphatic Hydroxylation,0.95
ipriflavone,CC(C)OC1=CC=C2C(=O)C(C3=CC=CC=C3)=COC2=C1,,O=C1C(C2=CC=CC=C2)=COC2=CC(O)=CC=C12,CYP1A2;CYP2C9;CYP2C19;CYP3A4,O-dealkylation,0.89
ipriflavone,CC(C)OC1=CC=C2C(=O)C(C3=CC=CC=C3)=COC2=C1,,CC(CO)OC1=CC=C2C(=O)C(C3=CC=CC=C3)=COC2=C1,CYP1A2;CYP2C9;CYP2C19,Aliphatic Hydroxylation,0.98
ipriflavone,CC(C)OC1=CC=C2C(=O)C(C3=CC=CC=C3)=COC2=C1,,CC(C)OC1=CC=C2C(=O)C(C3=CC=C(O)C=C3)=COC2=C1,CYP1A2;CYP2C9;CYP2C19,Aromatic Hydroxylation,0.98
irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,"2-(3-hydroxybutyl)-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one",CC(O)CCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,CYP2C9,Hydroxylation of penultimate aliphatic secondary carbon,0.98
irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,M7,CCCCC1=NC2(CCC(O)C2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,CYP2C9,Hydroxylation of alicyclic secondary carbon,0.92
irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,M3,O=C(O)CCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,CYP2C9,C-Oxidation,0.98
isoquinoline,C1=CC=C2C=NC=CC2=C1,isoquinoline N-oxide,[O-][N+]1=CC=C2C=CC=CC2=C1,CYP3A4; CYP2E1,N-Oxidation,0.71
isotretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,,CC(C=CC(O)=C(C)C=CC1=C(C)CCCC1(C)C)=CC(=O)O,CYP2B6;CYP2C8;CYP3A4,Hydroxylation,0.83
isoursodeoxycholic acid,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(=O)CCC4(C)C3CCC12C,CYP3A4,Dehydrogenation,0.81
isoursodeoxycholic acid,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,,CC(CCC(=O)O)C1CCC2C3C(O)C(O)C4CC(O)CCC4(C)C3CCC12C,CYP3A4,Aliphatic Hydroxylation,0.81
ivermectin,COC1CC(OC2C(C)OC(OC3C(C)=CCC4CCC(CC5(CCC(C(C)C)CO5)O4)OC(=O)C4C=C(C)C(O)C5CCC(=CC=CC3C)C45O)CC2OC)OC(C)C1O,,COC1CC(OC2(O)C(C)OC(OC3C(C)=CCC4CCC(CC5(CCC(C(C)C)CO5)O4)OC(=O)C4C=C(C)C(O)C5CCC(=CC=CC3C)C45O)CC2OC)OC(C)C1O,CYP3A4,Aliphatic Hydroxylation,0.95
k-11777,CN1CCN(C(O)=NC(CC2=CC=CC=C2)C(O)=NC(C=CS(=O)(=O)C2=CC=CC=C2)CCC2=CC=CC=C2)CC1,N-oxide k-11777,C[N+]1([O-])CCN(C(O)=NC(CC2=CC=CC=C2)C(O)=NC(C=CS(=O)(=O)C2=CC=CC=C2)CCC2=CC=CC=C2)CC1,CYP3A4,N-Oxidation,0.96
"N-[(2S)-1-[[(E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide",CN1CCN(C(O)=NC(CC2=CC=CC=C2)C(O)=NC(C=CS(=O)(=O)C2=CC=CC=C2)CCC2=CC=CC=C2)CC1,b-hydroxy-homoPhe K11777,CN1CCN(C(O)=NC(CC2=CC=CC=C2)C(O)=NC(C=CS(=O)(=O)C2=CC=CC=C2)C(O)CC2=CC=CC=C2)CC1,CYP3A4,Aliphatic Hydroxylation,0.91
kaempferide,COC1=CC=C(C2=C(O)C(=O)C3=C(O)C=C(O)C=C3O2)C=C1,4'-OH-galangin,O=C1C(O)=C(C2=CC=C(O)C=C2)OC2=CC(O)=CC(O)=C12,CYP1A2 ; CYP2C9,O-aryl demethylation,0.98
ketobemidone,CCC(=O)C1(C2=CC=CC(O)=C2)CCN(C)CC1,Norketobemidone,CCC(=O)C1(C2=CC=CC(O)=C2)CCNCC1,CYP3A4; CYP2C9,N-dealkylation of alicyclic tertiary amine,0.95
kr-60436,COC1=CC=C(N2CCC3=C2C2=CC=CC(OC(F)(F)F)=C2NC3=NCCO)C(C)=C1,O-demethyl-KR-60436,CC1=CC(O)=CC=C1N1CCC2=C1C1=CC=CC(OC(F)(F)F)=C1NC2=NCCO,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4,O-Demethylation,0.99
kr-60436,COC1=CC=C(N2CCC3=C2C2=CC=CC(OC(F)(F)F)=C2NC3=NCCO)C(C)=C1,,COC1=CC=C(N2CCC3=C2C2=CC=CC(OC(F)(F)F)=C2NC3=N)C(C)=C1,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4,N-dehydroxyethylation,0.92
kr-60436,COC1=CC=C(N2CCC3=C2C2=CC=CC(OC(F)(F)F)=C2NC3=NCCO)C(C)=C1,,COC1=CC=C(N2C=CC3=C2C2=CC=CC(OC(F)(F)F)=C2NC3=NCCO)C(C)=C1,CYP2D6;CYP3A4,Hydrogenation,0.56
"2â€(3â€{4â€[2â€(3â€fluorophenyl)ethyl]piperazinâ€1â€yl}propyl)â€5â€(1,2,4â€triazolâ€4â€yl)â€1Hâ€indole",FC1=CC=CC(CCN2CCN(CCCC3=CC4=CC(N5C=NN=C5)=CC=C4N3)CC2)=C1,,OC(CN1CCN(CCCC2=CC3=CC(N4C=NN=C4)=CC=C3N2)CC1)C1=CC=CC(F)=C1,CYP2C8;CYP3A4,Aliphatic Hydroxylation,0.91
l_775606,FC1=CC=CC(CCN2CCN(CCCC3=CC4=CC(N5C=NN=C5)=CC=C4N3)CC2)=C1,,CN1CCN(CCCC2=CC3=CC(N4C=NN=C4)=CC=C3N2)CC1,CYP2C8;CYP3A4,N-dealkylation,0.85
l-cyclophosphamide,O=P1(N(CCCl)CCCl)NCCCO1,Dechloroethyl cyclophosphamide,O=P1(NCCCl)NCCCO1,CYP2B6; CYP3A4; CYP3A5,N-dechloroethylation,0.66
l-ifosfamide,O=P1(NCCCl)OCCCN1CCCl,3-Dechloroethylifosfamide,O=P1(NCCCl)NCCCO1,CYP2B6; CYP3A4; CYP3A5,N-dechloroethylation,0.59
l-ifosfamide,O=P1(NCCCl)OCCCN1CCCl,2-Dechloroethylifosfamide,NP1(=O)OCCCN1CCCl,CYP2B6; CYP3A4; CYP3A5,N-dechloroethylation,0.83
l-ifosfamide,O=P1(NCCCl)OCCCN1CCCl,4-Hydroxyifosfamide,O=P1(NCCCl)OCCC(O)N1CCCl,CYP2B6 (major); CYP3A4 (major); CYP2A6 (minor); CYP2C8 (minor); CYP2C9 (minor); CYP2C19 (minor); CYP3A5 (minor),4-alkyl hydroxylation of oxoazaphosphorine,0.68
l-trofosfamide,O=P1(N(CCCl)CCCl)OCCCN1CCCl,l-ifosfamide,O=P1(N(CCCl)CCCl)OCCC(O)N1CCCl,CYP3A4; CYP2B6; CYP2A6; CYP2C9,4-alkyl hydroxylation of oxoazaphosphorine,0.68
l-trofosfamide,O=P1(N(CCCl)CCCl)OCCCN1CCCl,l-cyclophosphamide,O=P1(N(CCCl)CCCl)NCCCO1,CYP3A4; CYP2B6,N-dechloroethylation,0.87
laquinimod,CCN(C(=O)C1=C(O)C2=C(Cl)C=CC=C2N(C)C1=O)C1=CC=CC=C1,"5-chloro-N-ethyl-4-hydroxy-N-(4-hydroxyphenyl)-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide",CCN(C(=O)C1=C(O)C2=C(Cl)C=CC=C2N(C)C1=O)C1=CC=C(O)C=C1,CYP3A4,p-Hydroxylation of anilide,0.99
laquinimod,CCN(C(=O)C1=C(O)C2=C(Cl)C=CC=C2N(C)C1=O)C1=CC=CC=C1,"5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CN1C(=O)C(C(O)=NC2=CC=CC=C2)=C(O)C2=C(Cl)C=CC=C21,CYP3A4,N-dealkylation of secondary carboxamide,0.66
laquinimod,CCN(C(=O)C1=C(O)C2=C(Cl)C=CC=C2N(C)C1=O)C1=CC=CC=C1,"5-chloro-N-ethyl-4-hydroxy-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CCN(C(=O)C1=C(O)N=C2C=CC=C(Cl)C2=C1O)C1=CC=CC=C1,CYP3A4,N-dealkylation of secondary carboxamide,0.74
laquinimod,CCN(C(=O)C1=C(O)C2=C(Cl)C=CC=C2N(C)C1=O)C1=CC=CC=C1,"5-chloro-N-ethyl-4,8-dihydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CCN(C(=O)C1=C(O)C2=C(Cl)C=CC(O)=C2N(C)C1=O)C1=CC=CC=C1,CYP3A4,Aromatic hydroxylation of fused benzene ring,0.95
laquinimod,CCN(C(=O)C1=C(O)C2=C(Cl)C=CC=C2N(C)C1=O)C1=CC=CC=C1,"5-chloro-N-ethyl-4,7-dihydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CCN(C(=O)C1=C(O)C2=C(Cl)C=C(O)C=C2N(C)C1=O)C1=CC=CC=C1,CYP3A4,Aromatic hydroxylation of fused benzene ring,0.98
laquinimod,CCN(C(=O)C1=C(O)C2=C(Cl)C=CC=C2N(C)C1=O)C1=CC=CC=C1,"5-chloro-N-ethyl-4,6-dihydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CCN(C(=O)C1=C(O)C2=C(Cl)C(O)=CC=C2N(C)C1=O)C1=CC=CC=C1,CYP3A4,Aromatic hydroxylation of fused benzene ring,0.97
levobupivacaine,CCCCN1CCCCC1C(O)=NC1=C(C)C=CC=C1C,,CC1=CC=CC(C)=C1N=C(O)C1CCCCN1,CYP2C19;CYP2D6;CYP3A4,N-demethylation,0.88
licofelone,CC1(C)CC2=C(C3=CC=CC=C3)C(C3=CC=C(Cl)C=C3)=C(CC(=O)O)N2C1,licofelone M4,CC1(C)CC2=C(C3=CC=C(O)C=C3)C(C3=CC=C(Cl)C=C3)=C(CC(=O)O)N2C1,CYP3A4; CYP2C8; CYP2C19; CYP2D6,p-Hydroxylation of monosubstituted benzene,0.98
licofelone,CC1(C)CC2=C(C3=CC=CC=C3)C(C3=CC=C(Cl)C=C3)=C(CC(=O)O)N2C1,licofelone M2,CC1(C)CC2=C(C3=CC=CC=C3)C(C3=CC=C(Cl)C(O)=C3)=C(CC(=O)O)N2C1,CYP2C8; CYP2C9,Hydroxylation of aromatic carbon ortho to halide group,0.94
licofelone_M1,CC1(C)CC2=C(C3=CC=CC=C3)C(C3=CC=C(Cl)C=C3)=C(CC(=O)OCC3OC(O)C(O)C(O)C3O)N2C1,,CC1(CO)CC2=C(C3=CC=CC=C3)C(C3=CC=C(Cl)C=C3)=C(CC(=O)OCC3OC(O)C(O)C(O)C3O)N2C1,CYP2C8;CYP2C9,Aliphatic Hydroxylation,0.97
lidocaine,CCN(CC)CC(O)=NC1=C(C)C=CC=C1C,Monoethylglycinexylidide,CCNCC(O)=NC1=C(C)C=CC=C1C,CYP1A2; CYP3A4; CYP3A5; CYP2C8; CYP2C18; CYP2B6; CYP2A6,N-dealkylation of acyclic tertiary amine,0.92
lidocaine,CCN(CC)CC(O)=NC1=C(C)C=CC=C1C,3-Hydroxylidocaine,CCN(CC)CC(O)=NC1=C(C)C=CC(O)=C1C,CYP1A2; CYP2D6; CYP3A4,Hydroxylation of benzene on carbon ortho to an electron donating group,0.73
linomide,CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=CC=C1,"4,8-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CN(C(=O)C1=C(O)C2=CC=CC(O)=C2N(C)C1=O)C1=CC=CC=C1,CYP3A4,Aromatic hydroxylation of fused benzene ring,0.93
linomide,CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=CC=C1,"4,7-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CN(C(=O)C1=C(O)C2=CC=C(O)C=C2N(C)C1=O)C1=CC=CC=C1,CYP3A4,Aromatic hydroxylation of fused benzene ring,0.99
linomide,CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=CC=C1,"4,6-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CN(C(=O)C1=C(O)C2=CC(O)=CC=C2N(C)C1=O)C1=CC=CC=C1,CYP3A4,Aromatic hydroxylation of fused benzene ring,0.97
linomide,CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=CC=C1,"4-hydroxy-N-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CN(C(=O)C1=C(O)N=C2C=CC=CC2=C1O)C1=CC=CC=C1,CYP3A4,N-dealkylation of tertiary carboxamide,0.68
linomide,CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=CC=C1,"4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide",CN1C(=O)C(C(O)=NC2=CC=CC=C2)=C(O)C2=CC=CC=C21,CYP3A4,N-dealkylation of tertiary carboxamide,0.6
linomide,CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=CC=C1,"4-hydroxy-N-(4-hydroxyphenyl)-N,1-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide",CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=C(O)C=C1,CYP3A4,Hydroxylation of benzene on carbon para to an electron donating group,0.99
lisofylline,CC(O)CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O,"lisofylline 4,5-diol",CC(O)C(O)CCCN1C(=O)C2=C(N=CN2C)N(C)C1=O,CYP3A4; CYP2A6,Hydroxylation of acyclic aliphatic secondary carbon,0.98
lisofylline,CC(O)CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O,pentoxifylline,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O,CYP1A2,Oxidation of secondary alcohol to ketone,0.97
loperamide,CN(C)C(=O)C(CCN1CCC(O)(C2=CC=C(Cl)C=C2)CC1)(C1=CC=CC=C1)C1=CC=CC=C1,N-Desmethyloperamide,CN=C(O)C(CCN1CCC(O)(C2=CC=C(Cl)C=C2)CC1)(C1=CC=CC=C1)C1=CC=CC=C1,CYP3A4; CYP2D6; CYP2C8; CYP2B6,N-dealkylation of tertiary carboxamide,0.58
loratadine,CCOC(=O)N1CCC(=C2C3=CC=C(Cl)C=C3CCC3=CC=CN=C23)CC1,,ClC1=CC=C2C(=C3CCNCC3)C3=NC=CC=C3CCC2=C1,CYP1A2;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP3A4,N_DEALKYLATION,0.91
lornoxicam,CN1C(C(O)=NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O,5'-Hydroxylornoxicam,CN1C(C(O)=NC2=CC=C(O)C=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O,CYP2C9 ,HYDROXYLATION_OF_HETEROAROMATIC_CARBON,0.99
losartan,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,E-3174,CCCCC1=NC(Cl)=C(C(=O)O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,CYP2C9; CYP3A4; CYP3A5,OXIDATION_OF_PRIM_ALCOHOL_TO_CARBOXYLIC_ACID,0.9
losartan carboxaldehyde,CCCCC1=NC(Cl)=C(C=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,,CCCC(O)C1=NC(Cl)=C(C=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,CYP3A4,Aliphatic Hydroxylation,0.89
losartan carboxaldehyde,CCCCC1=NC(Cl)=C(C=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,,CCCCC1=NC(Cl)=C(C(=O)O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,CYP3A4,Aliphatic Hydroxylation,0.9
lovastatin,CCC(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,6'beta-Hydroxylovastatin,CCC(C)C(=O)OC1CC(C)(O)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,CYP3A4,Hydroxylation of penultimate aliphatic tertiary carbon,0.9
lovastatin,CCC(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,3-Hydroxylovastatin,CCC(O)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,CYP3A4,Hydroxylation of acyclic aliphatic secondary carbon,0.93
m-xylene,CC1=CC=CC(C)=C1,"2,4-Dimethylphenol",CC1=CC=C(O)C(C)=C1,CYP1A2,"2-Hydroxylation of 1,4-disubstituted benzene",0.44
m-xylene,CC1=CC=CC(C)=C1,3-Methylbenzylalcohol,CC1=CC=CC(CO)=C1,CYP2E1,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.58
maprotiline,CNCCCC12CCC(C3=CC=CC=C31)C1=CC=CC=C12,desmethylmaprotiline,NCCCC12CCC(C3=CC=CC=C31)C1=CC=CC=C12,CYP2D6; CYP1A2,N-dealkylation of acyclic secondary amine,0.97
maprotiline,CNCCCC12CCC(C3=CC=CC=C31)C1=CC=CC=C12,3-OH-maprotiline,CNCCCC12CCC(C3=CC=CC=C31)C1=CC=C(O)C=C12,CYP2D6; CYP1A2,Aromatic hydroxylation of fused benzene ring,0.85
maprotiline,CNCCCC12CCC(C3=CC=CC=C31)C1=CC=CC=C12,2-OH-maprotiline,CNCCCC12CCC(C3=CC=CC=C31)C1=CC(O)=CC=C12,CYP2D6; CYP1A2,Aromatic hydroxylation of fused benzene ring,0.85
mefenamic acid,CC1=CC=CC(NC2=CC=CC=C2C(=O)O)=C1C,3-hydroxymethyl mefenamic aci,CC1=C(CO)C=CC=C1NC1=CC=CC=C1C(=O)O,CYP2C9 ,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.91
meiqx,CC1=CN=C2C=CC3=C(NC(=N)N3C)C2=N1,N-OH-MeIQX,CC1=CN=C2C=CC3=C(N=C(NO)N3C)C2=N1,CYP1A2,N-hydroxylation of primary arylamine,0.67
meiqx,CC1=CN=C2C=CC3=C(NC(=N)N3C)C2=N1,IQx-8-COOH,CN1C(=N)NC2=C3N=C(C(=O)O)C=NC3=CC=C21,CYP1A2,OXIDATION_OF_METHYL_TO_CARBOXYLIC_ACID,0.86
melatonin,COC1=CC=C2NC=C(CCN=C(C)O)C2=C1,6-Hydroxymelatonin,COC1=CC2=C(C=C1O)NC=C2CCN=C(C)O,CYP1A1; CYP1A2; CYP2C19 (minor); CYP2E1,Aromatic hydroxylation of fused benzene ring,0.88
melatonin,COC1=CC=C2NC=C(CCN=C(C)O)C2=C1,N-Acetyl-5-hydroxytryptamine,CC(O)=NCCC1=CNC2=CC=C(O)C=C12,CYP2C19 (major); CYP1A2; CYP2E1,O-aryl demethylation,0.93
meloxicam,CC1=CN=C(N=C(O)C2=C(O)C3=CC=CC=C3S(=O)(=O)N2C)S1,,CN1C(C(O)=NC2=NC=C(CO)S2)=C(O)C2=CC=CC=C2S1(=O)=O,CYP2C9;CYP3A4,Aliphatic Hydroxylation,0.98
meperidine,CCOC(=O)C1(C2=CC=CC=C2)CCN(C)CC1,normeperidine,CCOC(=O)C1(C2=CC=CC=C2)CCNCC1,CYP1A2;CYP2B6;CYP2C8;CYP2C19;CYP2D6;CYP3A4,N-DEMETHYLATION,0.94
methaqualone,CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O,hydroxy-methaqualone,CC1=CC(O)=CC=C1N1C(C)=NC2=CC=CC=C2C1=O,CYP3A4,Aromatic Hydroxylation,0.94
methaqualone,CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O,hydroxy-methaqualone,CC1=C(O)C=CC=C1N1C(C)=NC2=CC=CC=C2C1=O,CYP3A4,Aromatic Hydroxylation,0.91
methaqualone,CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O,hydroxy-methaqualone,CC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1CO,CYP3A4,Aliphatic Hydroxylation,0.95
methoxsalen,COC1=C2OC=CC2=CC2=C1OC(=O)C=C2,,COC1=C2OC3OC3C2=CC2=C1OC(=O)C=C2,CYP2A6,Epoxidation,0.41
methyleugenol,C=CCC1=CC=C(OC)C(OC)=C1,1Ã¢â‚¬Ëœ-hydroxylate methyleugenol,C=CC(O)C1=CC=C(OC)C(OC)=C1,CYP1A2;CYP2C9;CYP2C19;CYP2D6,Aliphatic Hydroxylation,0.75
metoclopramide,CCN(CC)CCN=C(O)C1=CC(Cl)=C(N)C=C1OC,monodeethylmetoclopramide,CCNCCN=C(O)C1=CC(Cl)=C(N)C=C1OC,CYP1A2;CYP2C8;CYP2C19;CYP2D6;CYP3A4,N-dealkylation,0.98
midazolam,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N21,1'-Hydroxymidazolam,OCC1=NC=C2CN=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N21,CYP3A4; CYP3A5; CYP3A7; CYP2B6,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.95
midazolam,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N21,4-Hydroxymidazolam,CC1=NC=C2C(O)N=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N21,CYP3A4; CYP3A5; CYP3A7,"3-Hydroxylation of 5-aryl-1,4-benzodiazepine",0.91
mifepristone,CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(C3=CC=C(N(C)C)C=C3)CC21C,Monodemethylated mifepristone,CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(C3=CC=C(NC)C=C3)CC21C,CYP3A4,N-dealkylation of mixed tertiary amine,0.99
mifepristone,CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(C3=CC=C(N(C)C)C=C3)CC21C,17alpha-hydroxymifepristone ,CN(C)C1=CC=C(C2CC3(C)C(CCC3(O)C#CCO)C3CCC4=CC(=O)CCC4=C23)C=C1,CYP3A4,Aliphatic hydroxylation of methyl carbon adjacent to alkyne ring,0.99
minaprine,CC1=CC(C2=CC=CC=C2)=NNC1=NCCN1CCOCC1,4-Hydroxyminaprine,CC1=CC(C2=CC=C(O)C=C2)=NNC1=NCCN1CCOCC1,CYP2D6,p-Hydroxylation of monosubstituted benzene,0.94
miocamycin,CCC(=O)OC1CC(=O)OC(C)CC=CC=CC(OC(C)=O)C(C)CC(CC=O)C(OC2OC(C)C(OC3CC(C)(OC(C)=O)C(OC(=O)CC)C(C)O3)C(N(C)C)C2O)C1OC,,CCC(=O)OC1CC(=O)OC(C)CC=CC=CC(OC(C)=O)C(C)CC(CC=O)C(OC2OC(C)C(OC3CC(C)(OC(C)=O)C(O)(OC(=O)CC)C(C)O3)C(N(C)C)C2O)C1OC,CYP3A4,Aliphatic Hydroxylation,0.93
montelukast,CC(C)(O)C1=CC=CC=C1CCC(SCC1(CC(=O)O)CC1)C1=CC=CC(C=CC2=CC=C3C=CC(Cl)=CC3=N2)=C1,montelukast sulfoxide,CC(C)(O)C1=CC=CC=C1CCC(C1=CC=CC(C=CC2=CC=C3C=CC(Cl)=CC3=N2)=C1)S(=O)CC1(CC(=O)O)CC1,CYP3A4; CYP2A6,S-oxidation of dialkylthioether to sulfoxide,0.91
montelukast,CC(C)(O)C1=CC=CC=C1CCC(SCC1(CC(=O)O)CC1)C1=CC=CC(C=CC2=CC=C3C=CC(Cl)=CC3=N2)=C1,21-Hydroxymontelukast,CC(C)(O)C1=CC=CC=C1C(O)CC(SCC1(CC(=O)O)CC1)C1=CC=CC(C=CC2=CC=C3C=CC(Cl)=CC3=N2)=C1,CYP3A4,Hydroxylation of acyclic aliphatic secondary carbon,0.94
montelukast,CC(C)(O)C1=CC=CC=C1CCC(SCC1(CC(=O)O)CC1)C1=CC=CC(C=CC2=CC=C3C=CC(Cl)=CC3=N2)=C1,"[1Ã¢â‚¬Â({[(1R,3S)Ã¢â‚¬Â1Ã¢â‚¬Â{3Ã¢â‚¬Â[(E)Ã¢â‚¬Â2Ã¢â‚¬Â(7Ã¢â‚¬ÂchloroquinolinÃ¢â‚¬Â2Ã¢â‚¬Âyl)ethenyl]phenyl}Ã¢â‚¬Â3Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â3Ã¢â‚¬Â[2Ã¢â‚¬Â(2Ã¢â‚¬ÂhydroxypropanÃ¢â‚¬Â2Ã¢â‚¬Âyl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]aceticacid",CC(C)(O)C1=CC=CC=C1C(O)CC(SCC1(CC(=O)O)CC1)C1=CC=CC(C=CC2=CC=C3C=CC(Cl)=CC3=N2)=C1,CYP3A4,Hydroxylation of acyclic aliphatic secondary carbon,0.94
montelukast,CC(C)(O)C1=CC=CC=C1CCC(SCC1(CC(=O)O)CC1)C1=CC=CC(C=CC2=CC=C3C=CC(Cl)=CC3=N2)=C1,"[1Ã¢â‚¬Â({[(1R)Ã¢â‚¬Â1Ã¢â‚¬Â{3Ã¢â‚¬Â[(E)Ã¢â‚¬Â2Ã¢â‚¬Â(7Ã¢â‚¬ÂchloroquinolinÃ¢â‚¬Â2Ã¢â‚¬Âyl)ethenyl]phenyl}Ã¢â‚¬Â3Ã¢â‚¬Â[2Ã¢â‚¬Â(1,2Ã¢â‚¬ÂdihydroxypropanÃ¢â‚¬Â2Ã¢â‚¬Âyl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]aceticacid",CC(O)(CO)C1=CC=CC=C1CCC(SCC1(CC(=O)O)CC1)C1=CC=CC(C=CC2=CC=C3C=CC(Cl)=CC3=N2)=C1,CYP2C9,Hydroxylation of terminal methyl,0.95
morphine,CN1CC2CC3=CC=C(O)C4=C3C3(C1)C2C=CC(O)C3O4,Normorphine,OC1=CC=C2CC3CNCC45C2=C1OC4C(O)C=CC35,CYP2C8;CYP3A4,O-Demethylation,0.98
muraglitazar,COC1=CC=C(OC(=O)N(CC(=O)O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)C=C1,,COC1=CC=C(OC(=O)N(CC(=O)O)CC2=CC=C(OCCC3=C(CO)OC(C4=CC=CC=C4)=N3)C=C2)C=C1,CYP2C8;CYP2C9;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.94
muraglitazar,COC1=CC=C(OC(=O)N(CC(=O)O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)C=C1,,COC1=CC=C(OC(=O)N(CC(=O)O)CC2=CC=C(OCC(O)C3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)C=C1,CYP3A4,Aliphatic Hydroxylation,0.88
muraglitazar,COC1=CC=C(OC(=O)N(CC(=O)O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)C=C1,,COC1=CC=C(OC(=O)N(CC(=O)O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=C(O)C=C4)=N3)C=C2)C=C1,CYP2C19,Aromatic Hydroxylation,0.99
muraglitazar,COC1=CC=C(OC(=O)N(CC(=O)O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)C=C1,,COC1=CC=C(OC(=O)N(CC(=O)O)CC2=CC=C(O)C=C2)C=C1,CYP2C8;CYP2D6;CYP3A4,Aromatic Hydroxylation,0.51
mycophenolic acid,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1CC=C(C)CCC(=O)O,6-O-desmethyl-MPA (DM-MPA),CC(=CCC1=C(O)C(C)=C2COC(=O)C2=C1O)CCC(=O)O,CYP3A4,O-Desmethylation,0.91
myristicin,C=CCC1=CC(OC)=C2OCOC2=C1,"5-allyl-1-methoxy-2,3-dihydroxybenzene",C=CCC1=CC(O)=C(O)C(OC)=C1,CYP3A4;CYP1A2,Nifedipine Oxidation,0.75
n_ac_dfec,CC(O)=NC(CSC(F)(F)C(OCF)C(F)F)C(=O)O,N-Ac-DFEC-SO,CC(O)=NC(CS(=O)C(F)(F)C(OCF)C(F)F)C(=O)O,CYP3A4,S-Oxidation,0.76
n_ac_ffvc,CC(O)=NC(CSC(F)=C(OCF)C(F)F)C(=O)O,N-Ac-FFVC-SO,CC(O)=NC(CS(=O)C(F)=C(OCF)C(F)F)C(=O)O,CYP3A4,S-Oxidation,0.76
n_ac_pcbc,NC(CSC(Cl)=C(Cl)C(Cl)=C(Cl)Cl)C(=O)O,N-Ac-PCBC-SO,NC(CS(=O)C(Cl)=C(Cl)C(Cl)=C(Cl)Cl)C(=O)O,CYP3A4,S-Oxidation,0.71
n-({4-[(5-bromopyrimidin-2-yl)oxy]-3-methylphenyl}carbamoyl)-2-(dimethylamino)benzamide,CC1=CC(NC(=O)N=C(O)C2=CC=CC=C2N(C)C)=CC=C1OC1=NC=C(Br)C=N1,mmBPU,CNC1=CC=CC=C1C(O)=NC(=O)NC1=CC=C(OC2=NC=C(Br)C=N2)C(C)=C1,CYP1A1;CYP2D6;CYP2C9;CYP3A4;CYP3A5;CYP3A7,N-Demethylation,0.96
n-(2-phenylethyl)indomethacin amide,COC1=CC=C2C(=C1)C(CC(O)=NCCC1=CC=CC=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,,COC1=CC=C2C(=C1)C(CC(O)=NCC(O)C1=CC=CC=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.97
n-(2-phenylethyl)indomethacin amide,COC1=CC=C2C(=C1)C(CC(O)=NCCC1=CC=CC=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,,COC1=CC=C2C(=C1)C(CC(O)=NC(O)CC1=CC=CC=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,CYP3A4,Aliphatic Hydroxylation,0.98
n-(2-phenylethyl)indomethacin amide,COC1=CC=C2C(=C1)C(CC(O)=NCCC1=CC=CC=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,,CC1=C(CC(O)=NCCC2=CC=CC=C2)C2=CC(O)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1,CYP2C9;CYP2C19;CYP2D6,O-Demethylation,0.98
n-nitroso-n-methylaniline (NMPhA),CN(N=O)C1=CC=CC=C1,,O=NN(CO)C1=CC=CC=C1,CYP2A6,Aliphatic Hydroxylation,0.76
n-nitrosodibutylamine,CCCCN(CCCC)N=O,,CCCCN(N=O)C(O)CCC,CYP2A6;CYP2E1,Aliphatic Hydroxylation,0.47
"n,n-diethyl-n'-(1-ethyl-6-methylergolin-8alpha-yl)sulfamide",CCN(CC)S(=O)(=O)NC1CC2C3=CC=CC4=C3C(=CN4CC)CC2N(C)C1,,CCNS(=O)(=O)NC1CC2C3=CC=CC4=C3C(=CN4CC)CC2N(C)C1,CYP3A4,N-Dealkylation,0.98
"n,n-diethylformamide",CCN(C=O)CC,,CCN(C=O)C(C)O,CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.47
"n,n-dimethyl-5-methoxytryptamine",COC1=CC=C2NC=C(CCN(C)C)C2=C1,Bufotenine,CN(C)CCC1=CNC2=CC=C(O)C=C12,CYP2D6,O-demethylation,0.92
nabumetone,COC1=CC=C2C=C(CCC(C)=O)C=CC2=C1,4Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â4Ã¢â‚¬Â(6Ã¢â‚¬ÂmethoxynaphthalenÃ¢â‚¬Â2Ã¢â‚¬Âyl)butanÃ¢â‚¬Â2Ã¢â‚¬Âone,COC1=CC=C2C=C(C(O)CC(C)=O)C=CC2=C1,CYP1A2,Alpha hydroxylation of carbonyl group,0.77
naphthalene,C1=CC=C2C=CC=CC2=C1,2-Naphthol,OC1=CC=C2C=CC=CC2=C1,CYP3A4,Aromatic Hydroxylation,0.48
naphthalene,C1=CC=C2C=CC=CC2=C1,1-Naphthol,OC1=CC=CC2=CC=CC=C12,CYP1A2,Aromatic Hydroxylation,0.42
naphthalene,C1=CC=C2C=CC=CC2=C1,dihydrodiol,OC1=CC=C2C=CC=CC2=C1O,CYP1A2,Aromatic Hydroxylation,0.32
naphthalene,C1=CC=C2C=CC=CC2=C1,"naphthalene-1,2 Expodation",C1=CC2OC2C2=CC=CC=C12,CYP1A2;CYP3A4,Epoxidation,0.05
naproxen,COC1=CC=C2C=C(C(C)C(=O)O)C=CC2=C1,Desmethylnaproxen ,CC(C(=O)O)C1=CC=C2C=C(O)C=CC2=C1,CYP2C9 (major); CYP1A2 ,O-aryl dealkylation not adjacent to substituted carbon,0.91
nefazodone,CCC1=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,,CCC1=NN(CCCN2CCN(C3=CC=C(O)C(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,CYP3A4,Aromatic Hydroxylation,0.96
nefazodone,CCC1=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,,CC(O)C1=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,CYP3A4,Aliphatic Hydroxylation,0.91
nefazodone,CCC1=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,,ClC1=CC=CC(N2CCNCC2)=C1,CYP3A4,N-Dealkylation,0.26
nefazodone,CCC1=NN(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,,CCC1=NN(CCCO)C(=O)N1CCOC1=CC=CC=C1,CYP3A4,N-Dealkylation,0.75
nevirapine,CC1=CC=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,2-OH-nevirapine,CC1=CC(O)=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,CYP3A4,HYDROXYLATION_OF_HETEROAROMATIC_CARBON,0.93
nevirapine,CC1=CC=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,8-OH-nevirapine,CC1=CC=NC2=C1N=C(O)C1=CC(O)=CN=C1N2C1CC1,CYP2D6 (major); CYP2B6 (minor); CYP3A4 (minor),HYDROXYLATION_OF_HETEROAROMATIC_CARBON,0.95
nevirapine,CC1=CC=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,3-OH-nevirapine,CC1=C(O)C=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,CYP2B6,HYDROXYLATION_OF_HETEROAROMATIC_CARBON,0.93
nevirapine,CC1=CC=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,12-OH-nevirapine,OCCC1=CC=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,CYP3A4 (major); CYP2D6 (minor); CYP2C9 (minor),Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.96
nicotine,CN1CCCC1C1=CC=CN=C1,"(S)-Nicotine ÃŽâ€1Ã¢â‚¬Â²,5Ã¢â‚¬Â²-iminium ion",C[N+]1=CCCC1C1=CC=CN=C1,CYP2A6 (major); CYP2B6; CYP2A13,Formation of iminium from pyrrolidine ring,0.56
nicotine,CN1CCCC1C1=CC=CN=C1,2Ã¢â‚¬Â²-Hydroxynicotine,CN1CCCC1(O)C1=CC=CN=C1,CYP2A6,Hydroxylation of heteroalicyclic secondary carbon,0.66
nicotine,CN1CCCC1C1=CC=CN=C1,Nornicotine,C1=CN=CC(C2CCCN2)=C1,CYP2A6; CYP2B6; CYP2A13,N_DEALKYLATION_OF_CYCLIC_TERTIARY_AMINES; N_DEALKYLATION_OF_ALICYCLIC_TERTIARY_AMINES_PATTERN1,0.86
nifedipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+](=O)[O-],Oxidized nifedipine,COC(=O)C1=C(C)N=C(C)C(C(=O)OC)=C1C1=CC=CC=C1[N+](=O)[O-],CYP3A4,"Dehydrogenation of 4-aryl substituted 1,4-dihydropyridine",0.35
nnal,CN(CCC(O)C(=O)C1=CC=CN=C1)N=O,,CN(CCC(O)C(=O)C1=CC=C[N+]([O-])=C1)N=O,CYP3A4,N-Oxidation,0.86
nnal,CN(CCC(O)C(=O)C1=CC=CN=C1)N=O,,CN(N=O)C(O)CC(O)C(=O)C1=CC=CN=C1,CYP3A4,Aliphatic Hydroxylation,0.84
nordiazepam,OC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=NC1,OXAZEPAM,OC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=NC1O,CYP1A2;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.87
nortriptyline,CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,E-10-OH-nortriptyline,CNCCC=C1C2=CC=CC=C2CC(O)C2=CC=CC=C12,CYP2D6,Hydroxylation of alicyclic secondary carbon,0.73
nortriptyline,CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,demethylnortriptyline,NCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,CYP2C19,N-dealkylation of acyclic secondary amine,0.98
o-xylene,CC1=CC=CC=C1C,"2,3-Dimethylphenol",CC1=CC=C(O)C=C1C,CYP2E1,Aromatic Hydroxylation,0.47
o-xylene,CC1=CC=CC=C1C,"3,4-Dimethylphenol",CC1=CC=CC(O)=C1C,CYP2E1,Aromatic Hydroxylation,0.42
o-xylene,CC1=CC=CC=C1C,2 Methylbenzylalcohol,CC1=CC=CC=C1CO,CYP2E1,Aliphatic Hydroxylation,0.58
olanzapine,CC1=CC2=C(NC3=CC=CC=C3N=C2N2CCN(C)CC2)S1,,CN1CCN(C2=NC3=CC=CC=C3NC3=C2C=C(CO)S3)CC1,CYP1A2;CYP2D6;CYP3A4,ALIPHATIC HYDROXYLATION,0.95
olanzapine,CC1=CC2=C(NC3=CC=CC=C3N=C2N2CCN(C)CC2)S1,,CC1=CC2=C(NC3=CC=CC=C3N=C2N2CC[N+](C)([O-])CC2)S1,CYP1A2;CYP2D6;CYP3A4,N-OXIDATION,0.97
olanzapine,CC1=CC2=C(NC3=CC=CC=C3N=C2N2CCN(C)CC2)S1,,CC1=CC2=C(NC3=CC=C(O)C=C3N=C2N2CCN(C)CC2)S1,CYP1A2;CYP2D6,AROMATIC HYDROXYLATION,0.96
oleic acid,CCCCCCCCC=CCCCCCCCC(=O)O,,CC(O)CCCCCCC=CCCCCCCCC(=O)O,CYP2E1;CYP4A11,Aliphatic Hydroxylation,0.89
olopatadine,CN(C)CCC=C1C2=CC=CC=C2COC2=CC=C(CC(=O)O)C=C12,N-monodemethylolopatadine,CNCCC=C1C2=CC=CC=C2COC2=CC=C(CC(=O)O)C=C12,CYP3A4,N-Dementhylation,0.99
onapristone,CN(C)C1=CC=C(C2CC3(C)C(CCC3(O)CCCO)C3CCC4=CC(=O)CCC4=C23)C=C1,,CNC1=CC=C(C2CC3(C)C(CCC3(O)CCCO)C3CCC4=CC(=O)CCC4=C23)C=C1,CYP3A4,N-Demethylation,0.98
opc-13448,COC(=O)C1=C(C)N=C(C)C(C(=O)OCC=CC2=CC=CC=C2)=C1C1=CC=CC([N+](=O)[O-])=C1,OPC-13463,COC(=O)C1=C(C)N=C(C)C(C(=O)O)=C1C1=CC=CC([N+](=O)[O-])=C1,CYP1A2;CYP2D6;CYP3A4,N-Demethylation,0.92
org_30659,C#CC1(O)C=CC2C3CCC4=CC(=O)CCC4C3C(=C)CC21C,,C#CC1(O)C=CC2C3C(O)CC4=CC(=O)CCC4C3C(=C)CC21C,CYP3A4,Aliphatic Hydroxylation,0.92
oxycodone,COC1=CC=C2CC3N(C)CCC45C2=C1OC4C(=O)CCC35O,noroxycodone,COC1=CC=C2CC3NCCC45C2=C1OC4C(=O)CCC35O,CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4,N-demethylation,0.98
p-cresol,CC1=CC=C(O)C=C1,4-methyl-hydroquinone,CC1=CC=C(O)C(O)=C1,CYP2E1,Aromatic Hydroxylation,0.62
p-cresol,CC1=CC=C(O)C=C1,,CC1C=CC(=O)C=C1,CYP1A2;CYP2C19;CYP2D6;CYP2E1,Dehydrogenation,0.01
p-cresol,CC1=CC=C(O)C=C1,,OCC1=CC=C(O)C=C1,CYP1A2;CYP2C19;CYP2D6;CYP2E1,Aliphatic Hydroxylation,0.71
p-xylene,CC1=CC=C(C)C=C1,4-Methylbenzylalcohol,CC1=CC=C(CO)C=C1,CYP2E1,Aliphatic Hydroxylation,0.6
p-xylene,CC1=CC=C(C)C=C1,"2,5-dimethylphenol",CC1=CC=C(C)C(O)=C1,CYP2E1,Aliphatic Hydroxylation,0.38
palmitic acid,CCCCCCCCCCCCCCCC(=O)O,,CC(O)CCCCCCCCCCCCCC(=O)O,CYP2E1;CYP4A11,Aliphatic Hydroxylation,0.84
parathion,CCOP(=S)(OCC)OC1=CC=C([N+](=O)[O-])C=C1,Paraoxon,CCOP(=O)(OCC)OC1=CC=C([N+](=O)[O-])C=C1,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,Desulfation,0.65
pefloxacin,CCN1C=C(C(=O)O)C(=O)C2=CC(F)=C(N3CCN(C)CC3)C=C21,"pefloxacin, N-desmethyl",CCN1C=C(C(=O)O)C(=O)C2=CC(F)=C(N3CCNCC3)C=C21,CYP1A2,N-dealkylation of alicyclic tertiary amine,0.99
pentachlorobenzene,ClC1=CC(Cl)=C(Cl)C(Cl)=C1Cl,PCP,OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl,CYP3A4,Aromatic Hydroxylation,0.46
pentoxyresorufin,CCCCCOC1=CC=C2N=C3C=CC(=O)C=C3OC2=C1,Resorufin,O=C1C=CC2=NC3=CC=C(O)C=C3OC2=C1,CYP1A1; CYP1A2; CYP1B1,O-aryl dealkylation not adjacent to substituted carbon,0.91
perazine,CN1CCN(CCCN2C3=CC=CC=C3SC3=CC=CC=C32)CC1,,CN1CCN(CCCN2C3=CC=CC=C3S(=O)C3=CC=CC=C32)CC1,CYP1A2;CYP2A6;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,S-Oxidation,0.83
perphenazine,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C32)CC1,N-Dealkylated perphenazine,ClC1=CC=C2SC3=CC=CC=C3N(CCCN3CCNCC3)C2=C1,CYP1A2; CYP3A4; CYP2C9; CYP2C19; CYP2D6 ,N-dealkylation of alicyclic tertiary amine,0.98
perphenazine,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C32)CC1,Perphenazine sulfoxide,O=S1C2=CC=CC=C2N(CCCN2CCN(CCO)CC2)C2=CC(Cl)=CC=C21,CYP2D6,S-oxidation of diarylthioether to sulfoxide,0.85
phenacetin,CCOC1=CC=C(N=C(C)O)C=C1,Acetaminophen,CC(O)=NC1=CC=C(O)C=C1,CYP1A1; CYP1A2; CYP2E1; CYP2D6; CYP2C19; CYP2C9; CYP2A6,O-dealkylation,0.78
phenacetin,CCOC1=CC=C(N=C(C)O)C=C1,N-OH-phenacetin,CCOC1=CC=C(N(O)C(C)=O)C=C1,CYP1A1; CYP1A2,N-hydroxylation of secondary arylamide,0.36
phenanthrene,C1=CC=C2C(=C1)C=CC1=CC=CC=C12,,OC1=CC=C2C(=C1O)C=CC1=CC=CC=C12,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4,Aromatic Hydroxylation,0.37
phenanthrene,C1=CC=C2C(=C1)C=CC1=CC=CC=C12,,OC1=CC=C2C=CC3=CC=CC=C3C2=C1O,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4,Aromatic Hydroxylation,0.37
phenanthrene,C1=CC=C2C(=C1)C=CC1=CC=CC=C12,,OC1=C(O)C2=CC=CC=C2C2=CC=CC=C12,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4,Aromatic Hydroxylation,0.37
phencyclidine,C1=CC=C(C2(N3CCCCC3)CCCCC2)C=C1,PCHP,OC1CCN(C2(C3=CC=CC=C3)CCCCC2)CC1,CYP3A4,Aliphatic Hydroxylation,0.93
phencyclidine,C1=CC=C(C2(N3CCCCC3)CCCCC2)C=C1,c-PPC/t-PPC,OC1CCC(C2=CC=CC=C2)(N2CCCCC2)CC1,CYP3A4,Aliphatic Hydroxylation,0.89
phenformin,N=C(N)NC(=N)NCCC1=CC=CC=C1,,N=C(N)NC(=N)NCCC1=CC=C(O)C=C1,CYP2D6,Aromatic Hydroxylation,0.81
phenytoin,OC1=NC(C2=CC=CC=C2)(C2=CC=CC=C2)C(O)=N1,3'-HPPH,OC1=NC(C2=CC=CC=C2)(C2=CC=CC(O)=C2)C(O)=N1,CYP2C9; CYP2C19,m-Hydroxylation of monosubstituted benzene,0.86
phenytoin,OC1=NC(C2=CC=CC=C2)(C2=CC=CC=C2)C(O)=N1,4'-HPPH,OC1=NC(C2=CC=CC=C2)(C2=CC=C(O)C=C2)C(O)=N1,CYP2C9 (major); CYP2C19 (minor),p-Hydroxylation of monosubstituted benzene,0.93
phenytoin,OC1=NC(C2=CC=CC=C2)(C2=CC=CC=C2)C(O)=N1,"5Ã¢â‚¬Â(3,4Ã¢â‚¬ÂdihydroxycyclohexaÃ¢â‚¬Â1,5Ã¢â‚¬ÂdienÃ¢â‚¬Â1Ã¢â‚¬Âyl)Ã¢â‚¬Â5Ã¢â‚¬ÂphenylimidazolidineÃ¢â‚¬Â2,4Ã¢â‚¬Âdione",OC1=NC(C2=CC(O)C(O)C=C2)(C2=CC=CC=C2)C(O)=N1,CYP2C9; CYP2C19,DIHYDROXYLATION_OF_DOUBLE_BOND,0.4
pilocarpine,CCC1C(=O)OCC1CC1=CN=CN1C,3-hydroxypilocarpine,CCC1(O)C(=O)OCC1CC1=CN=CN1C,CYP2A6,Aliphatic Hydroxylation,0.82
pimozide,OC1=NC2=CC=CC=C2N1C1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1,"1,3- dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one (DHPBI)",OC1=NC2=CC=CC=C2N1C1CCNCC1,CYP1A2;CYP3A4,N-dealkylation,0.76
piroxicam,CN1C(C(O)=NC2=CC=CC=N2)=C(O)C2=CC=CC=C2S1(=O)=O,5'-Hydroxypiroxicam,CN1C(C(O)=NC2=CC=C(O)C=N2)=C(O)C2=CC=CC=C2S1(=O)=O,CYP2C9,HYDROXYLATION_OF_HETEROAROMATIC_CARBON,0.98
pradefovir,NC1=NC=NC2=C1N=CN2CCOCP1(=O)OCCC(C2=CC=CC(Cl)=C2)O1,PMEA,NC1=NC=NC2=C1N=CN2CCOCP(=O)(O)O,CYP3A4,Oxidation,0.63
pregnenolone,CC(=O)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,,CC(=O)C1C(O)CC2C3CC=C4CC(O)CCC4(C)C3CCC21C,CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.85
pregnenolone,CC(=O)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,,CC12CCC(O)CC1=CCC1C2CCC2(C)C(C(=O)CO)CCC12,CYP2C19;CYP2D6,Aliphatic Hydroxylation,0.96
progesterone,CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C,2beta-OH-progesterone,CC(=O)C1CCC2C3CCC4=CC(=O)C(O)CC4(C)C3CCC12C,CYP3A4,Alpha hydroxylation of carbonyl group,0.73
progesterone,CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C,6beta-OH-progesterone,CC(=O)C1CCC2C3CC(O)C4=CC(=O)CCC4(C)C3CCC12C,CYP3A4; CYP3A4; CYP4B1,Hydroxylation of carbon gamma to conjugated carbonyl,0.73
progesterone,CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C,16beta-OH-progesterone,CC(=O)C1C(O)CC2C3CCC4=CC(=O)CCC4(C)C3CCC21C,CYP3A4; CYP1A1; CYP2D6; CYP2C19,Hydroxylation of alicyclic secondary carbon,0.77
progesterone,CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C,17beta-OH-progesterone,CC(=O)C1(O)CCC2C3CCC4=CC(=O)CCC4(C)C3CCC21C,CYP2D4; CYP2D6; CYP2C19 ,Alpha hydroxylation of carbonyl group,0.71
progesterone,CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C,21-OH-progesterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(C(=O)CO)CCC12,CYP2C9,Alpha hydroxylation of carbonyl group,0.9
promazine,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C21,Promazine 5-sulfoxide,CN(C)CCCN1C2=CC=CC=C2S(=O)C2=CC=CC=C21,CYP1A2 (major); CYP3A4 (major); CYP2A6 (minor); CYP2B6 (minor; CYP2D6 (minor); CYP2E1 (minor),S-oxidation of alkylarylthioether to sulfoxide,0.81
promazine,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C21,N-Desmethyl promazine,CNCCCN1C2=CC=CC=C2SC2=CC=CC=C21,CYP1A2 (major); CYP2C9 (minor); CYP2C19 (major); CYP2A6 (minor); CYP2B6 (minor); CYP2D6 (minor); CYP2E1 (minor),N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES,0.98
propofol,CC(C)C1=CC=CC(C(C)C)=C1O,4-OH-propofol,CC(C)C1=CC(O)=CC(C(C)C)=C1O,CYP2B6 (major); CYP2C9 (major); CYP1A2 (minor); CYP2A6 (minor); CYP2C8 (minor); CYP2C19 (minor); CYP2D6 (minor),Hydroxylation of benzene on carbon para to a strongly electron donating group,0.83
psoralen,O=C1C=CC2=CC3=C(C=C2O1)OC=C3,,O=C1C=CC2=CC3=C(C=C2O1)OC1OC31,CYP2A6,Epoxidation,0.3
Stearic Acid,CCCCCCCCCCCCCCCCCC(=O)O,,CC(O)CCCCCCCCCCCCCCCC(=O)O,CYP2E1;CYP4A11,Aliphatic Hydroxylation,0.84
qttnoskslatgqb-uhfffaoysa-n,O=C(O)CCC1=C2CC3=C(CC(=O)O)C(CCC(=O)O)=C(CC4=C(CC(=O)O)C(CCC(=O)O)=C(CC5=C(CC(=O)O)C(CCC(=O)O)=C(CC(=C1CC(=O)O)N2)N5)N4)N3,uroporphyrin,O=C(O)CCC1=C2CC3=C(CC(=O)O)C(CCC(=O)O)=C(N3)C(O)C3=C(CC(=O)O)C(CCC(=O)O)=C(CC4=C(CC(=O)O)C(CCC(=O)O)=C(CC(=C1CC(=O)O)N2)N4)N3,CYP1A2;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.82
quazepam,FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12,2-Oxoquazepam,O=C1CN=C(C2=CC=CC=C2F)C2=CC(Cl)=CC=C2N1CC(F)(F)F,CYP2C9,Desulfurization of thioamide into amide,0.8
quazepam,FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12,2-Oxoquazepam,O=C1CN=C(C2=CC=CC=C2F)C2=CC(Cl)=CC=C2N1CC(F)(F)F,CYP2C19,Desulfurization of thioamide into amide,0.8
quazepam,FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12,2-Oxoquazepam,O=C1CN=C(C2=CC=CC=C2F)C2=CC(Cl)=CC=C2N1CC(F)(F)F,CYP3A4,Desulfurization of thioamide into amide,0.8
quetiapine,OCCOCCN1CCN(C2=NC3=CC=CC=C3SC3=CC=CC=C23)CC1,,O=S1C2=CC=CC=C2N=C(N2CCN(CCOCCO)CC2)C2=CC=CC=C21,CYP3A4,S-Oxidation,0.88
quetiapine,OCCOCCN1CCN(C2=NC3=CC=CC=C3SC3=CC=CC=C23)CC1,,OCCOCCN1CCN(C2=NC3=CC=C(O)C=C3SC3=CC=CC=C23)CC1,CYP2D6,Aromatic Hydroxylation,0.93
quinidine,C=CC1CN2CCC1CC2C(O)C1=CC=NC2=CC=C(OC)C=C12,3-Hydroxyquinidine,C=CC1(O)CN2CCC1CC2C(O)C1=CC=NC2=CC=C(OC)C=C12,CYP3A4,Allylic hydroxylation,0.89
quinidine,C=CC1CN2CCC1CC2C(O)C1=CC=NC2=CC=C(OC)C=C12,Quinidine-N-oxide,C=CC1C[N+]2([O-])CCC1CC2C(O)C1=CC=NC2=CC=C(OC)C=C12,CYP3A4; CYP2C9; CYP2E1,Oxidation of nitrogen in a strained ring system,0.88
quinine,C=CC1CN2CCC1CC2C(O)C1=CC=NC2=CC=C(OC)C=C12,,C=CC1(O)CN2CCC1CC2C(O)C1=CC=NC2=CC=C(OC)C=C12,CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.89
quinoline,C1=CC=C2N=CC=CC2=C1,"Q-8,6-epoxide",C1=CC2OC2C2=CC=CN=C12,CYP1A2;CYP2A6;CYP2D6;CYP2E1;,EPOXIDATION,0.09
quinoline,C1=CC=C2N=CC=CC2=C1,Quinoline 1-oxide,[O-][N+]1=CC=CC2=CC=CC=C21,CYP1A2;CYP2A6;CYP2E1;CYP3A4,N-OXIDATION,0.69
quinoline,C1=CC=C2N=CC=CC2=C1,3OHQ,OC1=CN=C2C=CC=CC2=C1,CYP1A2;CYP2A6;CYP2E1,AROMATIC HYDROXYLATION,0.62
qun,CCN(CC)CCCC(C)N=C1C2=CC=C(Cl)C=C2NC2=CC=C(OC)C=C12,,CCNCCCC(C)N=C1C2=CC=C(Cl)C=C2NC2=CC=C(OC)C=C12,CYP3A4,N-desethylation,0.98
qun,CCN(CC)CCCC(C)N=C1C2=CC=C(Cl)C=C2NC2=CC=C(OC)C=C12,,CCN(CC)CCCC(C)N=C1C2=CC=C(Cl)C=C2NC2=CC=C(O)C=C12,CYP3A4,O-dementhylation,0.95
qun,CCN(CC)CCCC(C)N=C1C2=CC=C(Cl)C=C2NC2=CC=C(OC)C=C12,,COC1=CC=C2NC3=CC(Cl)=CC=C3C(=N)C2=C1,CYP3A4,O-dementhylation,0.73
(R)-mianserin,CN1CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,"(R)-mianserin, N-Desmethyl",C1=CC=C2C(=C1)CC1=CC=CC=C1N1CCNCC21,CYP2D6; CYP1A2; CYP3A4; CYP2B6,N-dealkylation of alicyclic tertiary amine,0.96
(R)-mianserin,CN1CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,"(R)-mianserin, 8-hydroxy",CN1CCN2C3=CC(O)=CC=C3CC3=CC=CC=C3C2C1,CYP2D6; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.93
(R)-mianserin,CN1CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,"(R)-mianserin, N-oxide",C[N+]1([O-])CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,CYP3A4,N-oxidation of alicyclic tertiary amine,0.91
raloxifene,O=C(C1=CC=C(OCCN2CCCCC2)C=C1)C1=C(C2=CC=C(O)C=C2)SC2=CC(O)=CC=C12,,O=C(C1=CC=C(OCCN2CCCCC2)C=C1)C1=C(C2=CC=C(O)C=C2)SC2=C(O)C(O)=CC=C12,CYP2D6,Aromatic Hydroxylation,0.92
raloxifene,O=C(C1=CC=C(OCCN2CCCCC2)C=C1)C1=C(C2=CC=C(O)C=C2)SC2=CC(O)=CC=C12,,O=C(C1=CC=C(OCCN2CCCCC2)C=C1)C1=C(C2=CC=C(O)C(O)=C2)SC2=CC(O)=CC=C12,CYP2D6,Aromatic Hydroxylation,0.95
ranitidine,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(CN(C)C)O1,Desmethylranitidine,CNCC1=CC=C(CSCCNC(=C[N+](=O)[O-])NC)O1,CYP2C19; CYP1A2; CYP2D6,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES,0.96
reboxetine,CCOC1=CC=CC=C1OC(C1=CC=CC=C1)C1CNCCO1,O-desethylreboxetine,OC1=CC=CC=C1OC(C1=CC=CC=C1)C1CNCCO1,CYP3A4,Desethylation,0.97
reboxetine,CCOC1=CC=CC=C1OC(C1=CC=CC=C1)C1CNCCO1,Phenol B,CCOC1=CC(O)=CC=C1OC(C1=CC=CC=C1)C1CNCCO1,CYP3A4,Aromatic Hydroxylation,0.95
reboxetine,CCOC1=CC=CC=C1OC(C1=CC=CC=C1)C1CNCCO1,Phenol A,CCOC1=CC=C(O)C=C1OC(C1=CC=CC=C1)C1CNCCO1,CYP3A4,Aromatic Hydroxylation,0.94
reduced_dolasetron,O=C(OC1CC2CC3CC(C1)N2CC3O)C1=CNC2=CC=CC=C12,Dolasetron N-oxide,O=C(OC1CC2CC3CC(C1)[N+]2([O-])CC3O)C1=CNC2=CC=CC=C12,CYP3A4,Oxidation of nitrogen in a strained ring system,0.91
reduced_dolasetron,O=C(OC1CC2CC3CC(C1)N2CC3O)C1=CNC2=CC=CC=C12,6-Hydroxydolasetron,O=C(OC1CC2CC3CC(C1)N2CC3O)C1=CNC2=CC(O)=CC=C12,CYP2D6 (major); CYP3A4; CYP2C9,Aromatic hydroxylation of fused benzene ring,0.93
reduced_dolasetron,O=C(OC1CC2CC3CC(C1)N2CC3O)C1=CNC2=CC=CC=C12,5-Hydroxydolasetron,O=C(OC1CC2CC3CC(C1)N2CC3O)C1=CNC2=CC=C(O)C=C12,CYP2D6; CYP2C9,Aromatic hydroxylation of fused benzene ring,0.92
reduced_dolasetron,O=C(OC1CC2CC3CC(C1)N2CC3O)C1=CNC2=CC=CC=C12,7-Hydroxydolasetron,O=C(OC1CC2CC3CC(C1)N2CC3O)C1=CNC2=C(O)C=CC=C12,CYP2D6; CYP2C9,Aromatic hydroxylation of fused benzene ring,0.88
repaglinide,CCOC1=CC(CC(O)=NC(CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(=O)O,,CCOC1=CC(CC(O)=NC(CC(C)C)C2=CC=CC=C2N2CCCC(O)C2)=CC=C1C(=O)O,CYP2C8;CYP3A4,Aliphatic Hydroxylation,0.96
repaglinide,CCOC1=CC(CC(O)=NC(CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(=O)O,,CCOC1=CC(CC(O)=NC(CC(C)(C)O)C2=CC=CC=C2N2CCCCC2)=CC=C1C(=O)O,CYP2C8;CYP3A4,Aliphatic Hydroxylation,0.95
repaglinide,CCOC1=CC(CC(O)=NC(CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(=O)O,,CC(C)CC(N=C(O)CC1=CC=C(C(=O)O)C(O)=C1)C1=CC=CC=C1N1CCCCC1,CYP3A4,O-Demethylation,0.92
repaglinide,CCOC1=CC(CC(O)=NC(CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(=O)O,,CCOC1=CC(CC(O)=NC(CC(C)C)C2=CC=CC=C2N)=CC=C1C(=O)O,CYP2C8;CYP3A4,N-dealkylation,0.82
repaglinide,CCOC1=CC(CC(O)=NC(CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(=O)O,,CCOC1=CC(CC(O)=NC(CC(C)C)C2=CC=CC=C2NCCCCO)=CC=C1C(=O)O,CYP2C8;CYP3A4,N-dealkylation,0.92
retinal,CC(C=CC=C(C)C=CC1=C(C)CCCC1(C)C)=CC=O,all-trans retinoic acid,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,CYP1A2; CYP1A2; CYP1B1,Aldehyde oxidation,0.9
retinal,CC(C=CC=C(C)C=CC1=C(C)CCCC1(C)C)=CC=O,Tretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,CYP1A2; CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4,Aliphatic Hydroxylation,0.9
retinol,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CCO,All-trans-retinal,CC(C=CC=C(C)C=CC1=C(C)CCCC1(C)C)=CC=O,CYP1A1; CYP1A2; CYP3A4; CYP1B1,Oxidation of primary alcohol to aldehyde,0.88
retinol,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CCO,4-Hydroxyretinol,CC(C=CC1=C(C)C(O)CCC1(C)C)=CC=CC(C)=CCO,CYP2C8,Aliphatic Hydroxylation,0.72
retinol,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CCO,Retinal,CC(C=CC=C(C)C=CC1=C(C)CCCC1(C)C)=CC=O,CYP1A1;CYP2C8; CYP2C9; CYP2C19;CYP2D6;CYP3A4,Aliphatic Hydroxylation,0.88
riddelliine,C=C1CC(=CC)C(=O)OC2CCN3CC=C(COC(=O)C1(O)CO)C23,riddelliine N-Oxide,C=C1CC(=CC)C(=O)OC2CC[N+]3([O-])CC=C(COC(=O)C1(O)CO)C23,CYP3A4,N-Oxidation,0.89
riddelliine,C=C1CC(=CC)C(=O)OC2CCN3CC=C(COC(=O)C1(O)CO)C23,,C=C1CC(=CC)C(=O)OC2CCN3CC=C(COC(=O)C1(O)CO)C23O,CYP3A4,Aliphatic Hydroxylation,0.84
riddelliine,C=C1CC(=CC)C(=O)OC2CCN3CC=C(COC(=O)C1(O)CO)C23,,C=C1CC(=CC)C(=O)OC2CCN3C(O)C=C(COC(=O)C1(O)CO)C23,CYP3A4,Aliphatic Hydroxylation,0.91
rifabutin,COC1C=COC2(C)OC3=C(C)C(O)=C4C(=O)C(=C5NC6(CCN(CC(C)C)CC6)N=C5C4=C3C2=O)CC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C,,COC1C=COC2(C)OC3=C(C)C(O)=C4C(=O)C(=C5NC6(CCN(CC(C)C)CC6)N=C5C4=C3C2=O)CC(=O)C(C)=CC=CC(C)(O)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C,CYP3A4,Aliphatic Hydroxylation,0.99
riluzole,N=C1NC2=CC=C(OC(F)(F)F)C=C2S1,4-OH-riluzole,N=C1NC2=C(O)C=C(OC(F)(F)F)C=C2S1,CYP1A1,Aromatic hydroxylation of fused benzene ring,0.82
riluzole,N=C1NC2=CC=C(OC(F)(F)F)C=C2S1,5-OH-riluzole,N=C1NC2=CC(O)=C(OC(F)(F)F)C=C2S1,CYP1A1,Aromatic hydroxylation of fused benzene ring,0.82
riluzole,N=C1NC2=CC=C(OC(F)(F)F)C=C2S1,7-OH-riluzole,N=C1NC2=CC=C(OC(F)(F)F)C(O)=C2S1,CYP1A2; CYP1A1,Aromatic hydroxylation of fused benzene ring,0.74
riluzole,N=C1NC2=CC=C(OC(F)(F)F)C=C2S1,N-OH-riluzole,ONC1=NC2=CC=C(OC(F)(F)F)C=C2S1,CYP1A1,N-hydroxylation of primary arylamine,0.66
risperidone,CC1=C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(=O)N2CCCCC2=N1,,CC1=C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(=O)N2CC(O)CCC2=N1,CYP2D6;CYP3A4,Aliphatic Hydroxylation,0.95
risperidone,CC1=C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(=O)N2CCCCC2=N1,,CC1=C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(=O)N2CCCC(O)C2=N1,CYP2D6,Aliphatic Hydroxylation,0.94
risperidone,CC1=C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(=O)N2CCCCC2=N1,,CC1=C(CCN2CCC(C3=C4C=CC(F)=CC4=[O+]N3O)CC2)C(=O)N2CCCC(C)C2=N1,CYP2D6,N-Hydroxylation,0.92
risperidone,CC1=C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(=O)N2CCCCC2=N1,,FC1=CC=C2C(C3CCNCC3)=NOC2=C1,CYP3A4,N-Dealkylation,0.51
risperidone,CC1=C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)C(=O)N2CCCCC2=N1,,CCC1=C(C)N=C2C(C)CCCN2C1=O,CYP3A4,N-Dealkylation,0.66
ropinirole,CCCN(CCC)CCC1=CC=CC2=C1CC(O)=N2,,CCCNCCC1=CC=CC2=C1CC(O)=N2,CYP1A2;CYP3A4,N-Despropylation,0.96
ropinirole,CCCN(CCC)CCC1=CC=CC2=C1CC(O)=N2,,CCCN(CCC)CCC1=CC=C(O)C2=C1CC(O)=N2,CYP1A2;CYP3A4,Aromatic Hydroxylation,0.79
ropivacaine,CCCN1CCCCC1C(O)=NC1=C(C)C=CC=C1C,3-OH-ropivacaine,CCCN1CCCCC1C(O)=NC1=C(C)C=CC(O)=C1C,CYP1A2,Hydroxylation of benzene on carbon ortho to an electron donating group,0.84
ropivacaine,CCCN1CCCCC1C(O)=NC1=C(C)C=CC=C1C,PPX,CC1=CC=CC(C)=C1N=C(O)C1CCCCN1,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.89
roxithromycin,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=NOCOCCOC)C(C)C(O)C1(C)O,,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(NC)C2O)C(C)(O)CC(C)C(=NOCOCCOC)C(C)C(O)C1(C)O,CYP3A4,N-Dementhylation,0.98
rutaecarpine,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=CC=CC=C1N3,,O=C1C2=CC(O)=CC=C2N=C2C3=C(CCN21)C1=CC=CC=C1N3,CYP1A2;CYP2C9;CYP2D6;CYP3A4,Aromatic Hydroxylation,0.97
rutaecarpine,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=CC=CC=C1N3,,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=C(O)C=CC=C1N3,CYP1A2;CYP2C9;CYP2D6;CYP3A4,Aromatic Hydroxylation,0.93
rutaecarpine,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=CC=CC=C1N3,,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=CC=C(O)C=C1N3,CYP1A2;CYP2C9;CYP2D6;CYP3A4,Aromatic Hydroxylation,0.97
rutaecarpine,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=CC=CC=C1N3,,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=CC(O)=CC=C1N3,CYP2C9;CYP2D6;CYP3A4,Aromatic Hydroxylation,0.96
rutaecarpine,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=CC=CC=C1N3,,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=CC=CC(O)=C1N3,CYP1A2;CYP2C9;CYP2D6;CYP3A4,Aromatic Hydroxylation,0.93
rutaecarpine,O=C1C2=CC=CC=C2N=C2C3=C(CCN21)C1=CC=CC=C1N3,,O=C1C2=CC=CC=C2N=C2C3=C(C4=CC=CC=C4N3)C(O)CN21,CYP3A4,Aliphatic Hydroxylation,0.9
s-methyl diethylthiocarbamate,CCN(CC)C(=O)SC,MeDTC sulfoxide,CCN(CC)C(=O)S(C)=O,CYP3A4; CYP2A6; CYP2C9; CYP1A2; CYP2B6; CYP2E1; CYP2D6,S-oxidation of thiocarbamate,0.64
s-metolachlor,CCC1=CC=CC(C)=C1N(C(=O)CCl)C(C)COC,,CCC1=CC=CC(C)=C1N(C(=O)CCl)C(C)CO,CYP2B6;CYP3A4,O-demethylation,0.94
salicylic acid,O=C(O)C1=CC=CC=C1O,5-hydroxylation,O=C(O)C1=CC(O)=CC=C1O,CYP2E1;CYP3A4,Aromatic Hydroxylation,0.79
salmeterol,OCC1=CC(C(O)CNCCCCCCOCCCCC2=CC=CC=C2)=CC=C1O,,OCC1=CC(C(O)CNCCCCCCOCCCC(O)C2=CC=CC=C2)=CC=C1O,CYP3A4,Aliphatic Hydroxylation,0.94
schembl12998564,COC1=CC=CC=C1N=C(O)C(=NNC1=CC=C([N+](=O)[O-])C=C1OC)C(C)=O,py74-M1,COC1=CC(O)=CC=C1N=C(O)C(=NNC1=CC=C([N+](=O)[O-])C=C1OC)C(C)=O,CYP3A4,Aromatic Hydroxylation,0.95
schembl14141926,COC(=O)C(C1=CC=CC=C1Cl)N1CCC2=C(CC(=O)S2)C1,,COC(=O)C(C1=CC=CC=C1Cl)N1CCC(S)=C(CC=O)C1,CYP2B6;CYP2C9;CYP2C19;CYP3A4,Unknown reaction,0.87
schembl14329530,CCCCCCOC1=CC=C2C=CC(=O)OC2=C1,,CCCC(O)CCOC1=CC=C2C=CC(=O)OC2=C1,CYP3A4,Aliphatic Hydroxylation,0.95
schembl14329530,CCCCCCOC1=CC=C2C=CC(=O)OC2=C1,,CCC(O)CCCOC1=CC=C2C=CC(=O)OC2=C1,CYP3A4,Aliphatic Hydroxylation,0.96
schembl14329530,CCCCCCOC1=CC=C2C=CC(=O)OC2=C1,,CC(O)CCCCOC1=CC=C2C=CC(=O)OC2=C1,CYP3A4,Aliphatic Hydroxylation,0.97
schembl149458,CN1CCCCC1CCN1C2=CC=CC=C2SC2=CC=C(S(C)=O)C=C21,Sulphoridazine,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1,CYP2D6,S-REDUCTION,0.92
schembl17043265,CCC(C(=O)C1=CC=C(C)C=C1)N1CCCC1,HO-MPBP,CCC(C(=O)C1=CC=C(CO)C=C1)N1CCCC1,CYP1A2;CYP2C19;CYP2D6,Aliphatic Hydroxylation,0.94
schembl237672,CC[N+](C)(CC)CCC1=C(C)C2=CC=C(OC)C=C2OC1=O,"AMHC (3-[2-(N,N-diethyl-Nmethylammonium)ethyl]-7-hydroxy-4-methylcoumarin)",CC[N+](C)(CC)CCC1=C(O)OC2=CC(=O)C=CC2=C1C,CYP1A2;CYP2D6;CYP2B6,O-Demethylation,0.42
schembl29464,CN1C(=O)C(O)N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C21,Oxazepam,OC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=NC1O,CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP3A4,N-dementhylation,0.51
schembl3207291,CNC1CN(C2=CC=C3C(=O)C(C(=O)O)=CN(C4=NC=CS4)C3=N2)CC1OC,,COC1CN(C2=CC=C3C(=O)C(C(=O)O)=CN(C4=NC=CS4)C3=N2)CC1N,CYP1A2;CYP3A4,N-dealkylation,0.98
schembl3207291,CNC1CN(C2=CC=C3C(=O)C(C(=O)O)=CN(C4=NC=CS4)C3=N2)CC1OC,,CNC1CN(C2=CC=C3C(=O)C(C(=O)O)=CN(C4=NC=CS4)C3=N2)CC1O,CYP1A2;CYP3A4,O-dealkylation,0.98
schembl3207291,CNC1CN(C2=CC=C3C(=O)C(C(=O)O)=CN(C4=NC=CS4)C3=N2)CC1OC,,CNC1CN(C2=CC=C3C(=O)C(C(=O)O)CN(C4=NC=CS4)C3=N2)CC1OC,CYP1A2;CYP2D6;CYP3A4,Hydrogenation,0.62
schembl4023988,COC(OC)C1(C)OC2=CC=C(N)C=C2C(N(CC2=NN(C)N=N2)C2=CC=C(Cl)C=C2)C1O,hydroxy-KR-31543,CN1N=NC(CNC2=CC=C(Cl)C=C2)=N1,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,N-Demethylation,0.21
schembl4023988,COC(OC)C1(C)OC2=CC=C(N)C=C2C(N(CC2=NN(C)N=N2)C2=CC=C(Cl)C=C2)C1O,N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amine,COC(OC)C1(C)OC2=CC(O)=C(N)C=C2C(N(CC2=NN(C)N=N2)C2=CC=C(Cl)C=C2)C1O,CYP3A4,Aromatic Hydroxylation,0.97
schembl4081913,CN=C(O)CC1=CC=C2C=CN(C3CCN(CCC4=CC=CC=C4F)CC3)C2=C1,,CN=C(O)CC1=CC=C2C=CN(C3CCN(C(O)CC4=CC=CC=C4F)CC3)C2=C1,CYP3A4,Aliphatic Hydroxylation,0.92
schembl4081913,CN=C(O)CC1=CC=C2C=CN(C3CCN(CCC4=CC=CC=C4F)CC3)C2=C1,,CN=C(O)CC1=CC=C2C=CN(C3CCN(CC(O)C4=CC=CC=C4F)CC3)C2=C1,CYP3A4,Aliphatic Hydroxylation,0.91
schembl69463,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CCC,DA-8164,CCCOC1=CC=C(S(N)(=O)=O)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CCC,CYP3A4,N-Dealkylation,0.93
schembl69463,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CCC,N-Demethyl-DA-8159,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(CCC)NN=C2C(=O)N1,CYP3A4,N-Demethylation,0.93
schembl69463,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CCC,Hydroxy-DA-8164,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2C(O)CC,CYP3A4,Aliphatic Hydroxylation,0.95
schembl69463,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CCC,Hydroxy-DA-8164,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CC(C)O,CYP3A4,Aliphatic Hydroxylation,0.97
schembl69463,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CCC,Hydroxy-DA-8164,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CCCO,CYP3A4,Aliphatic Hydroxylation,0.99
schembl69463,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CCC,Hydroxy-DA-8164,CCCC1=NN(C)C2=C1N=C(C1=CC(S(=O)(=O)NCCC3CCCN3C)=CC=C1OC(O)CC)NC2=O,CYP3A4,Aliphatic Hydroxylation,0.98
schembl69463,CCCOC1=CC=C(S(=O)(=O)NCCC2CCCN2C)C=C1C1=NC2=C(C(=O)N1)N(C)N=C2CCC,Hydroxy-DA-8164,CCCC1=NN(C)C2=C1N=C(C1=CC(S(=O)(=O)NCCC3CCCN3C)=CC=C1OCC(C)O)NC2=O,CYP3A4,Aliphatic Hydroxylation,0.99
schembl7562446,CC(C)(C)C1=CC(CC2SCN=C2O)=CC(C(C)(C)C)=C1O,,CC(C)(C)C1=CC(CC2C(O)=NCS2=O)=CC(C(C)(C)C)=C1O,CYP3A4,S-Oxidation,0.84
schembl7750160,CN(C)CCCCCN1C2=CC=CC=C2SC2=CC=C(C(F)(F)F)C=C21,,C[N+](C)([O-])CCCCCN1C2=CC=CC=C2SC2=CC=C(C(F)(F)F)C=C21,CYP2D6,N-Oxidation,0.98
schembl7750160,CN(C)CCCCCN1C2=CC=CC=C2SC2=CC=C(C(F)(F)F)C=C21,,CN(C)CCCCCN1C2=CC=CC=C2S(=O)C2=CC=C(C(F)(F)F)C=C21,CYP2C19;CYP2D6;CYP2E1;CYP3A4,S-Oxidation,0.87
schembl895799,CC(C#CC1=CC=C(CC2=CC=CC=C2)S1)NC(=N)O,ABT-438 Hydroxy,CC(C#CC1=CC=C(C(O)C2=CC=CC=C2)S1)NC(=N)O,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4;CYP2E1,Aliphatic Hydroxylation,0.79
schembl896413,COC1=CC(CC2SC(=O)N=C2O)=CC=C1C(O)=NCC1=CC=C(C(F)(F)F)C=C1,M28,O=C1N=C(O)C(O)(CC2=CC=C(C(O)=NCC3=CC=C(C(F)(F)F)C=C3)C(O)=C2)S1,CYP2C9;CYP2C19,O-Demethylation,0.79
schembl896413,COC1=CC(CC2SC(=O)N=C2O)=CC=C1C(O)=NCC1=CC=C(C(F)(F)F)C=C1,M24,COC1=CC(CC2(O)SC(=O)N=C2O)=CC=C1C(O)=NCC1=CC=C(C(F)(F)F)C=C1,CYP3A4,Aliphatic Hydroxylation,0.84
schembl896413,COC1=CC(CC2SC(=O)N=C2O)=CC=C1C(O)=NCC1=CC=C(C(F)(F)F)C=C1,,COC1=CC(CC2C(O)=NC(=O)S2=O)=CC=C1C(O)=NCC1=CC=C(C(F)(F)F)C=C1,CYP3A4,S-Oxidation,0.88
schembl9652240,CC1SC(C2=CC=CN=C2)N(C)C1=O,,CC1C(=O)N(C)C(C2=CC=CN=C2)S1=O,CYP2A6,S-Oxidation,0.79
selegiline,C#CCN(C)C(C)CC1=CC=CC=C1,Desmethylselegiline,C#CCNC(C)CC1=CC=CC=C1,CYP2B6 (major); CYP2C19; CYP2D6; CYP1A2; CYP2C9; CYP3A4,N-dealkylation of acyclic tertiary amine,0.83
selegiline,C#CCN(C)C(C)CC1=CC=CC=C1,Methamphetamine,CNC(C)CC1=CC=CC=C1,CYP2B6; CYP2C19; CYP2D6; CYP1A2; CYP2C9; CYP3A4,N-depropargylation of secondary or tertiary amine,0.68
senecionine,CC=C1CC(C)C(C)(O)C(=O)OCC2=CCN3CCC(OC1=O)C23,"(Ã‚Â± )-6,7-dmydn>7-hydroxy-l-hydroxymethyl-5J/-pyrrolizine (DHP)",CC=C1CC(C)C(C)(O)C(=O)OCC2=CCN3CCC(OC1=O)C23O,CYP3A4,Aliphatic Hydroxylation,0.82
senecionine,CC=C1CC(C)C(C)(O)C(=O)OCC2=CCN3CCC(OC1=O)C23,,CC=C1CC(C)C(C)(O)C(=O)OCC2=CC(O)N3CCC(OC1=O)C23,CYP3A4,Aliphatic Hydroxylation,0.91
senecionine,CC=C1CC(C)C(C)(O)C(=O)OCC2=CCN3CCC(OC1=O)C23,senecionine N-oxide,CC=C1CC(C)C(C)(O)C(=O)OCC2=CC[N+]3([O-])CCC(OC1=O)C23,CYP3A4,N-Oxidation,0.87
serotonin,NCCC1=CNC2=CC=C(O)C=C12,,CCC1=CNC2=CC=C(O)C=C12,CYP2B6 (major); CYP2C19; CYP2D6; CYP1A2; CYP2C9; CYP3A4,Unknown Reduction,0.92
sertindole,OC1=NCCN1CCN1CCC(C2=CN(C3=CC=C(F)C=C3)C3=CC=C(Cl)C=C23)CC1,,OC1=NC(O)CN1CCN1CCC(C2=CN(C3=CC=C(F)C=C3)C3=CC=C(Cl)C=C23)CC1,CYP2D6,Aliphatic Hydroxylation,0.94
sertindole,OC1=NCCN1CCN1CCC(C2=CN(C3=CC=C(F)C=C3)C3=CC=C(Cl)C=C23)CC1,,FC1=CC=C(N2C=C(C3CCNCC3)C3=CC(Cl)=CC=C32)C=C1,CYP2D6,N-dealkylation,0.88
sertraline,CNC1CCC(C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C21,N-desmethylsertraline,NC1CCC(C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C21,CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,N-desmethylation,0.91
sildenafil,CCCC1=NN(C)C2=C1N=C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)NC2=O,N-Desmethyl sildenafil,CCCC1=NN(C)C2=C1N=C(C1=CC([SH](=O)=O)=CC=C1OCC)NC2=O,CYP3A4; CYP2C9; CYP2C19; CYP2D6,N-dealkylation of sulfonamide,0.9
simvastatin,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,6'-ÃŽÂ²-Hydroxysimvastatin ,CCC(C)(C)C(=O)OC1CC(C)(O)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,CYP3A4; CYP3A5,Allylic hydroxylation,0.91
simvastatin,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,"3', 5'-Dihydrodiol",CCC(C)(C)C(=O)OC1CC(C)C(O)C2=CC(O)C(C)C(CCC3CC(O)CC(=O)O3)C21,CYP3A4; CYP3A5,"Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene",0.75
simvastatin,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,6'-exomethylene,C=C1C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C2C(OC(=O)C(C)(C)CC)C1,CYP3A4; CYP3A5,Terminal desaturation,0.93
sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,16-O-Desmethylsirolimus,COC1CC(CC(C)C2CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C(C)C(O)CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)CCC1O,CYP3A4,O-dealkylation of dialkylether,0.98
sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,12-OH-sirolimus,COC1CC2CC(O)C(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,CYP3A4,Hydroxylation of heteroalicyclic secondary carbon,0.97
sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,11-OH-sirolimus,COC1CC2CCC(C)(O)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,CYP3A4,Hydroxylation of alkyl methine,0.93
sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,25-OH-sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)(O)CC(C)C=CC=CC=C1C,CYP3A4,Hydroxylation of alkyl methine,0.97
sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,24-OH-sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)C(O)C(C)C=CC=CC=C1C,CYP3A4,Hydroxylation of heteroalicyclic secondary carbon,0.98
sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,46-OH-sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(CO)CC(C)C=CC=CC=C1C,CYP3A4,Hydroxylation of terminal methyl,0.99
sparteine,C1CCN2CC3CC(CN4CCCCC34)C2C1,,OC12CCCCN1CC1CC2CN2CCCCC12,CYP2D6,Aliphatic Hydroxylation,0.53
sparteine,C1CCN2CC3CC(CN4CCCCC34)C2C1,,OC1CCCC2C3CC(CN12)C1CCCCN1C3,CYP2D6,Aliphatic Hydroxylation,0.71
sparteine,C1CCN2CC3CC(CN4CCCCC34)C2C1,,OC1CCCN2CC3CC(CN4CCCCC34)C12,CYP2D6,Aliphatic Hydroxylation,0.65
styrene,C=CC1=CC=CC=C1,"Styrene 7,8-oxide",C1=CC=C(C2CO2)C=C1,CYP2E1,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.23
sulfadiazine,NC1=CC=C(S(=O)(=O)NC2=NC=CC=N2)C=C1,,O=S(=O)(NC1=NC=CC=N1)C1=CC=C(NO)C=C1,CYP2B6;CYP2C8;CYP2C9;CYP2C19,Hydroxylation,0.93
sulfamethoxazole,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,Sulfamethoxazole N4-hydroxylamine,CC1=CC(NS(=O)(=O)C2=CC=C(NO)C=C2)=NO1,CYP2C9,N-hydroxylation of primary arylamine,0.95
tacrine,N=C1C2=C(CCCC2)NC2=CC=CC=C12,N4-hydroxylamine,N=C1C2=C(CCCC2O)NC2=CC=CC=C12,CYP1A2,Hydroxylation of alicyclic secondary carbon,0.82
tacrine,N=C1C2=C(CCCC2)NC2=CC=CC=C12,4- Hydroxytacrine,NC1=C2CCCC(O)C2=NC2=CC=CC=C12,CYP1A2,Hydroxylation of alicyclic secondary carbon,0.57
tacrine,N=C1C2=C(CCCC2)NC2=CC=CC=C12,2-Hydroxytacrine,N=C1C2=C(CCC(O)C2)NC2=CC=CC=C12,CYP1A2,Hydroxylation of alicyclic secondary carbon,0.88
tacrine,N=C1C2=C(CCCC2)NC2=CC=CC=C12,7-Hydroxytacrine,NC1=C2CCCCC2=NC2=C(O)C=CC=C12,CYP1A2,Aromatic hydroxylation of fused benzene ring,0.58
tamarixetin,COC1=CC=C(C2=C(O)C(=O)C3=C(O)C=C(O)C=C3O2)C=C1O,QUERCETIN,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC2=CC(O)=CC(O)=C12,CYP1A2;CYP2C9;CYP3A4,O-dealkylation,0.97
tamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,N-Desmethyltamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCNC)C=C1)C1=CC=CC=C1,CYP2D6; CYP1A2; CYP1A1; CYP3A4; CYP1B1 (at a high concentration (250ÃŽÂ¼M)); CYP2C9 (at a high concentration (250ÃŽÂ¼M)); CYP2C19 (at a high concentration (250ÃŽÂ¼M)); CYP3A5 (at a high concentration (250ÃŽÂ¼M)); CYP2E1,N-dealkylation of acyclic tertiary amine,0.98
tamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,4'-Hydroxytamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=C(O)C=C1,CYP2D6; CYP2B6,p-Hydroxylation of monosubstituted benzene,0.99
tamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,alpha-Hydroxytamoxifen,CC(O)C(=C(C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,CYP3A4; CYP2D6; CYP2B6 (give smaller amounts of ÃŽÂ±-hydroxylation); CYP2C9  (give smaller amounts of ÃŽÂ±-hydroxylation); CYP2C19 (give smaller amounts of ÃŽÂ±-hydroxylation); CYP3A5 (give smaller amounts of ÃŽÂ±-hydroxylation),Hydroxylation of penultimate aliphatic secondary carbon,0.86
tamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,3-Hydroxytamoxifen,CCC(=C(C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC(O)=C1)C1=CC=CC=C1,CYP3A4; CYP3A5; CYP2B6,m-Hydroxylation of monosubstituted benzene,0.89
tamsulosin,CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1,,CCOC1=CC=C(O)C=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1,CYP2D6,Aromatic Hydroxylation,0.95
tamsulosin,CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1,,CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(O)C(S(N)(=O)=O)=C1,CYP2D6,O-Dementhylation,0.94
tamsulosin,CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1,,COC1=CC=C(CC(C)NCCOC2=CC=CC=C2O)C=C1S(N)(=O)=O,CYP3A4,O-dealkylation,0.99
tangeretin,COC1=CC=C(C2=CC(=O)C3=C(OC)C(OC)=C(OC)C(OC)=C3O2)C=C1,,COC1=CC=C(C2=CC(=O)C3=C(O)C(O)=C(OC)C(OC)=C3O2)C=C1,CYP3A4,O-dealkylation,0.96
tauromustine,CN(C)S(=O)(=O)CCN=C(O)N(CCCl)N=O,,CNS(=O)(=O)CCN=C(O)N(CCCl)N=O,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4,N-Dealkylation,0.94
tauromustine,CN(C)S(=O)(=O)CCN=C(O)N(CCCl)N=O,,CN(C)S(=O)(=O)CCNC(O)=NCCCl,CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4,Denitrosation,0.47
taxol,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)C2=CC=CC=C2)C2(O)CC(OC(=O)C(O)C(N=C(O)C3=CC=CC=C3)C3=CC=CC=C3)C(C)=C1C2(C)C,6ÃŽÂ±-Hydroxypaclitaxel ,CC(=O)OC1C(=O)C2(C)C(O)C(O)C3OCC3(OC(C)=O)C2C(OC(=O)C2=CC=CC=C2)C2(O)CC(OC(=O)C(O)C(N=C(O)C3=CC=CC=C3)C3=CC=CC=C3)C(C)=C1C2(C)C,CYP2C8,Hydroxylation of alicyclic secondary carbon,0.99
taxol,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)C2=CC=CC=C2)C2(O)CC(OC(=O)C(O)C(N=C(O)C3=CC=CC=C3)C3=CC=CC=C3)C(C)=C1C2(C)C,3Ã¢â‚¬Â²-pHydroxypaclitaxel ,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)C2=CC=CC=C2)C2(O)CC(OC(=O)C(O)C(N=C(O)C3=CC=CC=C3)C3=CC=C(O)C=C3)C(C)=C1C2(C)C,CYP3A4 ,p-Hydroxylation of monosubstituted benzene,0.98
tecalcet,COC1=CC=CC(C(C)NCCCC2=CC=CC=C2Cl)=C1,,CC(NCCCC1=CC=CC=C1Cl)C1=CC=CC(O)=C1,CYP2D6,O-Dementhylation,0.88
tegaserod,CCCCCNC(=N)NN=CC1=CNC2=CC=C(OC)C=C12,,CCCCCNC(=N)NN=CC1=CNC2=CC=C(O)C=C12,CYP1A2;CYP2D6,O-desmethylation,0.93
tenoxicam,CN1C(=C(O)NC2=CC=CC=N2)C(=O)C2=C(C=CS2)S1(=O)=O,5'-Hydroxytenoxicam,CN1C(=C(O)NC2=CC=C(O)C=N2)C(=O)C2=C(C=CS2)S1(=O)=O,CYP2C9,HYDROXYLATION_OF_HETEROAROMATIC_CARBON,0.98
tentoxin,CC(C)CC1N=C(O)C(C)N(C)C(=O)CN=C(O)C(=CC2=CC=CC=C2)N(C)C1=O,,CC(C)CC1N=C(O)C(C)N(C)C(=O)CN=C(O)C(=CC2=CC=CC=C2)N=C1O,CYP3A4,N-Dementhylation,0.58
terbinafine,CN(CC=CC#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12,N-Desmethylterbinafine,CC(C)(C)C#CC=CCNCC1=CC=CC2=CC=CC=C12,CYP2C8; CYP2C9; CYP1A2,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES,0.88
terbinafine,CN(CC=CC#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12,Hydroxyterbinafine,CN(CC=CC#CC(C)(C)CO)CC1=CC=CC2=CC=CC=C12,CYP1A2; CYP2C8; CYP2C9; CYP2C19,Hydroxylation of terminal methyl,0.93
terbinafine,CN(CC=CC#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12,1-Naphtaldehyde,O=CC1=CC=CC2=CC=CC=C12,CYP3A4,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1,0.32
terbuthylazine,CCN=C1N=C(Cl)N=C(NC(C)(C)C)N1,,CC(O)N=C1N=C(Cl)N=C(NC(C)(C)C)N1,CYP1A2;CYP3A4,Aliphatic Hydroxylation,0.9
terbuthylazine,CCN=C1N=C(Cl)N=C(NC(C)(C)C)N1,,CCN=C1N=C(Cl)N=C(NC(C)(C)CO)N1,CYP1A2,Aliphatic Hydroxylation,0.91
territrem a,COC1=CC(C2=CC3=C(CC4(O)C(C)(CCC5(O)C(C)(C)C=CC(=O)C54C)O3)C(=O)O2)=CC2=C1OCO2,,COC1=CC(C2=CC3=C(CC4(O)C(C)(CCC5(O)C(C)(CO)C=CC(=O)C54C)O3)C(=O)O2)=CC2=C1OCO2,CYP2C9;CYP2D6;CYP3A4,Aliphatic Hydroxylation,0.99
testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,6ÃŽÂ²Hydroxytestosterone ,CC12CCC(=O)C=C1C(O)CC1C2CCC2(C)C(O)CCC12,CYP3A4; CYP3A5;  CYP2C9; CYP1A1; CYP1B1,Hydroxylation of carbon gamma to conjugated carbonyl,0.81
testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,2ÃŽÂ±-Hydroxytestosterone ,CC12CC(O)C(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,CYP3A4 ,Alpha hydroxylation of carbonyl group,0.82
testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,2ÃŽÂ²-Hydroxytestosterone ,CC12CC(O)C(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,CYP3A4 ,Alpha hydroxylation of carbonyl group,0.82
testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,15ÃŽÂ±-Hydroxytestosterone ,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CC(O)C12,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.92
testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,15ÃŽÂ²-Hydroxytestosterone ,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CC(O)C12,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.92
testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,16ÃŽÂ±-Hydroxytestosterone ,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)C(O)CC12,CYP3A4; CYP2B6 ,Hydroxylation of alicyclic secondary carbon,0.92
testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,16ÃŽÂ²-Hydroxytestosterone ,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)C(O)CC12,CYP3A4; CYP2B6 ,Hydroxylation of alicyclic secondary carbon,0.92
testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,Androstenedione ,CC12CCC3C(CCC4=CC(=O)CCC43C)C1CCC2=O,CYP2C19; CYP2C9 ,Oxidation of secondary alcohol to ketone,0.7
tetradecanoic acid,CCCCCCCCCCCCCC(=O)O,,CC(O)CCCCCCCCCCCC(=O)O,CYP2E1;CYP4A11,Aliphatic Hydroxylation,0.84
tetranor-(+)-s-145,O=C(O)CCC1C2CCC(C2)C1NS(=O)(=O)C1=CC=CC=C1,,O=C(O)CCC1C2CC(O)C(C2)C1NS(=O)(=O)C1=CC=CC=C1,CYP2C9,Aliphatic Hydroxylation,0.83
tetranor-(+)-s-145,O=C(O)CCC1C2CCC(C2)C1NS(=O)(=O)C1=CC=CC=C1,,O=C(O)CCC1C2CC(CC2O)C1NS(=O)(=O)C1=CC=CC=C1,CYP3A4,Aliphatic Hydroxylation,0.87
theobromine,CN1C=NC2=C1C(O)=NC(=O)N2C,,CN1C=NC2=NC(O)=NC(O)=C21,CYP1A2;CYP2E1,N-demethylation,0.57
theobromine,CN1C=NC2=C1C(O)=NC(=O)N2C,,CN1C(=O)N=C(O)C2=C1NC=N2,CYP2E1,N-demethylation,0.87
theobromine,CN1C=NC2=C1C(O)=NC(=O)N2C,,CN1C(O)=NC2=C1C(O)=NC(=O)N2C,CYP2E1,Aliphatic Hydroxylation,0.86
theophylline,CN1C(=O)C2=C(NC=N2)N(C)C1=O,"1,3-Dimethyluric acid",CN1C(=O)C2=C(NC(O)=N2)N(C)C1=O,CYP1A2; CYP1A1 ,HYDROXYLATION_OF_HETEROAROMATIC_CARBON; HYDROXYLATION_OF_AROMATIC_CARBON_ADJACENT_TO_N,0.87
theophylline,CN1C(=O)C2=C(NC=N2)N(C)C1=O,1-Methylxanthine ,CN1C(O)=NC2=C(N=CN2)C1=O,CYP1A2,N-dealkylation of N-acylurea,0.58
theophylline,CN1C(=O)C2=C(NC=N2)N(C)C1=O,3-Methylxanthine ,CN1C(=O)N=C(O)C2=C1NC=N2,CYP1A2,N-dealkylation of N-acylurea,0.57
thiabendazole,C1=CC=C2NC(C3=CSC=N3)=NC2=C1,5-hydroxythiabendazole ,OC1=CC=C2N=C(C3=CSC=N3)NC2=C1,CYP1A2,Aromatic hydroxylation of fused benzene ring,0.82
ticlopidine,ClC1=CC=CC=C1CN1CCC2=C(C=CS2)C1,Thienodihydropyridinium,ClC1=CC=CC=C1CN1C=C2C=C[S+]=C2CC1,CYP3A4; CYP2C19,Formation of imminium ion from N-substituted piperidine,0.32
ticlopidine,ClC1=CC=CC=C1CN1CCC2=C(C=CS2)C1,Ticlopidine S-oxide,O=S1C=CC2=C1CCN(CC1=CC=CC=C1Cl)C2,CYP2C19; CYP2D6,Thiohene S-oxidation,0.33
ticrynafen,O=C(O)COC1=CC=C(C(=O)C2=CC=CS2)C(Cl)=C1Cl,Tienilic acid-s-oxide,O=C(O)COC1=CC=C(C(=O)C2=CC=CS2=O)C(Cl)=C1Cl,CYP2C8; CYP2C9 (major),Thiohene S-oxidation,0.48
ticrynafen,O=C(O)COC1=CC=C(C(=O)C2=CC=CS2)C(Cl)=C1Cl,"Thiophene-4,5-epoxide",O=C(O)COC1=CC=C(C(=O)C2=CC3OC3S2)C(Cl)=C1Cl,CYP2C8; CYP2C9 (major); CYP2C18; CYP2C19,Epoxidation of thiophene,0.47
timolol,CC(C)(C)NCC(O)COC1=NSN=C1N1CCOCC1,,CC(C)(C)NCC(O)COC1=NSN=C1N1CCOC(O)C1,CYP2D6,Aliphatic Hydroxylation,0.92
tirilazad,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3=CCC2(C)C1C(=O)CN1CCN(C2=CC(N3CCCC3)=NC(N3CCCC3)=N2)CC1,,CC1CC2C3CC(O)C4=CC(=O)C=CC4(C)C3=CCC2(C)C1C(=O)CN1CCN(C2=CC(N3CCCC3)=NC(N3CCCC3)=N2)CC1,CYP3A4,Aliphatic Hydroxylation,0.9
tirilazad,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3=CCC2(C)C1C(=O)CN1CCN(C2=CC(N3CCCC3)=NC(N3CCCC3)=N2)CC1,,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3=CCC2(C)C1C(=O)CN1CCN(C2=CC(N3CCCC3)=NC(N3CCC(O)C3)=N2)CC1,CYP3A4,Aliphatic Hydroxylation,0.95
tirilazad,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3=CCC2(C)C1C(=O)CN1CCN(C2=CC(N3CCCC3)=NC(N3CCCC3)=N2)CC1,,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3=CCC2(C)C1C(=O)CN1CCN(C2=CC(N3CCC(O)C3)=NC(N3CCCC3)=N2)CC1,CYP3A4,Aliphatic Hydroxylation,0.94
tolbutamide,CCCCN=C(O)NS(=O)(=O)C1=CC=C(C)C=C1,4-Hydroxytolbutamide,CCCCN=C(O)NS(=O)(=O)C1=CC=C(CO)C=C1,CYP2C9; CYP2C19,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.94
tolterodine,CC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C2=CC=CC=C2)=C1,N-Dealkylated tolterodine,CC1=CC=C(O)C(C(CCNC(C)C)C2=CC=CC=C2)=C1,CYP3A4 (major); CYP2C9 (minor); CYP2C19 (minor),N-deisopropylation,0.95
tolterodine,CC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C2=CC=CC=C2)=C1,5-Hydroxymethyl tolterodine,CC(C)N(CCC(C1=CC=CC=C1)C1=CC(CO)=CC=C1O)C(C)C,CYP2D6,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.92
torasemide,CC1=CC=CC(N=C2C=CNC=C2S(=O)(=O)NC(O)=NC(C)C)=C1,"N-[(4-{[3-(hydroxymethyl)phenyl]imino}-1,4-dihydropyridin-3-yl)sulfonyl]propane-2-carbamimidic acid",CC(C)N=C(O)NS(=O)(=O)C1=CNC=CC1=NC1=CC=CC(CO)=C1,CYP2C9,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.96
toremifene,CN(C)CCOC1=CC=C(C(=C(CCCl)C2=CC=CC=C2)C2=CC=CC=C2)C=C1,N-desmethyltoremifene,CNCCOC1=CC=C(C(=C(CCCl)C2=CC=CC=C2)C2=CC=CC=C2)C=C1,CYP1A1; CYP1A2; CYP3A4 (major),N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES,0.98
toremifene,CN(C)CCOC1=CC=C(C(=C(CCCl)C2=CC=CC=C2)C2=CC=CC=C2)C=C1,N-desmethyltoremifene,CNCCOC1=CC=C(C(=C(CCCl)C2=CC=CC=C2)C2=CC=CC=C2)C=C1,CYP1A1; CYP1A2; CYP3A4 (major),Deamino,0.98
tozasertib,CC1=CC(=NC2=CC(N3CCN(C)CC3)=NC(SC3=CC=C(NC(=O)C4CC4)C=C3)=N2)NN1,,CC1=CC(=NC2=CC(N3CC[N+](C)([O-])CC3)=NC(SC3=CC=C(NC(=O)C4CC4)C=C3)=N2)NN1,CYP3A4,N-Oxidation,0.96
tozasertib,CC1=CC(=NC2=CC(N3CCN(C)CC3)=NC(SC3=CC=C(NC(=O)C4CC4)C=C3)=N2)NN1,,CC1=CC(=NC2=CC(N3CCNCC3)=NC(SC3=CC=C(NC(=O)C4CC4)C=C3)=N2)NN1,CYP2C8;CYP3A4,N-demethylation,0.98
tpa-023,CCN1N=CN=C1COC1=NN2C(C3=CC=CC=C3F)=NN=C2C=C1C(C)(C)C,,CCN1N=CN=C1COC1=NN2C(C3=CC=CC=C3F)=NN=C2C=C1C(C)(C)CO,CYP3A4,Aliphatic Hydroxylation,0.97
tpa-023,CCN1N=CN=C1COC1=NN2C(C3=CC=CC=C3F)=NN=C2C=C1C(C)(C)C,,CC(C)(C)C1=CC2=NN=C(C3=CC=CC=C3F)N2N=C1OCC1=NNC=N1,CYP3A4,N-demethylation,0.94
tramadol,COC1=CC=CC(C2(O)CCCCC2CN(C)C)=C1,N-desmethyltramadol,CNCC1CCCCC1(O)C1=CC=CC(OC)=C1,CYP1A2;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP3A4,N-demethylation,0.97
tramadol,COC1=CC=CC(C2(O)CCCCC2CN(C)C)=C1,O-desmethyl-tramadol,CN(C)CC1CCCCC1(O)C1=CC=CC(O)=C1,CYP1A2;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP3A4,O-demethylation,0.93
traxoprodil,CC(C(O)C1=CC=C(O)C=C1)N1CCC(O)(C2=CC=CC=C2)CC1,,CC(C(O)C1=CC=C(O)C(O)=C1)N1CCC(O)(C2=CC=CC=C2)CC1,CYP2D6,Aromatic Hydroxylation,0.88
trazodone,O=C1N(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)N=C2C=CC=CN12,m-CPP,ClC1=CC=CC(N2CCNCC2)=C1,CYP3A4,N-dealkylation of alicyclic tertiary amine,0.28
trazodone,O=C1N(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)N=C2C=CC=CN12,p-Hydroxytrazodone,O=C1N(CCCN2CCN(C3=CC=C(O)C(Cl)=C3)CC2)N=C2C=CC=CN12,CYP3A4,Hydroxylation of aromatic carbon ortho to halide group,0.95
trazodone,O=C1N(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)N=C2C=CC=CN12,Trazodone epoxide,O=C1N(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)N=C2C3OC3C=CN21,CYP3A4,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.47
triazolam,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=CC(Cl)=CC=C3N12,,OCC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=CC(Cl)=CC=C3N12,CYP3A4,Aliphatic Hydroxylation,0.94
triazolam,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=CC(Cl)=CC=C3N12,,CC1=NN=C2C(O)N=C(C3=CC=CC=C3Cl)C3=CC(Cl)=CC=C3N12,CYP3A4,Aliphatic Hydroxylation,0.89
trihydroxycoprostane,CC(C)CCCC(C)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,,CC(CCCC(C)(C)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,CYP2B6;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.96
trimethadione,CN1C(=O)OC(C)(C)C1=O,,CC1(C)OC(=O)N=C1O,CYP2C8;CYP2C9;CYP2E1;CYP3A4,N-demethylation,0.17
tropisetron,CN1C2CCC1CC(OC(=O)C1=CNC3=CC=CC=C13)C2,,CN1C2CCC1CC(OC(=O)C1=CNC3=CC=C(O)C=C13)C2,CYP2D6,Aromatic Hydroxylation,0.91
tropisetron,CN1C2CCC1CC(OC(=O)C1=CNC3=CC=CC=C13)C2,,CN1C2CCC1CC(OC(=O)C1=CNC3=CC(O)=CC=C13)C2,CYP2D6,Aromatic Hydroxylation,0.92
tropisetron,CN1C2CCC1CC(OC(=O)C1=CNC3=CC=CC=C13)C2,,O=C(OC1CC2CCC(C1)N2)C1=CNC2=CC=CC=C12,CYP3A4,N-demethylation,0.95
tyramine,NCCC1=CC=C(O)C=C1,,NCCC1=CC=C(O)C(O)=C1,CYP2D6,Aromatic Hydroxylation,0.68
MK-429,COC1=CC=C(C(CC(=O)O)N2CCN(CCCC3=CC=C4CCCNC4=N3)C2=O)C=N1,,O=C(O)CC(C1=CC=C(O)N=C1)N1CCN(CCCC2=CC=C3CCCNC3=N2)C1=O,CYP2D6,O-Demethylation,0.97
MK-429,COC1=CC=C(C(CC(=O)O)N2CCN(CCCC3=CC=C4CCCNC4=N3)C2=O)C=N1,,O=C(O)CC(C1=CC=C(O)N=C1)N1CCN(CCCC2=CC=C3CCC(O)NC3=N2)C1=O,CYP2D6;CYP3A4,Aromatic Hydroxylation,0.92
MK-429,COC1=CC=C(C(CC(=O)O)N2CCN(CCCC3=CC=C4CCCNC4=N3)C2=O)C=N1,,O=C(O)CC(C1=CC=C(O)N=C1)N1CCN(CCCC2=CC=C3C(=N2)NCCC3O)C1=O,CYP2D6;CYP3A4,Aromatic Hydroxylation,0.91
(R)-(+)-Rebamipide,O=C(NC(CC1=CC(O)=NC2=CC=CC=C12)C(=O)O)C1=CC=C(Cl)C=C1,8-Hydroxyrebamipide,O=C(NC(CC1=CC(O)=NC2=C(O)C=CC=C12)C(=O)O)C1=CC=C(Cl)C=C1,CYP3A4,Aromatic Hydroxylation,0.9
(R)-(+)-Rebamipide,O=C(NC(CC1=CC(O)=NC2=CC=CC=C12)C(=O)O)C1=CC=C(Cl)C=C1,6-Hydroxyrebamipide,O=C(NC(CC1=CC(O)=NC2=CC=C(O)C=C12)C(=O)O)C1=CC=C(Cl)C=C1,CYP3A4,Aromatic Hydroxylation,0.93
"p-Methoxymethamphetamine, R-(-)-",CNC(C)CC1=CC=C(OC)C=C1,HO-MA,CNC(C)CC1=CC=C(O)C=C1,CYP2D6,O-Demethylation,0.86
(S)-Methylenedioxyethylamphetamine,CCNC(C)CC1=CC=C2OCOC2=C1,"3,4-methylenedioxyamphetamine",CC(N)CC1=CC=C2OCOC2=C1,CYP1A2;CYP2B6;CYP3A4,N-Dealylation,0.92
(S)-Methylenedioxyethylamphetamine,CCNC(C)CC1=CC=C2OCOC2=C1,"N-methyl-3,4-methylenedioxyamphetamine",CCNC(C)CC1=CC=C(O)C(O)=C1,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2D6;CYP2E1;CYP3A4,Demethylenation,0.7
unii-3es85mm31y,CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C1=NC2=C(CC)N(CC3=CC=CC=N3)N=C2C(=O)N1,,CCCOC1=CC=C(S(=O)(=O)N2CCNCC2)C=C1C1=NC2=C(CC)N(CC3=CC=CC=N3)N=C2C(=O)N1,CYP3A4,N-dealkylation,0.99
Fenproporex,CC(CC1=CC=CC=C1)NCCC#N,amphetamine,CC(N)CC1=CC=CC=C1,CYP1A2;CYP2B6;CYP2D6;CYP3A4,N-dealkylation,0.64
Desmethylescitalopram,CNCCCC1(C2=CC=C(F)C=C2)OCC2=CC(C#N)=CC=C21,,N#CC1=CC=C2C(=C1)COC2(CCCN)C1=CC=C(F)C=C1,CYP2D6,N-Demethylation,0.99
RPR-106541,CCCC1OC2CC3C4CC(F)C5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)C2(SC)O1,,CCCC1OC2CC3C4CC(F)C5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)C2(S(C)=O)O1,CYP3A4;CYP3A5,S-Oxidation,0.91
"Desmethylsibutramine, (S)-",CNC(CC(C)C)C1(C2=CC=C(Cl)C=C2)CCC1,1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine,CC(C)CC(N)C1(C2=CC=C(Cl)C=C2)CCC1,CYP2B6,N-demethylation,0.86
unii-ku5u13xy7j component vwcugcyzzgrkee-dyesrhjhsa-n,CCC(OC(C)=O)C(CC(C)NC)(C1=CC=CC=C1)C1=CC=CC=C1,,CCC(OC(C)=O)C(CC(C)N)(C1=CC=CC=C1)C1=CC=CC=C1,CYP2B6,N-demethylation,0.94
"4'-Methoxy-alpha-pyrrolidinopropiophenone, (S)-",COC1=CC=C(C(=O)C(C)N2CCCC2)C=C1,,CC(C(=O)C1=CC=C(O)C=C1)N1CCCC1,CYP2C19;CYP2D6,O-demethylation,0.93
unii-s5969b6237 component anucdxcticzjrh-zmzpimszsa-n,CC1COC2(C3=CC=CC=C3Cl)C3=CC(Cl)=CC=C3N=C(O)CN12,,CC1(O)COC2(C3=CC=CC=C3Cl)C3=CC(Cl)=CC=C3N=C(O)CN12,CYP3A4,Aliphatic Hydroxylation,0.92
(S)-Sibutramine,CC(C)CC(N(C)C)C1(C2=CC=C(Cl)C=C2)CCC1,,CNC(CC(C)C)C1(C2=CC=C(Cl)C=C2)CCC1,CYP2B6;CYP2C19;CYP3A4,N-demethylation,0.92
R-Tolperisone,CC1=CC=C(C(=O)C(C)CN2CCCCC2)C=C1,hydroxymethyl-tolperisone,CC(CN1CCCCC1)C(=O)C1=CC=C(CO)C=C1,CYP1A2;CYP2C19;CYP2D6,Aliphatic Hydroxylation,0.92
CP-195543,O=C(O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C2C(=C1)OCC(CC1=CC=CC=C1)C2O,M1 and M2,O=C(O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C2C(=C1)OCC(C(O)C1=CC=CC=C1)C2O,CYP3A4 ,Aliphatic Hydroxylation,0.99
CP-195543,O=C(O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C2C(=C1)OCC(CC1=CC=CC=C1)C2O,M3,O=C(O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C2C(=C1)OCC(CC1=CC=CC=C1O)C2O,CYP3A4 ,Aromatic Hydroxylation,0.99
(R)-Bunitrolol,CC(C)(C)NCC(O)COC1=CC=CC=C1C#N,,CC(C)(C)NCC(O)COC1=CC=C(O)C=C1C#N,CYP2D6,Aromatic Hydroxylation,0.89
v11294,CCNC1=C2N=C(C(C)C)N=C2N(CC2=CC=C(OC)C(OC3CCCC3)=C2)C=N1,,CCNC1=C2N=C(C(C)C)N=C2N(CC2=CC=C(OC)C(OC3CCC(O)C3)=C2)C=N1,CYP2C9;CYP3A4;,Aliphatic Hydroxylation,0.98
v11294,CCNC1=C2N=C(C(C)C)N=C2N(CC2=CC=C(OC)C(OC3CCCC3)=C2)C=N1,,CCNC1=C2N=C(C(C)(C)O)N=C2N(CC2=CC=C(OC)C(OC3CCCC3)=C2)C=N1,CYP2C9;CYP3A4;,Aliphatic Hydroxylation,0.95
v11294,CCNC1=C2N=C(C(C)C)N=C2N(CC2=CC=C(OC)C(OC3CCCC3)=C2)C=N1,,COC1=CC=C(CN2C=NC(N)=C3N=C(C(C)C)N=C32)C=C1OC1CCCC1,CYP2C9;CYP2C19;CYP2D6;CYP3A4;,N-desethylation,0.93
valdecoxib,CC1=C(C2=CC=C(S(N)(=O)=O)C=C2)C(C2=CC=CC=C2)=NO1,"4Ã¢â‚¬Â[5Ã¢â‚¬Â(hydroxymethyl)Ã¢â‚¬Â3Ã¢â‚¬ÂphenylÃ¢â‚¬Â1,2Ã¢â‚¬ÂoxazolÃ¢â‚¬Â4Ã¢â‚¬Âyl]benzeneÃ¢â‚¬Â1Ã¢â‚¬Âsulfonamide",NS(=O)(=O)C1=CC=C(C2=C(CO)ON=C2C2=CC=CC=C2)C=C1,CYP2C9; CYP3A4,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.91
valdecoxib,CC1=C(C2=CC=C(S(N)(=O)=O)C=C2)C(C2=CC=CC=C2)=NO1,"4Ã¢â‚¬Â[3Ã¢â‚¬Â(3Ã¢â‚¬Âhydroxyphenyl)Ã¢â‚¬Â5Ã¢â‚¬ÂmethylÃ¢â‚¬Â1,2Ã¢â‚¬ÂoxazolÃ¢â‚¬Â4Ã¢â‚¬Âyl]benzeneÃ¢â‚¬Â1Ã¢â‚¬Âsulfonamide",CC1=C(C2=CC=C(S(N)(=O)=O)C=C2)C(C2=CC=CC(O)=C2)=NO1,CYP2C9; CYP3A4,m-Hydroxylation of monosubstituted benzene,0.91
valproic acid,CCCC(CCC)C(=O)O,4-Hydroxyvalproate,CCCC(CC(C)O)C(=O)O,CYP2C9; CYP2B6; CYP2A6,Hydroxylation of penultimate aliphatic secondary carbon,0.63
valproic acid,CCCC(CCC)C(=O)O,5-Hydroxyvalproate,CCCC(CCCO)C(=O)O,CYP2C9; CYP2B6; CYP2A6,Hydroxylation of terminal methyl,0.82
valproic acid,CCCC(CCC)C(=O)O,3-Hydroxyvalproate,CCCC(C(=O)O)C(O)CC,CYP2C9; CYP2B6; CYP2A6,Hydroxylation of acyclic aliphatic secondary carbon,0.56
valproic acid,CCCC(CCC)C(=O)O,4-ene-valproate,C=CCC(CCC)C(=O)O,CYP2C9,Terminal desaturation,0.67
valsartan,CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1)C(C(=O)O)C(C)C,4-OH-valsartan,CC(O)CCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1)C(C(=O)O)C(C)C,CYP2C9,Hydroxylation of acyclic aliphatic secondary carbon,0.98
vanoxerine,FC1=CC=C(C(OCCN2CCN(CCCC3=CC=CC=C3)CC2)C2=CC=C(F)C=C2)C=C1,,OC1=CC=C(CCCN2CCN(CCOC(C3=CC=C(F)C=C3)C3=CC=C(F)C=C3)CC2)C=C1,CYP2D6,Aromatic Hydroxylation,0.92
vanoxerine,FC1=CC=C(C(OCCN2CCN(CCCC3=CC=CC=C3)CC2)C2=CC=C(F)C=C2)C=C1,,OC(CCN1CCN(CCOC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC=CC=C1,CYP2D6,Aromatic Hydroxylation,0.9
vicriviroc,COCC(C1=CC=C(C(F)(F)F)C=C1)N1CCN(C2(C)CCN(C(=O)C3=C(C)N=CN=C3C)CC2)CC1C,N-Desalkylvicriviroc ,CC1=NC=NC(C)=C1C(=O)N1CCC(C)(N2CCNC(C)C2)CC1,CYP3A4; CYP3A5,N-dealkylation of alicyclic tertiary amine,0.69
vicriviroc,COCC(C1=CC=C(C(F)(F)F)C=C1)N1CCN(C2(C)CCN(C(=O)C3=C(C)N=CN=C3C)CC2)CC1C,O-Desmethylvicriviroc ,CC1=NC=NC(C)=C1C(=O)N1CCC(C)(N2CCN(C(CO)C3=CC=C(C(F)(F)F)C=C3)C(C)C2)CC1,CYP2C9; CYP3A4; CYP3A5,O-dealkylation of dialkylether,0.97
vicriviroc,COCC(C1=CC=C(C(F)(F)F)C=C1)N1CCN(C2(C)CCN(C(=O)C3=C(C)N=CN=C3C)CC2)CC1C,Vicriviroc N-oxide ,COCC(C1=CC=C(C(F)(F)F)C=C1)N1CCN(C2(C)CCN(C(=O)C3=C(C)N=C[N+]([O-])=C3C)CC2)CC1C,CYP3A4; CYP3A5,N-oxidation of pyrimidine,0.88
vitamin_d2,C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)C=CC(C)C(C)C,,C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)C=CC(C)(O)C(C)C,CYP3A4,Aliphatic Hydroxylation,0.9
voriconazole,CC(C1=NC=NC=C1F)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Hydroxymethyl Voriconazole,OCC(C1=NC=NC=C1F)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,CYP3A4,Hydroxylation of terminal methyl,0.96
voriconazole,CC(C1=NC=NC=C1F)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Voriconazole N-Oxide,CC(C1=NC=[N+]([O-])C=C1F)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,CYP2C9 (major); CYP2C19 (major); CYP3A4 (minor),N-oxidation of pyrimidine,0.96
warfarin-r,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,10-Hydroxywarfarin,CC(=O)C(O)C(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,CYP3A4,Alpha hydroxylation of carbonyl group,0.9
warfarin-r,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,6-Hydroxywarfarin,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=C(O)C=C2C1=O,CYP1A2; CYP1A1; CYP2C19,Aromatic hydroxylation of fused benzene ring,0.95
warfarin-r,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,8-Hydroxywarfarin,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=C(O)C=CC=C2C1=O,CYP1A2; CYP1A1; CYP2C19,HYDROXYLATION_OF_AROMATIC_CARBON,0.9
warfarin-r,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,#NAME?,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC(O)=CC=C2C1=O,CYP1A2; CYP1A1; CYP2C8,Aromatic hydroxylation of fused benzene ring,0.96
warfarin-r,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,4'- Hydroxywarfarin,CC(=O)CC(C1=CC=C(O)C=C1)C1=C(O)OC2=CC=CC=C2C1=O,CYP2C9; CYP2C18,p-Hydroxylation of monosubstituted benzene,0.98
warfarin-s,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,7-Hydroxywarfarin,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC(O)=CC=C2C1=O,CYP2C9,Aromatic hydroxylation of fused benzene ring,0.96
warfarin-s,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,4'-Hydroxywarfarin,CC(=O)CC(C1=CC=C(O)C=C1)C1=C(O)OC2=CC=CC=C2C1=O,CYP2C9,p-Hydroxylation of monosubstituted benzene,0.98
warfarin-s,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,6-Hydroxylation,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=C(O)C=C2C1=O,CYP2C9; CYP2C8; CYP2C18; CYP2C19; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.95
warfarin-s,CC(=O)CC(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,10-Hydroxylation,CC(=O)C(O)C(C1=CC=CC=C1)C1=C(O)OC2=CC=CC=C2C1=O,CYP3A4,Alpha hydroxylation of carbonyl group,0.9
7-Ethoxy-4-trifluoromethylcoumarin,CCOC1=CC=C2C(C(F)(F)F)=CC(=O)OC2=C1,7-Hydroxy-4-trifluoromethylcourmarin,O=C1C=C(C(F)(F)F)C2=CC=C(O)C=C2O1,CYP1A2; CYP2B6; CYP2E1; CYP2C9; CYP2C19,O-aryl dealkylation not adjacent to substituted carbon,0.91
7-methoxy-4-trifluoromethylcoumarin,COC1=CC=C2C(C(F)(F)F)=CC(=O)OC2=C1,7-Hydroxy-4-(trifluoromethyl)chromen-2-one,O=C1C=C(C(F)(F)F)C2=CC=C(O)C=C2O1,CYP1A2;CYP2A6;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP2E1,O-Demethylation ,0.93
7-Benzyloxyresorufin,O=C1C=CC2=NC3=CC=C(OCC4=CC=CC=C4)C=C3OC2=C1,Resorufin,O=C1C=CC2=NC3=CC=C(O)C=C3OC2=C1,CYP1A1; CYP1A2; CYP1B1,O-aryl dealkylation not adjacent to substituted carbon,0.88
"Dibenz[a,j]acridine",C1=CC=C2C(=C1)C=CC1=NC3=CC=C4C=CC=CC4=C3C=C12,,ON1C2=CC=C3C=CC=CC3=C2C=C2C3=CC=CC=C3C=CC21,CYP1A2;CYP3A4,N-Oxidation,0.11
"Dibenz[a,j]acridine",C1=CC=C2C(=C1)C=CC1=NC3=CC=C4C=CC=CC4=C3C=C12,,O=C1C2=C(C=CC3=CC=CC=C23)N=C2C=CC3=CC=CC=C3C12,CYP1A2;CYP3A4,Aromatic Oxidation ,0.09
"Dibenz[a,j]acridine",C1=CC=C2C(=C1)C=CC1=NC3=CC=C4C=CC=CC4=C3C=C12,"3,4-DHD",OC1=CC=C2C(=C1O)C=CC1=NC3=CC=C4C=CC=CC4=C3C=C12,CYP1A2;CYP3A4,Aromatic Hydroxylation,0.68
"Dibenz[a,j]acridine",C1=CC=C2C(=C1)C=CC1=NC3=CC=C4C=CC=CC4=C3C=C12,"1,2-DHD",OC1=CC=C2C=CC3=NC4=CC=C5C=CC=CC5=C4C=C3C2=C1O,CYP1A2;CYP3A4,Aromatic Hydroxylation,0.62
"Dibenz[a,j]acridine",C1=CC=C2C(=C1)C=CC1=NC3=CC=C4C=CC=CC4=C3C=C12,"5,6-DHD",OC1=C(O)C2=NC3=CC=C4C=CC=CC4=C3C=C2C2=CC=CC=C12,CYP1A2;CYP3A4,Aromatic Hydroxylation,0.5
"Methyl N,N-diethyldithiocarbamate",CCN(CC)C(=S)SC,MeDDC sulfine ,CCN(CC)C(SC)=S=O,CYP1A2; CYP2A6; CYP2B6; CYP2E1; CYP3A4; CYP3A5,S-oxidation of dithiocarbamate,0.7
"7,12 Dimethylbenzanthracene",CC1=C2C=CC=CC2=C(C)C2=C1C=CC1=CC=CC=C12,,CC1=C2C=CC=CC2=C(C)C2=C1C(O)=C(O)C1=CC=CC=C12,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4,Aromatic Hydroxylation,0.47
"7,12 Dimethylbenzanthracene",CC1=C2C=CC=CC2=C(C)C2=C1C=CC1=CC=CC=C12,,CC1=C2C=CC3=CC=CC=C3C2=C(C)C2=CC=C(O)C(O)=C12,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4,Aromatic Hydroxylation,0.47
"7,12 Dimethylbenzanthracene",CC1=C2C=CC=CC2=C(C)C2=C1C=CC1=CC=CC=C12,,CC1=C2C=CC=CC2=C(C)C2=C1C=CC1=C(O)C(O)=CC=C12,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4,Aromatic Hydroxylation,0.59
"7,12 Dimethylbenzanthracene",CC1=C2C=CC=CC2=C(C)C2=C1C=CC1=CC=CC=C12,,CC1=C2C=CC=CC2=C(C)C2=C1C=CC1=CC=C(O)C=C12,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4,Aromatic Hydroxylation,0.73
"7,12 Dimethylbenzanthracene",CC1=C2C=CC=CC2=C(C)C2=C1C=CC1=CC=CC=C12,,CC1=C2C=CC=CC2=C(CO)C2=CC=C3C=CC=CC3=C12,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.74
"7,12 Dimethylbenzanthracene",CC1=C2C=CC=CC2=C(C)C2=C1C=CC1=CC=CC=C12,,CC1=C2C=CC=CC2=C(CO)C2=C1C=CC1=CC=CC=C12,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.74
DMXAA,CC1=CC=C2C(=O)C3=CC=CC(CC(=O)O)=C3OC2=C1C,6-Hydroxy-MXAA,CC1=C(CO)C=CC2=C1OC1=C(CC(=O)O)C=CC=C1C2=O,CYP1A2,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.92
4-(Aminomethyl)-7-methoxycoumarin,COC1=CC=C2C(CN)=CC(=O)OC2=C1,7-hydroxy-4-(aminomethyl)-coumarin (HAMC),NCC1=CC(=O)OC2=CC(O)=CC=C12,CYP1A2;CYP2C19;CYP2D6,N-Dealkylation,0.93
NNK,CN(CCCC(=O)C1=CC=CN=C1)N=O,,O=NN(CO)CCCC(=O)C1=CC=CN=C1,CYP1A1; CYP1A2; CYP1B1; CYP2A6; CYP2B6; CYP2D6; CYP2E1,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.92
DEET,CCN(CC)C(=O)C1=CC=CC(C)=C1,"N,N-diethyl-m-hydroxymethylbenzamide",CCN(CC)C(=O)C1=CC=CC(CO)=C1,CYP1A2; CYP2B6; CYP2D6; CYP2E1,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.87
DEET,CCN(CC)C(=O)C1=CC=CC(C)=C1,,CCN(CCO)C(=O)C1=CC=CC(C)=C1,CYP2A6; CYP2C19; CYP3A4; CYP3A5,Hydroxylation of terminal methyl,0.88
"dibenzo(a,h)anthracene",C1=CC=C2C(=C1)C=CC1=CC3=C(C=CC4=CC=CC=C43)C=C12,"dibenzo(a,h)anthracene 1,2-epoxide",C1=CC2OC2C2=C1C=CC1=CC3=C(C=CC4=CC=CC=C43)C=C21,CYP1A1; CYP1A2,ARENE_EPOXIDATION,0.08
"dibenzo(a,h)anthracene",C1=CC=C2C(=C1)C=CC1=CC3=C(C=CC4=CC=CC=C43)C=C12,"dibenzo(a,h)anthracene 3,4-epoxide",C1=CC2=CC=C3C=C4C5=C(C=CC4=CC3=C2CC1)C1OC1C=C5,CYP1A2 (major); CYP2B6 (minor); CYP2C9 (major),ARENE_EPOXIDATION,0.08
Alvameline,CCN1N=NC(C2=CCCN(C)C2)=N1,,CCN1N=NC(C2=CCCNC2)=N1,CYP1A2;CYP2A6;CYP2C19;CYP3A4,N-demethylation,0.92
Alvameline,CCN1N=NC(C2=CCCN(C)C2)=N1,,CCN1N=NC(C2=CCC[N+](C)([O-])C2)=N1,CYP1A2;CYP2C19,N-Oxidation,0.84
Alvameline,CCN1N=NC(C2=CCCN(C)C2)=N1,,CN1CCC=C(C2=NNN=N2)C1,CYP2D6,N-demethylation,0.67
Alvameline,CCN1N=NC(C2=CCCN(C)C2)=N1,,CCN1N=NC(C2=CCC=[N+](C)C2)=N1,CYP1A2;CYP2A6;CYP2C19;CYP3A4,Hydrogenation,0.7
O-isopropyl acetaminophen,CC(O)=NC1=CC=C(OC(C)C)C=C1,Acetaminophen,CC(O)=NC1=CC=C(O)C=C1,CYP1A2,O-deethylation,0.73
O-isopropyl acetaminophen,CC(O)=NC1=CC=C(OC(C)C)C=C1,,COC1=CC=C(N=CO)C=C1,CYP1A2,C-DEALYLATION,0.7
p-Methoxyacetanilide,COC1=CC=C(N=C(C)O)C=C1,"p-Methoxyacetanilide, O-demethyl-",CC(O)=NC1=CC=C(O)C=C1,CYP1A2,O-aryl dealkylation not adjacent to substituted carbon,0.85
Terbutryn,CCN=C1N=C(NC(C)(C)C)NC(SC)=N1,,CCN=C1N=C(NC(C)(C)C)NC(S(C)=O)=N1,CYP1A2;CYP2B6;CYP3A4,S-Oxidation,0.83
Terbutryn,CCN=C1N=C(NC(C)(C)C)NC(SC)=N1,,CSC1=NC(=NC(C)O)N=C(NC(C)(C)C)N1,CYP1A2;CYP2B6;CYP3A4,Aliphatic Hydroxylation,0.91
Terbutryn,CCN=C1N=C(NC(C)(C)C)NC(SC)=N1,,CCN=C1N=C(NC(C)(C)CO)NC(SC)=N1,CYP1A2,Aliphatic Hydroxylation,0.93
MNAN,CCCCCN(C)N=O,,CCCCCN(CO)N=O,CYP2A6;CYP2E1,Aliphatic Hydroxylation,0.69
MNAN,CCCCCN(C)N=O,,CC(O)CCCN(C)N=O,CYP2A6;CYP2E1,Aliphatic Hydroxylation,0.72
NDPA,CCCN(CCC)N=O,Alpha-OH NDPA,CCCN(N=O)C(O)CC,CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2D6;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.47
NDPA,CCCN(CCC)N=O,Dipropylimine,CCCNCCC,CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.37
NPYR,O=NN1CCCC1,,O=NN1CCCC1O,CYP2A6;CYP2E1,Aliphatic Hydroxylation,0.46
RP73401,COC1=CC=C(C(=O)N=C2C(Cl)=CNC=C2Cl)C=C1OC1CCCC1,,COC1=CC=C(C(=O)N=C2C(Cl)=CNC=C2Cl)C=C1OC1CCC(O)C1,CYP2B6,Aliphatic Hydroxylation,0.96
sulfinpyrazone_sulfide,O=C1C(CCSC2=CC=CC=C2)C(=O)N(C2=CC=CC=C2)N1C1=CC=CC=C1,Sulfinpyrazone,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(C2=CC=CC=C2)N1C1=CC=CC=C1,CYP2C9;CYP3A4,S-Oxidation,0.93
sulfinpyrazone_sulfide,O=C1C(CCSC2=CC=CC=C2)C(=O)N(C2=CC=CC=C2)N1C1=CC=CC=C1,,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(C2=CC=C(O)C=C2)N1C1=CC=CC=C1,CYP2C9;CYP3A4,Aromatic Hydroxylation,0.89
sulfinpyrazone_sulfide,O=C1C(CCSC2=CC=CC=C2)C(=O)N(C2=CC=CC=C2)N1C1=CC=CC=C1,,O=C1C(CCS(=O)C2=CC=C(O)C=C2)C(=O)N(C2=CC=CC=C2)N1C1=CC=CC=C1,CYP2C9;CYP3A4,Aromatic Hydroxylation,0.9
Proguanil,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1,Cycloguanil,CC1(C)NC(=N)NC(=N)N1C1=CC=C(Cl)C=C1,CYP1A2; CYP2C19; CYP2D6; CYP3A4; CYP2C9 (minor),Formation of cycloguanide,0.51
Proguanil,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1,4-Chlorophenylbiguanide,N=C(N)NC(=N)NC1=CC=C(Cl)C=C1,CYP2C19,N-deisopropylation,0.79
4_nitro_phenol,O=[N+]([O-])C1=CC=C(O)C=C1,4-nitrocatechol (4NC) ,O=[N+]([O-])C1=CC=C(O)C(O)=C1,CYP2E1,Aromatic Hydroxylation,0.66
"7,8-Dihydrobenzo[a]pyrene-7,8-diol",OC1C=CC2=C(C=C3C=CC4=CC=CC5=CC=C2C3=C45)C1O,,OC1C2=CC3=CC=C4C=CC=C5C=CC(=C2C2OC2C1O)C3=C45,CYP1A1;CYP1B1,Epoxidation,0.47
Furametpyr,CC1=NN(C)C(Cl)=C1C(O)=NC1=CC=CC2=C1C(C)OC2(C)C,,CC1=C(C(O)=NC2=CC=CC3=C2C(C)OC3(C)C)C(Cl)=NN1,CYP1A1;CYP1A2;CYP2C19;CYP3A4,N-Demethylation ,0.91
Bioresmethrin,CC(C)=CC1C(C(=O)OCC2=COC(CC3=CC=CC=C3)=C2)C1(C)C,BFA,OCC1=COC(CC2=CC=CC=C2)=C1,CYP2C8;CYP2C9;CYP2C19;CYP3A4,Oxidation,0.46
TRANS-PERMETHRIN,CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC2=CC=CC=C2)=C1,(3-Phenoxyphenyl)methanol,OCC1=CC=CC(OC2=CC=CC=C2)=C1,CYP2C8;CYP2C9;CYP2C19;CYP3A4,Oxidation,0.36
LOSIGAMONE,COC1=CC(=O)OC1C(O)C1=CC=CC=C1Cl,,COC1=CC(=O)OC1C(O)C1=CC=C(O)C=C1Cl,CYP2A6,Aromatic Hydroxylation,0.93
LOSIGAMONE,COC1=CC(=O)OC1C(O)C1=CC=CC=C1Cl,,COC1=CC(=O)OC1C(O)C1=CC(O)=CC=C1Cl,CYP2A6,Aromatic Hydroxylation,0.91
Promethazine,CC(CN1C2=CC=CC=C2SC2=CC=CC=C21)N(C)C,,CC(CN1C2=CC=CC=C2S(=O)C2=CC=CC=C21)N(C)C,CYP2D6,S-Oxidation,0.83
Promethazine,CC(CN1C2=CC=CC=C2SC2=CC=CC=C21)N(C)C,,CNC(C)CN1C2=CC=CC=C2SC2=CC=CC=C21,CYP2D6,N-Demethylation,0.97
Verapamil,COC1=CC=C(CCN(C)CCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,Norverapamil,COC1=CC=C(CCNCCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,CYP2C8; CYP1A2; CYP3A4; CYP3A5,N-dealkylation of acyclic tertiary amine,0.95
Verapamil,COC1=CC=C(CCN(C)CCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,D-617,CNCCCC(C#N)(C1=CC=C(OC)C(OC)=C1)C(C)C,CYP2C8; CYP3A4; CYP1A2,N-dealkylation of acyclic tertiary amine,0.88
Verapamil,COC1=CC=C(CCN(C)CCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,"2-(3,4-dimethoxyphenyl)acetaldehyde",COC1=CC=C(CC=O)C=C1OC,CYP2C8; CYP3A4; CYP1A2,N-dealkylation of acyclic tertiary amine,0.39
METALAXYL,COCC(=O)N(C1=C(C)C=CC=C1C)C(C)C(=O)OC,,COC(=O)C(C)N(C(=O)CO)C1=C(C)C=CC=C1C,CYP2B6;CYP3A4,O-Demethylation,0.98
METALAXYL,COCC(=O)N(C1=C(C)C=CC=C1C)C(C)C(=O)OC,,COCC(=O)N(C1=C(C)C=CC=C1C)C(C)C(=O)O,CYP2B6;CYP3A4,O-Demethylation,0.95
METALAXYL,COCC(=O)N(C1=C(C)C=CC=C1C)C(C)C(=O)OC,,COCC(=O)N(C1=C(C)C=CC(O)=C1C)C(C)C(=O)OC,CYP3A4,Aromatic Hydroxylation,0.85
METALAXYL,COCC(=O)N(C1=C(C)C=CC=C1C)C(C)C(=O)OC,,COCC(=O)N(C1=C(C)C=CC=C1CO)C(C)C(=O)OC,CYP3A4,Aliphatic Hydroxylation,0.9
demethylmetalaxyl,COC(=O)C(C)N(C(=O)CO)C1=C(C)C=CC=C1C,,CC1=CC=CC(C)=C1N(C(=O)CO)C(C)C(=O)O,CYP2B6;CYP3A4,O-Demethylation,0.91
L-775606,FC1=CC=CC(CCN2CCN(CCCC3=CNC4=CC=C(N5C=NN=C5)C=C34)CC2)=C1,,OC(CN1CCN(CCCC2=CNC3=CC=C(N4C=NN=C4)C=C23)CC1)C1=CC=CC(F)=C1,CYP3A4;CYP2C8,Aliphatic Hydroxylation,0.92
L-775606,FC1=CC=CC(CCN2CCN(CCCC3=CNC4=CC=C(N5C=NN=C5)C=C34)CC2)=C1,,C1=CC2=C(C=C1N1C=NN=C1)C(CCCN1CCNCC1)=CN2,CYP3A4;CYP2C8,N-Dealkylation,0.87
Bufuralol,CCC1=CC=CC2=C1OC(C(O)CNC(C)(C)C)=C2,4-Hydroxybufuralol,CCC1=CC=C(O)C2=C1OC(C(O)CNC(C)(C)C)=C2,CYP1A2; CYP2D6,Aromatic hydroxylation of fused benzene ring,0.8
Bufuralol,CCC1=CC=CC2=C1OC(C(O)CNC(C)(C)C)=C2,6-Hydroxubufuralol,CCC1=C(O)C=CC2=C1OC(C(O)CNC(C)(C)C)=C2,CYP1A2; CYP2D6,Aromatic hydroxylation of fused benzene ring,0.83
Bufuralol,CCC1=CC=CC2=C1OC(C(O)CNC(C)(C)C)=C2,1'2'-Ethenylbufuralol,C=CC1=CC=CC2=C1OC(C(O)CNC(C)(C)C)=C2,CYP2D6,Terminal desaturation,0.88
Deltamethrin,CC1(C)C(C=C(Br)Br)C1C(=O)OC(C#N)C1=CC=CC(OC2=CC=CC=C2)=C1,4'-OH-deltamethrin,CC1(C)C(C=C(Br)Br)C1C(=O)OC(C#N)C1=CC=CC(OC2=CC=C(O)C=C2)=C1,CYP2C8; CYP2C19; CYP3A4; CYP3A5,p-Hydroxylation of monosubstituted benzene,0.99
(1S)-trans-Cyfluthrin,CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=C(F)C(OC2=CC=CC=C2)=C1,,CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=C(F)C(OC2=CC=C(O)C=C2)=C1,CYP1A1;CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP3A4,Aromatic Hydroxylation,0.99
Bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=CC2=C(C=C1C)C(C)(C)CCC2(C)C,6-hydroxy-bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=CC2=C(C=C1C)C(C)(C)C(O)CC2(C)C,CYP3A;CYP2C9;CYP2C19,Aliphatic Hydroxylation,0.8
Bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=CC2=C(C=C1C)C(C)(C)CCC2(C)C,7-hydroxy-bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=CC2=C(C=C1C)C(C)(C)CC(O)C2(C)C,CYP3A;CYP2C9;CYP2C19,Aliphatic Hydroxylation,0.79
Bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=CC2=C(C=C1C)C(C)(C)CCC2(C)C,7-oxo-bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=CC2=C(C=C1C)C(C)(C)C(=O)CC2(C)C,CYP3A;CYP2C9;CYP2C19,Aliphatic Hydroxylation,0.81
Bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=CC2=C(C=C1C)C(C)(C)CCC2(C)C,7-oxo-bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=CC2=C(C=C1C)C(C)(C)CC(=O)C2(C)C,CYP3A;CYP2C9;CYP2C19,Aliphatic Hydroxylation,0.81
Dolasetron,O=C(OC1CC2CC3CC(C1)N2CC3=O)C1=CNC2=CC=CC=C12,Reduced dolasetron,O=C(OC1CC2CC3CC(C1)N2CC3O)C1=CNC2=CC=CC=C12,CYP2D6;CYP3A4,Hydrogenation;Reduction,0.87
Halothane ,FC(F)(F)C(Cl)Br,Trifluoroacetyl chloride,O=C(Cl)C(F)(F)F,CYP2E1; CYP2A6,Oxidation of halotrifluoroethane,0.38
Halothane ,FC(F)(F)C(Cl)Br,chlorotrifluoroethane,FC(F)(F)CCl,CYP2A6; CYP3A4,Reduction of halotrifluoroethane,0.55
delta-9-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CCC(C)=CC21,11-OH-delata-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CCC(CO)=CC21,CYP2C9; CYP2C19; CYP3A4,Hydroxlation of methyl carbon adjacent to an aliphatic ring,0.97
delta-9-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CCC(C)=CC21,7-OH-delta-9-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1C(O)CC(C)=CC21,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.92
delta-9-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CCC(C)=CC21,7alpha-OH-delta-9-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1C(O)CC(C)=CC21,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.92
delta-9-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CCC(C)=CC21,8-OH-delta-9-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CC(O)C(C)=CC21,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.91
delta-9-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CCC(C)=CC21,8alpha-OH-delta-9-Tetrahydrocannabinol,CCCCCC1=CC(O)=C2C(=C1)OC(C)(C)C1CC(O)C(C)=CC21,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.91
S-Bioallethrin,C=CCC1=C(C)C(OC(=O)C2C(C=C(C)C)C2(C)C)CC1=O,,C=CCC1=C(C)C(OC(=O)C2C(C=C(C)CO)C2(C)C)CC1=O,CYP2C9;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.99
Droloxifene,CCC(=C(C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC(O)=C1)C1=CC=CC=C1,,CCC(=C(C1=CC=C(OCCNC)C=C1)C1=CC=CC(O)=C1)C1=CC=CC=C1,CYP2D6;CYP3A4,N-Dementhylation,0.98
Artesunate,CC1CCC2C(C)C(OC(=O)CCC(=O)O)OC3OC4(C)CCC1C32OO4,,CC1CCC2C(C)C(O)OC3OC4(C)CCC1C32OO4,CYP2A6,O-dealkylation,0.9
Rupatadine,CC1=CN=CC(CN2CCC(=C3C4=CC=C(Cl)C=C4CCC4=CC=CN=C34)CC2)=C1,,ClC1=CC=C2C(=C3CCNCC3)C3=NC=CC=C3CCC2=C1,CYP3A4,N-Dealkylation,0.9
RL-3142,CN(C)C1=CC=C(C=CC(=O)C2=CC=C(N3C=CN=C3)C=C2)C=C1,,CNC1=CC=C(C=CC(=O)C2=CC=C(N3C=CN=C3)C=C2)C=C1,CYP3A,N-Dementhylation,0.96
zafirlukast,COC1=CC(C(O)=NS(=O)(=O)C2=CC=CC=C2C)=CC=C1CC1=CN(C)C2=CC=C(N=C(O)OC3CCCC3)C=C12,cyclopentyl NÃ¢â‚¬Â[1Ã¢â‚¬Â(hydroxymethyl)Ã¢â‚¬Â3Ã¢â‚¬Â({2Ã¢â‚¬ÂmethoxyÃ¢â‚¬Â4Ã¢â‚¬Â[(2Ã¢â‚¬Âmethylbenzenesulfonyl)carbamoyl]phenyl}methyl)indolÃ¢â‚¬Â5Ã¢â‚¬Âyl]carbamate,COC1=CC(C(O)=NS(=O)(=O)C2=CC=CC=C2C)=CC=C1CC1=CN(CO)C2=CC=C(N=C(O)OC3CCCC3)C=C12,CYP2C9; CYP3A4,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.98
zafirlukast,COC1=CC(C(O)=NS(=O)(=O)C2=CC=CC=C2C)=CC=C1CC1=CN(C)C2=CC=C(N=C(O)OC3CCCC3)C=C12,3Ã¢â‚¬Âhydroxycyclopentyl NÃ¢â‚¬Â[3Ã¢â‚¬Â({2Ã¢â‚¬ÂmethoxyÃ¢â‚¬Â4Ã¢â‚¬Â[(2Ã¢â‚¬Âmethylbenzenesulfonyl)carbamoyl]phenyl}methyl)Ã¢â‚¬Â1Ã¢â‚¬ÂmethylindolÃ¢â‚¬Â5Ã¢â‚¬Âyl]carbamate,COC1=CC(C(O)=NS(=O)(=O)C2=CC=CC=C2C)=CC=C1CC1=CN(C)C2=CC=C(N=C(O)OC3CCC(O)C3)C=C12,CYP2C9; CYP3A4,Hydroxylation of alicyclic secondary carbon,0.98
zaleplon,CCN(C(C)=O)C1=CC=CC(C2=CC=NC3=C(C#N)C=NN23)=C1,Dementhylazed-zaleplon,CC(O)=NC1=CC=CC(C2=CC=NC3=C(C#N)C=NN23)=C1,CYP3A4,N-Dementhylation,0.85
zatosetron,CN1C2CCC1CC(N=C(O)C1=CC(Cl)=CC3=C1OC(C)(C)C3)C2,,CC1(C)CC2=CC(Cl)=CC(C(O)=NC3CC4CCC(C3)N4)=C2O1,CYP3A4,N-Dementhylation,0.97
zatosetron,CN1C2CCC1CC(N=C(O)C1=CC(Cl)=CC3=C1OC(C)(C)C3)C2,,CC1(C)CC2=CC(Cl)=CC(C(O)=NC3CC4CCC(C3)[N+]4(C)[O-])=C2O1,CYP3A4,N-Oxidation,0.94
zatosetron,CN1C2CCC1CC(N=C(O)C1=CC(Cl)=CC3=C1OC(C)(C)C3)C2,,CN1C2CCC1CC(N=C(O)C1=CC(Cl)=CC3=C1OC(C)(C)C3O)C2,CYP3A4,Aliphatic Hydroxylation,0.91
zinc02949712,CCCCOC1=CC=C2C(C(F)(F)F)=CC(=O)OC2=C1,HFC(7-hydroxy-4-trifluoromethylcoumarin),O=C1C=C(C(F)(F)F)C2=CC=C(O)C=C2O1,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP3A4,O-Demethylation,0.88
zinc03978059,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,free cortisol,CC12CCC(=O)C=C1C(O)CC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,CYP3A4,Alipathic Hydroxylation (6ÃŽÂ²-hydroxylation),0.89
zinc15020070,COC1=CC=C2C(=C1)OC1=CC(O)=CC=C1C21OC(=O)C2=CC=CC=C21,,O=C1OC2(C3=CC=C(O)C=C3OC3=CC(O)=CC=C32)C2=CC=CC=C12,CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19,O-Demethylation,0.97
zinc1698316,COC(=O)C1C(O)CCC2CN3CCC4=C(NC5=CC=CC=C45)C3CC21,,COC(=O)C1C(O)CCC2CN3CCC4=C(NC5=CC=C(O)C=C45)C3CC21,CYP2D6;CYP3A4,Aromatic Hydroxylation,0.96
zinc1698316,COC(=O)C1C(O)CCC2CN3CCC4=C(NC5=CC=CC=C45)C3CC21,,COC(=O)C1C(O)CCC2CN3CCC4=C(NC5=CC(O)=CC=C45)C3CC21,CYP2D6;CYP3A4,Aromatic Hydroxylation,0.96
zinc188,CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=C(C#N)C=C21,S-oxide cyamemazine,CC(CN(C)C)CN1C2=CC=CC=C2S(=O)C2=CC=C(C#N)C=C21,CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4,S-Oxidation,0.86
zinc188,CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=C(C#N)C=C21,N-demethyl-cyamemazine,CNCC(C)CN1C2=CC=CC=C2SC2=CC=C(C#N)C=C21,CYP1A2;CYP2B6;CYP2C8;CYP2C19;CYP3A4,N-demethylations,0.98
zinc21985223,CN(C)C1=CC=C(C2CC3(C)C(CCC3(O)C=CCO)C3CCC4=CC(=O)CCC4=C23)C=C1,,CNC1=CC=C(C2CC3(C)C(CCC3(O)C=CCO)C3CCC4=CC(=O)CCC4=C23)C=C1,CYP3A4,N-demethylations,0.98
zinc33952402,CC1=CC=C(C(=O)C(C)N2CCCC2)C=C1,HO-MPPP,CC(C(=O)C1=CC=C(CO)C=C1)N1CCCC1,CYP2C19;CYP2D6,Aliphatic Hydroxylation,0.93
zinc33952517,CC(C(=O)C1=CC=C2OCOC2=C1)N1CCCC1,di-HO-MDPPP,CC(C(=O)C1=CC=C(O)C(O)=C1)N1CCCC1,CYP2C19;CYP2D6,O-Demethylation,0.81
zinc36377943,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,6beta - HYDROXYBUDESONIDE,CCCC1OC2CC3C4CC(O)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,CYP3A4,Aliphatic Hydroxylation,0.94
zinc36377943,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,6beta - HYDROXYBUDESONIDE,CCCC(O)OC1CC2C3CCC4=CC(=O)C=CC4(C)C3C(O)CC2(C)C1C(=O)CO,CYP3A4,O-dealkylation,0.73
zinc38309998,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21,,C=C1C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C2C(OC(=O)C(C)(C)CC)C1,CYP2C8;CYP3A4;CYP3A5,Dehydrogenation,0.93
zinc38309998,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21,,CCC(C)(C)C(=O)OC1CC(C)C(O)=C2C=C(O)C(C)C(CCC(O)CC(O)CC(=O)O)C21,CYP2C8;CYP3A4;CYP3A5,Aliphatic Hydroxylation,0.79
zinc38309998,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21,,CCC(C)(C)C(=O)OC1CC(C)(O)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21,CYP2C8;CYP3A4;CYP3A5,Aliphatic Hydroxylation,0.88
zinc40442723,O=C1C=C2CN(C(C(=O)C3CC3)C3=CC=CC=C3F)CCC2S1,,O=CC=C1CN(C(C(=O)C2CC2)C2=CC=CC=C2F)CCC1S,CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP3A4,Unknown reaction,0.88
zinc4556587,CCC1CC2CC3C4=C(CCN(C2)C13)C1=CC(OC)=CC=C1N4,12-hydroxyibogamine,CCC1CC2CC3C4=C(CCN(C2)C13)C1=CC(O)=CC=C1N4,CYP2C19;CYP2D6;CYP3A4,O-DEMETHYLATION,0.98
zinc8660420,C=C(C)C1CC2=C(C=CC3=C2OC2COC4=CC(OC)=C(OC)C=C4C2C3=O)O1,,C=C(C)C1CC2=C(C=CC3=C2OC2COC4=CC(OC)=C(O)C=C4C2C3=O)O1,CYP3A4;CYP2C19,O-DEMETHYLATION,0.99
zinc8660420,C=C(C)C1CC2=C(C=CC3=C2OC2COC4=CC(OC)=C(OC)C=C4C2C3=O)O1,,C=C(C)C1CC2=C(C=CC3=C2OC2COC4=CC(OC)=C(OC)C=C4C2(O)C3=O)O1,CYP3A4;CYP2C19,Aliphatic Hydroxylation,0.87
zinc8660420,C=C(C)C1CC2=C(C=CC3=C2OC2COC4=CC(OC)=C(OC)C=C4C2C3=O)O1,,C=C(CO)C1CC2=C(C=CC3=C2OC2COC4=CC(OC)=C(OC)C=C4C2(O)C3=O)O1,CYP3A4,Aliphatic Hydroxylation,0.86
zinc8660420,C=C(C)C1CC2=C(C=CC3=C2OC2COC4=CC(OC)=C(OC)C=C4C2C3=O)O1,,COC1=CC2=C(C=C1OC)C1(O)C(=O)C3=CC=C4OC(C5(C)CO5)CC4=C3OC1CO2,CYP3A4,Epoxidation,0.81
zinc968306,CC(CC1=CC=CC=C1)N(C)CC1=CC=CC=C1,,CC(CC1=CC=CC=C1)NCC1=CC=CC=C1,CYP2B6;CYP2C8;CYP3A4,N-Demethylation,0.83
ziprasidone,OC1=NC2=CC(Cl)=C(CCN3CCN(C4=NSC5=CC=CC=C45)CC3)C=C2C1,,O=S1N=C(N2CCN(CCC3=CC4=C(C=C3Cl)N=C(O)C4)CC2)C2=CC=CC=C21,CYP3A4,S-Oxidation,0.55
ziprasidone,OC1=NC2=CC(Cl)=C(CCN3CCN(C4=NSC5=CC=CC=C45)CC3)C=C2C1,,C1=CC=C2C(N3CCNCC3)=NSC2=C1,CYP3A4,N-dealkylation,0.55
ziprasidone,OC1=NC2=CC(Cl)=C(CCN3CCN(C4=NSC5=CC=CC=C45)CC3)C=C2C1,,CCC1=CC2=C(C=C1Cl)N=C(O)C2,CYP3A4,N-dealkylation,0.54
zolmitriptan,CN(C)CCC1=CNC2=CC=C(CC3COC(O)=N3)C=C12,N-Desmethylzolmitriptan,CNCCC1=CNC2=CC=C(CC3COC(O)=N3)C=C12,CYP1A2,N-dealkylation of acyclic tertiary amine,0.98
zolmitriptan,CN(C)CCC1=CNC2=CC=C(CC3COC(O)=N3)C=C12,Zolmitriptan N-oxide,C[N+](C)([O-])CCC1=CNC2=CC=C(CC3COC(O)=N3)C=C12,CYP1A2,N-oxdation of aliphatic tertiary amine,0.95
zolpidem,CC1=CC=C(C2=C(CC(=O)N(C)C)N3C=C(C)C=CC3=N2)C=C1,methoxyzolpidem,CC1=CN2C(CC(=O)N(C)C)=C(C3=CC=C(CO)C=C3)N=C2C=C1O,CYP3A4(major); CYP1A2 (minor); CYP2D6 (minor); CYP2C9 (minor); CYP2C19 (minor),Hydroxylation of  carbon next to amide,0.92
zotepine,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,Norzotepine,CNCCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,CYP1A1; CYP1A2; CYP3A4; CYP3A5; CYP2B6; CYP2C19,N-dealkylation of acyclic tertiary amine,0.99
zotepine,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,Zotepine N-oxide,C[N+](C)([O-])CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,CYP3A4,N-oxdation of aliphatic tertiary amine,0.96
zotepine,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,2-OH-zotepine,CN(C)CCOC1=CC2=CC(O)=CC=C2SC2=CC=C(Cl)C=C12,CYP1A2,Aromatic hydroxylation of fused benzene ring,0.9
zotepine,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,3-OH-zotepine,CN(C)CCOC1=CC2=CC=C(O)C=C2SC2=CC=C(Cl)C=C12,CYP1A1; CYP1A2; CYP3A4; CYP2D6; CYP2C19,Aromatic hydroxylation of fused benzene ring,0.92
zotepine,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,Zotepine -oxide,CN(C)CCOC1=CC2=CC=CC=C2S(=O)C2=CC=C(Cl)C=C12,CYP1A1; CYP1A2; CYP2B6; CYP3A4; CYP3A5,S-oxidation of diarylthioether to sulfoxide,0.86
Benzo[a]pyrene,C1=CC=C2C(=C1)C=C1C=CC3=CC=CC4=CC=C2C1=C34,"Benzo[a]pyrene-7,8-epoxide",C1=CC2OC2C2=CC3=CC=C4C=CC=C5C=CC(=C12)C3=C45,CYP1A1; CYP1A2; CYP1B1,ARENE_EPOXIDATION,0.09
Benzo[a]pyrene,C1=CC=C2C(=C1)C=C1C=CC3=CC=CC4=CC=C2C1=C34,3-Hydroxybenzo[a]pyrene,C1=C2C=CC3=C4C=CC=CC4=CC4=CC=C(C2=C43)C2OC12,CYP3A4; CYP2C8; CYP2C9;CYP2C19; CYP1A1; CYP1B1,ARENE_EPOXIDATION,0.08
Benzo[a]pyrene,C1=CC=C2C(=C1)C=C1C=CC3=CC=CC4=CC=C2C1=C34,9-Hydroxybenzo[a]pyrene,C1=CC2OC2C2=C1C=C1C=CC3=CC=CC4=CC=C2C1=C34,CYP1A1; CYP1B1,ARENE_EPOXIDATION,0.08
Benzo[a]pyrene,C1=CC=C2C(=C1)C=C1C=CC3=CC=CC4=CC=C2C1=C34,1-Hydroxybenzo[a]pyrene,C1=C2C=CC3=CC4=CC=CC=C4C4=CC=C(C2=C34)C2OC12,CYP1A1,ARENE_EPOXIDATION,0.08
Benzo[a]pyrene,C1=CC=C2C(=C1)C=C1C=CC3=CC=CC4=CC=C2C1=C34,"Benzo[a]pyrene-4,5-epoxide",C1=CC=C2C(=C1)C=C1C3=C2C=CC2=CC=CC(=C23)C2OC12,CYP1A1; CYP1B1,ARENE_EPOXIDATION,0.13
ethinylestradiol,C#CC1(O)CCC2C3CCC4=CC(O)=CC=C4C3CCC21C,,C#CC1(O)CCC2C3CCC4=CC(O)=C(O)C=C4C3CCC21C,CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP3A4,Aliphatic Hydroxylation,0.96
ethinylestradiol,C#CC1(O)CCC2C3CCC4=CC(O)=CC=C4C3CCC21C,,C#CC1(O)CCC2C3CCC4=C(C=CC(O)=C4O)C3CCC21C,CYP3A4;,Aliphatic Hydroxylation,0.87
"Retinoic acid, all-trans",CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,4-Hydroxyretinoic acid,CC(C=CC1=C(C)C(O)CCC1(C)C)=CC=CC(C)=CC(=O)O,CYP1A2; CYP3A7; CYP2C8 (major); CYP3A4; CYP2C9 (minor); CYP2B6; CYP3A5; CYP2A6,Hydroxylation of alicyclic secondary carbon,0.75
"Retinoic acid, all-trans",CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,18-Hydroxyretinoic acid,CC(C=CC1=C(CO)CCCC1(C)C)=CC=CC(C)=CC(=O)O,CYP4A11; CYP3A7; CYP1A1; CYP2C8; CYP2C9; CYP2C18; CYP3A4; CYP3A5,Hydroxlation of methyl carbon adjacent to an aliphatic ring,0.86
"Retinoic acid, all-trans",CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,"5,6-Epoxy-retinoic acid",CC(C=CC12OC1(C)CCCC2(C)C)=CC=CC(C)=CC(=O)O,CYP2C8; CYP2C9; CYP1A1; CYP2D6,EPOXIDATION_OF_1122_TETRASUBSTITUTED_ALKLENE,0.35
1_2-dibromoethane,BrCCBr,2-bromoacetaldehyde ,O=CCBr,CYP2A6;CYP2B6;CYP2E1,Oxidation,0.43
2_2_4_4_5_5-hexachlorobiphenyl,ClC1=CC(Cl)=C(C2=CC(Cl)=C(Cl)C=C2Cl)C=C1Cl,,OC1=C(Cl)C(Cl)=CC(C2=CC(Cl)=C(Cl)C=C2Cl)=C1Cl,CYP2B6,Aromatic Hydroxylation,0.63
Nelfinavir,CC1=C(O)C=CC=C1C(O)=NC(CSC1=CC=CC=C1)C(O)CN1CC2CCCCC2CC1C(O)=NC(C)(C)C,Nelfinavir hydroxyl-t- butylamide,CC1=C(O)C=CC=C1C(O)=NC(CSC1=CC=CC=C1)C(O)CN1CC2CCCCC2CC1C(O)=NC(C)(C)CO,CYP2C19,Hydroxylation of terminal methyl,0.99
Nelfinavir,CC1=C(O)C=CC=C1C(O)=NC(CSC1=CC=CC=C1)C(O)CN1CC2CCCCC2CC1C(O)=NC(C)(C)C,"3,4-Dihydroxynelfinavir",CC1=C(C(O)=NC(CSC2=CC=CC=C2)C(O)CN2CC3CCCCC3CC2C(O)=NC(C)(C)C)C=CC(O)=C1O,CYP3A4,Hydroxylation of benzene on carbon orhto to a strongly electron donating group,0.97
Metamphetamine,CNC(C)CC1=CC=CC=C1,4-Hydroxymethamphetamine,CNC(C)CC1=CC=C(O)C=C1,CYP2D6,p-Hydroxylation of monosubstituted benzene,0.77
Metamphetamine,CNC(C)CC1=CC=CC=C1,Amphetamine,CC(N)CC1=CC=CC=C1,CYP2D6,N-dealkylation of acyclic secondary amine,0.84
desimipramine,CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C21,2-hydroxy-desipramine ,CNCCCN1C2=CC=CC=C2CCC2=CC(O)=CC=C21,CYP2D6,Aromatic Hydroxylation,0.86
Trichloroethane,CC(Cl)(Cl)Cl,Trichloroethanol,OCC(Cl)(Cl)Cl,CYP2E1,Aliphatic Hydroxylation,0.58
Duloxetine,CNCCC(OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,,CNCCC(OC1=CC=C(O)C2=CC=CC=C12)C1=CC=CS1,CYP1A2;CYP2D6,Aromatic Hydroxylation,0.97
Duloxetine,CNCCC(OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,,CNCCC(OC1=CC=CC2=CC(O)=CC=C12)C1=CC=CS1,CYP1A2;CYP2D6,Aromatic Hydroxylation,0.98
Duloxetine,CNCCC(OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,,CNCCC(OC1=CC=CC2=C(O)C=CC=C12)C1=CC=CS1,CYP1A2;CYP2D6,Aromatic Hydroxylation,0.96
leflunomide,CC1=C(C(=O)NC2=CC=C(C(F)(F)F)C=C2)C=NO1,,CC(O)=C(C=N)C(=O)NC1=CC=C(C(F)(F)F)C=C1,CYP1A2;CYP2C9;CYP3A4,N-O bond cleavage,0.32
paraxanthine,CN1C(O)=NC2=C(C1=O)N(C)C=N2,,CN1C(O)=NC2=C(C1=O)N(C)C(O)=N2,CYP1A2;CYP2A6,Aliphatic Hydroxylation,0.95
paraxanthine,CN1C(O)=NC2=C(C1=O)N(C)C=N2,,CN1C(O)=NC2=C(N=CN2)C1=O,CYP1A2,N-dementhylation,0.88
"N,N-Dimethylaniline",CN(C)C1=CC=CC=C1,,CNC1=CC=CC=C1,CYP1A2;CYP2B1;CYP4B1,N-dementhylation,0.77
Estradiol,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2O,2-hydroxyestradiol,CC12CCC3C4=CC(O)=C(O)C=C4CCC3C1CCC2O,CYP1A1;CYP1A2;CYP3A4;CYP3A5,Aromatic Hydroxylation,0.96
Estradiol,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2O,,CC12CCC3C4=CC=C(O)C(O)=C4CCC3C1CCC2O,CYP1B1,Aromatic Hydroxylation,0.85
alosetron,CC1=C(CN2CCC3=C(C2=O)C2=CC=CC=C2N3C)NC=N1,,CC1=C(CN2CCC3=C(C2=O)C2=CC=CC(O)=C2N3C)NC=N1,CYP1A2,Aromatic Hydroxylation,0.91
alosetron,CC1=C(CN2CCC3=C(C2=O)C2=CC=CC=C2N3C)NC=N1,,CC1=C(CN2CCC3=C(C2=O)C2=CC=CC(O)=C2N3C)NC(O)=N1,CYP1A2,Aromatic Hydroxylation,0.89
Phenobarbital,CCC1(C2=CC=CC=C2)C(O)=NC(=O)N=C1O,p-Hydroxyphenobarbital,CCC1(C2=CC=C(O)C=C2)C(O)=NC(=O)N=C1O,CYP2C9; CYP2C19; CYP2E1,p-Hydroxylation of monosubstituted benzene,0.95
Paroxetine,FC1=CC=C(C2CCNCC2COC2=CC=C3OCOC3=C2)C=C1,,OC1=CC=C(OCC2CNCCC2C2=CC=C(F)C=C2)C=C1O,CYP2D6,O-Demethylenation,0.91
bromperidol,O=C(CCCN1CCC(O)(C2=CC=C(Br)C=C2)CC1)C1=CC=C(F)C=C1,,OC1(C2=CC=C(Br)C=C2)CCNCC1,CYP3A4,N-Dealkylation,0.66
bromperidol,O=C(CCCN1CCC(O)(C2=CC=C(Br)C=C2)CC1)C1=CC=C(F)C=C1,,CCCC(=O)C1=CC=C(F)C=C1,CYP3A4,N-Dealkylation,0.41
Glyburide,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCCCC2)C=C1,2-trans-hydroxycyclohexyl glyburide ,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCCCC2O)C=C1,CYP3A4; CYP2C9; CYP2C19,Hydroxylation of alicyclic secondary carbon,0.92
Glyburide,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCCCC2)C=C1,4-cis-hydroxycyclohexyl glyburide ,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCC(O)CC2)C=C1,CYP3A4; CYP2C9; CYP2C19,Hydroxylation of alicyclic secondary carbon,0.97
Glyburide,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCCCC2)C=C1,4-trans-hydroxycyclohexyl glyburide ,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCC(O)CC2)C=C1,CYP3A4; CYP2C9; CYP2C19,Hydroxylation of alicyclic secondary carbon,0.97
Glyburide,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCCCC2)C=C1,3-trans-Hydroxycyclohexyl glyburide,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCCC(O)C2)C=C1,CYP3A4; CYP2C9; CYP2C19,Hydroxylation of alicyclic secondary carbon,0.94
Glyburide,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCCCC2)C=C1,3-cis-Hydroxycyclohexyl glyburide,COC1=CC=C(Cl)C=C1C(O)=NCCC1=CC=C(S(=O)(=O)NC(O)=NC2CCCC(O)C2)C=C1,CYP3A4; CYP2C9; CYP2C19,Hydroxylation of alicyclic secondary carbon,0.94
Troleandomycin,COC1CC(OC2C(C)C(=O)OC(C)C(C)C(OC(C)=O)C(C)C(=O)C3(CO3)CC(C)C(OC3OC(C)CC(N(C)C)C3OC(C)=O)C2C)OC(C)C1OC(C)=O,,CNC1CC(C)OC(OC2C(C)CC3(CO3)C(=O)C(C)C(OC(C)=O)C(C)C(C)OC(=O)C(C)C(OC3CC(OC)C(OC(C)=O)C(C)O3)C2C)C1OC(C)=O,CYP3A4;CYP3A5,N-Dementhylation,0.97
(-)-bisoprolol,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,"(-)-bisoprolol, O-deisopropyl",CC(C)NCC(O)COC1=CC=C(COCCO)C=C1,CYP2D6; CYP3A4,O-deisopropylation,0.94
"(r)-chloroquine, N-desethyl",CCNCCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,"(r)-chloroquine, N-desethyl",CC(CCCN)NC1=CC=NC2=CC(Cl)=CC=C12,CYP2C8; CYP2D6; CYP3A4; CYP3A5,N-dealkylation of acyclic secondary amine,0.96
(r)-fluoxetine,CNCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,(r)-Norfluoxetine,NCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,CYP2C9 (major); CYP2D6; CYP2C19; CYP3A5 ,N-dealkylation of acyclic secondary amine,0.95
(r)-fluoxetine,CNCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,p-Trifluoromethyl phenol,OC1=CC=C(C(F)(F)F)C=C1,CYP2D6,O-dealkylation,0.32
(r)-fluoxetine,CNCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,3-(methylamino)-1-phenylpropan-1-one,CNCCC(=O)C1=CC=CC=C1,CYP2D6,O-dealkylation,0.27
S-Mephenytoin,CCC1(C2=CC=CC=C2)N=C(O)N(C)C1=O,4Ã¢â‚¬Â²-Hydroxymephenytoin,CCC1(C2=CC=C(O)C=C2)N=C(O)N(C)C1=O,CYP2D6;  CYP2C19;  CYP1A2;  CYP2C18;  CYP3A4,p-Hydroxylation of monosubstituted benzene,0.96
S-Mephenytoin,CCC1(C2=CC=CC=C2)N=C(O)N(C)C1=O,Nirvanol,CCC1(C2=CC=CC=C2)N=C(O)N=C1O,CYP2C19; CYP2C18; CYP2D6; CYP1A2; CYP3A4; CYP2B6,N-dealkylation of dicarboximide,0.42
(S)-(-)-Mexiletine,CC1=CC=CC(C)=C1OCC(C)N,"(S)-(-)-Mexiletine, p-hydroxyl",CC1=CC(O)=CC(C)=C1OCC(C)N,CYP1A2 (minor); CYP2D6 (major),HYDROXYLATION_OF_AROMATIC_CARBON,0.85
(S)-(-)-Mexiletine,CC1=CC=CC(C)=C1OCC(C)N,"(S)-(-)-Mexiletine, m-hydroxyl",CC1=CC=C(O)C(C)=C1OCC(C)N,CYP1A2 (minor); CYP2D6 (major),HYDROXYLATION_OF_AROMATIC_CARBON,0.78
(S)-(-)-Mexiletine,CC1=CC=CC(C)=C1OCC(C)N,"(S)-(-)-Mexiletine, 2-OH-hydroxymethyl",CC1=CC=CC(CO)=C1OCC(C)N,CYP1A2 (minor); CYP2D6 (major),Hydroxylation of non-terminal aliphatic carbon adjacent to aromatic ring,0.77
(S)-(-)-Mexiletine,CC1=CC=CC(C)=C1OCC(C)N,"(S)-(-)-Mexiletine, N-hydroxy",CC1=CC=CC(C)=C1OCC(C)NO,CYP1A2 (major); CYP2B6; CYP2E1,N-hydroxylation of primary or secondary aliphatic amine,0.91
(S)-mianserin,CN1CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,"(S)-mianserin, N-Desmethyl",C1=CC=C2C(=C1)CC1=CC=CC=C1N1CCNCC21,CYP1A2; CYP2B6; CYP3A4,N-dealkylation of alicyclic tertiary amine,0.96
(S)-mianserin,CN1CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,"(S)-mianserin, 8-hydroxy",CN1CCN2C3=CC(O)=CC=C3CC3=CC=CC=C3C2C1,CYP1A2; CYP2D6; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.93
(S)-mianserin,CN1CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,"(S)-mianserin, N-oxide",C[N+]1([O-])CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,CYP1A2,N-oxidation of alicyclic tertiary amine,0.91
(s)-azelastine,CN1CCCC(N2N=C(CC3=CC=C(Cl)C=C3)C3=CC=CC=C3C2=O)CC1,"(s)-azelastine, N-desmethyl",O=C1C2=CC=CC=C2C(CC2=CC=C(Cl)C=C2)=NN1C1CCCNCC1,CYP3A4; CYP2D6; CYP1A2 (minor),N-dealkylation of alicyclic tertiary amine,0.98
(s)-bupropion,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,(2S)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one,CC(NC(C)(C)CO)C(=O)C1=CC=CC(Cl)=C1,CYP2B6; CYP3A4,Hydroxylation of terminal methyl,0.92
(s)-bupropion,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,(2S)-2-(tert-butylamino)-1-(3-chlorophenyl)-3-hydroxypropan-1-one,CC(C)(C)NC(CO)C(=O)C1=CC=CC(Cl)=C1,CYP2C19,Hydroxylation of terminal methyl,0.86
(s)-bupropion,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,(2S)-2-(tert-butylamino)-1-(3-chloro-4-hydroxyphenyl)propan-1-one,CC(NC(C)(C)C)C(=O)C1=CC=C(O)C(Cl)=C1,CYP2B6;CYP2C19; CYP2E1,Hydroxylation of aromatic carbon ortho to halide group,0.82
(s)-bupropion,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,(2S)-2-(tert-butylamino)-1-(3-chloro-5-hydroxyphenyl)propan-1-one,CC(NC(C)(C)C)C(=O)C1=CC(O)=CC(Cl)=C1,CYP2B6;CYP2C19; CYP2E1,Hydroxylation of aromatic carbon meta to halide group,0.78
"1,4-dichlorobenzene",ClC1=CC=C(Cl)C=C1,"2,5-dichlorophenol",OC1=CC(Cl)=CC=C1Cl,CYP2E1 (major),Hydroxylation of aromatic carbon ortho to halide group,0.38
P-Hydroxynefazodone,CCC1=NN(CCCN2CCN(C3=CC=C(O)C(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,"1Ã¢â‚¬Â(3Ã¢â‚¬ÂchloroÃ¢â‚¬Â4Ã¢â‚¬ÂoxocyclohexaÃ¢â‚¬Â2,5Ã¢â‚¬ÂdienÃ¢â‚¬Â1Ã¢â‚¬Âylidene)Ã¢â‚¬Â4Ã¢â‚¬Â{3Ã¢â‚¬Â[3Ã¢â‚¬ÂethylÃ¢â‚¬Â5Ã¢â‚¬ÂoxoÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â1Ã¢â‚¬Âyl]propyl}Ã¢â‚¬Â1lambda5Ã¢â‚¬ÂpiperazinÃ¢â‚¬Â1Ã¢â‚¬Âylium",CCC1=NN(CCCN2CCN(C3=CC(=[Cl+])C(=O)C=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,CYP3A4,_2_ELECTRON_OXIDATION_OF_P_AMINOPHENOLS_TO_QUINONE_IMINES_PATTERN1,0.71
"1Ã¢â‚¬Â{3Ã¢â‚¬Â[4Ã¢â‚¬Â(3Ã¢â‚¬ÂchloroÃ¢â‚¬Â4Ã¢â‚¬Âhydroxyphenyl)piperazinÃ¢â‚¬Â1Ã¢â‚¬Âyl]propyl}Ã¢â‚¬Â3Ã¢â‚¬ÂethylÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â5Ã¢â‚¬Âone",CCC1=NN(CCCN2CCN(C3=CC=C(O)C(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,"1Ã¢â‚¬Â{3Ã¢â‚¬Â[4Ã¢â‚¬Â(3Ã¢â‚¬ÂchloroÃ¢â‚¬Â1Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â4Ã¢â‚¬ÂoxocyclohexaÃ¢â‚¬Â2,5Ã¢â‚¬ÂdienÃ¢â‚¬Â1Ã¢â‚¬Âyl)piperazinÃ¢â‚¬Â1Ã¢â‚¬Âyl]propyl}Ã¢â‚¬Â3Ã¢â‚¬ÂethylÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â5Ã¢â‚¬Âone",CCC1=NN(CCCN2CCN(C3(O)C=CC(=O)C(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,CYP3A4,Oxidation of 4-substituted phenol,0.69
"1Ã¢â‚¬Â{3Ã¢â‚¬Â[4Ã¢â‚¬Â(3Ã¢â‚¬ÂchloroÃ¢â‚¬Â4Ã¢â‚¬Âhydroxyphenyl)piperazinÃ¢â‚¬Â1Ã¢â‚¬Âyl]propyl}Ã¢â‚¬Â3Ã¢â‚¬ÂethylÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â5Ã¢â‚¬Âone",CCC1=NN(CCCN2CCN(C3=CC=C(O)C(Cl)=C3)CC2)C(=O)N1CCOC1=CC=CC=C1,"1Ã¢â‚¬Â[3Ã¢â‚¬Â(4Ã¢â‚¬Â{3Ã¢â‚¬ÂchloroÃ¢â‚¬Â4Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â7Ã¢â‚¬Âoxabicyclo[4.1.0]heptaÃ¢â‚¬Â2,4Ã¢â‚¬ÂdienÃ¢â‚¬Â1Ã¢â‚¬Âyl}piperazinÃ¢â‚¬Â1Ã¢â‚¬Âyl)propyl]Ã¢â‚¬Â3Ã¢â‚¬ÂethylÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â5Ã¢â‚¬Âone",CCC1=NN(CCCN2CCN(C34C=C(Cl)C(O)=CC3O4)CC2)C(=O)N1CCOC1=CC=CC=C1,CYP3A4,EPOXIDATION,0.62
1-aminopyrene,NC1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,N-hydroxy-1-aminopyrene,ONC1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,CYP1A1; CYP1A2; CYP3A4,N-hydroxylation of primary arylamine,0.75
17alpha-Ethinylestradiol,C#CC1(O)CCC2C3(C)CCC4=CC(O)=CC=C4C3CCC21C,2beta-OH-17beta-Ethinylestradiol,C#CC1(O)CCC2C3(C)CCC4=CC(O)=C(O)C=C4C3CCC21C,CYP2C9; CYP3A4; CYP2C19; CYP1A2,Aromatic hydroxylation of fused benzene ring,0.97
17alpha-Ethinylestradiol,C#CC1(O)CCC2C3(C)CCC4=CC(O)=CC=C4C3CCC21C,4beta-OH-17beta-Ethinylestradiol,C#CC1(O)CCC2C3(C)CCC4=C(C=CC(O)=C4O)C3CCC21C,CYP2C9; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.88
17alpha-Ethinylestradiol,C#CC1(O)CCC2C3(C)CCC4=CC(O)=CC=C4C3CCC21C,6beta-OH-17beta-Ethinylestradiol,C#CC1(O)CCC2C3(C)CC(O)C4=CC(O)=CC=C4C3CCC21C,CYP2C9; CYP3A4,Hydroxylation of alicyclic secondary carbon,0.83
17alpha-Ethinylestradiol,C#CC1(O)CCC2C3(C)CCC4=CC(O)=CC=C4C3CCC21C,6alpha-OH-17beta-Ethinylestradiol,C#CC1(O)CCC2C3(C)CC(O)C4=CC(O)=CC=C4C3CCC21C,CYP2C9; CYP3A4,Hydroxylation of alicyclic secondary carbon,0.83
"2,6-Xylidine",CC1=CC=CC(C)=C1N,"4-hydroxy-2,6-dimethylaniline",CC1=CC(O)=CC(C)=C1N,CYP2A6; CYP2E1,Hydroxylation of benzene on carbon para to a strongly electron donating group,0.61
"2,6-Xylidine",CC1=CC=CC(C)=C1N,"N-(2,6-dimethylphenyl)hydroxylamine",CC1=CC=CC(C)=C1NO,CYP2A6; CYP2E1,N-hydroxylation of primary arylamine,0.71
3-aminobenzanthrone,NC1C=CC2=C3C(=CC=CC31)C(=O)C1=CC=CC=C21,N-hydroxy-3-aminobenzanthrone,O=C1C2=CC=CC3C2=C(C=CC3NO)C2=CC=CC=C12,CYP1A1; CYP1A2; CYP1B1; CYP2A6; CYP2B6; ,N-hydroxylation of primary arylamine,0.96
3-Hydroxylidocaine,CCN(CC)CC(O)=NC1=C(C)C=CC(O)=C1C,3-Hydroxymonoethyl glycinexylidide,CCNCC(O)=NC1=C(C)C=CC(O)=C1C,CYP1A2; CYP2D6; CYP3A4,N-dealkylation of acyclic tertiary amine,0.95
3'-HPPH,OC1=NC(C2=CC=CC=C2)(C2=CC=CC(O)=C2)C(O)=N1,"3Ã¢â‚¬â„¢,4Ã¢â‚¬â„¢- diHPPH",OC1=NC(C2=CC=CC=C2)(C2=CC=C(O)C(O)=C2)C(O)=N1,CYP2C9; CYP2C19,Hydroxylation of benzene on carbon orhto to a strongly electron donating group,0.94
4'-HPPH,OC1=NC(C2=CC=CC=C2)(C2=CC=C(O)C=C2)C(O)=N1,"3Ã¢â‚¬â„¢,4Ã¢â‚¬â„¢- diHPPH",OC1=NC(C2=CC=CC=C2)(C2=CC=C(O)C(O)=C2)C(O)=N1,CYP2C9; CYP2C19,Hydroxylation of benzene on carbon orhto to a strongly electron donating group,0.87
"4,4'-Dichlorobiphenyl",ClC1=CC=C(C2=CC=C(Cl)C=C2)C=C1,"4,4Ã¢â‚¬Â²-Dichloro-3-biphenylol",OC1=CC(C2=CC=C(Cl)C=C2)=CC=C1Cl,CYP1A2,Hydroxylation of aromatic carbon ortho to halide group,0.55
7-Methoxyresorufin,COC1=CC=C2N=C3C=CC(=O)C=C3OC2=C1,Resorufin,O=C1C=CC2=NC3=CC=C(O)C=C3OC2=C1,CYP1A1; CYP1A2,O-aryl demethylation,0.95
"(R)-mianserin, 8-hydroxy",CN1CCN2C3=CC(O)=CC=C3CC3=CC=CC=C3C2C1,"(R)-mianserin, 8-OH-N-desmethyl",OC1=CC=C2CC3=CC=CC=C3C3CNCCN3C2=C1,CYP2D6; CYP1A2; CYP3A4,N-dealkylation of alicyclic tertiary amine,0.97
Acetachlor,CCOCN(C(=O)CCl)C1=C(C)C=CC=C1CC,,CCC1=CC=CC(C)=C1N=C(O)CCl,CYP2B6; CYP3A4,N-dealkoxylation of N-aryl-N-chloroacetamide,0.3
Acetachlor,CCOCN(C(=O)CCl)C1=C(C)C=CC=C1CC,,CCOCNC1=C(C)C=CC=C1CC,CYP2B6; CYP3A4,N-demethoxymethylation,0.51
(R)-acenocoumarol,CC(=O)CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC=CC=C2OC1=O,6-OH-R-acenocoumarol,CC(=O)CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC=CC(O)=C2OC1=O,CYP2C9; CYP1A2; CYP2C19,Aromatic hydroxylation of fused benzene ring,0.93
(R)-acenocoumarol,CC(=O)CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC=CC=C2OC1=O,7-OH-R-acenocoumarol,CC(=O)CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC=C(O)C=C2OC1=O,CYP2C9; CYP2C19,Aromatic hydroxylation of fused benzene ring,0.99
(R)-acenocoumarol,CC(=O)CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC=CC=C2OC1=O,8-OH-R-acenocoumarol,CC(=O)CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC(O)=CC=C2OC1=O,CYP2C9; CYP2C19,Aromatic hydroxylation of fused benzene ring,0.97
Bromazepam,OC1=NC2=CC=C(Br)C=C2C(C2=CC=CC=N2)=NC1,,OC1=NC2=CC=C(Br)C=C2C(C2=CC=CC=N2)=NC1O,CYP1A2; CYP2D6,"3-Hydroxylation of 5-aryl-1,4-benzodiazepine",0.89
Alachlor,CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl,,CCC1=CC=CC(CC)=C1N=C(O)CCl,CYP2B6; CYP3A4,N-dealkoxylation of N-aryl-N-chloroacetamide,0.31
Alachlor,CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl,,CCC1=CC=CC(CC)=C1NCOC,CYP2B6; CYP3A4,N-demethoxymethylation,0.52
6-Aminochrysene,NC1=CC2=C3C=CC=CC3=CC=C2C2=CC=CC=C12,N-Hydroxychrysene,ONC1=CC2=C3C=CC=CC3=CC=C2C2=CC=CC=C12,CYP1B1; CYP1A2; CYP1A1; CYP2A6; CYP2B6,N-hydroxylation of primary arylamine,0.75
Aminoflavone,CC1=C(F)C(N)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,"Aminoflavone, N4'-Hydroxy",CC1=C(F)C(N)=C2C(=O)C=C(C3=CC=C(NO)C(F)=C3)OC2=C1F,CYP1A2; CYP1A1; CYP2C9; CYP2C19,N-hydroxylation of primary arylamine,0.98
Aminoflavone,CC1=C(F)C(N)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,,CC1=C(F)C(NO)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,CYP1A2; CYP2C9; CYP2C19,N-hydroxylation of primary arylamine,0.94
Aminoflavone,CC1=C(F)C(N)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,"Aminoflavone, C3-hydroxy",CC1=C(F)C(N)=C2C(=O)C(O)=C(C3=CC=C(N)C(F)=C3)OC2=C1F,CYP1A2,Hydroxylation of carbon alpha to conjugated carbonyl,0.88
"Aminoflavone, N4'-Hydroxyl",CC1=C(F)C(N)=C2C(=O)C=C(C3=CC=C(NO)C(F)=C3)OC2=C1F,"Aminoflavone, N4', N5-dihydroxy",CC1=C(F)C(NO)=C2C(=O)C=C(C3=CC=C(NO)C(F)=C3)OC2=C1F,CYP1A2; CYP2C9; CYP2C19,N-hydroxylation of primary arylamine,0.95
Amphetamine,CC(N)CC1=CC=CC=C1,4-Hydroxyamphetamine,CC(N)CC1=CC=C(O)C=C1,CYP2D6,p-Hydroxylation of monosubstituted benzene,0.73
Aprindine,CCN(CC)CCCN(C1=CC=CC=C1)C1CC2=CC=CC=C2C1,"N-[3-(N,NDiethylamino)propyl]-N-phenyl-2-aminoindan-5-ol",CCN(CC)CCCN(C1=CC=CC=C1)C1CC2=CC=C(O)C=C2C1,CYP2D6,Aromatic hydroxylation of fused benzene ring,0.87
Aprindine,CCN(CC)CCCN(C1=CC=CC=C1)C1CC2=CC=CC=C2C1,p-Hydroxyphenylaprindine,CCN(CC)CCCN(C1=CC=C(O)C=C1)C1CC2=CC=CC=C2C1,CYP2D6,Hydroxylation of benzene on carbon para to a strongly electron donating group,0.93
Aprindine,CCN(CC)CCCN(C1=CC=CC=C1)C1CC2=CC=CC=C2C1,Desethylaprindine,CCNCCCN(C1=CC=CC=C1)C1CC2=CC=CC=C2C1,CYP2D6,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES,0.97
Butachlor,CCCCOCN(C(=O)CCl)C1=C(CC)C=CC=C1CC,,CCC1=CC=CC(CC)=C1N=C(O)CCl,CYP2B6; CYP3A4,N-dealkoxylation of N-aryl-N-chloroacetamide,0.3
Butachlor,CCCCOCN(C(=O)CCl)C1=C(CC)C=CC=C1CC,,CCC1=CC=CC(CC)=C1N=C(O)CCl,CYP2B6; CYP3A4,N-demethoxymethylation,0.3
Buprenorphine,COC12CCC3(CC1C(C)(O)C(C)(C)C)C1CC4=CC=C(O)C5=C4C3(CCN1CC1CC1)C2O5,Norbuprenorphine,COC12CCC3(CC1C(C)(O)C(C)(C)C)C1CC4=CC=C(O)C5=C4C3(CCN1)C2O5,CYP3A4; CYP2C8; CYP2C9; CYP3A5,N-dealkylation of alicyclic tertiary amine,0.98
(+)-Camphor,CC12CCC(CC1=O)C2(C)C,5-exo-hydroxycamphor,CC12CCC(CC1=O)C2(C)CO,CYP2D6,Hydroxlation of methyl carbon adjacent to an aliphatic ring,0.74
(+)-Camphor,CC12CCC(CC1=O)C2(C)C,8-hydroxycamphor,CC12CC(O)C(CC1=O)C2(C)C,CYP2D6,Hydroxylation of alicyclic secondary carbon,0.62
Carbosulfan,CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2,carbofuran,CN=C(O)OC1=CC=CC2=C1OC(C)(C)C2,CYP1A1; CYP1A2; CYP2A6; CYP2B6; CYP2C8; CYP2C19; CYP3A4,NS-cleavage,0.6
Carbosulfan,CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2,dibutyl(sulfanyl)amine,CCCCN(S)CCCC,CYP1A1; CYP1A2; CYP2A6; CYP2B6; CYP2C8; CYP2C19; CYP3A4,NS-cleavage,0.07
Carbosulfan,CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2,,CCCCN(CCCC)S(=O)N(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2,CYP1A1; CYP2B6; CYP2C19; CYP3A4,Oxidation of S adjacent to an aliphatic nitrogen,0.9
Chlorpyrifos-oxon,CCOP(=O)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl,"3,5,6-Trichloro-2-pyridinol",OC1=NC(Cl)=C(Cl)C=C1Cl,CYP2C19; CYP2B6; CYP3A4,Dearylation of organphosphosulfur compound,0.46
Chlorpyrifos-oxon,CCOP(=O)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl,Diethyl phosphate,CCOP(=O)(O)OCC,CYP2C19; CYP2B6; CYP3A4,Dearylation of organphosphosulfur compound,0.1
Citalopram,CN(C)CCCC1(C2=CC=C(F)C=C2)OCC2=CC(C#N)=CC=C21,Citalopram N-oxide,C[N+](C)([O-])CCCC1(C2=CC=C(F)C=C2)OCC2=CC(C#N)=CC=C21,CYP2D6,N-oxdation of aliphatic tertiary amine,0.96
Citalopram,CN(C)CCCC1(C2=CC=C(F)C=C2)OCC2=CC(C#N)=CC=C21,N-Desmethylcitalopram,CNCCCC1(C2=CC=C(F)C=C2)OCC2=CC(C#N)=CC=C21,CYP2D6; CYP2C19; CYP3A4,N-dealkylation of acyclic tertiary amine,0.99
D-617,CNCCCC(C#N)(C1=CC=C(OC)C(OC)=C1)C(C)C,D-620,COC1=CC=C(C(C#N)(CCCN)C(C)C)C=C1OC,CYP3A4; CYP3A5,N-dealkylation of acyclic secondary amine,0.98
D-702,COC1=CC(CCN(C)CCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)=CC=C1O,,COC1=CC=C(C(C#N)(CCCN)C(C)C)C=C1OC,CYP3A4; CYP3A5,N-dealkylation of acyclic tertiary amine,0.86
Dimethoate,CN=C(O)CSP(=S)(OC)OC,Omethoate,CN=C(O)CSP(=O)(OC)OC,CYP1A1; CYP1A2; CYP2A6; CYP2B6; CYP2C8; CYP2C9; CYP2C19; CYP3A4,Desulfuration of organophosphorodithioate,0.49
DEET,CCN(CC)C(=O)C1=CC=CC(C)=C1,N-ethyl-m-toluamide,CCN=C(O)C1=CC=CC(C)=C1,CYP2C19; CYP3A4,N-dealkylation of tertiary carboxamide,0.19
Diazoxon,CCOP(=O)(OCC)OC1=CC(C)=NC(C(C)C)=N1,Pyrimidinol,CC1=CC(O)=NC(C(C)C)=N1,CYP2C19,C-DE-ESTERIFICATION,0.48
Diazoxon,CCOP(=O)(OCC)OC1=CC(C)=NC(C(C)C)=N1,Diethy phosphate,CCOP(=O)(O)OCC,CYP2C19,Dearylation of organphosphosulfur compound,0.11
Disulfoton,CCOP(=S)(OCC)SCCSCC,Disulfoton sulfoxide,CCOP(=S)(OCC)SCCS(=O)CC,CYP1A2; CYP2B6; CYP2C9; CYP2C18; CYP2C19; CYP2D6; CYP3A4,S-oxidation of dialkylthioether to sulfoxide,0.85
Diuron,CN(C)C(O)=NC1=CC=C(Cl)C(Cl)=C1,N-demethyldiuron,CN=C(O)NC1=CC=C(Cl)C(Cl)=C1,CYP1A1; CYP1A2; CYP2C19; CYP3A4,N-dealkylation of urea,0.43
donepezil,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2,"2Ã¢â‚¬Â[(1Ã¢â‚¬ÂbenzylpiperidinÃ¢â‚¬Â4Ã¢â‚¬Âyl)methyl]Ã¢â‚¬Â5Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â6Ã¢â‚¬ÂmethoxyÃ¢â‚¬Â2,3Ã¢â‚¬ÂdihydroindenÃ¢â‚¬Â1Ã¢â‚¬Âone",COC1=CC2=C(C=C1O)CC(CC1CCN(CC3=CC=CC=C3)CC1)C2=O,CYP3A4; CYP2C9; CYP2D6,O-aryl dealkylation adjacent to substituted carbon,0.99
donepezil,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2,"5,6Ã¢â‚¬ÂdimethoxyÃ¢â‚¬Â2Ã¢â‚¬Â(piperidinÃ¢â‚¬Â4Ã¢â‚¬Âylmethyl)Ã¢â‚¬Â2,3Ã¢â‚¬ÂdihydroindenÃ¢â‚¬Â1Ã¢â‚¬Âone",COC1=CC2=C(C=C1OC)C(=O)C(CC1CCNCC1)C2,CYP3A4; CYP2C9,N-dealkylation of alicyclic tertiary amine,0.89
donepezil,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2,"2Ã¢â‚¬Â[(1Ã¢â‚¬ÂbenzylpiperidinÃ¢â‚¬Â4Ã¢â‚¬Âyl)methyl]Ã¢â‚¬Â6Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â5Ã¢â‚¬ÂmethoxyÃ¢â‚¬Â2,3Ã¢â‚¬ÂdihydroindenÃ¢â‚¬Â1Ã¢â‚¬Âone",COC1=CC2=C(C=C1O)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2,CYP3A4; CYP2C9,O-aryl dealkylation adjacent to substituted carbon,0.99
Encainide,COC1=CC=C(C(=O)NC2=CC=CC=C2CCC2CCCCN2C)C=C1,N-demethylencainide,COC1=CC=C(C(=O)NC2=CC=CC=C2CCC2CCCCN2)C=C1,CYP2D6,N-dealkylation of alicyclic tertiary amine,0.95
Encainide,COC1=CC=C(C(=O)NC2=CC=CC=C2CCC2CCCCN2C)C=C1,O-demethylencainide,CN1CCCCC1CCC1=CC=CC=C1NC(=O)C1=CC=C(O)C=C1,CYP2D6,O-aryl demethylation,0.96
Esfenvalerate,CC(C)C(C(=O)OC(C#N)C1=CC=CC(OC2=CC=CC=C2)=C1)C1=CC=C(Cl)C=C1,2'-OH-esfenvalerate,CC(C)C(C(=O)OC(C#N)C1=CC=CC(OC2=CC=CC=C2O)=C1)C1=CC=C(Cl)C=C1,CYP2C8; CYP2C9; CYP2C19; CYP3A4; CYP3A5,o-Hydroxylation of monosubstituted benzene,0.94
Esfenvalerate,CC(C)C(C(=O)OC(C#N)C1=CC=CC(OC2=CC=CC=C2)=C1)C1=CC=C(Cl)C=C1,4'-OH-esfenvalerate,CC(C)C(C(=O)OC(C#N)C1=CC=CC(OC2=CC=C(O)C=C2)=C1)C1=CC=C(Cl)C=C1,CYP2C8; CYP2C9; CYP2C19; CYP3A4; CYP3A5,p-Hydroxylation of monosubstituted benzene,0.99
N-Desmethylclomipramine,CNCCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C21,N-Didesmethylclomipramine,NCCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C21,CYP2C19; CYP3A4; CYP1A2,N-dealkylation of acyclic secondary amine,0.99
N-Desmethylclomipramine,CNCCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C21,8-OH-N-desmethylclomipramine,CNCCCN1C2=CC(Cl)=CC=C2CCC2=C(O)C=CC=C21,CYP2D6,Aromatic hydroxylation of fused benzene ring,0.81
N-demethylencainide,COC1=CC=C(C(=O)NC2=CC=CC=C2CCC2CCCCN2)C=C1,"N,O-didemethylencainide",O=C(NC1=CC=CC=C1CCC1CCCCN1)C1=CC=C(O)C=C1,CYP2D6,O-aryl demethylation,0.96
O-demethylencainide,CN1CCCCC1CCC1=CC=CC=C1NC(=O)C1=CC=C(O)C=C1,"N,O-didemethylencainide",O=C(NC1=CC=CC=C1CCC1CCCCN1)C1=CC=C(O)C=C1,CYP2D6,N-dealkylation of alicyclic tertiary amine,0.95
Endosulfan-alpha,O=S1OCC2C(CO1)C1(Cl)C(Cl)=C(Cl)C2(Cl)C1(Cl)Cl,Endosulfan sulfate,O=S1(=O)OCC2C(CO1)C1(Cl)C(Cl)=C(Cl)C2(Cl)C1(Cl)Cl,CYP2C9; CYP2C19; CYP3A4; CYP3A5; CYP3A7,S-oxidation of organosulfurous compounds,0.98
Fenthion,COP(=S)(OC)OC1=CC=C(SC)C(C)=C1,Fenthion oxon,COP(=O)(OC)OC1=CC=C(SC)C(C)=C1,CYP1A2; CYP2B6; CYP2C9; CYP2C19; CYP3A4; CYP3A5,Desulfuration of organophosphothioates,0.71
Flecainide,OC(=NCC1CCCCN1)C1=CC(OCC(F)(F)F)=CC=C1OCC(F)(F)F,"2-hydroxy-N-[(piperidin-2-yl)methyl]-5-(2,2,2-trifluoroethoxy)benzamide",OC(=NCC1CCCCN1)C1=CC(OCC(F)(F)F)=CC=C1O,CYP2D6,O-aryl dealkylation adjacent to substituted carbon,0.91
Fluoxetine ,CNCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,Norfluoxetine,NCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,CYP2C9 (major); CYP2D6,N-dealkylation of acyclic secondary amine,0.95
Fluoxetine ,CNCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,p-Trifluoromethylphenol,OC1=CC=C(C(F)(F)F)C=C1,CYP2C19; CYP3A4,O-aryl dealkylation not adjacent to substituted carbon,0.32
lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)(=O)C1=NC2=CC=CC=C2N1,CYP3A4,S-Oxidation,0.94
lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C(O)C=C2N1,CYP2C9;CYP2C19;CYP3A4,Aromatic Hydroxylation,0.94
Gavestinel,O=C(O)C1=C(C=CC(O)=NC2=CC=CC=C2)C2=C(Cl)C=C(Cl)C=C2N1,p-OH-gavestinel,O=C(C=CC1=C(C(=O)O)NC2=CC(Cl)=CC(Cl)=C12)NC1=CC=C(O)C=C1,CYP2C9,Hydroxylation of benzene on carbon para to an electron donating group,0.8
Gliclazide,CC1=CC=C(S(=O)(=O)NC(O)=NN2CC3CCCC3C2)C=C1,7-OH-gliclazide,CC1=CC=C(S(=O)(=O)NC(O)=NN2CC3CC(O)CC3C2)C=C1,CYP2C9,Hydroxylation of alicyclic secondary carbon,0.9
Gliclazide,CC1=CC=C(S(=O)(=O)NC(O)=NN2CC3CCCC3C2)C=C1,Methylhydroxygliclazide,O=S(=O)(NC(O)=NN1CC2CCCC2C1)C1=CC=C(CO)C=C1,CYP2C9; CYP2C19,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.95
Gliclazide,CC1=CC=C(S(=O)(=O)NC(O)=NN2CC3CCCC3C2)C=C1,6-OH-gliclazide,CC1=CC=C(S(=O)(=O)NC(O)=NN2CC3CCC(O)C3C2)C=C1,CYP2C9,Hydroxylation of alicyclic secondary carbon,0.82
Glimepiride,CCC1=C(C)CN(C(O)=NCCC2=CC=C(S(=O)(=O)NC(O)=NC3CCC(C)CC3)C=C2)C1=O,Cyclohexylhydroymethylglimepiride,CCC1=C(C)CN(C(O)=NCCC2=CC=C(S(=O)(=O)NC(O)=NC3CCC(CO)CC3)C=C2)C1=O,CYP2C9,Hydroxylation of terminal methyl,0.98
Glipizide,CC1=CN=C(C(O)=NCCC2=CC=C(S(=O)(=O)NC(O)=NC3CCCCC3)C=C2)C=N1,4-trans-OH-glipizide,CC1=CN=C(C(O)=NCCC2=CC=C(S(=O)(=O)NC(O)=NC3CCC(O)CC3)C=C2)C=N1,CYP2C9,Hydroxylation of alicyclic secondary carbon,0.96
Hydromorphone,CN1CCC23C4=C5C=CC(O)=C4OC2C(=O)CCC3C1C5,Norhydromorphone,O=C1CCC2C3CC4=CC=C(O)C5=C4C2(CCN3)C1O5,CYP3A4; CYP2C9; CYP2D6,N-dealkylation of mixed tertiary amine,0.98
R-Ibuprofen,CC(C)CC1=CC=C(C(C)C(=O)O)C=C1,"R,S-3-Hydroxyibuprofen",CC(CO)CC1=CC=C(C(C)C(=O)O)C=C1,CYP2C8; CYP2C9,Hydroxylation of terminal methyl,0.92
R-Ibuprofen,CC(C)CC1=CC=C(C(C)C(=O)O)C=C1,R-2-Hydroxyibuprofen,CC(C(=O)O)C1=CC=C(CC(C)(C)O)C=C1,CYP2C8; CYP2C9,Hydroxylation of alkyl methine,0.91
Lansoprazole,CC1=CC(OCC(F)(F)F)=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=N1,Hydroxylansoprazole,CC1=CC(OCC(F)(F)F)=C(C)C(CS(=O)C2=NC3=CC=CC(O)=C3N2)=N1,CYP2C19; CYP2C9; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.89
Lansoprazole,CC1=CC(OCC(F)(F)F)=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=N1,Lansoprazole sulfone,CC1=CC(OCC(F)(F)F)=C(C)C(CS(=O)(=O)C2=NC3=CC=CC=C3N2)=N1,CYP3A4,S-oxidation of sulfoxide to sulfone,0.94
Imidacloprid,O=[N+]([O-])NC1=NCCN1CC1=CC=C(Cl)N=C1,,ON=NC1=NCCN1CC1=CC=C(Cl)N=C1,CYP2B6; CYP2D6; CYP2E1; CYP3A4,Reduction of nitroimine,0.65
Linoleic acid,CCCCCC=CCC=CCCCCCCCC(=O)O,Leukotoxin,CCCCCC=CCC1OC1CCCCCCCC(=O)O,CYP2C9; CYP2C19,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.44
Linoleic acid,CCCCCC=CCC=CCCCCCCCC(=O)O,Isoleukotoxin,CCCCCC1OC1CC=CCCCCCCCC(=O)O,CYP2C9; CYP2C19,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.44
Lithocholic Acid,CC(CCC(=O)O)C1CCC2C3CCC4CC(O)CCC4(C)C3CCC12C,6ÃŽÂ±-Hydroxylithocholic acid,CC(CCC(=O)O)C1CCC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C,CYP3A4,Hydroxylation of alicyclic secondary carbon,0.79
Lumiracoxib,CC1=CC=C(NC2=C(F)C=CC=C2Cl)C(CC(=O)O)=C1,Lumiracoxib metabolite 1,O=C(O)CC1=CC(CO)=CC=C1NC1=C(F)C=CC=C1Cl,CYP2C9; CYP2C19,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.94
Lumiracoxib,CC1=CC=C(NC2=C(F)C=CC=C2Cl)C(CC(=O)O)=C1,Lumiracoxib metabolite 2,CC1=CC=C(NC2=C(F)C=C(O)C=C2Cl)C(CC(=O)O)=C1,CYP2C9; CYP2C19,Hydroxylation of aromatic carbon meta to halide group,0.87
M7,CCCCC1=NC2(CCC(O)C2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,M1,CC(O)CCC1=NC2(CCC(O)C2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,CYP2C9,Hydroxylation of alicyclic secondary carbon,0.99
Malathion,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,Maloxon,CCOC(=O)CC(SP(=O)(OC)OC)C(=O)OCC,CYP1A2; CYP2B6; CYP2C19; CYP3A4,Desulfuration of organophosphorodithioate,0.65
Mianserine,CN1CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,8-Hydroxymianserin,CN1CCN2C3=CC=C(O)C=C3CC3=CC=CC=C3C2C1,"CYP2D6 (major; (major, RÃ¢â€°Ë†S)); CYP2B6 (R>S); CYP3A4  (S>R) ",Aromatic hydroxylation of fused benzene ring,0.93
Mianserine,CN1CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,Desmethylmianserin,C1=CC=C2C(=C1)CC1=CC=CC=C1N1CCNCC21,CYP2B6 (R>S); CYP3A4 (R>S); CYP2C19 (R>S); CYP1A2 (RÃ¢â€°Ë†S),N-dealkylation of alicyclic tertiary amine,0.96
Mianserine,CN1CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,Mianserin N-oxide,C[N+]1([O-])CCN2C3=CC=CC=C3CC3=CC=CC=C3C2C1,CYP3A4 (RÃ¢â€°Ë†S); CYP1A2 (S>R),N-oxidation of alicyclic tertiary amine,0.91
Mirtazapine,CN1CCN2C3=NC=CC=C3CC3=CC=CC=C3C2C1,Mirtazapine N-oxide,C[N+]1([O-])CCN2C3=NC=CC=C3CC3=CC=CC=C3C2C1,CYP1A2; CYP2D6; CYP3A4,N-oxidation of alicyclic tertiary amine,0.93
Mirtazapine,CN1CCN2C3=NC=CC=C3CC3=CC=CC=C3C2C1,N-Desmethylmirtazapine,C1=CC=C2C(=C1)CC1=CC=CN=C1N1CCNCC21,CYP1A2; CYP2D6; CYP3A4,N-dealkylation of mixed tertiary amine,0.97
Mirtazapine,CN1CCN2C3=NC=CC=C3CC3=CC=CC=C3C2C1,8-OH-mirtazapine,CN1CCN2C3=NC(O)=CC=C3CC3=CC=CC=C3C2C1,CYP1A2; CYP2D6; CYP3A4,HYDROXYLATION_OF_HETEROAROMATIC_CARBON,0.94
(-)-Menthol,CC1CCC(C(C)C)C(O)C1,"p-Menthane-3,-8-diol",CC1CCC(C(C)(C)O)C(O)C1,CYP2A6,Hydroxylation of alkyl methine,0.73
Mestranol,C#CC1(O)CCC2C3CCC4=CC(OC)=CC=C4C3CCC21C,Ethinylestradiol,C#CC1(O)CCC2C3CCC4=CC(O)=CC=C4C3CCC21C,CYP2C9,O-aryl dealkylation not adjacent to substituted carbon,0.94
Mono-OH-methoxychlor,COC1=CC=C(C(C2=CC=C(O)C=C2)C(Cl)(Cl)Cl)C=C1,Catechol-methoxychlor,COC1=CC=C(C(C2=CC=C(O)C(O)=C2)C(Cl)(Cl)Cl)C=C1,CYP2B6; CYP3A4; CYP3A5,o-Hydroxylation of phenol,0.78
Mono-OH-methoxychlor,COC1=CC=C(C(C2=CC=C(O)C=C2)C(Cl)(Cl)Cl)C=C1,Bis-OH-methoxychlor,OC1=CC=C(C(C2=CC=C(O)C=C2)C(Cl)(Cl)Cl)C=C1,CYP1A2; CYP2C8; CYP2C19; CYP2D6,O-aryl dealkylation not adjacent to substituted carbon,0.89
Monodemethylated mifepristone,CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(C3=CC=C(NC)C=C3)CC21C,Didemethylated mifepristone,CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(C3=CC=C(N)C=C3)CC21C,CYP3A4,N-dealkylation of secondary arylalkylamine,0.99
Bis-OH-methoxychlor,OC1=CC=C(C(C2=CC=C(O)C=C2)C(Cl)(Cl)Cl)C=C1,Tris-OH-methoxychlor,OC1=CC=C(C(C2=CC=C(O)C(O)=C2)C(Cl)(Cl)Cl)C=C1,CYP3A4,o-Hydroxylation of phenol,0.76
methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,"2ethylidene-1,5-dimethyl-3,3-diphenylpyrolidine",CCC1C(C)N(C)CC1(C1=CC=CC=C1)C1=CC=CC=C1,CYP2D6; CYP3A4 (major); CYP2B6; CYP2C8; CYP2C19,N-dealkylation of acyclic tertiary amine,0.49
Monoethylglycinexylidide,CCNCC(O)=NC1=C(C)C=CC=C1C,3-Hydroxymonoethyl glycinexylidide,CCNCC(O)=NC1=C(C)C=CC(O)=C1C,CYP1A2; CYP2D6; CYP3A4,HYDROXYLATION_OF_AROMATIC_CARBON,0.71
Monoethylglycinexylidide,CCNCC(O)=NC1=C(C)C=CC=C1C,Glycinexylidide,CC1=CC=CC(C)=C1N=C(O)CN,CYP1A2; CYP3A4,N-dealkylation of acyclic secondary amine,0.9
N-Desmethyldiphenhydramine,CNCCOC(C1=CC=CC=C1)C1=CC=CC=C1,"N,N-Didesmethyldiphenhydramine",NCCOC(C1=CC=CC=C1)C1=CC=CC=C1,CYP2D6; CYP1A2; CYP2C9; CYP2C19,N-dealkylation of acyclic secondary amine,0.94
N-Desmethylmianserin,C1=CC=C2C(=C1)CC1=CC=CC=C1N1CCNCC21,"(R)-mianserin, 8-OH-N-desmethyl",OC1=CC=C2CC3=CC=CC=C3C3CNCCN3C2=C1,CYP2D6; CYP1A2; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.92
N-Desmethyltamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCNC)C=C1)C1=CC=CC=C1,N-Desdimethyltamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCN)C=C1)C1=CC=CC=C1,CYP3A4; CYP3A5,N-dealkylation of acyclic secondary amine,0.98
N-Desmethyltamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCNC)C=C1)C1=CC=CC=C1,alpha-OH-N-desmethyltamoxifen,CNCCOC1=CC=C(C(=C(C2=CC=CC=C2)C(C)O)C2=CC=CC=C2)C=C1,CYP3A4; CYP3A5,Hydroxylation of penultimate aliphatic secondary carbon,0.85
"N-methyl-3,4methylenedioxyamphetamine ",CNC(C)CC1=CC=C2OCOC2=C1,"N-Methyl-3,4dihydroxyamphetamine ",CNC(C)CC1=CC=C(O)C(O)=C1,CYP2D6; CYP1A2 ,Methylenedioxy ring opening,0.69
1-Naphtaldehyde,O=CC1=CC=CC2=CC=CC=C12,1-Nahthalenethanol,OCC1=CC=CC2=CC=CC=C12,CYP3A4,Reduction of aldehyde to alcohol,0.58
1-Naphtaldehyde,O=CC1=CC=CC2=CC=CC=C12,1-Naphthoic acid,O=C(O)C1=CC=CC2=CC=CC=C12,CYP3A4,Aldehyde oxidation,0.7
Nateglinide,CC(C)C1CCC(C(O)=NC(CC2=CC=CC=C2)C(=O)O)CC1,2Ã¢â‚¬Â{[4Ã¢â‚¬Â(1Ã¢â‚¬ÂhydroxypropanÃ¢â‚¬Â2Ã¢â‚¬Âyl)cyclohexyl]formamido}Ã¢â‚¬Â3Ã¢â‚¬Âphenylpropanoic acid,CC(CO)C1CCC(C(O)=NC(CC2=CC=CC=C2)C(=O)O)CC1,CYP2C9; CYP3A4,Hydroxylation of terminal methyl,0.99
Nateglinide,CC(C)C1CCC(C(O)=NC(CC2=CC=CC=C2)C(=O)O)CC1,2Ã¢â‚¬Â{[4Ã¢â‚¬Â(2Ã¢â‚¬ÂhydroxypropanÃ¢â‚¬Â2Ã¢â‚¬Âyl)cyclohexyl]formamido}Ã¢â‚¬Â3Ã¢â‚¬Âphenylpropanoic acid,CC(C)(O)C1CCC(C(O)=NC(CC2=CC=CC=C2)C(=O)O)CC1,CYP2C9; CYP3A4,Hydroxylation of penultimate aliphatic tertiary carbon,0.95
Nicardipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1,De-benzylated nicardipine,CNCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+](=O)[O-])=C1,CYP2C8; CYP3A4,N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES,0.95
Nicardipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1,Dehydronicardipine,COC(=O)C1=C(C)N=C(C)C(C(=O)OCCN(C)CC2=CC=CC=C2)=C1C1=CC=CC([N+](=O)[O-])=C1,CYP1A1; CYP1A2; CYP2C8; CYP2D6; CYP2E1; CYP3A4; CYP3A5,"Dehydrogenation of 4-aryl substituted 1,4-dihydropyridine",0.38
Nordoxepin,CNCCC=C1C2=CC=CC=C2COC2=CC=CC=C12,2-Hydroxynordoxepin,CNCCC=C1C2=CC(O)=CC=C2COC2=CC=CC=C12,CYP2D6,Aromatic hydroxylation of fused benzene ring,0.93
Norverapamil,COC1=CC=C(CCNCCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,D-620,COC1=CC=C(C(C#N)(CCCN)C(C)C)C=C1OC,CYP2C8; CYP3A4; CYP2D6,N-dealkylation of acyclic secondary amine,0.9
Norverapamil,COC1=CC=C(CCNCCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,"2-(3,4-dimethoxyphenyl)acetaldehyde",COC1=CC=C(CC=O)C=C1OC,CYP2C8; CYP3A4; CYP2D6,N-dealkylation of acyclic secondary amine,0.41
omeprazole,COC1=CC=C2N=C(S(=O)CC3=NC=C(C)C(OC)=C3C)NC2=C1,3-Hydroxyomeprazole,COC1=CC=C2N=C(S(=O)CC3=NC=C(C)C(OC)=C3CO)NC2=C1,CYP3A4,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.92
omeprazole,COC1=CC=C2N=C(S(=O)CC3=NC=C(C)C(OC)=C3C)NC2=C1,5-Hydroxyomeprazole,COC1=CC=C2N=C(S(=O)CC3=NC=C(CO)C(OC)=C3C)NC2=C1,CYP2C19; CYP3A4; CYP2C9,Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring,0.94
omeprazole,COC1=CC=C2N=C(S(=O)CC3=NC=C(C)C(OC)=C3C)NC2=C1,5'-O-Desmethyl omeprazole,COC1=C(C)C=NC(CS(=O)C2=NC3=CC=C(O)C=C3N2)=C1C,CYP2C19,O-aryl dealkylation not adjacent to substituted carbon,0.98
omeprazole,COC1=CC=C2N=C(S(=O)CC3=NC=C(C)C(OC)=C3C)NC2=C1,Omeprazole sulfone,COC1=CC=C2N=C(S(=O)(=O)CC3=NC=C(C)C(OC)=C3C)NC2=C1,CYP3A4,S-oxidation of sulfoxide to sulfone,0.94
Ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=CC=C1N2C,6-OH-ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC(O)=CC=C1N2C,CYP3A4; CYP2D6; CYP1A2,Aromatic hydroxylation of fused benzene ring,0.95
Ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=CC=C1N2C,7-OH-ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=C(O)C=C1N2C,CYP1A2; CYP2D6; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.96
Ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=CC=C1N2C,8-OH-ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=CC(O)=C1N2C,CYP1A2; CYP2D6; CYP3A4,Aromatic hydroxylation of fused benzene ring,0.91
Phorate,CCOP(=S)(OCC)SCSCC,Phorate sulfoxide,CCOP(=S)(OCC)SCS(=O)CC,CYP1A2; CYP3A4; CYP2B6; CYP2C9; CYP2C18; CYP2C19; CYP2D6,S-oxidation of dialkylthioether to sulfoxide,0.78
Pioglitazone,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)N=C3O)C=C2)N=C1,"2Ã¢â‚¬Â[6Ã¢â‚¬Â(2Ã¢â‚¬Â{4Ã¢â‚¬Â[(2,4Ã¢â‚¬ÂdioxoÃ¢â‚¬Â1,3Ã¢â‚¬ÂthiazolidinÃ¢â‚¬Â5Ã¢â‚¬Âyl)methyl]phenoxy}ethyl)pyridinÃ¢â‚¬Â3Ã¢â‚¬Âyl]acetic acid",O=C(O)CC1=CC=C(CCOC2=CC=C(CC3SC(=O)N=C3O)C=C2)N=C1,CYP2C8; CYP3A4,OXIDATION_OF_PRIM_ALCOHOL_TO_CARBOXYLIC_ACID,0.93
Pioglitazone,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)N=C3O)C=C2)N=C1,"5Ã¢â‚¬Â[(4Ã¢â‚¬Â{2Ã¢â‚¬Â[5Ã¢â‚¬Â(1Ã¢â‚¬Âhydroxyethyl)pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl]ethoxy}phenyl)methyl]Ã¢â‚¬Â1,3Ã¢â‚¬ÂthiazolidineÃ¢â‚¬Â2,4Ã¢â‚¬Âdione",CC(O)C1=CC=C(CCOC2=CC=C(CC3SC(=O)N=C3O)C=C2)N=C1,CYP2C8; CYP3A4,Hydroxylation of non-terminal aliphatic carbon adjacent to aromatic ring,0.93
Pioglitazone,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)N=C3O)C=C2)N=C1,"5Ã¢â‚¬Â({4Ã¢â‚¬Â[2Ã¢â‚¬Â(5Ã¢â‚¬ÂethylpyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl)Ã¢â‚¬Â2Ã¢â‚¬Âhydroxyethoxy]phenyl}methyl)Ã¢â‚¬Â1,3Ã¢â‚¬ÂthiazolidineÃ¢â‚¬Â2,4Ã¢â‚¬Âdione",CCC1=CC=C(C(O)COC2=CC=C(CC3SC(=O)N=C3O)C=C2)N=C1,CYP2C8; CYP3A4,HYDROXYLATION_OF_ALIPHATIC_SECONDARY_CARBON,0.89
17ÃŽÂ²-OH-progesterone,CC(=O)C1(O)CCC2C3CCC4=CC(=O)CCC4(C)C3CCC21C,17Beta-21-dihydroxyprogesterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C1CCC2(O)C(=O)CO,CYP2D4; CYP2D6,Alpha hydroxylation of carbonyl group,0.95
Pranidipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=CC2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1,Dehydrogenated pranidipine,COC(=O)C1=C(C)N=C(C)C(C(=O)OCC=CC2=CC=CC=C2)=C1C1=CC=CC([N+](=O)[O-])=C1,CYP3A4,"Dehydrogenation of 4-aryl substituted 1,4-dihydropyridine",0.37
Pranidipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=CC2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1,transÃ¢â‚¬Â1Ã¢â‚¬ÂphenylÃ¢â‚¬Â1Ã¢â‚¬Âpropene,CC=CC1=CC=CC=C1,CYP1A2; CYP2D6; CYP3A4,C-DE-ESTERIFICATION,0.08
Pranidipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=CC2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1,"5Ã¢â‚¬Â(methoxycarbonyl)Ã¢â‚¬Â2,6Ã¢â‚¬ÂdimethylÃ¢â‚¬Â4Ã¢â‚¬Â(3Ã¢â‚¬Ânitrophenyl)Ã¢â‚¬Â 1,4Ã¢â‚¬ÂdihydropyridineÃ¢â‚¬Â3Ã¢â‚¬Âcarboxylic acid",COC(=O)C1=C(C)NC(C)=C(C(=O)O)C1C1=CC=CC([N+](=O)[O-])=C1,CYP1A2; CYP2D6; CYP3A4,C-DE-ESTERIFICATION,0.93
Propafenone ,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,5-Hydroxypropafenone,CCCNCC(O)COC1=CC=C(O)C=C1C(=O)CCC1=CC=CC=C1,CYP2D6,Hydroxylation of benzene on carbon para to an electron donating group,0.9
Propafenone ,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,N-Despropylpropafenone,NCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,CYP1A2; CYP3A4,N-dealkylation of acyclic secondary amine,0.94
(+)-limonene,C=C(C)C1CC=C(C)CC1,Carveol,C=C(C)C1CC=C(C)C(O)C1,CYP2C9; CYP2C19,Hydroxylation of alicyclic secondary carbon,0.58
(+)-limonene,C=C(C)C1CC=C(C)CC1,Perillyl alcohol,C=C(C)C1CC=C(CO)CC1,CYP2C9; CYP2C19; CYP3A4,Hydroxlation of methyl carbon adjacent to an aliphatic ring,0.76
Monodesethylchloroquine,CCNCCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,"N,N-didesethylchloroquinone",CC(CCCN)NC1=CC=NC2=CC(Cl)=CC=C12,CYP2D6,N-dealkylation of acyclic secondary amine,0.96
Rofecoxib,CS(=O)(=O)C1=CC=C(C2=C(C3=CC=CC=C3)C(=O)OC2)C=C1,5-OH-rofecoxib,CS(=O)(=O)C1=CC=C(C2=C(C3=CC=CC=C3)C(=O)OC2O)C=C1,CYP1A2; CYP3A4,ALIPHATIC_HYDROXYLATION_OF_CARBON_ADJACENT_TO_OXYGEN,0.85
rosiglitazone,CN(CCOC1=CC=C(CC2SC(=O)N=C2O)C=C1)C1=CC=CC=N1,para-hydroxyrosiglitazone ,CN(CCOC1=CC=C(CC2SC(=O)N=C2O)C=C1)C1=CC=C(O)C=N1,CYP2C8,HYDROXYLATION_OF_HETEROAROMATIC_CARBON,0.94
rosiglitazone,CN(CCOC1=CC=C(CC2SC(=O)N=C2O)C=C1)C1=CC=CC=N1,N-Desmethylrosiglitazone ,O=C1N=C(O)C(CC2=CC=C(OCCNC3=CC=CC=N3)C=C2)S1,CYP2C8,N-dealkylation of mixed tertiary amine,0.92
rosiglitazone,CN(CCOC1=CC=C(CC2SC(=O)N=C2O)C=C1)C1=CC=CC=N1,ortho-hydroxyrosiglitazone,CN(CCOC1=CC=C(CC2SC(=O)N=C2O)C=C1)C1=NC=CC=C1O,CYP2C8,HYDROXYLATION_OF_HETEROAROMATIC_CARBON,0.89
Rosuvastatin,CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C2=CC=C(F)C=C2)=C1C=CC(O)CC(O)CC(=O)O,N-Desmethylrosuvastatin,CC(C)C1=NC(NS(C)(=O)=O)=NC(C2=CC=C(F)C=C2)=C1C=CC(O)CC(O)CC(=O)O,CYP2C9; CYP2C19 ,N-dealkylation of mixed tertiary amine,0.93
Rosuvastatin,CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C2=CC=C(F)C=C2)=C1C=CC(O)CC(O)CC(=O)O,Rosuvastatin 5 S-lactone,CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C2=CC=C(F)C=C2)=C1C=CC1=CC(O)=CC(=O)O1,CYP2C9,ESTERIFICATION,0.77
Simazine,CCN=C1N=C(Cl)NC(=NCC)N1,N-Desethylsimazine,CCN=C1NC(Cl)=NC(=N)N1,CYP1A1; CYP1A2; CYP2A6; CYP2C19; CYP2D6,N-dealkylation of secondary arylalkylamine,0.97
Styrene,C=CC1=CC=CC=C1,"Styrene 7,8-oxide",C1=CC=C(C2CO2)C=C1,CYP2E1,EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE,0.23
Sulfinpyrazone,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(C2=CC=CC=C2)N1C1=CC=CC=C1,Sulfinpyrazone sulfone,O=C1C(CCS(=O)(=O)C2=CC=CC=C2)C(=O)N(C2=CC=CC=C2)N1C1=CC=CC=C1,CYP3A4; CYP2C9,S-oxidation of sulfoxide to sulfone,0.97
Pyributicarb,COC1=CC=CC(N(C)C(=S)OC2=CC=CC(C(C)(C)C)=C2)=N1,Pyributicarb metabolite 1,CN(C(=S)OC1=CC=CC(C(C)(C)C)=C1)C1=CC=CC(O)=N1,CYP2C19,O-aryl demethylation,0.94
Sulprofos,CCCSP(=S)(OCC)OC1=CC=C(SC)C=C1,Sulprofos sulfoxide,CCCSP(=S)(OCC)OC1=CC=C(S(C)=O)C=C1,CYP1A1; CYP1A2; CYP3A4; CYP2C9; CYP2C18; CYP2C19; CYP2D6,S-oxidation of dialkylthioether to sulfoxide,0.9
suprofen,CC(C(=O)O)C1=CC=C(C(=O)C2=CC=CS2)C=C1,Suprofen -sulfoxide,CC(C(=O)O)C1=CC=C(C(=O)C2=CC=CS2=O)C=C1,CYP2C9,Thiohene S-oxidation,0.35
suprofen,CC(C(=O)O)C1=CC=C(C(=O)C2=CC=CS2)C=C1,"Thiophene-4,5-epoxide",CC(C(=O)O)C1=CC=C(C(=O)C2=CC3OC3S2)C=C1,CYP2C9,Epoxidation of thiophene,0.32
Tamoxifen N-oxide,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCC[N+](C)(C)[O-])C=C1)C1=CC=CC=C1,alpha-OH-tamoxifen N-oxide,CC(O)C(=C(C1=CC=CC=C1)C1=CC=C(OCC[N+](C)(C)[O-])C=C1)C1=CC=CC=C1,CYP3A4; CYP3A5,Hydroxylation of penultimate aliphatic secondary carbon,0.87
Tegafur,O=C1N=C(O)C(F)=CN1C1CCCO1,5-Fluorouracil,OC1=NC=C(F)C(O)=N1,CYP2A6; CYP1A2; CYP2C8,N-dealkylation of mixed tertiary amine,0.21
Thioridazine,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1,Thioridazine 2-sulfoxide ,CN1CCCCC1CCN1C2=CC=CC=C2SC2=CC=C(S(C)=O)C=C21,CYP2D6; CYP3A4,S-oxidation of alkylarylthioether to sulfoxide,0.92
Thioridazine,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1,N-desmethylthioridazine ,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3)C2=C1,CYP1A2; CYP3A4,N-dealkylation of mixed tertiary amine,0.96
Thioridazine,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1,Thioridazine 5-sulfoxide,CSC1=CC=C2C(=C1)N(CCC1CCCCN1C)C1=CC=CC=C1S2=O,CYP1A2; CYP3A4,S-oxidation of diarylthioether to sulfoxide,0.87
Thymol,CC1=CC=C(C(C)C)C(O)=C1,"p-Cymene-2,3-diol",CC1=CC=C(C(C)C)C(O)=C1O,CYP1A2; CYP2A6; CYP2D6,o-Hydroxylation of phenol,0.8
Thymol,CC1=CC=C(C(C)C)C(O)=C1,Thymoquinol,CC1=CC(O)=C(C(C)C)C=C1O,CYP1A2; CYP2A6; CYP2D6,p-Hydroxylation of phenol,0.88
Thymol,CC1=CC=C(C(C)C)C(O)=C1,p-Cymen-8-en-3-ol,C=C(C)C1=CC=C(C)C=C1O,CYP1A2; CYP2A6; CYP2D6,Terminal desaturation,0.62
Tizanidine,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,"2Ã¢â‚¬Â[(5Ã¢â‚¬ÂchloroÃ¢â‚¬Â2,1,3Ã¢â‚¬ÂbenzothiadiazolÃ¢â‚¬Â4Ã¢â‚¬Âyl)amino]Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬ÂimidazolÃ¢â‚¬Â4Ã¢â‚¬Âol",OC1CN=C(NC2=C(Cl)C=CC3=NSN=C23)N1,CYP1A2,Hydroxylation of heteroalicyclic secondary carbon,0.93
Trichloroethylene,ClC=C(Cl)Cl,Chloral hydrate,OC(O)C(Cl)(Cl)Cl,CYP2E1; CYP1A2; CYP3A4,EPOXIDATION,0.09
TSU-68,CC1=C(CCC(=O)O)C(C)=C(C=C2C(O)=NC3=CC=CC=C23)N1,TSU-68 metabolite 1,CC1=C(CCC(=O)O)C(C)=C(C=C2C(O)=NC3=CC=C(O)C=C23)N1,CYP1A2; CYP1A1; CYP2C8,Aromatic hydroxylation of fused benzene ring,0.94
TSU-68,CC1=C(CCC(=O)O)C(C)=C(C=C2C(O)=NC3=CC=CC=C23)N1,TSU-68 metabolite 2,CC1=C(CCC(=O)O)C(C)=C(C=C2C(O)=NC3=C(O)C=CC=C23)N1,CYP1A1; CYP1A2; CYP2C8,Aromatic hydroxylation of fused benzene ring,0.9
TSU-68,CC1=C(CCC(=O)O)C(C)=C(C=C2C(O)=NC3=CC=CC=C23)N1,TSU-68 metabolite 3,CC1=C(CCC(=O)O)C(C)=C(C=C2C(O)=NC3=CC(O)=CC=C23)N1,CYP1A1; CYP1A2; CYP2C8,Aromatic hydroxylation of fused benzene ring,0.94
YM-64227,CCC1=CC=C2C(C3CCCCC3)=NC(=O)N(CC)C2=N1,"M-2 (1,3-cis)",CCC1=CC=C2C(C3CCCC(O)C3)=NC(=O)N(CC)C2=N1,CYP1A2,Hydroxylation of alicyclic secondary carbon,0.95
YM-64227,CCC1=CC=C2C(C3CCCCC3)=NC(=O)N(CC)C2=N1,"M-3 (1,3-trans)",CCC1=CC=C2C(C3CCCC(O)C3)=NC(=O)N(CC)C2=N1,CYP1A2,Hydroxylation of alicyclic secondary carbon,0.95
Zaltoprofen,CC(C(=O)O)C1=CC=C2SC3=CC=CC=C3C(=O)CC2=C1,10-OH-zaltoprofen,CC(C(=O)O)C1=CC=C2SC3=CC=CC=C3C(O)CC2=C1,CYP2C9,REDUCTION_OF_KETONES_TO_ALCOHOL,0.68
Zaltoprofen,CC(C(=O)O)C1=CC=C2SC3=CC=CC=C3C(=O)CC2=C1,Zaltoprofen S-oxide,CC(C(=O)O)C1=CC=C2C(=C1)CC(=O)C1=CC=CC=C1S2=O,CYP2C9,S-oxidation of dialkylthioether to sulfoxide,0.83
Zoplicone,CN1CCN(C(=O)OC2C3=NC=CN=C3C(=O)N2C2=CC=C(Cl)C=N2)CC1,"4Ã¢â‚¬Â({[6Ã¢â‚¬Â(5Ã¢â‚¬ÂchloropyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl)Ã¢â‚¬Â7Ã¢â‚¬ÂoxoÃ¢â‚¬Â5H,6H,7HÃ¢â‚¬Âpyrrolo[3,4Ã¢â‚¬Âb]pyrazinÃ¢â‚¬Â5Ã¢â‚¬Âyl]oxy}carbonyl)Ã¢â‚¬Â1Ã¢â‚¬ÂmethylpiperazinÃ¢â‚¬Â1Ã¢â‚¬ÂiumÃ¢â‚¬Â1Ã¢â‚¬Âolate",C[N+]1([O-])CCN(C(=O)OC2C3=NC=CN=C3C(=O)N2C2=CC=C(Cl)C=N2)CC1,CYP3A4,N_HYDROXYLATION_OF_ALICYCLIC_TERTIARY_AMINE,0.98
4-VINYLCYCLOHEXENE,C=CC1CC=CCC1,"VCH-7,8-epoxide",C1=CCC(C2CO2)CC1,CYP2B6; CYP2E1,ALKENE_EPXODATION,0.28
4-VINYLCYCLOHEXENE,C=CC1CC=CCC1,"VCH-1,2-epoxide",C=CC1CCC2OC2C1,CYP2B6; CYP2E1,ALKENE_EPXODATION,0.22
"VCH-1,2-epoxide",C1=CCC(C2CO2)CC1,VCH-diepoxide,C1CC2OC2CC1C1CO1,CYP2B6; CYP2E1,ALKENE_EPXODATION,0.39
"VCH-7,8-epoxide",C=CC1CCC2OC2C1,VCH-diepoxide,C1CC2OC2CC1C1CO1,CYP2B6; CYP2E1,ALKENE_EPXODATION,0.51
Medroxyprogesterone Acetate,CC(=O)OC1(C(C)=O)CCC2C3CC(C)C4=CC(=O)CCC4(C)C3CCC21C,M-4,CC(=O)OC1(C(C)=O)CCC2C3CC(C)C4=CC(=O)C(O)CC4(C)C3CCC21C,CYP3A4;,Aliphatic Hydroxylation,0.92
Medroxyprogesterone Acetate,CC(=O)OC1(C(C)=O)CCC2C3CC(C)C4=CC(=O)CCC4(C)C3CCC21C,M-2,CC(=O)OC1(C(C)=O)CCC2C3CC(C)(O)C4=CC(=O)CCC4(C)C3CCC21C,CYP3A4;,Aliphatic Hydroxylation,0.87
Medroxyprogesterone Acetate,CC(=O)OC1(C(C)=O)CCC2C3CC(C)C4=CC(=O)CCC4(C)C3CCC21C,M-3,CC(=O)OC1(C(C)=O)CCC2C3CC(C)C4=CC(=O)CC(O)C4(C)C3CCC21C,CYP3A4;,Aliphatic Hydroxylation,0.89
Medroxyprogesterone Acetate (M4),CC(=O)OC1(C(C)=O)CCC2C3CC(C)C4=CC(=O)C(O)CC4(C)C3CCC21C,M-1,CC(=O)OC1(C(C)=O)CCC2C3CC(C)(O)C4=CC(=O)C(O)CC4(C)C3CCC21C,CYP3A4;,Aliphatic Hydroxylation,0.89
Methoxymorpholinyldoxorubicin,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(CC(O)(C(=O)CO)CC3OC3CC(N4CCOC(OC)C4)C(O)C(C)O3)C(O)=C1C2=O,PNU-159682,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(CC(O)(C(=O)CO)CC3OC3CC4C(OC5COC(OC)CN54)C(C)O3)C(O)=C1C2=O,CYP3A,Dehydroxylation ,0.95
Perospirone,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(C2=NSC3=CC=CC=C23)CC1,,O=C1C2=C(CCCC2)C(=O)N1CCCCN1CCN(C2=NSC3=CC=CC=C23)CC1,CYP3A4,Dehydrogenation,0.73
Perospirone,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(C2=NSC3=CC=CC=C23)CC1,,O=C1C2CCC(O)CC2C(=O)N1CCCCN1CCN(C2=NSC3=CC=CC=C23)CC1,CYP1A1;CYP2C8;CYP2D6,Aliphatic Hydroxylation,0.93
Perospirone,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(C2=NSC3=CC=CC=C23)CC1,,O=C1C2CCCCC2(O)C(=O)N1CCCCN1CCN(C2=NSC3=CC=CC=C23)CC1,CYP1A1;CYP2C8;CYP3A4,Aliphatic Hydroxylation,0.82
Perospirone,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(C2=NSC3=CC=CC=C23)CC1,,C1=CC=C2C(N3CCNCC3)=NSC2=C1,CYP1A1;CYP2C8;CYP3A4,N-Dealkylatiion,0.68
Perospirone,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(C2=NSC3=CC=CC=C23)CC1,,O=C1C2CCCCC2C(=O)N1CCCCO,CYP1A1;CYP2C8;CYP3A4,N-Dealkylatiion,0.39
Azimilide,CN1CCN(CCCCN2C(=O)CN(N=CC3=CC=C(C4=CC=C(Cl)C=C4)O3)C2=O)CC1,,C[N+]1([O-])CCN(CCCCN2C(=O)CN(N=CC3=CC=C(C4=CC=C(Cl)C=C4)O3)C2=O)CC1,CYP3A4;CYP3A5,N-Oxidation,0.98
Disopyramide,CC(C)N(CCC(C(=N)O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C,N-Desisopropyldisopyramide,CC(C)NCCC(C(=N)O)(C1=CC=CC=C1)C1=CC=CC=N1,CYP,N-Dealkylatiion,0.97
Nimodipine,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+](=O)[O-])=C1,,COCCOC(=O)C1=C(C)N=C(C)C(C(=O)OC(C)C)=C1C1=CC=CC([N+](=O)[O-])=C1,CYP3A4,Dehydrogenation,0.35
Nimodipine,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+](=O)[O-])=C1,,CC1=NC(C)=C(C(=O)OC(C)C)C(C2=CC=CC([N+](=O)[O-])=C2)=C1C(=O)OCCO,CYP3A4,O-Dementhylation,0.34
Nimodipine,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+](=O)[O-])=C1,,CC1=C(C(=O)O)C(C2=CC=CC([N+](=O)[O-])=C2)C(C(=O)OC(C)C)=C(C)N1,CYP3A4,O-dealkylation,0.98
nisoldipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+](=O)[O-],,COC(=O)C1=C(C)N=C(C)C(C(=O)OCC(C)C)=C1C1=CC=CC=C1[N+](=O)[O-],CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4,Dehydrogenation,0.38
nisoldipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+](=O)[O-],,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(O)C(C)C)C1C1=CC=CC=C1[N+](=O)[O-],CYP1A2;CYP2C19;CYP2D6;CYP2E1;CYP3A4,Aliphatic Hydroxylation,0.96
OXODIPINE,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC2=C1OCO2,OXODIPINE(m1),CCOC(=O)C1=C(C)N=C(C)C(C(=O)OC)=C1C1=CC=CC2=C1OCO2,CYP3A,Dehydrogenation,0.38
Tasosartan,CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C4=CC=CC=C4C4=NNN=N4)C=C3)C2=N1,enoltasosartanÃ¢â‚¬â€°,CC1=NC(C)=C2C(=N1)N(CC1=CC=C(C3=CC=CC=C3C3=NNN=N3)C=C1)C(=O)CC2O,CYP3A4,Aromatic Hydroxylation,0.92
HEXACHLOROBENZENE,ClC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl,Pentachlorophenol,OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl,CYP3A4,Aliphatic Hydroxylation,0.46
(-)-Epigallocatechin gallate,O=C(OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1)C1=CC(O)=C(O)C(O)=C1,"(-)-Epigallocatechin gallate, 3p-OH-glucuronide",O=C(OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(OC2OC(C(=O)O)C(O)C(O)C2O)=C1)C1=CC(O)=C(O)C(O)=C1,UGT1A9,Aromatic -OH glucuronidation,0.72
(-)-Epigallocatechin gallate,O=C(OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1)C1=CC(O)=C(O)C(O)=C1,"(-)-Epigallocatechin gallate, 4p-OH-glucuronide",O=C(OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(OC2OC(C(=O)O)C(O)C(O)C2O)C(O)=C1)C1=CC(O)=C(O)C(O)=C1,UGT1A9,Aromatic -OH glucuronidation,0.73
(-)-Epigallocatechin,OC1=CC(O)=C2CC(O)C(C3=CC(O)=C(O)C(O)=C3)OC2=C1,"(-)-Epigallocatechin, 3p-OH-glucuronide",O=C(O)C1OC(OC2=CC(C3OC4=CC(O)=CC(O)=C4CC3O)=CC(O)=C2O)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.63
2-Hydroxychalcone,O=C(C=CC1=CC=CC=C1O)C1=CC=CC=C1,"2-Hydroxychalcone, 2-OH glucuronide",O=C(C=CC1=CC=CC=C1OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=CC=C1,UGT1A9,Aromatic -OH glucuronidation,0.33
4-Hydroxychalcone,O=C(C=CC1=CC=C(O)C=C1)C1=CC=CC=C1,"4-Hydroxychalcone, 4-OH-glucuronide",O=C(C=CC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1)C1=CC=CC=C1,UGT1A9,Aromatic -OH glucuronidation,0.32
2p-Hydroxychalcone,O=C(C=CC1=CC=CC=C1)C1=CC=CC=C1O,"2p-Hydroxychalcone, 2p-OH-glucuronide",O=C(C=CC1=CC=CC=C1)C1=CC=CC=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.35
4p-Hydroxychalcone,O=C(C=CC1=CC=CC=C1)C1=CC=C(O)C=C1,"4p-Hydroxychalcone, 4p-OH-glucuronide",O=C(C=CC1=CC=CC=C1)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,Aromatic -OH glucuronidation,0.32
Phloretin,O=C(CCC1=CC=C(O)C=C1)C1=C(O)C=C(O)C=C1O,"Phloretin, 2p-OH-glucuronide",O=CC1OC(OC2=CC(O)=CC(O)=C2C(=O)CCC2=CC=C(O)C=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.38
Phloretin,O=C(CCC1=CC=C(O)C=C1)C1=C(O)C=C(O)C=C1O,"Phloretin, 4p-OH-glucuronide",O=C(CCC1=CC=C(O)C=C1)C1=C(O)C=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1O,UGT1A9,Aromatic -OH glucuronidation,0.39
7-Hydroxychromone,O=C1C=COC2=CC(O)=CC=C12,"7-Hydroxychromone, 7-OH-glucuronide",O=C(O)C1OC(OC2=CC=C3C(=O)C=COC3=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.38
"3,4-Diphenyl-7-hydroxycoumarin",O=C1OC2=CC(O)=CC=C2C(C2=CC=CC=C2)=C1C1=CC=CC=C1,"3,4-Diphenyl-7-hydroxycoumarin, 7-OH-glucuronide",O=C(O)C1OC(OC2=CC=C3C(C4=CC=CC=C4)=C(C4=CC=CC=C4)C(=O)OC3=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.65
4-Methylumbelliferone,CC1=CC(=O)OC2=CC(O)=CC=C12,4-Methylumbelliferone O-glucuronide,CC1=CC(=O)OC2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC=C12,UGT1A9,Aromatic -OH glucuronidation,0.46
4-Hydroxy-6-methylcoumarin,CC1=CC=C2OC(=O)C=C(O)C2=C1,"6-methylcoumarin, 4-O-glucuronide",CC1=CC=C2OC(=O)C=C(OC3OC(C(=O)O)C(O)C(O)C3O)C2=C1,UGT1A9,Aromatic -OH glucuronidation,0.44
6-Hydroxy-7-methoxyl-4-phenylcoumarin,COC1=CC2=C(C=C1O)C(C1=CC=CC=C1)=CC(=O)O2,"7-methoxyl-4-phenylcoumarin, 6-O-glucuronide",COC1=CC2=C(C=C1OC1OC(C(=O)O)C(O)C(O)C1O)C(C1=CC=CC=C1)=CC(=O)O2,UGT1A9,Aromatic -OH glucuronidation,0.6
8-Hydroxywarfarin,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC(O)=C2OC1=O,Warfarin 8-O-glucuronide,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=C2OC1=O,UGT1A9,Aromatic -OH glucuronidation,0.74
7-Hydroxywarfarin,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=C(O)C=C2OC1=O,Warfarin 7-O-glucuronide,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C2OC1=O,UGT1A9,Aromatic -OH glucuronidation,0.73
6-Hydroxywarfarin,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC(O)=CC=C2OC1=O,Warfarin 6-O-glucuronide,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC=C2OC1=O,UGT1A9,Aromatic -OH glucuronidation,0.75
Scopoletin,COC1=CC2=C(C=C1O)OC(=O)C=C2,Scopoletin OH-glucuronide,COC1=CC2=C(C=C1OC1OC(C(=O)O)C(O)C(O)C1O)OC(=O)C=C2,UGT1A9,Aromatic -OH glucuronidation,0.44
Curcumin,COC1=CC(C=CC(=O)CC(=O)C=CC2=CC=C(O)C(OC)=C2)=CC=C1O,Curcumin 4-O-glucuronide,COC1=CC(C=CC(=O)CC(=O)C=CC2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(OC)=C2)=CC=C1O,UGT1A9,Aromatic -OH glucuronidation,0.38
Demethoxycurcumin,COC1=CC(C=CC(=O)CC(=O)C=CC2=CC=C(O)C=C2)=CC=C1O,Demethoxycurcumin O-glucuronide,COC1=CC(C=CC(=O)CC(=O)C=CC2=CC=C(O)C=C2)=CC=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.38
Bisdemethoxycurcumin,O=C(C=CC1=CC=C(O)C=C1)CC(=O)C=CC1=CC=C(O)C=C1,"Bisdemethoxycurcumin, 4-O-glucuronide",O=C(C=CC1=CC=C(O)C=C1)CC(=O)C=CC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,Aromatic -OH glucuronidation,0.29
Emodin,CC1=CC(O)=C2C(=O)C3=C(O)C=C(O)C=C3C(=O)C2=C1,Emodin 3-OH-glucuronide,CC1=CC(O)=C2C(=O)C3=C(O)C=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3C(=O)C2=C1,UGT1A9,Aromatic -OH glucuronidation,0.55
Endoxifen,CCC(=C(C1=CC=C(O)C=C1)C1=CC=C(OCCNC)C=C1)C1=CC=CC=C1,Endoxifen O-glucuronide,CCC(=C(C1=CC=C(OCCNC)C=C1)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1)C1=CC=CC=C1,UGT1A9,Aromatic -OH glucuronidation,0.51
Endoxifen,CCC(=C(C1=CC=C(O)C=C1)C1=CC=C(OCCNC)C=C1)C1=CC=CC=C1,Endoxifen O-sulfate,CCC(=C(C1=CC=C(OCCNC)C=C1)C1=CC=C(OS(=O)(=O)O)C=C1)C1=CC=CC=C1,SULT,4-OH sulfonation of phenolic compound,0.84
Enterolactone,O=C1OCC(CC2=CC=CC(O)=C2)C1CC1=CC=CC(O)=C1,Enterolactone O-glucuronide,O=C1OCC(CC2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC=C2)C1CC1=CC=CC(O)=C1,UGT1A9,Aromatic -OH glucuronidation,0.46
1-Naphthol,OC1=CC=CC2=CC=CC=C12,1-Naphthyl glucuronide,O=C(O)C1OC(OC2=CC=CC3=CC=CC=C23)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.14
Raloxifene,O=C(C1=CC=C(OCCN2CCCCC2)C=C1)C1=C(C2=CC=C(O)C=C2)SC2=CC(O)=CC=C12,Raloxifene 6-O-glucuronide,O=C(C1=CC=C(OCCN2CCCCC2)C=C1)C1=C(C2=CC=C(O)C=C2)SC2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC=C12,UGT1A9,Aromatic -OH glucuronidation,0.78
Tyrphostin B42,N#CC(=CC1=CC=C(O)C(O)=C1)C(O)=NCC1=CC=CC=C1,"Tyrphostin B42, 3-O-glucuronide",N#CC(=CC1=CC=C(O)C(OC2OC(C(=O)O)C(O)C(O)C2O)=C1)C(O)=NCC1=CC=CC=C1,UGT1A9,Aromatic -OH glucuronidation,0.45
Tyrphostin B42,N#CC(=CC1=CC=C(O)C(O)=C1)C(O)=NCC1=CC=CC=C1,"Tyrphostin B42, 4-O-glucuronide",N#CC(=CC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C(O)=C1)C(O)=NCC1=CC=CC=C1,UGT1A9,Aromatic -OH glucuronidation,0.46
7-Hydroxyflavanone,O=C1CC(C2=CC=CC=C2)OC2=CC(O)=CC=C12,Flavanone 7-O-glucuronide,O=C1CC(C2=CC=CC=C2)OC2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC=C12,UGT1A9,Aromatic -OH glucuronidation,0.63
4p-Hydroxy-3-methoxyflavanone,COC1C(=O)C2=CC=CC=C2OC1C1=CC=C(O)C=C1,3-methoxyflavanone 4p-O-glucuronide,COC1C(=O)C2=CC=CC=C2OC1C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,Aromatic -OH glucuronidation,0.74
Hesperetin,COC1=CC=C(C2CC(=O)C3=C(O)C=C(O)C=C3O2)C=C1O,Hesperetin 7-O-glucuronide,COC1=CC=C(C2CC(=O)C3=C(O)C=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)C=C1O,UGT1A9,Aromatic -OH glucuronidation,0.68
Hesperetin,COC1=CC=C(C2CC(=O)C3=C(O)C=C(O)C=C3O2)C=C1O,Hesperetin 3p-O-glucuronide,COC1=CC=C(C2CC(=O)C3=C(O)C=C(O)C=C3O2)C=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.65
Narigenin,O=C1CC(C2=CC=C(O)C=C2)OC2=CC(O)=CC(O)=C12,Narigenin 7-O-glucuronide,O=C1CC(C2=CC=C(O)C=C2)OC2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC(O)=C12,UGT1A9,Aromatic -OH glucuronidation,0.64
2p-Hydroxyflavone,O=C1C=C(C2=CC=CC=C2O)OC2=CC=CC=C12,Flavone 2p-O-glucuronide,O=C(O)C1OC(OC2=CC=CC=C2C2=CC(=O)C3=CC=CC=C3O2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.54
"3,4p-Dimethoxy-5,7,3p-trihydroxyflavone",COC1=CC=C(C2=C(OC)C(=O)C3=C(O)C=C(O)C=C3O2)C=C1O,"3,4p-Dimethoxy-5,3p-dihydroxyflavone, 7-O-glucuronide",COC1=CC=C(C2=C(OC)C(=O)C3=C(O)C=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)C=C1O,UGT1A9,Aromatic -OH glucuronidation,0.74
"3p-Benzyloxy-5,7-dihydroxy-3,4p-dimethoxyflavone",COC1=CC=C(C2=C(OC)C(=O)C3=C(O)C=C(O)C=C3O2)C=C1OCC1=CC=CC=C1,"3p-Benzyloxy-5-hydroxy-3,4p-dimethoxyflavone, 7-O-glucuronide",COC1=CC=C(C2=C(OC)C(=O)C3=C(O)C=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)C=C1OCC1=CC=CC=C1,UGT1A9,Aromatic -OH glucuronidation,0.77
3p-Hydroxyflavone,O=C1C=C(C2=CC=CC(O)=C2)OC2=CC=CC=C12,Flavone 3p-O-glucuronide,O=C(O)C1OC(OC2=CC=CC(C3=CC(=O)C4=CC=CC=C4O3)=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.54
4p-Hydroxyflavone,O=C1C=C(C2=CC=C(O)C=C2)OC2=CC=CC=C12,Flavone 4p-O-glucuronide,O=C(O)C1OC(OC2=CC=C(C3=CC(=O)C4=CC=CC=C4O3)C=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.53
"5,7-Dihydroxy-3p,4p,5p-trimethoxyflavone",COC1=CC(C2=CC(=O)C3=C(O)C=C(O)C=C3O2)=CC(OC)=C1OC,"5-Hydroxy-3p,4p,5p-trimethoxyflavone, 7-O-glucuronide",COC1=CC(C2=CC(=O)C3=C(O)C=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)=CC(OC)=C1OC,UGT1A9,Aromatic -OH glucuronidation,0.67
"2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine",CN1C(=N)NC2=NC=C(C3=CC=CC=C3)C=C21,"2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, N2-glucuronide",CN1C(NC2OC(C(=O)O)C(O)C(O)C2O)=NC2=NC=C(C3=CC=CC=C3)C=C21,UGT1A1; UGT1A3; UGT1A4),Glucuronidation of primary aromatic amine,0.46
N2-OH-PhIP,CN1C(NO)=NC2=NC=C(C3=CC=CC=C3)C=C21,N2-OH-PhIP-N3-glucuronide,C[N+]1=C(NO)N(C2OC(C(=O)O)C(O)C(O)C2O)C2=NC=C(C3=CC=CC=C3)C=C21,UGT,N-Glucuronidation,0.5
N2-OH-PhIP,CN1C(NO)=NC2=NC=C(C3=CC=CC=C3)C=C21,N2-OH-PhIP-N2-glucuronide,CN1C(NOC2OC(C(=O)O)C(O)C(O)C2O)=NC2=NC=C(C3=CC=CC=C3)C=C21,UGT,Hydroxylamine O-glucuronidation,0.65
4'-OH-PhIP,CN1C(=N)NC2=NC=C(C3=CC=C(O)C=C3)C=C21,PhIP 4'-O-glucuronide,CN1C(=N)NC2=NC=C(C3=CC=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3)C=C21,UGT,Aromatic -OH glucuronidation,0.63
2-hydroxyestradiol,CC12CCC3C4=CC(O)=C(O)C=C4CCC3C1CCC2O,Estradiol 2-O-glucuronide,CC12CCC3C4=CC(OC5OC(C(=O)O)C(O)C(O)C5O)=C(O)C=C4CCC3C1CCC2O,UGT1A1; UGT1A3; UGT1A7; UGT1A8; UGT1A10,Aromatic -OH glucuronidation,0.54
2-hydroxyestradiol,CC12CCC3C4=CC(O)=C(O)C=C4CCC3C1CCC2O,2-O-methoxyestradiol,COC1=CC2=C(C=C1O)CCC1C2CCC2(C)C(O)CCC12,S-COMT,O-methylation,0.92
2-hydroxyestradiol,CC12CCC3C4=CC(O)=C(O)C=C4CCC3C1CCC2O,3-O-methoxyestradiol,COC1=CC2=C(C=C1O)C1CCC3(C)C(O)CCC3C1CC2,S-COMT,O-methylation,0.92
2-hydroxyestrone,CC12CCC3C4=CC(O)=C(O)C=C4CCC3C1CCC2=O,2-O-methoxyestrone,COC1=CC2=C(C=C1O)CCC1C2CCC2(C)C(=O)CCC12,S-COMT,O-methylation,0.92
2-hydroxyestrone,CC12CCC3C4=CC(O)=C(O)C=C4CCC3C1CCC2=O,3-O-methoxyestrone,COC1=CC2=C(C=C1O)C1CCC3(C)C(=O)CCC3C1CC2,S-COMT,O-methylation,0.92
2-hydroxyestrone,CC12CCC3C4=CC(O)=C(O)C=C4CCC3C1CCC2=O,Estrone 2-O-glucuronide,CC12CCC3C4=CC(OC5OC(C(=O)O)C(O)C(O)C5O)=C(O)C=C4CCC3C1CCC2=O,UGT1A1; UGT1A7; UGT1A8; UGT1A10,Aromatic -OH glucuronidation,0.54
4-hydroxyestrone,CC12CCC3C4=CC=C(O)C(O)=C4CCC3C1CCC2=O,Estrone 4-O-glucuronide,CC12CCC3C4=CC=C(O)C(OC5OC(C(=O)O)C(O)C(O)C5O)=C4CCC3C1CCC2=O,UGT1A1; UGT1A3; UGT1A7; UGT1A8; UGT1A10,Aromatic -OH glucuronidation,0.56
4-hydroxyestrone,CC12CCC3C4=CC=C(O)C(O)=C4CCC3C1CCC2=O,4-methoxyestrone,COC1=C(O)C=CC2=C1CCC1C2CCC2(C)C(=O)CCC12,S-COMT,O-methylation,0.9
"dibenzo[a,l]pyrene-11,12- diol",OC1=CC=C2C(=C1O)C=C1C=CC3=CC=CC4=C5C=CC=CC5=C2C1=C34,"dibenzo[a,l]pyrene-11-ol, 12-O-glucuronide",O=C(O)C1OC(OC2=CC=C3C(=C2O)C=C2C=CC4=CC=CC5=C6C=CC=CC6=C3C2=C45)C(O)C(O)C1O,UGT1A1; UGT1A4,Aromatic -OH glucuronidation,0.18
"dibenzo[a,l]pyrene-11,12- diol",OC1=CC=C2C(=C1O)C=C1C=CC3=CC=CC4=C5C=CC=CC5=C2C1=C34,"dibenzo[a,l]pyrene-12-ol, 11-O-glucuronide",O=C(O)C1OC(OC2=C(O)C=CC3=C2C=C2C=CC4=CC=CC5=C6C=CC=CC6=C3C2=C45)C(O)C(O)C1O,UGT1A1; UGT1A4,Aromatic -OH glucuronidation,0.18
17-beta-estradiol,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2O,17-beta-Estradiol glucuronide,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2OC1OC(C(=O)O)C(O)C(O)C1O,UGT1A1; UGT1A3; UGT1A7; UGT1A8; UGT1A10,17-OH glucuronidation of sterol,0.61
4-hydroxytamoxifen,CCC(=C(C1=CC=C(O)C=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,Tamoxifen 4-O-glucuronide,CCC(=C(C1=CC=C(OCCN(C)C)C=C1)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1)C1=CC=CC=C1,UGT1A1; UGT1A4; UGT1A6; UGT1A7; UGT1A8; UGT1A9; UGT1A10; UGT2B15; UGT2B17; UGT2B7,Aromatic -OH glucuronidation,0.51
4-hydroxytamoxifen,CCC(=C(C1=CC=C(O)C=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,Tamoxifen 4-O-sulfate,CCC(=C(C1=CC=C(OCCN(C)C)C=C1)C1=CC=C(OS(=O)(=O)O)C=C1)C1=CC=CC=C1,SULT1A1,4-OH sulfonation of phenolic compound,0.84
tamoxifen,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,Tamoxifen N-glucuronide,CCC(=C(C1=CC=CC=C1)C1=CC=C(OCC[N+](C)(C)C2OC(C(=O)O)C(O)C(O)C2O)C=C1)C1=CC=CC=C1,UGT1A4,N-glucuronidation of tertiary aliphatic amine,0.48
NÃ¢â‚¬â„¢-nitrosoanabasine,O=NN1CCCCC1C1=CC=CN=C1,"NÃ¢â‚¬â„¢-nitrosoanabasine, N-glucuronide",O=NN1CCCCC1C1=CC=C[N+](C2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT2B10,N-Glucuronidation,0.47
Np-nitrosonornicotine,O=NN1CCCC1C1=CC=CN=C1,"Np-nitrosonornicotine, N-glucuronide",O=NN1CCCC1C1=CC=C[N+](C2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT2B10,N-Glucuronidation,0.45
Nicotine,CN1CCCC1C1=CC=CN=C1,Nicotine N-glucuronide,CN1CCCC1C1=CC=C[N+](C2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT1A4; UGT1A9,N-Glucuronidation,0.38
Cotinine,CN1C(=O)CCC1C1=CC=CN=C1,Cotinine N-glucuronide,CN1C(=O)CCC1C1=CC=C[N+](C2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT1A4; UGT1A9,N-Glucuronidation,0.46
3-Phenoxybenozoic acid,O=C(O)C1=CC=CC(OC2=CC=CC=C2)=C1,3-Phenoxybenzoic acid glucuronide,O=C(OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=CC(OC2=CC=CC=C2)=C1,UGT,O-glucuronidation of aromatic acid,0.31
3-Phenoxybenozoic acid,O=C(O)C1=CC=CC(OC2=CC=CC=C2)=C1,3-Phenoxybenzoylglycine,O=C(O)CN=C(O)C1=CC=CC(OC2=CC=CC=C2)=C1,GLYAT (EC 2.3.1.13),Glycination of aromatic acid,0.49
"4-hydroxy-2p,3,5-trichlorobiphenyl",OC1=C(Cl)C=C(C2=CC=CC=C2Cl)C=C1Cl,"2p,3,5-trichlorobiphenyl, 4-sulfate",O=S(=O)(O)OC1=C(Cl)C=C(C2=CC=CC=C2Cl)C=C1Cl,SULT1A2,4-OH sulfonation of phenolic compound,0.65
Dopamine,NCCC1=CC=C(O)C(O)=C1,dopamine 3-O-sulfate,NCCC1=CC=C(O)C(OS(=O)(=O)O)=C1,SULT,3-OH sulfonation of phenolic compound,0.5
Dopamine,NCCC1=CC=C(O)C(O)=C1,Dopamine 4- D-Glucuronide,NCCC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C(O)=C1,UGT,Aromatic -OH glucuronidation,0.22
Gavestinel,O=C(O)C1=C(C=CC(O)=NC2=CC=CC=C2)C2=C(Cl)C=C(Cl)C=C2N1,gavestinel 4-O-acyl glucuronide,O=C(OC1OC(C(=O)O)C(O)C(O)C1O)C1=C(C=CC(O)=NC2=CC=CC=C2)C2=C(Cl)C=C(Cl)C=C2N1,UGT,O-glucuronidation of aromatic acid,0.73
p-OH-gavestinel,O=C(C=CC1=C(C(=O)O)NC2=CC(Cl)=CC(Cl)=C12)NC1=CC=C(O)C=C1,gavestinel 4-sulfate,O=C(C=CC1=C(C(=O)O)NC2=CC(Cl)=CC(Cl)=C12)NC1=CC=C(OS(=O)(=O)O)C=C1,SULT,4-OH sulfonation of phenolic compound,0.95
3-hydroxyguanfacine,N=C(N)N=C(O)CC1=C(Cl)C(O)=CC(O)=C1Cl,3-hydroxyguanfacine glucuronide,N=C(N)N=C(O)CC1=C(Cl)C(O)=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=C1Cl,UGT,Aromatic -OH glucuronidation,0.45
3-Hydroxymorphinan,OC1=CC=C2CC3NCCC4(CCCCC34)C2=C1,3-OH-morphinan -glucuronide,O=C(O)C1OC(OC2=CC=C3CC4NCCC5(CCCCC45)C3=C2)C(O)C(O)C1O,UGT,Aromatic -OH glucuronidation,0.65
3-Hydroxymorphinan,OC1=CC=C2CC3NCCC4(CCCCC34)C2=C1,3-Hydroxymorphinan sulfate,O=S(=O)(O)OC1=CC=C2CC3NCCC4(CCCCC34)C2=C1,SULT,Aromatic -OH glucuronidation,0.87
8-Hydroxynevirapine,CC1=CC=NC2=C1N=C(O)C1=CC(O)=CN=C1N2C1CC1,8-Hydroxynevirapine O-glucuronide,CC1=CC=NC2=C1N=C(O)C1=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CN=C1N2C1CC1,UGT,Aromatic -OH glucuronidation,0.82
12-Hydroxynevirapine,CC1=CC=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1O,12-Hydroxynevirapine O-glucuronide,CC1=CC=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1OC1OC(C(=O)O)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.84
3-Hydroxynevirapine,CC1=C(O)C=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,3-Hydroxynevirapine O-glucuronide,CC1=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,UGT,Aromatic -OH glucuronidation,0.82
2-Hydroxynevirapine,CC1=CC(O)=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,2-Hydroxynevirapine glucuronide,CC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,UGT,Aromatic -OH glucuronidation,0.82
thymol,CC1=CC=C(C(C)C)C(O)=C1,thymol O-glucuronide,CC1=CC=C(C(C)C)C(OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,Aromatic -OH glucuronidation,0.23
thymol,CC1=CC=C(C(C)C)C(O)=C1,thymol sulfate,CC1=CC=C(C(C)C)C(OS(=O)(=O)O)=C1,SULT,3-OH sulfonation of phenolic compound,0.49
Catechol,OC1=CC=CC=C1O,catechol sulfate,O=S(=O)(O)OC1=CC=CC=C1O,SULT,O-sulfonation,0.27
Catechol,OC1=CC=CC=C1O,,O=C(O)C1OC(OC2=CC=CC=C2O)C(O)C(O)C1O,UGT,Aromatic -OH glucuronidation,0.08
3-OH-7-ethoxycourmarin,CCOC1=CC2=C(C=CC(=O)O2)C=C1O,3-OH-7-ethoxycourmarin O-glucuronide,CCOC1=CC2=C(C=CC(=O)O2)C=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT,Aromatic -OH glucuronidation,0.48
Aminoflavone,CC1=C(F)C(N)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,Aminoflavone N-glucuronide (MX),CC1=C(F)C(NC2OC(C(=O)O)C(O)C(O)C2O)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,UGT,Glucuronidation of primary aromatic amine,0.72
Aminoflavone M-II,CC1=C(F)C(NO)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,Aminoflavone M-II O-glucuronide,CC1=C(F)C(NOC2OC(C(=O)O)C(O)C(O)C2O)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,UGT,O-glucuronidation,0.79
Aminoflavone M-II,CC1=C(F)C(NO)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,Aminoflavone M-II O-sulfate,CC1=C(F)C(NOS(=O)(=O)O)=C2C(=O)C=C(C3=CC=C(N)C(F)=C3)OC2=C1F,SULT,O-sulfonation,0.94
Aminoflavone MIII,CC1=C(F)C(N)=C2C(=O)C=C(C3=CC=C(NO)C(F)=C3)OC2=C1F,Aminoflavone MIII O-glucuronide,CC1=C(F)C(N)=C2C(=O)C=C(C3=CC=C(NOC4OC(C(=O)O)C(O)C(O)C4O)C(F)=C3)OC2=C1F,UGT,Glucuronidation of primary aromatic amine,0.78
Aminoflavone M-IV,CC1=C(F)C(N)=C2C(=O)C(O)=C(C3=CC=C(N)C(F)=C3)OC2=C1F,Aminoflavone M-IV O-sulfate,CC1=C(F)C(N)=C2C(=O)C(OS(=O)(=O)O)=C(C3=CC=C(N)C(F)=C3)OC2=C1F,SULT,O-sulfonation,0.89
Aminoflavone M-V,CC1=C(F)C(NO)=C2C(=O)C=C(C3=CC=C(NO)C(F)=C3)OC2=C1F,Aminoflavone M-V O-sulfate,CC1=C(F)C(NOS(=O)(=O)O)=C2C(=O)C=C(C3=CC=C(NO)C(F)=C3)OC2=C1F,SULT,O-sulfonation,0.94
8-OH-ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=CC(O)=C1N2C,ondansetron 8-O-glucuronide,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=C1N2C,UGT,Aromatic -OH glucuronidation,0.81
8-OH-ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=CC(O)=C1N2C,ondansetron 8-O-sulfate,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=CC(OS(=O)(=O)O)=C1N2C,SULT,O-sulfonation,0.93
7-OH-ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=C(O)C=C1N2C,ondansetron 7-O-glucuronide,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C1N2C,UGT,Aromatic -OH glucuronidation,0.81
7-OH-ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=C(O)C=C1N2C,ondansetron 7-O-sulfate,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC=C(OS(=O)(=O)O)C=C1N2C,SULT,O-sulfonation,0.95
6-OH-ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC(O)=CC=C1N2C,ondansetron 6-O-glucuronide,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC=C1N2C,UGT,Aromatic -OH glucuronidation,0.82
6-OH-ondansetron,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC(O)=CC=C1N2C,ondansetron 6-O-sulfate,CC1=NC=CN1CC1CCC2=C(C1=O)C1=CC(OS(=O)(=O)O)=CC=C1N2C,SULT,O-sulfonation,0.96
linoleyl alcohol,CCCCCC=CCC=CCCCCCCCCO,linoleyl O-glucuronide,CCCCCC=CCC=CCCCCCCCCOC1OC(C(=O)O)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.12
All-trans-retinoic acid,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,All-trans-retinoyl glucuronide,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation of aliphatic acid,0.37
Bilirubin,C=CC1=C(C)C(O)=NC1=CC1=C(C)C(CCC(=O)O)=C(CC2=C(CCC(=O)O)C(C)=C(C=C3N=C(O)C(C=C)=C3C)N2)N1,"6-[3-[2-[[3-(2-carboxyethyl)-5-[(Z)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid",C=CC1=C(C)C(O)=NC1=CC1=C(C)C(CCC(=O)OC2OC(C(=O)O)C(O)C(O)C2O)=C(CC2=C(CCC(=O)O)C(C)=C(C=C3N=C(O)C(C=C)=C3C)N2)N1,UGT,O-glucuronidation of aliphatic acid,0.84
Bilirubin,C=CC1=C(C)C(O)=NC1=CC1=C(C)C(CCC(=O)O)=C(CC2=C(CCC(=O)O)C(C)=C(C=C3N=C(O)C(C=C)=C3C)N2)N1,"(2S,3S,4S,5R,6S)Ã¢â‚¬Â6Ã¢â‚¬Â{[3Ã¢â‚¬Â(2Ã¢â‚¬Â{[3Ã¢â‚¬Â(2Ã¢â‚¬Âcarboxyethyl)Ã¢â‚¬Â5Ã¢â‚¬Â{[(2Z)Ã¢â‚¬Â4Ã¢â‚¬ÂethenylÃ¢â‚¬Â3Ã¢â‚¬ÂmethylÃ¢â‚¬Â5Ã¢â‚¬ÂoxoÃ¢â‚¬Â1HÃ¢â‚¬ÂpyrrolÃ¢â‚¬Â2Ã¢â‚¬Âylidene]methyl}Ã¢â‚¬Â4Ã¢â‚¬ÂmethylÃ¢â‚¬Â1HÃ¢â‚¬ÂpyrrolÃ¢â‚¬Â2Ã¢â‚¬Âyl]methyl}Ã¢â‚¬Â5Ã¢â‚¬Â{[(2Z)Ã¢â‚¬Â3Ã¢â‚¬ÂethenylÃ¢â‚¬Â4Ã¢â‚¬ÂmethylÃ¢â‚¬Â5Ã¢â‚¬ÂoxoÃ¢â‚¬Â1HÃ¢â‚¬ÂpyrrolÃ¢â‚¬Â2Ã¢â‚¬Âylidene]methyl}Ã¢â‚¬Â4Ã¢â‚¬ÂmethylÃ¢â‚¬Â1HÃ¢â‚¬ÂpyrrolÃ¢â‚¬Â3Ã¢â‚¬Âyl)propanoyl]oxy}Ã¢â‚¬Â3,4,5Ã¢â‚¬ÂtrihydroxyoxaneÃ¢â‚¬Â2Ã¢â‚¬Âcarboxylic acid",C=CC1=C(C)C(O)=NC1=CC1=C(C)C(CCC(=O)O)=C(CC2=C(CCC(=O)OC3OC(C(=O)O)C(O)C(O)C3O)C(C)=C(C=C3N=C(O)C(C=C)=C3C)N2)N1,UGT,O-glucuronidation of aliphatic acid,0.84
Epitestosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,Epitestosterone O-glucuronide,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(OC3OC(C(=O)O)C(O)C(O)C3O)CCC12,UGT,17-OH glucuronidation of sterol,0.49
hyocholic acid,CC(CCC(=O)O)C1CCC2C3C(O)C(O)C4CC(O)CCC4(C)C3CCC12C,hyocholic acid 24-O-glucuronide,CC(CCC(=O)OC1OC(C(=O)O)C(O)C(O)C1O)C1CCC2C3C(O)C(O)C4CC(O)CCC4(C)C3CCC12C,UGT,Bile acid C24 acyl glucuronidation,0.36
hyocholic acid,CC(CCC(=O)O)C1CCC2C3C(O)C(O)C4CC(O)CCC4(C)C3CCC12C,hyocholic acid 6-O-glucuronide,CC(CCC(=O)O)C1CCC2C3C(O)C(OC4OC(C(=O)O)C(O)C(O)C4O)C4CC(O)CCC4(C)C3CCC12C,UGT,6-OH glucuronidation of sterol,0.38
Resveratrol,OC1=CC=C(C=CC2=CC(O)=CC(O)=C2)C=C1,Resveratrol 3-O-glucuronide,O=C(O)C1OC(OC2=CC(O)=CC(C=CC3=CC=C(O)C=C3)=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.24
Entacapone,CCN(CC)C(=O)C(C#N)=CC1=CC(O)=C(O)C([N+](=O)[O-])=C1,,CCN(CC)C(=O)C(C#N)=CC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=C(O)C([N+](=O)[O-])=C1,UGT1A9,Aromatic -OH glucuronidation,0.59
Ezetimibe,O=C1C(CCC(O)C2=CC=C(F)C=C2)C(C2=CC=C(O)C=C2)N1C1=CC=C(F)C=C1,,O=C(O)C1OC(OC2=CC=C(C3C(CCC(O)C4=CC=C(F)C=C4)C(=O)N3C3=CC=C(F)C=C3)C=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.75
Mycophenolic Acid,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1CC=C(C)CCC(=O)O,,COC1=C(C)C2=C(C(=O)OC2)C(OC2OC(C(=O)O)C(O)C(O)C2O)=C1CC=C(C)CCC(=O)O,UGT1A9,Aromatic -OH glucuronidation,0.65
2‐(pyren‐1‐yl)ethanol,OCCC1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,,O=S(=O)(O)OCCC1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,SULT1A1; SULT1A2; SULT1C1; SULT1C2; SULT1C3; SULT1E1; SULT2A1,Sulfation of primary alcohol,0.73
1-(1-pyrenyl)ethanol,CC(O)C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,,CC(OS(=O)(=O)O)C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,SULT1A1; SULT1E1,Sulfation of secondary alcohol,0.62
1-hydroxymethylpyrene,OCC1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,,O=S(=O)(O)OCC1=CC=C2C=CC3=CC=CC4=CC=C1C2=C34,"SULT1A1; SULT1B1, SULT2A1",Sulfation of primary alcohol,0.64
1-methoxy-3-indolylmethyl-alcohol,CON1C=C(CO)C2=CC=CC=C21,,CON1C=C(COS(=O)(=O)O)C2=CC=CC=C21,SULT1A1,Sulfation of primary alcohol,0.81
"2,4-dinitrobenzylalcohol",O=[N+]([O-])C1=CC=C(CO)C([N+](=O)[O-])=C1,,O=[N+]([O-])C1=CC=C(COS(=O)(=O)O)C([N+](=O)[O-])=C1,SULT1A1,Sulfation of primary alcohol,0.78
2-aminobenzylalcohol,NC1=CC=CC=C1CO,,NC1=CC=CC=C1COS(=O)(=O)O,SULT1A1,Sulfation of primary alcohol,0.55
"2-hydroxylamino-3-methyl-9H-pyrido[2,3-b]indole",CC1=CC2=C(N=C1NO)NC1=CC=CC=C12,,CC1=CC2=C(N=C1NOS(=O)(=O)O)NC1=CC=CC=C12,SULT1A1,Hydroxylamine O-sulfonation,0.85
2-hydroxylamino-5-phenylpyridine,ONC1=CC=C(C2=CC=CC=C2)C=N1,,O=S(=O)(O)ONC1=CC=C(C2=CC=CC=C2)C=N1,SULT1A1,Hydroxylamine O-sulfonation,0.73
5-hydroxymethylfurfural,O=CC1=CC=C(CO)O1,,O=CC1=CC=C(COS(=O)(=O)O)O1,SULT1A1,Sulfation of primary alcohol,0.57
"7-hydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene",OC1CCCC2=C1C=C1C=CC3=CC=CC4=CC=C2C1=C34,,O=S(=O)(O)OC1CCCC2=C1C=C1C=CC3=CC=CC4=CC=C2C1=C34,SULT1A1,Sulfation of secondary alcohol,0.68
N-acetyl-N-hydroxy-3-aminobenzanthrone,CC(=O)N(O)C1C=CC2=C3C(=CC=CC31)C(=O)C1=CC=CC=C21,,CC(=O)N(OS(=O)(=O)O)C1C=CC2=C3C(=CC=CC31)C(=O)C1=CC=CC=C21,SULT1A1,O-sulfonation,0.94
N-acetyl-N-hydroxy-3-aminobenzanthrone,CC(=O)N(O)C1C=CC2=C3C(=CC=CC31)C(=O)C1=CC=CC=C21,,CC(=O)ON(C(C)=O)C1C=CC2=C3C(=CC=CC31)C(=O)C1=CC=CC=C21,NAT1; NAT2,O-acetylation,0.95
6-hydroxymethylanthanthrene,OCC1=C2C=CC=C3C=CC4=CC5=CC=CC6=CC=C1C(=C65)C4=C32,,O=S(=O)(O)OCC1=C2C=CC=C3C=CC4=CC5=CC=CC6=CC=C1C(=C65)C4=C32,SULT1C3,Sulfation of primary alcohol,0.64
N-hydroxy-aminophenylnorharman,ONC1=CC=C(N2C3=CC=CC=C3C3=CC=NC=C32)C=C1,,CC(=O)ONC1=CC=C(N2C3=CC=CC=C3C3=CC=NC=C32)C=C1,NAT1; NAT2,O-acetylation of N-hydroxylarylamine,0.92
N-hydroxy-aminophenylharman,CC1=NC=CC2=C1N(C1=CC=C(NO)C=C1)C1=CC=CC=C21,,CC(=O)ONC1=CC=C(N2C3=CC=CC=C3C3=CC=NC(C)=C32)C=C1,NAT1; NAT2,O-acetylation of N-hydroxylarylamine,0.94
N-hydroxy-benzidine,NC1=CC=C(C2=CC=C(NO)C=C2)C=C1,N-hydroxy-benzidine O-acetyl,CC(=O)ONC1=CC=C(C2=CC=C(N)C=C2)C=C1,NAT1,O-acetylation of N-hydroxylarylamine,0.69
N-hydroxy-2-aminofluorene,ONC1=CC=C2C(=C1)CC1=CC=CC=C12,"N-hydroxy-2-aminofluorene, O-acetyl",CC(=O)ONC1=CC=C2C(=C1)CC1=CC=CC=C12,NAT1,O-acetylation of N-hydroxylarylamine,0.87
"N-[4-(2,4-dichlorophenoxy)phenyl]hydroxylamine",ONC1=CC=C(OC2=CC=C(Cl)C=C2Cl)C=C1,"N-[4-(2,4-dichlorophenoxy)phenyl]hydroxylamine O-acetyl",CC(=O)ONC1=CC=C(OC2=CC=C(Cl)C=C2Cl)C=C1,NAT1,O-acetylation of N-hydroxylarylamine,0.82
N‐(2‐methoxyphenyl)hydroxylamine,COC1=CC=CC=C1NO,"NÃ¢â‚¬Â(2Ã¢â‚¬Âmethoxyphenyl)hydroxylamine, O-acetyl",COC1=CC=CC=C1NOC(C)=O,NAT1,O-acetylation of N-hydroxylarylamine,0.65
isoniazid,NNC(=O)C1=CC=NC=C1,isoniazid N-acetyl,CC(O)=NNC(=O)C1=CC=NC=C1,NAT2,N-acetylation of Hydrazine derivative,0.67
hydralazine,NN=C1NN=CC2=CC=CC=C12,hydralazine N-acetyl,CC(O)=NNC1=NN=CC2=CC=CC=C12,NAT,N-acetylation of Hydrazine derivative,0.29
mesalazine,NC1=CC=C(O)C(C(=O)O)=C1,"mesalazine, N-acetyl",CC(O)=NC1=CC=C(O)C(C(=O)O)=C1,NAT,N-acetylation of arylamine,0.71
Sulfapyridine,NC1=CC=C(S(=O)(=O)NC2=CC=CC=N2)C=C1,"Sulfapyridine, N-acetyl",CC(O)=NC1=CC=C(S(=O)(=O)NC2=CC=CC=N2)C=C1,NAT,N-acetylation of arylamine,0.85
4-aminobenzoate,NC1=CC=C(C(=O)[O-])C=C1,4-acetylaminobenzoate,CC([O-])=NC1=CC=C(C(=O)O)C=C1,NAT,N-acetylation of arylamine,0.63
4-amino-3-methylbenzoic acid,CC1=CC(C(=O)O)=CC=C1N,,CC(O)=NC1=CC=C(C(=O)O)C=C1C,NAT1; NAT2,N-acetylation of arylamine,0.65
"2,3-dimethylaniline",CC1=CC=CC(N)=C1C," 2,3Ã¢â‚¬Âdimethylacetanilide",CC(O)=NC1=CC=CC(C)=C1C,NAT1; NAT2,N-acetylation of arylamine,0.47
"2,4-dimethylaniline",CC1=CC=C(N)C(C)=C1," 2,4Ã¢â‚¬Âdimethylacetanilide",CC(O)=NC1=CC=C(C)C=C1C,NAT1; NAT2,N-acetylation of arylamine,0.48
"2,5-dimethylaniline",CC1=CC=C(C)C(N)=C1," 2,5Ã¢â‚¬Âdimethylacetanilide",CC(O)=NC1=CC(C)=CC=C1C,NAT1; NAT2,N-acetylation of arylamine,0.46
2-(4-aminobenzamido)pyridine,NC1=CC=C(C(=O)NC2=CC=CC=N2)C=C1,4Ã¢â‚¬ÂacetamidoÃ¢â‚¬ÂNÃ¢â‚¬Â(pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl)benzamide,CC(O)=NC1=CC=C(C(=O)NC2=CC=CC=N2)C=C1,GST,N-acetylation of arylamine,0.84
(+)-2-bromo-3-(4-nitrophenyl)propanoic acid,O=C(O)C(Br)CC1=CC=C([N+](=O)[O-])C=C1,2-(glutathion-S-yl)-3-(4-nitrophenyl)propanoic acid,NC(CCC(O)=NC(CSC(CC1=CC=C([N+](=O)[O-])C=C1)C(=O)O)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation of organohalide,0.33
"1,3,5-trinitrobenzene",O=[N+]([O-])C1=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1,"S-(2,4,6-trinitrocyclohexa-2,5-dien-1-yl)glutathione",NC(CCC(O)=NC(CSC1C([N+](=O)[O-])=CC([N+](=O)[O-])C=C1[N+](=O)[O-])C(O)=NCC(=O)O)C(=O)O,GSTA1,GSH-conjugation of benzene substituted with an electron donating group,0.07
"1-chloro-2,3-dinitrobenzene",O=[N+]([O-])C1=CC=CC(Cl)=C1[N+](=O)[O-],"S-(2,3-dinitrophenyl)glutathione",NC(CCC(O)=NC(CSC1=CC=CC([N+](=O)[O-])=C1[N+](=O)[O-])C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.26
"1-chloro-2,4-dinitrobenzene",O=[N+]([O-])C1=CC=C(Cl)C([N+](=O)[O-])=C1,"S-(2,4-dinitrophenyl)glutathione",NC(CCC(O)=NC(CSC1=CC=C([N+](=O)[O-])C=C1[N+](=O)[O-])C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.24
"1-Chloro-2,4-dinitrobenzene",O=[N+]([O-])C1=CC=C(Cl)C([N+](=O)[O-])=C1,,NC(CCC(O)=NC(CSC1(Cl)C=CC([N+](=O)[O-])C=C1[N+](=O)[O-])C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.12
Pefloxacin,CCN1C=C(C(=O)O)C(=O)C2=CC(F)=C(N3CCN(C)CC3)C=C21,Pefloxacin O-glucuronide,CCN1C=C(C(=O)OC2OC(C(=O)O)C(O)C(O)C2O)C(=O)C2=CC(F)=C(N3CCN(C)CC3)C=C21,GST,O-glucuronidation of aromatic acid,0.75
Brodifacoum,O=C1OC2=CC=CC=C2C(O)=C1C1CC(C2=CC=C(C3=CC=C(Br)C=C3)C=C2)CC2=CC=CC=C21,Brodifacoum O-glucuronide,O=C(O)C1OC(OC2=C(C3CC(C4=CC=C(C5=CC=C(Br)C=C5)C=C4)CC4=CC=CC=C43)C(=O)OC3=CC=CC=C23)C(O)C(O)C1O,UGT,Aromatic -OH glucuronidation,0.77
Nornalmefene,C=C1CCC2(O)C3CC4=CC=C(O)C5=C4C2(CCN3)C1O5,Nornalmefene O-glucuronide,C=C1CCC2(O)C3CC4=CC=C(OC5OC(C(=O)O)C(O)C(O)C5O)C5=C4C2(CCN3)C1O5,UGT,Aromatic -OH glucuronidation,0.9
Prechrysophanol,CC1=CC(O)=C2C(O)=C3CC(O)CCC3=CC2=C1,Prechrysophanol O-glucuronide,CC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=C2C(O)=C3CC(O)CCC3=CC2=C1,UGT,Aromatic -OH glucuronidation,0.51
Lumiracoxib,CC1=CC=C(NC2=C(F)C=CC=C2Cl)C(CC(=O)O)=C1,Lumiracoxib O-glucuronide,CC1=CC=C(NC2=C(F)C=CC=C2Cl)C(CC(=O)OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation of aliphatic acid,0.57
4-Hydroxy-alpha-thujone,CC(C)C12CC(=O)C(C)(O)C1C2,"alpha-thujone, 4-O-glucuronide",CC(C)C12CC1C(C)(O)C(=O)C2OC1OC(C(=O)O)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.43
Scutellarein,O=C1C=C(C2=CC=C(O)C=C2)OC2=CC(O)=C(O)C(O)=C12,Scutellarein 7-O-glucuronide,O=C(O)C1OC(OC2=CC3=C(C(O)=C2O)C(=O)C=C(C2=CC=C(O)C=C2)O3)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.61
Desogestrel,C#CC1(O)CCC2C3CCC4=CCCCC4C3C(=C)CC21CC,Desogestrel 17-O-glucuronide,C#CC1(OC2OC(C(=O)O)C(O)C(O)C2O)CCC2C3CCC4=CCCCC4C3C(=C)CC21CC,UGT,O-glucuronidation,0.49
3-Iodobenzoic acid,O=C(O)C1=CC=CC(I)=C1,3-Iodobenzoyl glyucuronide,O=C(OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=CC(I)=C1,UGT,O-glucuronidation of aromatic acid,0.23
4-Iodobenzoic acid,O=C(O)C1=CC=C(I)C=C1,4-Iodobenzoyl glyucuronide,O=C(OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=C(I)C=C1,UGT,O-glucuronidation of aromatic acid,0.2
Oxoprenolol,C=CCOC1=CC=CC=C1OCC(O)CNC(C)C,Oxprenolol glucuronide,C=CCOC1=CC=CC=C1OCC(CNC(C)C)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.37
Zomepirac,CC1=C(C(=O)C2=CC=C(Cl)C=C2)N(C)C(CC(=O)O)=C1,Zomepirac O-glucuronide,CC1=C(C(=O)C2=CC=C(Cl)C=C2)N(C)C(CC(=O)OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation of aliphatic acid,0.72
Clioquinol,OC1=C(I)C=C(Cl)C2=CC=CN=C12,Clioquinol O-glucuronide,O=C(O)C1OC(OC2=C(I)C=C(Cl)C3=CC=CN=C23)C(O)C(O)C1O,UGT,Aromatic -OH glucuronidation,0.48
Quinotolast,O=C1C(C(O)=NC2=NNN=N2)=CC(OC2=CC=CC=C2)=C2C=CC=CN12,Quinotolast N-glucuronide,O=C(N=C1N=NN(OC2OC(C(=O)O)C(O)C(O)C2O)N1)C1=CC(OC2=CC=CC=C2)=C2C=CC=CN2C1=O,UGT,N-glucuronidation,0.53
RG12525,C1=CC=C(C2=NNN=N2)C(COC2=CC=C(OCC3=CC=C4C=CC=CC4=N3)C=C2)=C1,RG12525 N2-glucuronide,O=C(O)C1OC(N2N=NC(C3=CC=CC=C3COC3=CC=C(OCC4=CC=C5C=CC=CC5=[NH+]4)C=C3)=N2)C(O)C(O)C1O,UGT1A1; UGT2B7,N-glucuronidation of azole,0.54
JNJ-10198409,COC1=CC2=C(C=C1OC)C1=C(C2)C(=NC2=CC=CC(F)=C2)NN1,JNJ-10198409 N-glucuronide B,COC1=CC2=C(C=C1OC)C1=C(C2)C(=NC2=CC=CC(F)=C2)NN1C1OC(C(=O)O)C(O)C(O)C1O,UGT1A9,N-glucuronidation of azole,0.67
JNJ-10198409,COC1=CC2=C(C=C1OC)C1=C(C2)C(=NC2=CC=CC(F)=C2)NN1,JNJ-10198409 N-glucuronide C,COC1=CC2=C(C=C1OC)C1=C(C2)C(=[NH+]C2=CC=CC(F)=C2)N(C2OC(C(=O)O)C(O)C([OH2+])C2O)[N-]1,UGT,N-glucuronidation of azole,0.67
JNJ-10198409,COC1=CC2=C(C=C1OC)C1=C(C2)C(=NC2=CC=CC(F)=C2)NN1,JNJ-10198409 N-glucuronide C,COC1=CC2=C(C=C1OC)C1=C(C2)C(N(C2=CC=CC(F)=C2)C2OC(C(=O)O)C(O)C(O)C2O)=NN1,UGT1A4; UGT1A9,N-glucuronidation of azole,0.62
Midazolam,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N21,Midazolam N-glucuronide,CC1=[N+](C2OC(C(=O)O)C(O)C(O)C2O)C=C2CN=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N21,UGT1A4,N-glucuronidation of azole,0.7
Afloqualone,CC1=CC=CC=C1N1C(CF)=NC2=CC=C(N)C=C2C1=O,Afloqualone N-glucuronide,CC1=CC=CC=C1N1C(CF)=NC2=CC=C(NC3OC(C(=O)O)C(O)C(O)C3O)C=C2C1=O,UGT1A4,Glucuronidation of primary aromatic amine,0.73
N-Acetylbenzidine,CC(O)=NC1=CC=C(C2=CC=C(N)C=C2)C=C1,"N-Acetylbenzidine, N-glucuronide",CC(O)=NC1=CC=C(C2=CC=C(NC3OC(C(=O)O)C(O)C(O)C3O)C=C2)C=C1,UGT1A1; UGT1A4; UGT1A9,Glucuronidation of primary aromatic amine,0.25
retigabine,CCOC(O)=NC1=CC=C(NCC2=CC=C(F)C=C2)C=C1N,retigabine N2-glucuronide,CCOC(O)=NC1=CC=C(NCC2=CC=C(F)C=C2)C=C1NC1OC(C(=O)O)C(O)C(O)C1O,UGT1A1; UGT1A9,Glucuronidation of primary aromatic amine,0.41
Desmethylclozapine,ClC1=CC=C2NC3=CC=CC=C3C(N3CCNCC3)=NC2=C1,Desmethylclozapine N-glucuronide,O=C(O)C1OC(N2CCN(C3=NC4=CC(Cl)=CC=C4NC4=CC=CC=C34)CC2)C(O)C(O)C1O,UGT1A3,N-glucuronidation,0.68
Desipramine,CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C21,Desipramine N-glucuronide,CN(CCCN1C2=CC=CC=C2CCC2=CC=CC=C21)C1OC(C(=O)O)C(O)C(O)C1O,UGT1A3,N-glucuronidation,0.51
Diphenylamine,C1=CC=C(NC2=CC=CC=C2)C=C1,Diphenylamine N-glucuronide,O=C(O)C1OC(N(C2=CC=CC=C2)C2=CC=CC=C2)C(O)C(O)C1O,UGT1A3,N-glucuronidation,0.1
Promethazine,CC(CN1C2=CC=CC=C2SC2=CC=CC=C21)N(C)C,Promethazine N-glucuronide,CC(CN1C2=CC=CC=C2SC2=CC=CC=C21)[N+](C)(C)C1OC(C(=O)O)C(O)C(O)C1O,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.52
Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,Diphenhydramine N-glucuronide,C[N+](C)(CCOC(C1=CC=CC=C1)C1=CC=CC=C1)C1OC(C(=O)O)C(O)C(O)C1O,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.28
Loxepine,CN1CCN(C2=NC3=CC=CC=C3OC3=CC=C(Cl)C=C23)CC1,Loxepine N-glucuronide,C[N+]1(C2OC(C(=O)O)C(O)C(O)C2O)CCN(C2=NC3=CC=CC=C3OC3=CC=C(Cl)C=C23)CC1,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.69
Clozapine,CN1CCN(C2=NC3=CC(Cl)=CC=C3NC3=CC=CC=C23)CC1,Clozapine N-glucuronide,C[N+]1(C2OC(C(=O)O)C(O)C(O)C2O)CCN(C2=NC3=CC(Cl)=CC=C3NC3=CC=CC=C23)CC1,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.67
Ketotifen,CN1CCC(=C2C3=CC=CC=C3CC(=O)C3=C2C=CS3)CC1,Ketotifen N-glucuronide,C[N+]1(C2OC(C(=O)O)C(O)C(O)C2O)CCC(=C2C3=CC=CC=C3CC(=O)C3=C2C=CS3)CC1,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.73
Chlorpromazine,CN(C)CCCN1C2=CC=CC=C2SC2=CC=C(Cl)C=C21,Chlorpromazine N-glucuronide,C[N+](C)(CCCN1C2=CC=CC=C2SC2=CC=C(Cl)C=C21)C1OC(C(=O)O)C(O)C(O)C1O,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.57
Doxepin,CN(C)CCC=C1C2=CC=CC=C2COC2=CC=CC=C12,Doxepin N-glucuronide,C[N+](C)(CCC=C1C2=CC=CC=C2COC2=CC=CC=C12)C1OC(C(=O)O)C(O)C(O)C1O,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.61
Tripelennamine,CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1,Tripelennamine N-glucuronide,C[N+](C)(CCN(CC1=CC=CC=C1)C1=CC=CC=N1)C1OC(C(=O)O)C(O)C(O)C1O,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.45
Cyproheptadine,CN1CCC(=C2C3=CC=CC=C3C=CC3=CC=CC=C23)CC1,Cyproheptadine N-glucuronide,C[N+]1(C2OC(C(=O)O)C(O)C(O)C2O)CCC(=C2C3=CC=CC=C3C=CC3=CC=CC=C23)CC1,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.51
Imipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C21,Imipramine N-glucuronide,C[N+](C)(CCCN1C2=CC=CC=C2CCC2=CC=CC=C21)C1OC(C(=O)O)C(O)C(O)C1O,UGT1A3,N-glucuronidation of tertiary aliphatic amine,0.51
Nirvanol,CCC1(C2=CC=CC=C2)N=C(O)N=C1O,Nirvanol N-glucuronide,CCC1(C2=CC=CC=C2)N=C(O)N(C2OC(C(=O)O)C(O)C(O)C2O)C1=O,UGT,N-glucuronidation,0.38
Isonicotinoylhydrazine,NNC(=O)C1=CC=NC=C1,,O=C(NNC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=NC=C1,UGT,O-glucuronidation,0.21
Ketobemidone,CCC(=O)C1(C2=CC=CC(O)=C2)CCN(C)CC1,Ketobemidone O-glucuronide,CCC(=O)C1(C2=CC=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=C2)CCN(C)CC1,UGT,Aromatic -OH glucuronidation,0.49
Ketobemidone,CCC(=O)C1(C2=CC=CC(O)=C2)CCN(C)CC1,Ketobemidone sulfate,CCC(=O)C1(C2=CC=CC(OS(=O)(=O)O)=C2)CCN(C)CC1,SULT,3-OH sulfonation of phenolic compound,0.81
chlorofluoroacetic acid,O=C(O)C(F)Cl,chloroacetyl-S-glutathione,NC(CCC(O)=NC(CSC(Cl)C(=O)O)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation of organohalide,0.05
4-nitrobenzyl chloride,O=[N+]([O-])C1=CC=C(CCl)C=C1,S-(4-Nitrobenzyl)glutathione,NC(CCC(O)=NC(CSCC1=CC=C([N+](=O)[O-])C=C1)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation of organohalide,0.24
4-nitrobenzyl chloride,O=[N+]([O-])C1=CC=C(CCl)C=C1,4-nitrobenzyl-glutathione,NC(CCC(O)=NC(CSCC1=CC=C([N+](=O)[O-])C=C1)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.24
4-nitrobenzyl chloride,O=[N+]([O-])C1=CC=C(CCl)C=C1,"S-(2,4-dinitrophenyl)glutathione",NC(CCC(O)=NC(CSC1=CC=C([N+](=O)[O-])C=C1[N+](=O)[O-])C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.16
alachlor,CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl,S-(alachlor)glutathione,CCC1=CC=CC(CC)=C1N(COC)C(=O)CSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugation of organohalide,0.55
monochlorobimane,CC1=C(C)N2C(CCl)=C(C)C(=O)N2C1=O,Bimane-glutathione,CC1=C(C)N2C(CSCC(N=C(O)CCC(N)C(=O)O)C(=O)CNC(=O)O)=C(C)C(=O)N2C1=O,GST,GSH-conjugation of organohalide,0.56
aminochrome,O=C1C=C2CCNC2=CC1=O,,NC(CCC(O)=NC(CSC1=C(O)C(O)=CC2=C1NCC2)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.18
Prunetin,COC1=CC(O)=C2C(=O)C(C3=CC=C(O)C=C3)=COC2=C1,,COC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=C2C(=O)C(C3=CC=C(O)C=C3)=COC2=C1,UGT1A9,O-glucuronidation,0.61
Indacaterol,CCC1=CC2=C(C=C1CC)CC(NCC(O)C1=CC=C(O)C3=NC(O)=CC=C13)C2,,CCC1=CC2=C(C=C1CC)CC(NCC(OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=C(O)C3=NC(O)=CC=C13)C2,UGT,O-glucuronidation,0.66
Triiodothyronine,NC(CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C(=O)O,,NC(CC1=CC(I)=C(OC2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(I)=C2)C(I)=C1)C(=O)O,UGT,Aromatic -OH glucuronidation,0.48
"3-Hydroxy-2p,3p-dimethoxyflavone",COC1=CC=CC(C2=C(O)C(=O)C3=CC=CC=C3O2)=C1OC,,COC1=CC=CC(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=CC=CC=C3O2)=C1OC,UGT1A9,O-glucuronidation,0.67
"8-aminoisoindolo (1,2-b)quinazolin-12(10H)-one",NC1=CC=C2N=C3C4=CC=CC=C4C(=O)N3CC2=C1,,CC(O)=NC1=CC=C2N=C3C4=CC=CC=C4C(=O)N3CC2=C1,NAT,N-acetylation of arylamine,0.94
Irbesartan M8,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2N=N[N+](C3C(O)C(O)C(O)C(C(=O)O)C3O)=N2)C=C1,UGT,O-glucuronidation,0.63
Perindopril,CCCC(NC(C)C(=O)N1C(C(=O)O)CC2CCCCC21)C(=O)OCC,,CCC(NC(C)C(=O)N1C(C(=O)OC2(C(=O)O)OC(C)C(O)C(O)C2O)CC2CCCCC21)C(=O)O,UGT,O-glucuronidation of aliphatic acid,0.58
Resokaempferol,O=C1C(O)=C(C2=CC=C(O)C=C2)OC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=CC=C(C3=C(O)C(=O)C4=CC=C(O)C=C4O3)C=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.64
Cholic acid,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,Cholic acid glucuronide,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(OC5OC(C(=O)O)C(O)C(O)C5O)CCC4(C)C3CC(O)C12C,UGT,3-OH glucuronidation of sterol,0.34
7-Hydroxy-beta-thujone,CC1C(=O)CC2(C(C)(C)O)CC12,,CC1C(=O)CC2(C(C)(C)OC3OC(C(=O)O)C(O)C(O)C3O)CC12,UGT,Alkyl-OH glucuronidation,0.43
4-Hydroxy-beta-thujone,CC(C)C12CC(=O)C(C)(O)C1C2,,CC(C)C12CC(=O)C(C)(OC3OC(C(=O)O)C(O)C(O)C3O)C1C2,UGT,Alkyl-OH glucuronidation,0.45
2-iodobenzyl bromide,BrCC1=CC=CC=C1I,,NC(CCC(O)=NC(CSC1=CC=CC=C1CBr)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.12
Hexafluoroisopropanol,OC(C(F)(F)F)C(F)(F)F,,O=C(O)C1OC(OC(C(F)(F)F)C(F)(F)F)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.1
"2,4-diene-VPA",C=CC=C(CCC)C(=O)O,,C=CC=C(CCC)C(=O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation of aliphatic acid,0.19
"3,7-Dihydroxyfavone",O=C1C(O)=C(C2=CC=CC=C2)OC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=CC=C3C(=O)C(O)=C(C4=CC=CC=C4)OC3=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.62
"3,7-Dihydroxyfavone",O=C1C(O)=C(C2=CC=CC=C2)OC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=C(C3=CC=CC=C3)OC3=CC(O)=CC=C3C2=O)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.57
Indole-3-acetic-acid,O=C(O)CC1=CNC2=CC=CC=C12,,O=C(CC1=CNC2=CC=CC=C12)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation of aliphatic acid,0.47
Paeonol,COC1=CC=C(C(C)=O)C(O)=C1,,COC1=CC=C(C(C)=O)C(OS(=O)(=O)O)=C1,SULT,Aromatic -OH glucuronidation,0.56
8-Hydroxy-7-methoxyisoflavone,COC1=CC(O)=C2OC=C(C3=CC=CC=C3)C(=O)C2=C1,,COC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=C2OC=C(C3=CC=CC=C3)C(=O)C2=C1,UGT1A9,O-glucuronidation,0.6
"8,14-diOH-efavirenz",OC1=NC2=C(O)C=C(Cl)C=C2C(C#CC2(O)CC2)(C(F)(F)F)O1,,O=C(O)C1OC(OC2(C#CC3(C(F)(F)F)OC(O)=NC4=C(O)C=C(Cl)C=C43)CC2)C(O)C(O)C1O,UGT,O-glucuronidation,0.83
"4p-hydroxy-2,3p,4-trichlorobiphenyl",OC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1Cl,,O=S(=O)(O)OC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1Cl,SULT,4-OH sulfonation of phenolic compound,0.66
Hydroxyoxid acid,CC1(C)C2CCC3(C)C(C2)C(C(=O)O)CCC13O,,CC1(C)C2CCC3(C)C(C2)C(C(=O)O)CCC13OC1OC(C(=O)O)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.38
N-Desmethyl-4-OH- atomoxetine,CC1=CC(O)=CC=C1OC(CCN)C1=CC=CC=C1,,CC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=CC=C1OC(CCN)C1=CC=CC=C1,UGT,Aromatic -OH glucuronidation,0.47
cis-6-(2-acetylvinylthio)purine,CC(=O)C=CSC1=NC=NC2=C1N=CN2,,CC([O-])=CC(SCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O)SC1=NC=NC2=C1N=CN2,GST,GSH-conjugation,0.4
benzoic acid,O=C(O)C1=CC=CC=C1,,O=C(OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=CC=C1,UGT,O-glucuronidation of aromatic acid,0.14
N-Desmethyl p-hydroxyrosiglitazone,O=C1N=C(O)C(CC2=CC=C(OCCN=C3C=CC(O)=CN3)C=C2)S1,,O=C1N=C(O)C(CC2=CC=C(OCCN=C3C=CC(OS(=O)(=O)O)=CN3)C=C2)S1,SULT,O-sulfonation,0.85
Tizoxanide,O=[N+]([O-])C1=CN=C(N=C(O)C2=CC=CC=C2O)S1,,O=C(O)C1OC(OC2=CC=CC=C2C(O)=NC2=NC=C([N+](=O)[O-])S2)C(O)C(O)C1O,UGT,Aromatic -OH glucuronidation,0.55
epicatechin metabo5,O=C1CCC(CC2=CC=CC(O)=C2)O1,,O=C1CCC(CC2=CC=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=C2)O1,UGT,Aromatic -OH glucuronidation,0.41
carvone metabo6,C=C(C)C1CC=C(C)C(=O)C1O,,C=C(C)C1CC=C(C)C(=O)C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.46
"5,7,2p-Trihydroxyflavone",O=C1C=C(C2=CC=CC=C2O)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=CC(O)=C3C(=O)C=C(C4=CC=CC=C4O)OC3=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.63
Estradiol acetate,CC(=O)OC1=CC=C2C(=C1)CCC1C2CCC2(C)C(O)CCC12,,CC(=O)OC1=CC=C2C(=C1)CCC1C2CCC2(C)C(OC3OC(C(=O)O)C(O)C(O)C3O)CCC12,UGT,17-OH glucuronidation of sterol,0.67
"N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine",CN1C(NO)=NC2=NC=C(C3=CC=CC=C3)C=C21,,CN1C(NOC2OC(C(=O)O)C(O)C(O)C2O)=NC2=NC=C(C3=CC=CC=C3)C=C21,"UGT1A1, 1A3, 1A6",Hydroxylamine O-glucuronidation,0.65
"N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine",CN1C(NO)=NC2=NC=C(C3=CC=CC=C3)C=C21,,CN1C(NOS(=O)(=O)O)=NC2=NC=C(C3=CC=CC=C3)C=C21,SULT1A1,Hydroxylamine O-sulfonation,0.91
Carboxy celecoxib,NS(=O)(=O)C1=CC=C(N2N=C(C(F)(F)F)C=C2C2=CC=C(C(=O)O)C=C2)C=C1,,NS(=O)(=O)C1=CC=C(N2N=C(C(F)(F)F)C=C2C2=CC=C(C(=O)OC3OC(C(=O)O)C(O)C(O)C3O)C=C2)C=C1,UGT,O-glucuronidation of aromatic acid,0.74
estrone,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2=O,,CC12CCC3C4=CC=C(OC5OC(C(=O)O)C(O)C(O)C5O)C=C4CCC3C1CCC2=O,"UGT1A1, 1A3, 1A7,1A8, 1A10",3-OH glucuronidation of sterol,0.55
Carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,,COC1=CC=CC=C1OCCNCC(COC1=CC=CC2=C1C1=CC=CC=C1N2)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.6
6-gingerol,CCCCCC(O)CC(=O)CCC1=CC=C(OC)C(O)=C1,,CCCCCC(O)CC(=O)CCC1=CC=C(OC)C(OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,Aromatic -OH glucuronidation,0.38
6-gingerol,CCCCCC(O)CC(=O)CCC1=CC=C(OC)C(O)=C1,,CCCCCC(O)CC(=O)CCC1=CC=C(OC)C(OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,3-OH-glucuronidation of a phenolic compound,0.38
6-gingerol,CCCCCC(O)CC(=O)CCC1=CC=C(OC)C(O)=C1,,CCCCCC(CC(=O)CCC1=CC=C(OC)C(O)=C1)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.47
O-Desmethylnaproxen,CC(C(=O)O)C1=CC=C2C=C(O)C=CC2=C1,,CC(C(=O)O)C1=CC=C2C=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=CC2=C1,UGT,Aromatic -OH glucuronidation,0.34
O-Desmethylnaproxen,CC(C(=O)O)C1=CC=C2C=C(O)C=CC2=C1,,CC(C(=O)OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=C2C=C(O)C=CC2=C1,UGT,O-glucuronidation of aliphatic acid,0.35
O-Desmethylnaproxen,CC(C(=O)O)C1=CC=C2C=C(O)C=CC2=C1,,CC(C(=O)O)C1=CC=C2C=C(OS(=O)(=O)O)C=CC2=C1,SULT1A1; SULT1B1; SULT1E1,O-sulfonation,0.74
O-Desmethylnaproxen,CC(C(=O)O)C1=CC=C2C=C(O)C=CC2=C1,,CC(C(=O)OS(=O)(=O)O)C1=CC=C2C=C(O)C=CC2=C1,SULT1A1; SULT1B1; SULT1E1,O-sulfonation,0.67
4-hydroxycyclopenta[def]chrysene,OC1C2=CC=CC3=CC=C4C5=CC=CC=C5C=C1C4=C23,,O=S(=O)(O)OC1C2=CC=CC3=CC=C4C5=CC=CC=C5C=C1C4=C23,SULT1E1,Sulfation of secondary alcohol,0.69
Rhamnetin,COC1=CC(O)=C2C(=O)C(O)=C(C3=CC=C(O)C(O)=C3)OC2=C1,,COC1=CC(O)=C2C(=O)C(OC3OC(C(=O)O)C(O)C(O)C3O)=C(C3=CC=C(O)C(O)=C3)OC2=C1,UGT1A9,Aromatic -OH glucuronidation,0.66
4-Fluorophenol,OC1=CC=C(F)C=C1,,O=C(O)C1OC(OC2=CC=C(F)C=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.11
"7,3p-Dihydroxyflavone",O=C1C=C(C2=CC=CC(O)=C2)OC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=CC=C3C(=O)C=C(C4=CC=CC(O)=C4)OC3=C2)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.57
Methyl-4-hydroxybenzoate,CCOC(=O)C1=CC=C(O)C=C1,,CCOC(=O)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,Aromatic -OH glucuronidation,0.26
13-hydroxyoctadecadienoic acid,CCCCCC(O)C=CC=CCCCCCCCC(=O)O,,CCCCCC(C=CC=CCCCCCCCC(=O)O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.21
13-hydroxyoctadecadienoic acid,CCCCCC(O)C=CC=CCCCCCCCC(=O)O,,CCCCCC(O)C=CC=CCCCCCCCC(=O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation of aliphatic acid,0.21
Dihydrodaidzein,O=C1C2=CC=C(O)C=C2OCC1C1=CC=C(O)C=C1,,O=C1C2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C2OCC1C1=CC=C(O)C=C1,UGT1A9,Aromatic -OH glucuronidation,0.63
Aminoflavone M-VI,CC1=C(F)C(NO)=C2C(=O)C(O)=C(C3=CC=C(N)C(F)=C3)OC2=C1F,,CC1=C(F)C(NO)=C2C(=O)C(OC3OC(C(=O)O)C(O)C(O)C3O)=C(C3=CC=C(N)C(F)=C3)OC2=C1F,UGT,Aromatic -OH glucuronidation,0.79
Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(=O)O,,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(=O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation of aliphatic acid,0.82
fenchone metabo3,CC1(C)C(=O)C2(C)CC1CC2O,,CC1(C)C(=O)C2(C)CC1CC2OC1OC(C(=O)O)C(O)C(O)C1O,UGT,Alkyl-OH glucuronidation,0.42
FYX-051,N#CC1=CC(C2=NC(C3=CC=NC=C3)=NN2)=CC=N1,,N#CC1=CC(C2=NN(C3OC(C(=O)O)C(O)C(O)C3O)C(C3=CC=NC=C3)=N2)=CC=N1,UGT1A9,N-glucuronidation of azole,0.32
FYX-051,N#CC1=CC(C2=NC(C3=CC=NC=C3)=NN2)=CC=N1,,[NH+]#CC1=CC(C2=NC(C3=CC=NC=C3)=NN2C2OC(C(=O)O)C(O)C(O)C2O)=CC=N1,UGT1A9,N-glucuronidation,0.32
"3-Hydroxy-7,4p-dimethoxyflavone",COC1=CC=C(C2=C(O)C(=O)C3=CC=C(OC)C=C3O2)C=C1,,COC1=CC=C(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=CC=C(OC)C=C3O2)C=C1,UGT1A9,O-glucuronidation,0.61
10-hydroxycarbazepine,N=C(O)N1C2=CC=CC=C2CC(O)C2=CC=CC=C21,,N=C(O)N1C2=CC=CC=C2CC(OC2OC(C(=O)O)C(O)C(O)C2O)C2=CC=CC=C21,UGT,Alkyl-OH glucuronidation,0.6
O-Desmethyl-2p-OH-Indomethacin phenethylamide,CC1=C(CC(O)=NCC(O)C2=CC=CC=C2)C2=CC(O)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1,,CC1=C(CC(O)=NCC(OC2OC(C(=O)O)C(O)C(O)C2O)C2=CC=CC=C2)C2=CC(O)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1,UGT,O-glucuronidation,0.81
5-Hydroxyflavone,O=C1C=C(C2=CC=CC=C2)OC2=CC=CC(O)=C12,,O=C(O)C1OC(OC2=CC=CC3=C2C(=O)C=C(C2=CC=CC=C2)O3)C(O)C(O)C1O,UGT1A9,Aromatic -OH glucuronidation,0.55
Oroxylin A,COC1=C(O)C=C2OC(C3=CC=CC=C3)=CC(=O)C2=C1O,,COC1=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C2OC(C3=CC=CC=C3)=CC(=O)C2=C1O,UGT1A9,Aromatic -OH glucuronidation,0.63
ketotifen,CN1CCC(=C2C3=CC=CC=C3CC(=O)C3=C2C=CS3)CC1,,C[N+]1(C2OC(C(=O)O)C(O)C(O)C2O)CCC(=C2C3=CC=CC=C3CC(=O)C3=C2C=CS3)CC1,UGT,N-glucuronidation,0.73
7-ethyl-10-hydroxycamptothecin,CCC1=C2CN3C(=CC4=C(COC(=O)C4(O)CC)C3=O)C2=NC2=CC=C(O)C=C12,,CCC1=C2CN3C(=CC4=C(COC(=O)C4(O)CC)C3=O)C2=NC2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C12,UGT1A9,Aromatic -OH glucuronidation,0.93
Fenretinide,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)NC1=CC=C(O)C=C1,,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)NC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT,Aromatic -OH glucuronidation,0.48
Fenretinide,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)NC1=CC=C(O)C=C1,,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)NC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT,4-OH sulfonation of phenolic compound,0.48
"3-Hydroxy-6-methyl-3p,4p-methylenedioxyflavone",CC1=CC=C2OC(C3=CC=C4OCOC4=C3)=C(O)C(=O)C2=C1,,CC1=CC=C2OC(C3=CC=C4OCOC4=C3)=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C2=C1,UGT1A9,Aromatic -OH glucuronidation,0.66
6-Hydroxymelatonin,COC1=CC2=C(C=C1O)NC=C2CCN=C(C)O,,COC1=CC2=C(C=C1OC1OC(C(=O)O)C(O)C(O)C1O)NC=C2CCN=C(C)O,UGT,Aromatic -OH glucuronidation,0.57
Sinapinic acid,COC1=CC(C=CC(=O)O)=CC(OC)=C1O,,COC1=CC(C=CC(=O)OC2OC(C(=O)O)C(O)C(O)C2O)=CC(OC)=C1O,UGT,O-glucuronidation,0.4
Tolmetin,CC1=CC=C(C(=O)C2=CC=C(CC(=O)O)N2C)C=C1,,CC1=CC=C(C(=O)C2=CC=C(CC(=O)OC3OC(C(=O)O)C(O)C(O)C3O)N2C)C=C1,UGT,O-glucuronidation of aliphatic acid,0.64
Licofelone M2,CC1(C)CC2=C(C3=CC=CC=C3)C(C3=CC=C(Cl)C(O)=C3)=C(CC(=O)O)N2C1,,CC1(C)CC2=C(C3=CC=CC=C3)C(C3=CC=C(Cl)C(O)=C3)=C(CC(=O)OC3OC(C(=O)O)C(O)C(O)C3O)N2C1,UGT,O-glucuronidation of aliphatic acid,0.8
O-methoxycatechol,COOC1=CC=CC=C1O,,COC1=CC=CC=C1OS(=O)(=O)O,SULT,Aromatic -OH glucuronidation,0.2
phenethyl isothiocyanate,S=C=NCCC1=CC=CC=C1,,NC(CCC(O)=NC(CSC([S])=NCCC1=CC=CC=C1)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.17
6-hydroxymethylbenzo[a]pyrene,OCC1=C2C=CC=CC2=C2C=CC3=CC=CC4=CC=C1C2=C43,,O=S(=O)(O)OCC1=C2C=CC=CC2=C2C=CC3=CC=CC4=CC=C1C2=C43,SULT1B1; SULT1C3,O-sulfonation,0.64
Lonidamine,O=C(O)C1=NN(CC2=CC=C(Cl)C=C2Cl)C2=CC=CC=C12,,O=C(OC1OC(C(=O)O)C(O)C(O)C1O)C1=NN(CC2=CC=C(Cl)C=C2Cl)C2=CC=CC=C12,UGT,O-glucuronidation,0.67
"2,2‐dichloro‐2‐fluoroethanol",OCC(F)(Cl)Cl,,O=C(O)C1OC(OCC(F)(Cl)Cl)C(O)C(O)C1O,UGT,O-glucuronidation,0.06
Geraniol,CC(C)=CCCC(C)=CCO,,CC(C)=CCCC(C)=CCOS(=O)(=O)O,GST,GSH-conjugation,0.51
Buprenorphine,COC12CCC3(CC1C(C)(O)C(C)(C)C)C1CC4=CC=C(O)C5=C4C3(CCN1CC1CC1)C2O5,Buprenorphine glucuronide,COC12CCC3(CC1C(C)(O)C(C)(C)C)C1CC4=CC=C(OC5OC(C(=O)O)C(O)C(O)C5O)C5=C4C3(CCN1CC1CC1)C2O5,UGT,O-glucuronidation,0.91
Nateglinide,CC(C)C1CCC(C(O)=NC(CC2=CC=CC=C2)C(=O)O)CC1,,CC(C)C1CCC(C(O)=NC(CC2=CC=CC=C2)C(=O)OC2OC(C(=O)O)C(O)C(O)C2O)CC1,UGT,O-glucuronidation,0.49
trans-isoeugenol,CC=CC1=CC=C(O)C(OC)=C1,,CC=CC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C(OC)=C1,UGT,O-glucuronidation,0.29
Clofibric acid,CC(C)(OC1=CC=C(Cl)C=C1)C(=O)O,,CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.32
N-Hydroxymexiletine,CC1=CC=CC(C)=C1OCC(C)NO,,CC1=CC=CC(C)=C1OCC(C)NOC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.33
Dehydroisoandrosterone,CC12CCC3C(CC=C4CC(O)CCC43C)C1CCC2=O,,CC12CCC3C(CC=C4CC(OC5OC(C(=O)O)C(O)C(O)C5O)CCC43C)C1CCC2=O,UGT,O-glucuronidation,0.5
4-hydroxymethyl ambrisentan,COC(C1=CC=CC=C1)(C1=CC=CC=C1)C(OC1=NC(C)=CC(CO)=N1)C(=O)O,,COC(C1=CC=CC=C1)(C1=CC=CC=C1)C(OC1=NC(C)=CC(CO)=N1)C(=O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.74
4-Methoxyphenol,COC1=CC=C(O)C=C1,,COC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.11
N-OH-ABA,O=C1C2=CC=CC=C2C2=C3C1=CC=CC3=C(NO)C=C2,,O=C1C2=CC=CC=C2C2=C3C1=CC=CC3=C(NOS(=O)(=O)O)C=C2,"SULT1A1, SULT1A2",O-sulfonation,0.93
"3,5-Dihydroxyflavone",O=C1C(O)=C(C2=CC=CC=C2)OC2=CC=CC(O)=C12,,O=C(O)C1OC(OC2=C(C3=CC=CC=C3)OC3=CC=CC(O)=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.6
"2-amino-6- methyldipyrido[1,2-a:3p,2p-d]- imidazole (Glu-P-1)",CC1=CC=CN2C1=NC1=C2NC(=N)C=C1,,CC(O)=NC1=CC=C2N=C3C(C)=CC=CN3C2=N1,"NAT1,NAT2",N-acetylation,0.64
Thalifendine,COC1=CC=C2C=C3C4=CC5=C(C=C4CC[NH+]3C=C2C1=O)OCO5,,COC1=CC=C2C=C3C4=CC5=C(C=C4CC[N+]3=CC2=C1OC1OC(C(=O)O)C(O)C(O)C1O)OCO5,UGT,O-glucuronidation,0.53
1-iodoethane,CCI,ethylglutathione,CCSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugation,0.01
Dihydroferulic acid,COC1=CC(CCC(=O)O)=CC=C1O,,COC1=CC(CCC(=O)O)=CC=C1OS(=O)(=O)O,SULT,O-sulfonation,0.64
4-Propoxyphenol,CCCOC1=CC=C(O)C=C1,,CCCOC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,Aromatic -OH glucuronidation,0.17
valproic acid,CCCC(CCC)C(=O)O,,CCCC(CCC)C(=O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation of aliphatic acid,0.13
Diclofenac,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,,O=C(CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation of aliphatic acid,0.48
Eugenol,C=CCC1=CC=C(O)C(OC)=C1,,C=CCC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C(OC)=C1,UGT1A9,Aromatic -OH glucuronidation,0.29
3-ethylphenol,CCC1=CC=CC(O)=C1,,CCC1=CC=CC(OS(=O)(=O)O)=C1,SULT,3-OH sulfonation of phenolic compound,0.47
"(R,R)-1-phenylpropylene oxide",CC1OC1C1=CC=CC=C1,,NC(CCC(O)=NC(CSCC1OC1C1=CC=CC=C1)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation of epoxide,0.31
Wogonin,COC1=C(O)C=C(O)C2=C1OC(C1=CC=CC=C1)=CC2=O,,COC1=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C(O)C2=C1OC(C1=CC=CC=C1)=CC2=O,UGT1A9,O-glucuronidation,0.67
"3,3p,4p-Trihydroxyflavone",O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC2=CC=CC=C12,,O=C(O)C1OC(OC2=C(C3=CC=C(O)C(O)=C3)OC3=CC=CC=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.59
fenchone metabo4,CC12CC(O)C(C1)C(C)(C)C2=O,,CC12CC(OC3OC(C(=O)O)C(O)C(O)C3O)C(C1)C(C)(C)C2=O,UGT,O-glucuronidation,0.41
Sorafenib,CNC(=O)C1=CC(OC2=CC=C(NC(O)=NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=CC=N1,,CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)C3OC(C(=O)O)C(O)C(O)C3O)C=C2)=CC=N1,UGT,O-glucuronidation,0.51
4-Iodophenol,OC1=CC=C(I)C=C1,,O=C(O)C1OC(OC2=CC=C(I)C=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.1
4-Hydroxyacetophenone,CC(=O)C1=CC=C(O)C=C1,,CC(=O)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.2
Triclosan,OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl,,O=C(O)C1OC(OC2=CC(Cl)=CC=C2OC2=CC=C(Cl)C=C2Cl)C(O)C(O)C1O,UGT,O-glucuronidation,0.32
Triclosan,OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl,,O=S(=O)(O)OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl,SULT,Aromatic -OH glucuronidation,0.62
Combretastatin A4,COC1=CC=C(C=CC2=CC(OC)=C(OC)C(OC)=C2)C=C1O,,COC1=CC=C(C=CC2=CC(OC)=C(OC)C(OC)=C2)C=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.34
Ascorbic acid,O=C1OC(C(O)CO)C(O)=C1O,,O=C1OC(C(O)CO)C(O)=C1OS(=O)(=O)O,SULT,O-sulfonation,0.65
testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(OS(=O)(=O)O)CCC12,SULT,O-sulfonation,0.75
2-aminofluorene,NC1=CC=C2C(=C1)CC1=CC=CC=C12,,CC(O)=NC1=CC=C2C(=C1)CC1=CC=CC=C12,NAT,N-acetylation,0.78
Droloxifene,CCC(=C(C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC(O)=C1)C1=CC=CC=C1,,CCC(=C(C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=C1)C1=CC=CC=C1,UGT,O-glucuronidation,0.54
Berberrubine,COC1=C(O)C=CC2=CC3=[N+](C=C12)CCC1=CC2=C(C=C13)OCO2,,COC1=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=CC2=CC3=[N+](C=C12)CCC1=CC2=C(C=C13)OCO2,UGT,O-glucuronidation,0.79
7-Hydroxy-3-methylflavone,CC1=C(C2=CC=CC=C2)OC2=CC(O)=CC=C2C1=O,,CC1=C(C2=CC=CC=C2)OC2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC=C2C1=O,UGT1A9,O-glucuronidation,0.64
4-aminoveratrole,COC1=CC=C(N)C=C1OC,,COC1=CC=C(N=C(C)O)C=C1OC,NAT,N-acetylation,0.62
phentolamine,CC1=CC=C(N(CC2=NCCN2)C2=CC=CC(O)=C2)C=C1,,CC1=CC=C(N(CC2=NCCN2)C2=CC=CC(OS(=O)(=O)O)=C2)C=C1,SULT1A3; SULT1A5,O-sulfonation,0.79
Resacetophenone,CC(=O)C1=CC=C(O)C=C1O,,CC(=O)C1=CC=C(O)C=C1OS(=O)(=O)O,SULT,O-sulfonation,0.52
Epinephrine,CNCC(O)C1=CC=C(O)C(O)=C1,,CNCC(O)C1=CC=C(OS(=O)(=O)O)C(O)=C1,SULT,O-sulfonation,0.66
Diallyl disulfide,C=CCSSCC=C,,C=CCSSCC=CSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugation,0.06
"10-hydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene",OC1CCCC2=CC3=CC=C4C=CC=C5C=CC(=C21)C3=C45,,O=S(=O)(O)OC1CCCC2=CC3=CC=C4C=CC=C5C=CC(=C21)C3=C45,SULT1E1,O-sulfonation,0.68
trovafloxacin,NC1C2CN(C3=NC4=C(C=C3F)C(=O)C(C(=O)O)=CN4C3=CC=C(F)C=C3F)CC12,,NC1C2CN(C3=NC4=C(C=C3F)C(=O)C(C(=O)OC3OC(C(=O)O)C(O)C(O)C3O)=CN4C3=CC=C(F)C=C3F)CC12,UGT,O-glucuronidation,0.86
2-hydroxymethylpyrene,OCC1=CC2=CC=C3C=CC=C4C=CC(=C1)C2=C34,,O=S(=O)(O)OCC1=CC2=CC=C3C=CC=C4C=CC(=C1)C2=C34,SULT2A1,O-sulfonation,0.61
alpha-methyl benzyl alcohol,CC(O)C1=CC=CC=C1,,CC(OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=CC=C1,UGT,O-glucuronidation,0.15
Propofol,CC(C)C1=CC=CC(C(C)C)=C1O,,CC(C)C1=CC=CC(C(C)C)=C1OC1OC(C(=O)O)C(O)C(O)C1O,"UGT1A8, UGT1A9",O-glucuronidation,0.25
Kaempferol,O=C1C(O)=C(C2=CC=C(O)C=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=CC(O)=C3C(=O)C(O)=C(C4=CC=C(O)C=C4)OC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.66
Kaempferol,O=C1C(O)=C(C2=CC=C(O)C=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=C(C3=CC=C(O)C=C3)OC3=CC(O)=CC(O)=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.62
2-ethylaniline,CCC1=CC=CC=C1N,,CCC1=CC=CC=C1N=C(C)O,NAT,N-acetylation,0.47
"N-hydroxy-2-amino-6-methyldipyrido[1,2-a:3p,2p-d]-imidazole",CC1=CC=CN2C1=NC1=CC=C(NO)N=C12,,CC1=CC=CN2C1=NC1=CC=C(NOS(=O)(=O)O)N=C12,SULT1A1,O-sulfonation,0.88
4-nonylphenol,CCCCCCCCCC1=CC=C(O)C=C1,,CCCCCCCCCC1=CC=C(OS(=O)(=O)O)C=C1,SULT1C1; SULT1C2,O-sulfonation,0.59
Tizanidine M6,OC1=CC(Cl)=C(NC2=NCCN2)C2=NSN=C12,,O=C(O)C1OC(OC2=CC(Cl)=C(NC3=NCCN3)C3=NSN=C23)C(O)C(O)C1O,UGT,O-glucuronidation,0.67
Tizanidine M6,OC1=CC(Cl)=C(NC2=NCCN2)C2=NSN=C12,,O=S(=O)(O)OC1=CC(Cl)=C(NC2=NCCN2)C2=NSN=C12,SULT,O-sulfonation,0.85
Dezocine,CC12CCCCCC(CC3=CC=C(O)C=C31)C2N,,CC12CCCCCC(CC3=CC=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C31)C2N,UGT,O-glucuronidation,0.59
Dulcin,CCOC1=CC=C(NC(=N)O)C=C1,,CCOC1=CC=C(NC(O)=NC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.26
S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid,CC1=C(C2=CC=C(C(C)C(=O)O)C=C2)SC=C1,,CC1=C(C2=CC=C(C(C)C(=O)OC3OC(C(=O)O)C(O)C(O)C3O)C=C2)SC=C1,UGT,O-glucuronidation,0.5
S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid,CC1=C(C2=CC=C(C(C)C(=O)O)C=C2)SC=C1,,CC1=C(C2=CC=C(C(C)C(=O)ONCCS(=O)(=O)O)C=C2)SC=C1,TAU,Taurine conjugation of aliphatic acid,0.76
Jaceidin,COC1=CC(C2=C(OC)C(=O)C3=C(O)C(OC)=C(O)C=C3O2)=CC=C1O,,COC1=CC(C2=C(OC)C(=O)C3=C(O)C(OC)=C(O)C=C3O2)=CC=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.76
menthol,CC1CCC(C(C)C)C(O)C1,,CC1CCC(C(C)C)C(OC2OC(C(=O)O)C(O)C(O)C2O)C1,UGT,O-glucuronidation,0.19
"5,6-O-DiDesmethyl Donepezil",O=C1C2=CC(O)=C(O)C=C2CC1CC1CCN(CC2=CC=CC=C2)CC1,,O=C1C2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=C(O)C=C2CC1CC1CCN(CC2=CC=CC=C2)CC1,UGT,O-glucuronidation,0.57
"5,6-O-DiDesmethyl Donepezil",O=C1C2=CC(O)=C(O)C=C2CC1CC1CCN(CC2=CC=CC=C2)CC1,,O=C1C2=CC(O)=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C2CC1CC1CCN(CC2=CC=CC=C2)CC1,UGT,O-glucuronidation,0.57
"3,6,4p-Trihydroxyflavone",O=C1C(O)=C(C2=CC=C(O)C=C2)OC2=CC=C(O)C=C12,,O=C(O)C1OC(OC2=C(C3=CC=C(O)C=C3)OC3=CC=C(O)C=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.57
4p-Carboxylumiracoxib,CC1=CC=C(NC2=C(F)C=C(O)C=C2Cl)C(CC(=O)O)=C1,,CC1=CC=C(NC2=C(F)C=C(O)C=C2Cl)C(CC(=O)OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation,0.62
Norbuprenorphine,COC12CCC3(CC1C(C)(O)C(C)(C)C)C1CC4=CC=C(O)C5=C4C3(CCN1)C2O5,,COC12CCC3(CC1C(C)(O)C(C)(C)C)C1CC4=CC=C(OC5OC(C(=O)O)C(O)C(O)C5O)C5=C4C3(CCN1)C2O5,UGT,O-glucuronidation,0.91
O-Desmethylvenlafaxine,NCC(C1=CC=C(O)C=C1)C1(O)CCCCC1,,NCC(C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1)C1(O)CCCCC1,UGT,O-glucuronidation,0.49
"2,8-Dihydroxyquinoline",OC1=CC=C2C=CC=C(O)C2=N1,,O=C(O)C1OC(OC2=CC=C3C=CC=C(O)C3=N2)C(O)C(O)C1O,UGT,O-glucuronidation,0.34
Hydroxyfarnesol,CC(=CCCC(C)=CCCC(C)=CCO)CO,,CC(=CCO)CCC=C(C)CCC=C(C)COC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.15
Dihydromorphine,CN1CCC23C4=C5C=CC(O)=C4OC2C(O)CCC3C1C5,,CN1CCC23C4=C5C=CC(OC6OC(C(=O)O)C(O)C(O)C6O)=C4OC2C(O)CCC3C1C5,UGT,O-glucuronidation,0.87
Ketoprofen,CC(C(=O)O)C1=CC=CC(C(=O)C2=CC=CC=C2)=C1,,CC(C(=O)OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=CC(C(=O)C2=CC=CC=C2)=C1,UGT,O-glucuronidation,0.43
1-iodopropane,CCCI,propyl-glutathione,CCCSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,O-glucuronidation,0.01
7-hydroxy-12-methylbenz[a]anthracene,CC1=C2C=CC=CC2=C(O)C2=CC=C3C=CC=CC3=C12,,CC1=C2C=CC=CC2=C(OS(=O)(=O)O)C2=CC=C3C=CC=CC3=C12,SULT2A1,O-sulfonation,0.59
Lasofoxifene,OC1=CC=C2C(=C1)CCC(C1=CC=CC=C1)C2C1=CC=C(OCCN2CCCC2)C=C1,,O=C(O)C1OC(OC2=CC=C3C(=C2)CCC(C2=CC=CC=C2)C3C2=CC=C(OCCN3CCCC3)C=C2)C(O)C(O)C1O,UGT,O-glucuronidation,0.64
1-iodo-3-phenylpropane,ICCCC1=CC=CC=C1,3-phenylpropyl-glutathione,NC(CCC(O)=NC(CSCCCC1=CC=CC=C1)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.16
4p-OH-aceclofenac,O=C(O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=C(O)C=C1Cl,,O=C(O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1Cl,UGT,O-glucuronidation,0.56
4p-OH-aceclofenac,O=C(O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=C(O)C=C1Cl,,O=C(O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=C(OS(=O)(=O)O)C=C1Cl,SULT,O-sulfonation,0.84
"4-Hydroxy-5-(3p,5p-dihydroxyphenyl)-valeric acid",O=C(O)CCC(O)CC1=CC(O)=CC(O)=C1,,O=C(CCC(O)CC1=CC(O)=CC(O)=C1)OCOC1OC(C(O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.46
1-iodobutane,CCCCI,butyl-glutathione,CCCCSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugation,0.02
4-hydroxyatomoxetine,CNCCC(OC1=CC=C(O)C=C1C)C1=CC=CC=C1,,CNCCC(OC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1C)C1=CC=CC=C1,UGT,O-glucuronidation,0.49
7-Hydoxy-5-methylflavone,CC1=CC(O)=CC2=C1C(=O)C=C(C1=CC=CC=C1)O2,,CC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=CC2=C1C(=O)C=C(C1=CC=CC=C1)O2,UGT1A9,O-glucuronidation,0.62
"6,7,3p-Trihydroxflavone",O=C1C=C(C2=CC=CC(O)=C2)OC2=CC(O)=C(O)C=C12,,O=C(O)C1OC(OC2=CC3=C(C=C2O)C(=O)C=C(C2=CC=CC(O)=C2)O3)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.59
N-hydroxy-2-acetylaminofluorene,CC(=O)N(O)C1=CC=C2C(=C1)CC1=CC=CC=C12,,CC(=O)N(OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=C2C(=C1)CC1=CC=CC=C12,"UGT1A4, 1A6",O-glucuronidation,0.51
N-hydroxy-2-acetylaminofluorene,CC(=O)N(O)C1=CC=C2C(=C1)CC1=CC=CC=C12,,CC(=O)N(OS(=O)(=O)O)C1=CC=C2C(=C1)CC1=CC=CC=C12,SULT1A1,O-sulfonation,0.79
7-Hydroxy-alpha-thujone,CC1C(=O)CC2(C(C)(C)O)CC12,,CC1C(=O)CC2(C(C)(C)OC3OC(C(=O)O)C(O)C(O)C3O)CC12,UGT,O-glucuronidation,0.43
Pentaerythritol Dibromide,OCC(CO)(CBr)CBr,,O=C(O)C1OC(OCC(CO)(CBr)CBr)C(O)C(O)C1O,UGT,O-glucuronidation,0.1
"5-(3p,4p-Dihydroxyphenyl)-gamma-valerolactone-4p-O-methyl",COC1=CC=C(CC2CCC(=O)O2)C=C1O,,COC1=CC=C(CC2CCC(=O)O2)C=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.45
2-Methoxyestrone,COC1=CC2=C(C=C1O)CCC1C2CCC2(C)C(=O)CCC12,,COC1=CC2=C(C=C1OC1OC(O)C(O)C(O)C1O)CCC1C2CCC2(C)C(=O)CCC12,UGT,O-glucuronidation,0.67
Carveol,C=C(C)C1CC=C(C)C(O)C1,,C=C(C)C1CC=C(C)C(OC2OC(C(=O)O)C(O)C(O)C2O)C1,UGT,O-glucuronidation,0.32
7-Hydroxyflavone,O=C1C=C(C2=CC=CC=C2)OC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=CC=C3C(=O)C=C(C4=CC=CC=C4)OC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.54
Bisphenol A,CC(C)(C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,,CC(C)(C1=CC=C(O)C=C1)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.28
25-Hydroxyvitamin D2,C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)C=CC(C)C(C)(C)O,,C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)C=CC(C)C(C)(C)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.5
Edaravone,CC1=NN(C2=CC=CC=C2)C(O)=C1,,CC1=NN(C2=CC=CC=C2)C(OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation,0.4
"6,7-Dihydroxyflavone",O=C1C=C(C2=CC=CC=C2)OC2=CC(O)=C(O)C=C12,,O=C(O)C1OC(OC2=CC3=C(C=C2O)C(=O)C=C(C2=CC=CC=C2)O3)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.57
Flurbiprofen,CC(C(=O)O)C1=CC=C(C2=CC=CC=C2)C(F)=C1,,CC(C(=O)OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=C(C2=CC=CC=C2)C(F)=C1,"UGT2B7, UGT1A1, UGT1A3, UGT1A9, UGT2B4",O-glucuronidation,0.46
Codeine,COC1=CC=C2CC3C4C=CC(O)C5OC1=C2C45CCN3C,,COC1=CC=C2CC3C4C=CC(OC5OC(C(=O)O)C(O)C(O)C5O)C5OC1=C2C45CCN3C,UGT,O-glucuronidation,0.9
Losartan,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,,CCCCC1=[NH+]C(Cl)=C(CO)N1CC1=CC=C(C2=CC=CC=C2C2N=NN(C3OC(C(O)O)C(O)C(O)C3O)N2)C=C1,"UGT1A1, UGT1A3, UGT1A10. UGT2B7, UGT2B17",O-glucuronidation,0.58
N-hydroxy-2-acetylamino-3-methyl-5-phenylpyridine,CC(=O)N(O)C1=NC=C(C2=CC=CC=C2)C=C1C,,CC(=O)N(OC1OC(C(=O)O)C(O)C(O)C1O)C1=NC=C(C2=CC=CC=C2)C=C1C,SULT1A1,O-sulfonation,0.54
5-OH-paeonol,COC1=CC(O)=C(C(C)=O)C=C1O,,COC1=CC(OS(=O)(=O)O)=C(C(C)=O)C=C1O,SULT,O-sulfonation,0.61
1-iodooctane,CCCCCCCCI,octyl-glutathione,CCCCCCCCSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugation,0.03
4-phenoxyaniline,NC1=CC=C(OC2=CC=CC=C2)C=C1,,CC(O)=NC1=CC=C(OC2=CC=CC=C2)C=C1,NAT,N-acetylation,0.59
N-hydroxy-2-aminobenzanthrone,O=C1C=C2C=C3C=CC4=CC=C(NO)C=C4C3=CC2=CC1,,O=C1C=C2C=C3C=CC4=CC=C(NOC5OC(C(=O)O)C(O)C(O)C5O)C=C4C3=CC2=CC1,SULT1A1,O-sulfonation,0.45
xanthurenic acid,O=C(O)C1=CC(O)=C2C=CC=C(O)C2=N1,,O=C(O)C1=CC(O)=C2C=CC=C(OS(=O)(=O)O)C2=N1,SULT,O-sulfonation,0.79
Acetaminophen,CC(O)=NC1=CC=C(O)C=C1,,CC(O)=NC1=CC=C(OS(=O)(=O)O)C=C1,SULT,O-sulfonation,0.6
Acetaminophen,CC(O)=NC1=CC=C(O)C=C1,,CC(O)=NC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT,O-glucuronidation,0.22
serotonin,NCCC1=CNC2=CC=C(O)C=C12,,NCCC1=CNC2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C12,UGT,O-glucuronidation,0.47
Misonidazole,COCC(O)CN1C=CN=C1[N+](=O)[O-],,COCC(CN1C=CN=C1[N+](=O)[O-])OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.51
Etiocholanolone,CC12CCC3C(CCC4CC(O)CCC43C)C1CCC2=O,,CC12CCC3C(CCC4CC(OC5OC(C(=O)O)C(O)C(O)C5O)CCC43C)C1CCC2=O,UGT,O-glucuronidation,0.35
3-alpha-hydroxydesogestrel,C#CC1(O)CCC2C3CCC4=CC(O)CCC4C3C(=C)CC21CC,,C#CC1(O)CCC2C3CCC4=CC(OC5OC(C(=O)O)C(O)C(O)C5O)CCC4C3C(=C)CC21CC,UGT,O-glucuronidation,0.55
3-alpha-hydroxydesogestrel,C#CC1(O)CCC2C3CCC4=CC(O)CCC4C3C(=C)CC21CC,,C#CC1(O)CCC2C3CCC4=CC(OS(=O)(=O)O)CCC4C3C(=C)CC21CC,SULT,O-sulfonation,0.8
"B[a]P 7,8-epoxide",C1=CC2OC2C2=CC3=CC=C4C=CC=C5C=CC(=C12)C3=C45,,NC(CCC(O)=NC(CSOC1C2=CC3=CC=C4C=CC=C5C=CC(=C2C=CC1O)C3=C45)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.53
4-Chlorophenol,OC1=CC=C(Cl)C=C1,,O=C(O)C1OC(OC2=CC=C(Cl)C=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.11
Tyramine,NCCC1=CC=C(O)C=C1,,NCCC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT,O-glucuronidation,0.17
Minoxidil,N=C1N=C(N2CCCCC2)C=C(N)N1O,,N=C1N=C(N2CCCCC2)C=C(N)N1OS(=O)(=O)O,SULT,O-sulfonation,0.72
3p-Oxohexobarbital,CN1C(=O)N=C(O)C(C)(C2=CC(=O)CCC2)C1=O,,CN1C(=O)N=C(O)C(C)(C2(SCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O)CCCC(=O)C2)C1=O,GST,GSH-conjugation,0.56
Fluoxetine,CNCCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1,,CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)C1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.45
Vitamin D2,C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)C=CC(C)C(C)C,,C=C1CCC(OC2OC(C(=O)O)C(O)C(O)C2O)CC1=CC=C1CCCC2(C)C1CCC2C(C)C=CC(C)C(C)C,UGT,O-glucuronidation,0.48
5-O-Desmethyl Donepezil,COC1=CC2=C(C=C1O)CC(CC1CCN(CC3=CC=CC=C3)CC1)C2=O,,COC1=CC2=C(C=C1OC1OC(C(=O)O)C(O)C(O)C1O)CC(CC1CCN(CC3=CC=CC=C3)CC1)C2=O,UGT,O-glucuronidation,0.62
6-Hydroxyflavone,O=C1C=C(C2=CC=CC=C2)OC2=CC=C(O)C=C12,,O=C(O)C1OC(OC2=CC=C3OC(C4=CC=CC=C4)=CC(=O)C3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.55
Dihydrocurcumin,COC1=CC(C=CC(=O)C=C(O)CCC2=CC=C(O)C(OC)=C2)=CC=C1O,,COC1=CC(CCC(O)=CC(=O)C=CC2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(OC)=C2)=CC=C1O,UGT,O-glucuronidation,0.48
"4-OH-2,6-dimethylaniline",CC1=CC(O)=CC(C)=C1N,,CC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=CC(C)=C1N,UGT,O-glucuronidation,0.23
3-Hydroxy-6-methylflavone,CC1=CC=C2OC(C3=CC=CC=C3)=C(O)C(=O)C2=C1,,CC1=CC=C2OC(C3=CC=CC=C3)=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C2=C1,UGT1A9,O-glucuronidation,0.59
1-iodoheptane,CCCCCCCI,heptyl-glutathione,CCCCCCCSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugation,0.03
Tolcapone,CC1=CC=C(C(=O)C2=CC(O)=C(O)C([N+](=O)[O-])=C2)C=C1,,CC1=CC=C(C(=O)C2=CC(O)=C(OC3OC(C(=O)O)C(O)C(O)C3O)C([N+](=O)[O-])=C2)C=C1,UGT1A9,O-glucuronidation,0.51
4-Nitrophenol,O=[N+]([O-])C1=CC=C(O)C=C1,,O=C(O)C1OC(OC2=CC=C([N+](=O)[O-])C=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.21
3-Indole carboxylic acid,O=C(O)C1=CNC2=CC=CC=C12,,O=C(OC1OC(C(=O)O)C(O)C(O)C1O)C1=CNC2=CC=CC=C12,UGT,O-glucuronidation,0.43
Fisetin,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=C(C3=CC=C(O)C(O)=C3)OC3=CC(O)=CC=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.61
Ornidazole,CC1=NC=C([N+](=O)[O-])N1CC(O)CCl,,CC1=NC=C([N+](=O)[O-])N1CC(CCl)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.58
"3-Hydroxy-6,4p-dimethoxyflavone",COC1=CC=C(C2=C(O)C(=O)C3=CC(OC)=CC=C3O2)C=C1,,COC1=CC=C(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=CC(OC)=CC=C3O2)C=C1,UGT1A9,O-glucuronidation,0.6
Lumiracoxib M25,CC1=CC=C2C(=C1)CC(=O)N2C1=C(F)C=C(O)C=C1Cl,,CC1=CC=C2C(=C1)CC(=O)N2C1=C(F)C=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1Cl,UGT,O-glucuronidation,0.73
3p-Amino-3p-deoxythimidine,CC1=CN(C2CC(N)C(CO)O2)C(=O)N=C1O,,CC1=CN(C2CC(N)C(COC3C(O)C(O)OC(C(=O)O)C3O)O2)C(=O)N=C1O,UGT,O-glucuronidation,0.77
4-Ethylphenol,CCC1=CC=C(O)C=C1,,CCC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.15
"3,3p-Dihydroxyflavone",O=C1C(O)=C(C2=CC=CC(O)=C2)OC2=CC=CC=C12,,O=C(O)C1OC(OC2=C(C3=CC=CC(O)=C3)OC3=CC=CC=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.57
MaxiPost,COC1=CC=C(Cl)C=C1C1(F)C(O)=NC2=CC(C(F)(F)F)=CC=C21,,COC1=CC=C(Cl)C=C1C1(F)C(=O)N(C2OC(C(=O)O)C(O)C(O)C2O)C2=CC(C(F)(F)F)=CC=C21,UGT2B7,O-glucuronidation,0.6
3-Methoxy-4-hydroxyphenylglycol,COC1=CC(C(O)CO)=CC=C1O,,COC1=CC(C(O)CO)=CC=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.37
4p-OH-diclofenac,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=C(O)C=C1Cl,,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1Cl,UGT,O-glucuronidation,0.51
4p-OH-diclofenac,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=C(O)C=C1Cl,,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=C(OS(=O)(=O)O)C=C1Cl,SULT,O-sulfonation,0.82
Farnesol,CC(C)=CCCC(C)=CCCC(C)=CCO,,CC(C)=CCCC(C)=CCCC(C)=CCOC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.14
4-n-Butylphenol,CCCCC1=CC=C(O)C=C1,,CCCCC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.19
Arbidol,CCOC(=O)C1=C(CSC2=CC=CC=C2)N(C)C2=CC(Br)=C(O)C(CN(C)C)=C12,,CCOC(=O)C1=C(CSC2=CC=CC=C2)N(C)C2=CC(Br)=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(CN(C)C)=C12,UGT,Aromatic -OH glucuronidation,0.83
"2,3-Dihydroxynaphthalene",OC1=CC2=CC=CC=C2C=C1O,,COC1=CC2=CC=CC=C2C=C1O,COMT,O-methylation,0.69
3-Hydroxy-4-aminopyridine,N=C1C=CNC=C1O,,N=C1C=CNC=C1OS(=O)(=O)O,SULT,O-sulfonation,0.41
Lorazepam,OC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2Cl)=NC1O,,O=C(O)C1OC(OC2N=C(C3=CC=CC=C3Cl)C3=CC(Cl)=CC=C3N=C2O)C(O)C(O)C1O,UGT,O-glucuronidation,0.68
Thyroxine,NC(CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(=O)O,,NC(CC1=CC(I)=C(OC2=CC(I)=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(I)=C2)C(I)=C1)C(=O)O,UGT,O-glucuronidation,0.48
fenchone metabo2,CC1(C)C(=O)C2(C)CCC1C2O,,CC1(C)C(=O)C2(C)CCC1C2OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.43
4-Phenylphenol,OC1=CC=C(C2=CC=CC=C2)C=C1,,O=C(O)C1OC(OC2=CC=C(C3=CC=CC=C3)C=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.16
3p-OH-diclofenac,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=CC(O)=C1Cl,,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=C1Cl,UGT,O-glucuronidation,0.52
3p-OH-diclofenac,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=CC(O)=C1Cl,,O=C(O)CC1=CC=CC=C1NC1=C(Cl)C=CC(OS(=O)(=O)O)=C1Cl,SULT,O-sulfonation,0.77
Irinotecan,CCC1=C2CN3C(=CC4=C(COC(=O)C4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(N4CCCCC4)CC3)C=C12,,CCC1=C2CN3C(=CC4=C(COC(=O)C4(CC)OC4OC(C(=O)O)C(O)C(O)C4O)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(N4CCCCC4)CC3)C=C12,UGT,O-glucuronidation,0.94
Syringetin,COC1=CC(C2=C(O)C(=O)C3=C(O)C=C(O)C=C3O2)=CC(OC)=C1O,,COC1=CC(C2=C(O)C(=O)C3=C(O)C=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)=CC(OC)=C1O,UGT1A9,O-glucuronidation,0.72
Syringetin,COC1=CC(C2=C(O)C(=O)C3=C(O)C=C(O)C=C3O2)=CC(OC)=C1O,,COC1=CC(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=C(O)C=C(O)C=C3O2)=CC(OC)=C1O,UGT1A9,O-glucuronidation,0.67
6-Methoxyluteolin,COC1=C(O)C=C2OC(C3=CC=C(O)C(O)=C3)=CC(=O)C2=C1O,,COC1=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C2OC(C3=CC=C(O)C(O)=C3)=CC(=O)C2=C1O,UGT1A9,O-glucuronidation,0.66
morphine,CN1CCC23C4=C5C=CC(O)=C4OC2C(O)C=CC3C1C5,,CN1CCC23C4=C5C=CC(O)=C4OC2C(OC2OC(C(=O)O)C(O)C(O)C2O)C=CC3C1C5,UGT,O-glucuronidation,0.9
morphine,CN1CCC23C4=C5C=CC(O)=C4OC2C(O)C=CC3C1C5,,CN1CCC23C4=C5C=CC(OC6OC(C(=O)O)C(O)C(O)C6O)=C4OC2C(O)C=CC3C1C5,UGT,O-glucuronidation,0.9
Chrysin,O=C1C=C(C2=CC=CC=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=CC(O)=C3C(=O)C=C(C4=CC=CC=C4)OC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.58
Quinagolide,CCCN1CC(NS(=O)(=O)N(CC)CC)CC2CC3=C(O)C=CC=C3CC21,,CCCN1CC(NS(=O)(=O)N(CC)CC)CC2CC3=C(C=CC=C3OC3OC(C(=O)O)C(O)C(O)C3O)CC21,UGT,O-glucuronidation,0.69
"4,5-Dihydrodrospirenone",CC12CCC(O)CC1C1CC1C1C2CCC2(C)C1C1CC1C21CCC(=O)O1,,CC12CCC(S(=O)(=O)O)CC1C1CC1C1C2CCC2(C)C1C1CC1C21CCC(=O)O1,SULT,O-sulfonation,0.75
fenchone metabo1,CC12CCC(C1)C(C)(CO)C2=O,,CC12CCC(C1)C(C)(COC1OC(C(=O)O)C(O)C(O)C1O)C2=O,UGT,O-glucuronidation,0.37
"7,3p,4p-Trihydroxyflavone",O=C1C=C(C2=CC=C(O)C(O)=C2)OC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=CC=C3C(=O)C=C(C4=CC=C(O)C(O)=C4)OC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.59
Caffeic Acid,O=C(O)C=CC1=CC=C(O)C(O)=C1,,O=C(O)C=CC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C(O)=C1,UGT1A9,O-glucuronidation,0.28
Caffeic Acid,O=C(O)C=CC1=CC=C(O)C(O)=C1,,O=C(O)C=CC1=CC=C(O)C(OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT1A9,O-glucuronidation,0.27
Daidzein,O=C1C(C2=CC=C(O)C=C2)=COC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=CC=C3C(=O)C(C4=CC=C(O)C=C4)=COC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.55
Lumiracoxib M23,CC1=CC=C(NC2=C(F)C=C(O)C=C2Cl)C(CC(=O)O)=C1,Lumiracoxib M22,CC1=CC=C(NC2=C(F)C=C(O)C=C2Cl)C(CC(=O)OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation,0.62
sulfamerazine,CC1=CC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1,,CC(O)=NC1=CC=C(S(=O)(=O)NC2=NC=CC(C)=N2)C=C1,NAT,N-acetylation,0.87
Dihyroxy-1H-indole,OC1=CC2=C(C=C1O)NC=C2,,O=C(O)C1OC(OC2=CC3=C(C=CN3)C=C2O)C(O)C(O)C1O,UGT,O-glucuronidation,0.31
5-OH-diclofenac,O=C(O)CC1=CC(O)=CC=C1NC1=C(Cl)C=CC=C1Cl,,O=C(O)CC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=CC=C1NC1=C(Cl)C=CC=C1Cl,UGT,O-glucuronidation,0.51
5-OH-diclofenac,O=C(O)CC1=CC(O)=CC=C1NC1=C(Cl)C=CC=C1Cl,,O=C(O)CC1=CC(OS(=O)(=O)O)=CC=C1NC1=C(Cl)C=CC=C1Cl,SULT,O-sulfonation,0.81
M23OH,CCCCC1=NC2=C(O)C=NN2C(N)=C1,,CCCCC1=NC2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=NN2C(N)=C1,UGT,O-glucuronidation,0.64
M23OH,CCCCC1=NC2=C(O)C=NN2C(N)=C1,,CCCCC1=NC2=C(OS(=O)(=O)O)C=NN2C(N)=C1,SULT,O-sulfonation,0.86
Fraxetin,COC1=CC2=C(OC(=O)C=C2)C(O)=C1O,,COC1=CC2=C(OC(=O)C=C2)C(O)=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.5
17-beta estradiol,CC12CCC3C4=CC=C(O)C=C4CCC3C1CCC2O,,CC12CCC3C4=CC=C(OC5OC(C(=O)O)C(O)C(O)C5O)C=C4CCC3C1CCC2O,"UGT1A1, UGT1A3",O-glucuronidation,0.55
"3,2p-Dihydroxyflavone",O=C1C(O)=C(C2=CC=CC=C2O)OC2=CC=CC=C12,,O=C(O)C1OC(OC2=C(C3=CC=CC=C3O)OC3=CC=CC=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.59
Dexmedetomidine,CC1=CC=CC(C(C)C2=CN=CN2)=C1C,,CC1=CC=CC(C(C)C2=CN(C3OC(C(=O)O)C(O)C(O)C3O)C=[NH+]2)=C1C,UGT2B20; UGT1A4,O-glucuronidation,0.4
Dexmedetomidine,CC1=CC=CC(C(C)C2=CN=CN2)=C1C,,CC1=CC=CC(C(C)C2=CN=CN2C2OC(C(=O)O)C(O)C(O)C2O)=C1C,UGT2B20; UGT1A4,O-glucuronidation,0.37
4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol,CN(CCCC(O)C1=CC=CN=C1)N=O,,CN(CCCC(O)C1=CC=C[N+](C2OC(C(=O)O)C(O)C(O)C2O)=C1)N=O,UGT,O-glucuronidation,0.33
Ferulic Acid,COC1=CC(C=CC(=O)O)=CC=C1O,,COC1=CC(C=CC(=O)O)=CC=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.33
Ethyl-4-hydroxybenzoate,CCOC(=O)C1=CC=C(O)C=C1,,CCOC(=O)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.26
3-Hydroxy-5-methoxyflavone,COC1=CC=CC2=C1C(=O)C(O)=C(C1=CC=CC=C1)O2,,COC1=CC=CC2=C1C(=O)C(OC1OC(C(=O)O)C(O)C(O)C1O)=C(C1=CC=CC=C1)O2,UGT1A9,O-glucuronidation,0.64
3-Hydroxy-4p-methoxyflavone,COC1=CC=C(C2=C(O)C(=O)C3=CC=CC=C3O2)C=C1,,COC1=CC=C(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=CC=CC=C3O2)C=C1,UGT1A9,O-glucuronidation,0.58
4-OH-propofol,CC(C)C1=CC(O)=CC(C(C)C)=C1O,,CC(C)C1=CC(O)=CC(C(C)C)=C1OC1OC(C(=O)O)C(O)C(O)C1O,"UGT1A8, UGT1A9",O-glucuronidation,0.29
4-OH-propofol,CC(C)C1=CC(O)=CC(C(C)C)=C1O,,CC(C)C1=CC(OS(=O)(=O)O)=CC(C(C)C)=C1O,SULT,O-sulfonation,0.65
"Aflatoxin B1 exo 8,9-epoxide",COC1=CC2=C(C3=C1C1=C(C(=O)CC1)C(=O)O3)C1C(O2)OC2OC21,,COC1=CC2=C(C3=C1C1=C(C(=O)CC1)C(=O)O3)C1C(O2)OC(SCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O)C1O,GST1A1; GST1A2; GSTM1; GSTM3; GSTP1,GSH-conjugation,0.88
Gypsogenin,CC1(C)CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CCC(O)C(C)(C=O)C5CCC43C)C2C1,,CC1(C)CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C(=O)O)C(O)C(O)C6O)C(C)(C=O)C5CCC43C)C2C1,UGT,O-glucuronidation,0.55
p-Toluidine,CC1=CC=C(N)C=C1,,CC(O)=NC1=CC=C(C)C=C1,NAT,N-acetylation,0.45
Geraldol,COC1=CC(C2=C(O)C(=O)C3=CC=C(O)C=C3O2)=CC=C1O,,COC1=CC(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=CC=C(O)C=C3O2)=CC=C1O,UGT1A9,O-glucuronidation,0.63
3-Hydroxyflavone,O=C1C(O)=C(C2=CC=CC=C2)OC2=CC=CC=C12,,O=C(O)C1OC(OC2=C(C3=CC=CC=C3)OC3=CC=CC=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.55
Myricetin,O=C1C(O)=C(C2=CC(O)=C(O)C(O)=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=C(C3=CC(O)=C(O)C(O)=C3)OC3=CC(O)=CC(O)=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.64
4-Methylphenol,CC1=CC=C(O)C=C1,,CC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.11
abiraterone,CC12CCC(O)CC1=CCC1C2CCC2(C)C(C3=CC=CN=C3)=CCC12,abiraterone sulfate,CC12CCC(OS(=O)(=O)O)CC1=CCC1C2CCC2(C)C(C3=CC=CN=C3)=CCC12,SULT,O-sulfonation,0.89
Biochanin A,COC1=CC=C2C(=O)C(C3=CC=CC=C3)=COC2=C1O,,COC1=CC=C2C(=O)C(C3=CC=CC=C3)=COC2=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.6
Datiscetin,O=C1C(O)=C(C2=CC=CC=C2O)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=C(C3=CC=CC=C3O)OC3=CC(O)=CC(O)=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.64
"3,7,3p-Trihydroxyflavone",O=C1C(O)=C(C2=CC=CC(O)=C2)OC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=C(C3=CC=CC(O)=C3)OC3=CC(O)=CC=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.59
Limonen-10-ol,C=C(C)C1CC=C(CO)CC1,,C=C(C)C1CC=C(COC2OC(C(=O)O)C(O)C(O)C2O)CC1,UGT,O-glucuronidation,0.27
Nirvanol (N-demethylmephenytoin,CCC1(C2=CC=C(O)C=C2)N=C(O)N=C1O,,CCC1(C2=CC=C(O)C=C2)N=C(O)N(C2OC(C(=O)O)C(O)C(O)C2O)C1=O,UGT,O-glucuronidation,0.41
Galangin,O=C1C(O)=C(C2=CC=CC=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=CC(O)=C3C(=O)C(O)=C(C4=CC=CC=C4)OC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.65
Galangin,O=C1C(O)=C(C2=CC=CC=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=C(C3=CC=CC=C3)OC3=CC(O)=CC(O)=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.61
7-Hydroxy-4p-methoxyflavone,COC1=CC=C(C2=CC(=O)C3=CC=C(O)C=C3O2)C=C1,,COC1=CC=C(C2=CC(=O)C3=CC=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)C=C1,UGT1A9,O-glucuronidation,0.58
3-Hydroxy-3p-methoxyflavone,COC1=CC=CC(C2=C(O)C(=O)C3=CC=CC=C3O2)=C1,,COC1=CC=CC(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=CC=CC=C3O2)=C1,UGT1A9,O-glucuronidation,0.59
1-iodomethane,CI,methylglutathione,CSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugation of organohalide,0.0
Zileuton,CC(C1=CC2=CC=CC=C2S1)N(O)C(=N)O,Zileuton O-glucuronide,CC(C1=CC2=CC=CC=C2S1)N(OC1OC(C(=O)O)C(O)C(O)C1O)C(=N)O,UDP-glucuronosyltransferase 1-9,N-hydroxy glucuronidation,0.52
cis-Dibromochrysanthemic acid,CC1(C)C(C=C(Br)Br)C1C(=O)O,,CC1(C)C(C=C(Br)Br)C1C(=O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.36
N-Acetyl-5-HT,CC(O)=NCCC1=CNC2=CC=C(O)C=C12,,CC(O)=NCCC1=CNC2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C12,UGT,O-glucuronidation,0.51
N-Acetyl-5-HT,CC(O)=NCCC1=CNC2=CC=C(O)C=C12,,CC(O)=NCCC1=CNC2=CC=C(OS(=O)(=O)O)C=C12,SULT,O-sulfonation,0.82
4-Cyclopentylphenol,OC1=CC=C(C2CCCC2)C=C1,,O=C(O)C1OC(OC2=CC=C(C3CCCC3)C=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.25
2-Methoxy-estradiol-17beta,COC1=CC2=C(C=C1O)CCC1C2CCC2(C)C(O)CCC12,,COC1=CC2=C(C=C1OC1OC(C(=O)O)C(O)C(O)C1O)CCC1C2CCC2(C)C(O)CCC12,UGT,O-glucuronidation,0.59
"5-Hydroxy, 6-methoxy duloxetine",CNCCC(OC1=CC=CC2=C(O)C(OC)=CC=C12)C1=CC=CO1,,CNCCC(OC1=CC=CC2=C(OS(=O)(=O)O)C(OC)=CC=C12)C1=CC=CO1,SULT,O-sulfonation,0.8
4-Bromophenol,OC1=CC=C(Br)C=C1,,O=C(O)C1OC(OC2=CC=C(Br)C=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.11
Hydromorphone,CN1CCC23C4=C5C=CC(O)=C4OC2C(=O)CCC3C1C5,Hydromorphone 3-beta-O-glucuronide,CN1CCC23C4=C5C=CC(OC6OC(C(=O)O)C(O)C(O)C6O)=C4OC2C(=O)CCC3C1C5,UGT,Aromatic -OH glucuronidation,0.87
Hydromorphone,CN1CCC23C4=C5C=CC(O)=C4OC2C(=O)CCC3C1C5,Hydromorphone 3-sulfate,CN1CCC23C4=C5C=CC(OS(=O)(=O)O)=C4OC2C(=O)CCC3C1C5,SULT,O-sulfonation,0.94
Licofelone,CC1(C)CC2=C(C3=CC=CC=C3)C(C3=CC=C(Cl)C=C3)=C(CC(=O)O)N2C1,,CC1(C)CC2=C(C3=CC=CC=C3)C(C3=CC=C(Cl)C=C3)=C(CC(=O)OC3OC(C(=O)O)C(O)C(O)C3O)N2C1,UGT,O-glucuronidation,0.78
4-Phenylazophenol,OC1=CC=C(N=NC2=CC=CC=C2)C=C1,,O=C(O)C1OC(OC2=CC=C(N=NC3=CC=CC=C3)C=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.18
4-Nitrososulfamethoxazole,CC1=CC(NS(=O)(=O)C2=CC=C(N=O)C=C2)=NO1,,CC1=CC(NS(=O)(=O)C2=CC=C([NH+]([O-])SCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O)C=C2)=NO1,GST,GSH-conjugation,0.53
2-Hydroxymethyatomoxetine,CNCCC(OC1=CC=CC=C1CO)C1=CC=CC=C1,,CNCCC(OC1=CC=CC=C1COC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=CC=C1,UGT,O-glucuronidation,0.49
1-iodopentane,CCCCCI,pentyl-glutathione,CCCCCSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugation,0.02
O-Desmethyl-tramado,CN(C)CC1CCCCC1(O)C1=CC=CC(O)=C1,,CN(C)CC1CCCCC1(O)C1=CC=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation,0.56
4-Hydroxyandrostenedione,CC12CCC3C(CCC4=C(O)C(=O)CCC43C)C1CCC2=O,,CC12CCC3C(CCC4=C(OC5OC(C(=O)O)C(O)C(O)C5O)C(=O)CCC43C)C1CCC2=O,UGT,O-glucuronidation,0.49
7-Hydroxy-6-methoxyisoflavone,COC1=CC2=C(C=C1O)OC=C(C1=CC=CC=C1)C2=O,,COC1=CC2=C(C=C1OC1OC(C(=O)O)C(O)C(O)C1O)OC=C(C1=CC=CC=C1)C2=O,UGT1A9,O-glucuronidation,0.6
OT-7100 M5,CCCCC1=NC2=CC=NN2C(N)=C1,,CCCCC1=NC2=CC=NN2C(NC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation,0.51
OT-7100 M5,CCCCC1=NC2=CC=NN2C(N)=C1,,CCCCC1=NC2=CC=NN2C(NS(=O)(=O)O)=C1,SULT,O-sulfonation,0.75
Erlotinib M18,C#CC1=CC=CC(NC2=NC=NC3=CC(OCCOC)=C(O)C=C23)=C1,,C#CC1=CC=CC(NC2=NC=NC3=CC(OCCOC)=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C23)=C1,UGT,O-glucuronidation,0.66
zaltoprofen,CC(C(=O)O)C1=CC=C2SC3=CC=CC=C3C(=O)CC2=C1,,CC(C(=O)OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=C2SC3=CC=CC=C3C(=O)CC2=C1,UGT,O-glucuronidation,0.59
4p-OH-triamterene,N=C1NC2=NC(=N)C(C3=CC=C(O)C=C3)=NC2=C(N)N1,,N=C1NC2=NC(=N)C(C3=CC=C(OS(=O)(=O)O)C=C3)=NC2=C(N)N1,SULT,O-sulfonation,0.93
4-Ethoxyphenol,CCOC1=CC=C(O)C=C1,,CCOC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.15
4-Hydroxyduloxetine,CNCCC(OC1=CC=C(O)C2=CC=CC=C12)C1=CC=CS1,,CNCCC(OC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C2=CC=CC=C12)C1=CC=CS1,UGT,O-glucuronidation,0.57
Pterostilbene,COC1=CC(C=CC2=CC=C(O)C=C2)=CC(OC)=C1,,COC1=CC(C=CC2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C2)=CC(OC)=C1,UGT1A9,O-glucuronidation,0.31
6-OH-harmaline,CC1=NC=CC2=C1NC1=CC(O)=CC=C12,,CC1=NC=CC2=C1NC1=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC=C12,UGT,O-glucuronidation,0.49
6-OH-harmaline,CC1=NC=CC2=C1NC1=CC(O)=CC=C12,,CC1=NC=CC2=C1NC1=CC(OS(=O)(=O)O)=CC=C12,SULT,O-sulfonation,0.82
Magnolol,C=CCC1=CC=C(O)C(C2=CC(CC=C)=CC=C2O)=C1,,C=CCC1=CC=C(O)C(C2=CC(CC=C)=CC=C2OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation,0.36
7-OH-efavirenz,OC1=NC2=CC(O)=C(Cl)C=C2C(C#CC2CC2)(C(F)(F)F)O1,,O=C(O)C1OC(OC2=CC3=C(C=C2Cl)C(C#CC2CC2)(C(F)(F)F)OC(O)=N3)C(O)C(O)C1O,UGT,O-glucuronidation,0.78
6-O-Desmethyl Donepezil,COC1=CC2=C(C=C1O)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2,,COC1=CC2=C(C=C1OC1OC(C(=O)O)C(O)C(O)C1O)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2,UGT,O-glucuronidation,0.61
Morin,O=C1C(O)=C(C2=CC=C(O)C=C2O)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=C(C3=CC=C(O)C=C3O)OC3=CC(O)=CC(O)=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.65
6-OH-MXAA,CC1=C(CO)C=CC2=C1OC1=C(CC(=O)O)C=CC=C1C2=O,,CC1=C(COC2OC(C(=O)O)C(O)C(O)C2O)C=CC2=C1OC1=C(CC(=O)O)C=CC=C1C2=O,UGT,O-glucuronidation,0.62
Procainamide,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1,,CCN(CC)CCNC(=O)C1=CC=C(N=C(C)O)C=C1,NAT,N-acetylation of arylamine,0.76
"3,4p-Dihydroxyfavone",O=C1C(O)=C(C2=CC=C(O)C=C2)OC2=CC=CC=C12,,O=C(O)C1OC(OC2=C(C3=CC=C(O)C=C3)OC3=CC=CC=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.56
3-OH-nevirapine,CC1=C(O)C=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,,CC1=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=NC2=C1N=C(O)C1=CC=CN=C1N2C1CC1,UGT,O-glucuronidation,0.82
Neomenthol,CC1CCC(C(C)C)C(O)C1,,CC1CCC(C(C)C)C(OC2OC(C(=O)O)C(O)C(O)C2O)C1,UGT,Alkyl-OH glucuronidation,0.19
Glycitein,COC1=CC2=C(C=C1O)OC=C(C1=CC=C(O)C=C1)C2=O,,COC1=CC2=C(C=C1OC1OC(C(=O)O)C(O)C(O)C1O)OC=C(C1=CC=C(O)C=C1)C2=O,UGT1A9,7-O-glucuronidation of isoflavone,0.61
N-Desmethyl o-hydroxyrosiglitazone,O=C1N=C(O)C(CC2=CC=C(OCCNC3=NC=CC=C3O)C=C2)S1,,O=C1N=C(O)C(CC2=CC=C(OCCNC3=NC=CC=C3OS(=O)(=O)O)C=C2)S1,SULT,O-sulfonation,0.82
cumene hydroperoxide,CC(C)(OO)C1=CC=CC=C1,,CC(C)(OOSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O)C1=CC=CC=C1,GST,GSH-conjugation,0.27
(11S)-11-hydroperoxylinoleic acid,CCCCCC=CC(C=CCCCCCCCC(=O)O)OO,,CCCCCC=CC(C=CCCCCCCCC(=O)O)OOSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugation,0.25
Naproxen,COC1=CC=C2C=C(C(C)C(=O)O)C=CC2=C1,,COC1=CC=C2C=C(C(C)C(=O)OC3OC(C(=O)O)C(O)C(O)C3O)C=CC2=C1,UGT,O-glucuronidation of aliphatic acid,0.37
Flavopiridol,CN1CCC(C2=C(O)C=C(O)C3=C2OC(C2=CC=CC=C2Cl)=CC3=O)C(O)C1,,CN1CCC(C2=C3OC(C4=CC=CC=C4Cl)=CC(=O)C3=C(O)C=C2OC2OC(C(=O)O)C(O)C(O)C2O)C(O)C1,UGT1A9,Aromatic -OH glucuronidation,0.8
5-OH-resacetophenone,CC(=O)C1=CC(O)=C(O)C=C1O,,CC(=O)C1=CC(OS(=O)(=O)O)=C(O)C=C1O,SULT,O-sulfonation,0.61
15-alpha-hydroxydesogestrel,C#CC1(O)CC(O)C2C3CCC4=CCCCC4C3C(=C)CC21CC,,C#CC1(OC2OC(C(=O)O)C(O)C(O)C2O)CC(O)C2C3CCC4=CCCCC4C3C(=C)CC21CC,UGT,O-glucuronidation,0.54
cyclic N-Acetylserotonin,CC(=O)N1CCC2=C1NC1=CC=C(O)C=C21,,CC(=O)N1CCC2=C1NC1=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C21,UGT,O-glucuronidation,0.71
7-Hydroxy-2p-methoxyflavone,COC1=CC=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1,,COC1=CC=CC=C1C1=CC(=O)C2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C2O1,UGT1A9,O-glucuronidation,0.65
8-OH efivarenz,OC1=NC2=C(O)C=C(Cl)C=C2C(C#CC2CC2)(C(F)(F)F)O1,,O=C(O)C1OC(OC2=CC(Cl)=CC3=C2N=C(O)OC3(C#CC2CC2)C(F)(F)F)C(O)C(O)C1O,UGT,O-glucuronidation,0.78
fenchone metabo5,CC12CCC(O)(C1)C(C)(C)C2=O,,CC12CCC(OC3OC(C(=O)O)C(O)C(O)C3O)(C1)C(C)(C)C2=O,UGT,O-glucuronidation,0.44
Genistein,O=C1C(C2=CC=C(O)C=C2)=COC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=CC(O)=C3C(=O)C(C4=CC=C(O)C=C4)=COC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.59
Maackiain,OC1=CC=C2C(=C1)OCC1C3=CC4=C(C=C3OC21)OCO4,,O=C(O)C1OC(OC2=CC=C3C(=C2)OCC2C4=CC5=C(C=C4OC32)OCO5)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.77
O-Desmethylgalantamine,CN1CCC23C=CC(O)CC2OC2=C(O)C=CC(=C23)C1,,CN1CCC23C=CC(O)CC2OC2=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=CC(=C23)C1,UGT,O-glucuronidation,0.86
O-Desmethylgalantamine,CN1CCC23C=CC(O)CC2OC2=C(O)C=CC(=C23)C1,,CN1CCC23C=CC(O)CC2OC2=C(OS(=O)(=O)O)C=CC(=C23)C1,SULT,O-sulfonation,0.92
Diosmetin,COC1=CC=C(C2=CC(=O)C3=C(O)C=C(O)C=C3O2)C=C1O,,COC1=CC=C(C2=CC(=O)C3=C(O)C=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)C=C1O,UGT1A9,Aromatic O-glucuronidation,0.64
"5-(3p,4p,5p-Trihydroxyphenyl)-gamma-valerolactone",O=C1CCC(CC2=CC(O)=C(O)C(O)=C2)O1,,O=C1CCC(CC2=CC(O)=C(O)C(OC3OC(C(=O)O)C(O)C(O)C3O)=C2)O1,UGT,O-glucuronidation,0.42
carvacrol,CC1=CC=C(C(C)C)C=C1O,,CC1=CC=C(C(C)C)C=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.22
carvacrol,CC1=CC=C(C(C)C)C=C1O,,CC1=CC=C(C(C)C)C=C1OS(=O)(=O)O,SULT,O-sulfonation,0.5
11-Hydroxyprogesterone,CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3C(O)CC12C,,CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3C(OC3OC(C(=O)O)C(O)C(O)C3O)CC12C,UGT,O-glucuronidation,0.55
2-Hydroxydoxepin,CN(C)CCC=C1C2=CC=CC=C2COC2=CC=C(O)C=C12,,CN(C)CCC=C1C2=CC=CC=C2COC2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C12,UGT,O-glucuronidation,0.64
N-Oxide abiraterone,CC12CCC(O)CC1=CCC1C2CCC2(C)C(C3=CC=C[N+]([O-])=C3)=CCC12,,CC12CCC(OS(=O)(=O)O)CC1=CCC1C2CCC2(C)C(C3=CC=C[N+]([O-])=C3)=CCC12,SULT,O-sulfonation,0.9
N-Carbamoyllorcaserin,CC1CN(C(=O)O)CCC2=CC=C(Cl)C=C21,,CC1CN(C(=O)OC2OC(C(=O)O)C(C)C(C)C2C)CCC2=CC=C(Cl)C=C21,UGT,O-glucuronidation,0.49
Suprofen,CC(C(=O)O)C1=CC=C(C(=O)C2=CC=CS2)C=C1,,CC(C(=O)OC1OC(C(=O)O)C(O)C(O)C1O)C1=CC=C(C(=O)C2=CC=CS2)C=C1,UGT,O-glucuronidation,0.49
Indomethacin,COC1=CC=C2C(=C1)C(CC(=O)O)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,,COC1=CC=C2C(=C1)C(CC(=O)OC1OC(C(=O)O)C(O)C(O)C1O)=C(C)N2C(=O)C1=CC=C(Cl)C=C1,UGT,O-glucuronidation,0.8
Norpatchoulenol,CC1(C)C2CCC3(C)C(C=CCC13O)C2,,CC1(C)C2CCC3(C)C(C=CCC13OC1OC(C(=O)O)C(O)C(O)C1O)C2,UGT,O-glucuronidation,0.39
5-OH-aceclofenac,O=C(O)COC(=O)CC1=CC(O)=CC=C1NC1=C(Cl)C=CC=C1Cl,,O=C(O)COC(=O)CC1=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=CC=C1NC1=C(Cl)C=CC=C1Cl,UGT,O-glucuronidation,0.56
5-OH-aceclofenac,O=C(O)COC(=O)CC1=CC(O)=CC=C1NC1=C(Cl)C=CC=C1Cl,,O=C(O)COC(=O)CC1=CC(OS(=O)(=O)O)=CC=C1NC1=C(Cl)C=CC=C1Cl,SULT,O-sulfonation,0.84
3-Hydroxy-2p-methoxyflavone,COC1=CC=CC=C1C1=C(O)C(=O)C2=CC=CC=C2O1,,COC1=CC=CC=C1C1=C(OC2OC(C(=O)O)C(O)C(O)C2O)C(=O)C2=CC=CC=C2O1,UGT1A9,O-glucuronidation,0.64
Licofelone M4,CC1(C)CC2=C(C3=CC=C(O)C=C3)C(C3=CC=C(Cl)C=C3)=C(CC(=O)O)N2C1,,CC1(C)CC2=C(C3=CC=C(O)C=C3)C(C3=CC=C(Cl)C=C3)=C(CC(=O)OC3OC(C(=O)O)C(O)C(O)C3O)N2C1,UGT,O-glucuronidation,0.78
Chrysoeriol,COC1=CC(C2=CC(=O)C3=C(O)C=C(O)C=C3O2)=CC=C1O,,COC1=CC(C2=CC(=O)C3=C(O)C=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)=CC=C1O,UGT1A9,O-glucuronidation,0.65
Nitroso-dapsone,NC1=CC=C(S(=O)(=O)C2=CC=C(N=O)C=C2)C=C1,,NC1=CC=C(S(=O)(=O)C2=CC=C([NH+]([O-])SCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O)C=C2)C=C1,GST,GSH-conjugation,0.3
"(1-methyl-5-piperazin-1-yl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-(5-methyl-pyridin-2-yl)-amine",CCCC1=NN(C)C2=C(NC3=CC=C(C)C=N3)N=C(N3CCNCC3)N=C12,,CCCC1=NN(C)C2=C(NC3=CC=C(C)C=N3)N=C(N3CCN(C(C)=O)CC3)N=C12,NAT,N-acetylation,0.97
S-MTPPA,CC1=C(C2=CC=C(C(C)(C)C(=O)O)C=C2)SC=C1,,CC1=C(C2=CC=C(C(C)(C)C(=O)OC3OC(C(=O)O)C(O)C(O)C3O)C=C2)SC=C1,UGT,O-glucuronidation,0.51
"8-OH-2,3,7-TriCDD",OC1=CC2=C(C=C1Cl)OC1=CC(Cl)=C(Cl)C=C1O2,,O=C(O)C1OC(OC2=CC3=C(C=C2Cl)OC2=CC(Cl)=C(Cl)C=C2O3)C(O)C(O)C1O,UGT,O-glucuronidation,0.36
Oxazepam,OC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=NC1O,,O=C(O)C1OC(OC2N=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N=C2O)C(O)C(O)C1O,UGT,O-glucuronidation,0.64
3p-OH-hexobarbital,CN1C(=O)N=C(O)C(C)(C2=CC(O)CCC2)C1=O,,CN1C(=O)N=C(O)C(C)(C2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)CCC2)C1=O,UGT,O-glucuronidation,0.78
p-Hydroxyphenobarbital,CCC1(C2=CC=C(O)C=C2)C(O)=NC(=O)N=C1O,,CCC1(C2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C2)C(O)=NC(=O)N=C1O,UGT (primary),O-glucuronidation,0.61
p-Hydroxyphenobarbital,CCC1(C2=CC=C(O)C=C2)C(O)=NC(=O)N=C1O,,CCC1(C2=CC=C(OS(=O)(=O)O)C=C2)C(O)=NC(=O)N=C1O,SULT,O-sulfonation,0.89
Sulfamethoxazole,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,,CC1=CC(NS(=O)(=O)C2=CC=C(NC3OC(C(=O)O)C(O)C(O)C3O)C=C2)=NO1,UGT,O-glucuronidation,0.5
Sulfamethoxazole,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,,CC(O)=NC1=CC=C(S(=O)(=O)NC2=NOC(C)=C2)C=C1,"NAT1, NAT2",N-acetylation of arylamine,0.88
4-n-Propylphenol,CCCC1=CC=C(O)C=C1,,CCCC1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.17
Butyl-4-hydroxybenzoate,CCCCOC(=O)C1=CC=C(O)C=C1,,CCCCOC(=O)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.3
Quercetin,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=C(C3=CC=C(O)C(O)=C3)OC3=CC(O)=CC(O)=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.64
Taurocholic acid,CC(CCC(O)=NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,,CC(CCC(O)=NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(OS(=O)(=O)O)CCC4(C)C3CC(O)C12C,SULT,O-sulfonation,0.78
Propranolol,CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12,,CC(C)NCC(COC1=CC=CC2=CC=CC=C12)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.37
"3,7-Dihydroxy-3p,4p-dimethoxyflavone",COC1=CC=C(C2=C(O)C(=O)C3=CC=C(O)C=C3O2)C=C1OC,,COC1=CC=C(C2=C(O)C(=O)C3=CC=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)C=C1OC,UGT1A9,O-glucuronidation,0.69
"3,7-Dihydroxy-3p,4p-dimethoxyflavone",COC1=CC=C(C2=C(O)C(=O)C3=CC=C(O)C=C3O2)C=C1OC,,COC1=CC=C(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=CC=C(O)C=C3O2)C=C1OC,UGT1A9,O-glucuronidation,0.64
Erlotinib M16,C#CC1=CC(NC2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C23)=CC=C1O,,C#CC1=CC(NC2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C23)=CC=C1OS(=O)(=O)O,SULT,O-sulfonation,0.88
Equol,OC1=CC=C(C2COC3=CC(O)=CC=C3C2)C=C1,,O=C(O)C1OC(OC2=CC=C3CC(C4=CC=C(O)C=C4)COC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.52
4-Hydroxybenzophenone,O=C(C1=CC=CC=C1)C1=CC=C(O)C=C1,,O=C(C1=CC=CC=C1)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.25
4p-Hydroxyfenoprofen,CC(C(=O)O)C1=CC=CC(OC2=CC=C(O)C=C2)=C1,,CC(C(=O)O)C1=CC=CC(OC2=CC=C(OC3C(O)C(O)OC(C(=O)O)C3O)C=C2)=C1,UGT,O-glucuronidation,0.41
4-Hydroxyifosfamide,O=P1(NCCCl)OCCC(O)N1CCCl,,NC(CCC(O)=NC(CSOC1CCOP(=O)(NCCCl)N1CCCl)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation,0.57
"4p,5-diOH-diclofenac",O=C(O)CC1=CC(O)=CC=C1NC1=C(Cl)C=C(O)C=C1Cl,,O=C(O)CC1=CC(O)=CC=C1NC1=C(Cl)C=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1Cl,UGT,O-glucuronidation,0.54
"4p,5-diOH-diclofenac",O=C(O)CC1=CC(O)=CC=C1NC1=C(Cl)C=C(O)C=C1Cl,,O=C(O)CC1=CC(O)=CC=C1NC1=C(Cl)C=C(OS(=O)(=O)O)C=C1Cl,SULT,O-sulfonation,0.83
15-Hydroxypatchoulol,CC1(C)C2CCC3(C)C(C2)C(CO)CCC13O,,CC1(C)C2CCC3(C)C(C2)C(COC2OC(C(=O)O)C(O)C(O)C2O)CCC13O,UGT,O-glucuronidation,0.3
3-Methoxy-4-hydroxyphenylethyleneglycol,COC1=CC(C(O)CO)=CC=C1O,,COC1=CC(C(O)CO)=CC=C1OS(=O)(=O)O,SULT,4-OH sulfonation of phenolic compound,0.67
Seratrodast,CC1=C(C)C(=O)C(C(CCCCCC(=O)O)C2=CC=CC=C2)=C(C)C1=O,,CC1=C(C)C(=O)C(C(CCCCCC(=O)OC2OC(C(=O)O)C(O)C(O)C2O)C2=CC=CC=C2)=C(C)C1=O,UGT,O-glucuronidation,0.65
Isorhamnetin,COC1=CC(C2=C(O)C(=O)C3=C(O)C=C(O)C=C3O2)=CC=C1O,,COC1=CC(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=C(O)C=C(O)C=C3O2)=CC=C1O,UGT1A9,O-glucuronidation,0.66
3-Hydroxy-7-methoxyflavone,COC1=CC=C2C(=O)C(O)=C(C3=CC=CC=C3)OC2=C1,,COC1=CC=C2C(=O)C(OC3OC(C(=O)O)C(O)C(O)C3O)=C(C3=CC=CC=C3)OC2=C1,UGT1A9,O-glucuronidation,0.6
Thienorphine,COC12CCC3(CC1C(C)(O)CCC1=CC=CS1)C1CC4=CC=C(O)C5=C4C3(CCN1CC1CC1)C2O5,,COC12CCC3(CC1C(C)(O)CCC1=CC=CS1)C1CC4=CC=C(OC5OC(C(=O)O)C(O)C(O)C5O)C5=C4C3(CCN1CC1CC1)C2O5,UGT,O-glucuronidation,0.92
Mexiletine alcohol,CC1=CC=CC(C)=C1OCC(C)O,,CC1=CC=CC(C)=C1OCC(C)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.34
Luteolin,O=C1C=C(C2=CC=C(O)C(O)=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=CC(O)=C3C(=O)C=C(C4=CC=C(O)C(O)=C4)OC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.62
Luteolin,O=C1C=C(C2=CC=C(O)C(O)=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=CC(C3=CC(=O)C4=C(O)C=C(O)C=C4O3)=CC=C2O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.61
4-OH-S-flurbiprofen,CC(C(=O)O)C1=CC=C(C2=CC=C(O)C=C2)C(F)=C1,,CC(C(=O)O)C1=CC=C(C2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C=C2)C(F)=C1,UGT,O-glucuronidation,0.48
3-Hydroxy-6-methoxyflavone,COC1=CC=C2OC(C3=CC=CC=C3)=C(O)C(=O)C2=C1,,COC1=CC=C2OC(C3=CC=CC=C3)=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C2=C1,UGT1A9,O-glucuronidation,0.59
"7,2p-Dihydroxyflavone",O=C1C=C(C2=CC=CC=C2O)OC2=CC(O)=CC=C12,,O=C(O)C1OC(OC2=CC=C3C(=O)C=C(C4=CC=CC=C4O)OC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.6
4-Hydroxyphenytoin,OC1=NC(C2=CC=CC=C2)(C2=CC=C(O)C=C2)C(O)=N1,,O=C(O)C1OC(OC2=CC=C(C3(C4=CC=CC=C4)N=C(O)N=C3O)C=C2)C(O)C(O)C1O,UGT,O-glucuronidation,0.63
Candesartan,CCOC1=NC2=CC=CC(C(=O)O)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,,CCOC1=NC2=CC=CC(C(=O)OC3OC(C(=O)O)C(O)C(O)C3O)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,UGT1A3,O-glucuronidation,0.79
Candesartan,CCOC1=NC2=CC=CC(C(=O)O)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,,CCOC1=[NH+]C2=CC=CC(C(=O)O)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NN(C3OC(C(=O)O)C(O)C(O)C3O)N=N2)C=C1,UGT1A3,O-glucuronidation,0.75
Formononetin,COC1=CC=C(C2=COC3=CC(O)=CC=C3C2=O)C=C1,,COC1=CC=C(C2=COC3=CC(OC4OC(C(=O)O)C(O)C(O)C4O)=CC=C3C2=O)C=C1,UGT1A9,O-glucuronidation,0.58
Phenytoin,OC1=NC(C2=CC=CC=C2)(C2=CC=CC=C2)C(O)=N1,,O=C(O)C1OC(N2C(=O)C(C3=CC=CC=C3)(C3=CC=CC=C3)N=C2O)C(O)C(O)C1O,UGT,O-glucuronidation,0.37
Haloperidol,O=C(CCCN1CCC(O)(C2=CC=C(Cl)C=C2)CC1)C1=CC=C(F)C=C1,,O=C(CCCN1CCC(OC2OC(C(=O)O)C(O)C(O)C2O)(C2=CC=C(Cl)C=C2)CC1)C1=CC=C(F)C=C1,UGT,O-glucuronidation,0.49
"benzo[a]pyrene-7,8-diol",OC1=CC=C2C(=C1O)C=C1C=CC3=CC=CC4=CC=C2C1=C34,,O=C(O)C1OC(OC2=C(O)C=CC3=C2C=C2C=CC4=CC=CC5=CC=C3C2=C45)C(O)C(O)C1O,UGT1A1,O-glucuronidation,0.18
N-OH-mexiletine,CC1=CC=CC(C)=C1OCC(C)NO,,CC1=CC=CC(C)=C1OCC(C)NOC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.33
(R)-(-)-Ibuprofen,CC(C)CC1=CC=C(C(C)C(=O)O)C=C1,,CC(C)CC1=CC=C(C(C)C(=O)OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,"UGT1A1, UGT1A3, UGTA9, UGT2B4, UGT2B7",O-glucuronidation of aliphatic acid,0.29
6-Hydroxymethyletoricoxib,CS(=O)(=O)C1=CC=C(C2=CC(Cl)=CN=C2C2=CC=C(CO)N=C2)C=C1,,CS(=O)(=O)C1=CC=C(C2=CC(Cl)=CN=C2C2=CC=C(COC3OC(C(=O)O)C(O)C(O)C3O)N=C2)C=C1,UGT,O-glucuronidation,0.68
"N-hydroxy-2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline",CC1=CN=C2C=CC3=C(N=C(NO)N3C)C2=N1,,CC1=CN=C2C=CC3=C(N=C(NOC4OC(C(=O)O)C(O)C(O)C4O)N3C)C2=N1,UGT1A1,O-glucuronidation,0.61
(11R)-11-hydroperoxylinoleic acid,CCCCCC=CC(C=CCCCCCCCC(=O)O)OO,,CCCCCC=CC(C=CCCCCCCCC(=O)O)OOSCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,GSH-conjugatoon,0.25
Galantamine,COC1=CC=C2CN(C)CCC34C=CC(O)CC3OC1=C24,,CN1CCC23C=CC(O)CC2OC2=C(OS(=O)(=O)O)C=CC(=C23)C1,UGT,O-glucuronidation,0.92
Gemfibrozil,CC1=CC=C(C)C(OCCCC(C)(C)C(=O)O)=C1,,CC1=CC=C(C)C(OCCCC(C)(C)C(=O)OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation,0.41
4-Isopropylphenol,CC(C)C1=CC=C(O)C=C1,,CC(C)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.17
Troglitazone,CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)N=C4O)C=C3)O2)C(C)=C1O,,CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)N=C4O)C=C3)O2)C(C)=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.73
"3,6-Dihydroxyfavone",O=C1C(O)=C(C2=CC=CC=C2)OC2=CC=C(O)C=C12,,O=C(O)C1OC(OC2=C(C3=CC=CC=C3)OC3=CC=C(O)C=C3C2=O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.57
4-Oxo-9-cis-retinoic acid,CC(C=CC1=C(C)CCC(=O)C1(C)C)=CC=CC(C)=CC(=O)O,,CC(C=CC1=C(C)CCC(=O)C1(C)C)=CC=CC(C)=CC(=O)OC1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.48
Tetrahydrocurcumin,COC1=CC(CCC(=O)C=C(O)CCC2=CC=C(O)C(OC)=C2)=CC=C1O,,COC1=CC(CCC(O)=CC(=O)CCC2=CC=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(OC)=C2)=CC=C1O,UGT,O-glucuronidation,0.43
7-Hydroxy-3p-methoxyflavone,COC1=C(C2=CC=CC=C2)OC2=CC(O)=CC=C2C1=O,,COC1=C(C2=CC=CC=C2)OC2=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=CC=C2C1=O,UGT1A9,O-glucuronidation,0.68
"3-Hydroxy-5,7-dimethoxyflavone",COC1=CC(OC)=C2C(=O)C(O)=C(C3=CC=CC=C3)OC2=C1,,COC1=CC(OC)=C2C(=O)C(OC3OC(C(=O)O)C(O)C(O)C3O)=C(C3=CC=CC=C3)OC2=C1,UGT1A9,O-glucuronidation,0.65
Psilocin,CN(C)CCC1=CNC2=CC=CC(O)=C12,,CN(C)CCC1=CNC2=CC=CC(OC3OC(C(=O)O)C(O)C(O)C3O)=C12,UGT1A9,O-glucuronidation,0.51
Apigenin,O=C1C=C(C2=CC=C(O)C=C2)OC2=CC(O)=CC(O)=C12,,O=C(O)C1OC(OC2=CC(O)=C3C(=O)C=C(C4=CC=C(O)C=C4)OC3=C2)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.59
4-sec-Butylphenol,CCC(C)C1=CC=C(O)C=C1,,CCC(C)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.21
Isoferulic Acid,COC1=CC=C(C=CC(=O)O)C=C1O,,COC1=CC=C(C=CC(=O)O)C=C1OC1OC(C(=O)O)C(O)C(O)C1O,UGT1A9,O-glucuronidation,0.31
DMXAA,CC1=CC=C2C(=O)C3=CC=CC(CC(=O)O)=C3OC2=C1C,,CC1=CC=C2C(=O)C3=CC=CC(CC(=O)OC4OC(C(=O)O)C(O)C(O)C4O)=C3OC2=C1C,"UGT1A9, UGT2B7",O-glucuronidation,0.59
"3,7-Dihydroxy-3p,4p,5p-trimethoxyflavone",COC1=CC(C2=C(O)C(=O)C3=CC=C(O)C=C3O2)=CC(OC)=C1OC,,COC1=CC(C2=C(O)C(=O)C3=CC=C(OC4OC(C(=O)O)C(O)C(O)C4O)C=C3O2)=CC(OC)=C1OC,UGT1A9,O-glucuronidation,0.7
"3,7-Dihydroxy-3p,4p,5p-trimethoxyflavone",COC1=CC(C2=C(O)C(=O)C3=CC=C(O)C=C3O2)=CC(OC)=C1OC,,COC1=CC(C2=C(OC3OC(C(=O)O)C(O)C(O)C3O)C(=O)C3=CC=C(O)C=C3O2)=CC(OC)=C1OC,UGT1A9,O-glucuronidation,0.65
4-nitrophenethyl bromide,O=[N+]([O-])C1=CC=C(CCBr)C=C1,4-nitrophenethyl-glutathione,NC(CCC(O)=NC(CSCCC1=CC=C([N+](=O)[O-])C=C1)C(O)=NCC(=O)O)C(=O)O,GST,GSH-conjugation of organohalide,0.29
Erlotinib M14,C#CC1=CC=CC(NC2=NC=NC3=CC(OCCO)=C(OCCOC)C=C23)=C1,,C#CC1=CC=CC(NC2=NC=NC3=CC(OCCOC4OC(C(=O)O)C(O)C(O)C4O)=C(OCCOC)C=C23)=C1,UGT,O-glucuronidation,0.74
Dapsone,NC1=CC=C(S(=O)(=O)C2=CC=C(N)C=C2)C=C1,,CC(O)=NC1=CC=C(S(=O)(=O)C2=CC=C(N)C=C2)C=C1,NAT2,N-acetylation of arylamine,0.72
Phenylephrine,CNCC(O)C1=CC=CC(O)=C1,,CNCC(O)C1=CC=CC(OC2OC(C(=O)O)C(O)C(O)C2O)=C1,UGT,O-glucuronidation,0.29
"AFB1exo 8,9-epoxide",COC1=CC2=C(C3=C1C1=C(C(=O)CC1)C(=O)O3)C1C(O)COC1O2,,COC1=CC2=C(C3=C1C1=C(C(=O)CC1)C(=O)O3)C1C(O2)OC(SCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O)C1O,"GSTA1/A2, GSTM1/M3, GSTP1",GSH-conjugatoon,0.88
Pregnenolone,CC(=O)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,,CC(=O)C1CCC2C3CC=C4CC(OS(=O)(=O)O)CCC4(C)C3CCC12C,SULT,3-OH-sulfation of sterol,0.76
4-tert-Butylphenol,CC(C)(C)C1=CC=C(O)C=C1,,CC(C)(C)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,O-glucuronidation,0.19
Melatonin,COC1=CC=C2NC=C(CCN=C(C)O)C2=C1,,COC1=CC=C2C(=C1)C(CCN=C(C)O)=CN2C1OC(C(=O)O)C(O)C(O)C1O,UGT,O-glucuronidation,0.45
Dihydroisomorphine,CN1CCC23C4=C5C=CC(O)=C4OC2C(O)CCC3C1C5,,CN1CCC23C4=C5C=CC(OC6OC(C(=O)O)C(O)C(O)C6O)=C4OC2C(O)CCC3C1C5,UGT,O-glucuronidation,0.87
Propyl-4-hydroxybenzoate,CCCOC(=O)C1=CC=C(O)C=C1,,CCCOC(=O)C1=CC=C(OC2OC(C(=O)O)C(O)C(O)C2O)C=C1,UGT1A9,Aromatic -OH glucuronidation,0.29
rac-4-hydroxynonenal,CCCCCC(O)C=CC=O,S-(4-hydroxy-1-oxononan-3-yl)glutathione,CCCCCC(O)C(CC=O)SCC(N=C(O)CCC(N)C(=O)O)C(O)=NCC(=O)O,GST,"GSH-conjugation of apha,beta-unsaturated carbonyl",0.09
Epicatechin,OC1=CC(O)=C2CC(O)C(C3=CC=C(O)C(O)=C3)OC2=C1,"5-(3',4'-dihydroxyphenyl)-gamma-valerolactone",O=C1CCC(CC2=CC=C(O)C(O)=C2)O1,Unspecified gut bacterial enzyme,Flavan-3-ol C-ring fission,0.33
Epicatechin,OC1=CC(O)=C2CC(O)C(C3=CC=C(O)C(O)=C3)OC2=C1,Phloroglucinol,OC1=CC(O)=CC(O)=C1,Unspecified gut bacterial enzyme,Flavan-3-ol C-ring fission,0.07
Daidzein,O=C1C(C2=CC=C(O)C=C2)=COC2=CC(O)=CC=C12,Dihydrodazein,O=C1C2=CC=C(O)C=C2OCC1C1=CC=C(O)C=C1,Unspecified bacterial dehydroxylase,4'-Deydroxylation of substitued benzene,0.22
Dihydrodazein,O=C1C2=CC=C(O)C=C2OCC1C1=CC=C(O)C=C1,Tetrahydrodaidzein,OC1=CC=C(C2COC3=CC(O)=CC=C3C2O)C=C1,Unspecified gut bacterial enzyme,Dehydration of isoflavanone,0.64
Tetrahydrodaidzein,OC1=CC=C(C2COC3=CC(O)=CC=C3C2O)C=C1,Equol,OC1=CC=C(C2COC3=CC(O)=CC=C3C2)C=C1,Unspecified gut bacterial enzyme,Isoflavan-4-ol dehydroxylation,0.76
Quercitrin,CC1OC(OC2=C(C3=CC=C(O)C(O)=C3)OC3=CC(O)=CC(O)=C3C2=O)C(O)C(O)C1O,L-Rhamnose,CC1OC(O)C(O)C(O)C1O,EC 3.2.1.X,Glycoside hydrolysis,0.22
Quercitrin,CC1OC(OC2=C(C3=CC=C(O)C(O)=C3)OC3=CC(O)=CC(O)=C3C2=O)C(O)C(O)C1O,Quercetin,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC2=CC(O)=CC(O)=C12,EC 3.2.1.X,Glycoside hydrolysis,0.68
Quercitrin,CC1OC(OC2=C(C3=CC=C(O)C(O)=C3)OC3=CC(O)=CC(O)=C3C2=O)C(O)C(O)C1O,alpha-L-Rhamnose,CC1OC(O)C(O)C(O)C1O,EC 3.2.1.40,Rhamnohydrolysis of alpha-L-rhamnoside,0.22
Quercetin,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC2=CC(O)=CC(O)=C12,Dihydroquercetin,O=C1C2=C(O)C=C(O)C=C2OC(C2=CC=C(O)C(O)=C2)C1O,Unspecified gut bacterial enzyme,Flavonoid C-ring reduction,0.31
3-hydroxyphenylacetic acid,O=C(O)CC1=CC=CC(O)=C1,2-Phenylacetic acid,O=C(O)CC1=CC=CC=C1,Unspecified bacterial dehydroxylase,3'-Deydroxylation of substitued benzene,0.62
4-hydroxyphenylacetic acid,O=C(O)CC1=CC=C(O)C=C1,2-Phenylacetic acid,O=C(O)CC1=CC=CC=C1,Unspecified bacterial dehydroxylase,4'-Deydroxylation of substitued benzene,0.72
"3,4-dihydroxyphenylacetic acid",O=C(O)CC1=CC=C(O)C(O)=C1,3-hydroxyphenylacetic acid,O=C(O)CC1=CC=CC(O)=C1,Unspecified bacterial dehydroxylase,Dehydroxylation of catechol,0.82
"3,4-dihydroxyphenylacetic acid",O=C(O)CC1=CC=C(O)C(O)=C1,4-hydroxyphenylacetic acid,O=C(O)CC1=CC=C(O)C=C1,Unspecified bacterial dehydroxylase,Dehydroxylation of catechol,0.7
"3,4-dihydroxyphenylacetic acid",O=C(O)CC1=CC=C(O)C(O)=C1,Protocatehuic acid,O=C(O)C1=CC=C(O)C(O)=C1,Unspecified gut bacterial enzyme,Alpha-oxidation of carboxylic acid,0.39
"3,4-dihydroxyphenylpropionic acid",O=C(O)CCC1=CC=C(O)C(O)=C1,3-(3-hydroxyphenyl)propanoic acid,O=C(O)CCC1=CC=CC(O)=C1,Unspecified bacterial dehydroxylase,Dehydroxylation of catechol,0.83
"3,4-dihydroxyphenylpropionic acid",O=C(O)CCC1=CC=C(O)C(O)=C1,4-hydroxy- 4-Hydroxyphenylpropionic acid,O=C(O)CCC1=CC=C(O)C=C1,Unspecified bacterial dehydroxylase,Dehydroxylation of catechol,0.73
Cyanidin,OC1=CC(O)=C2C=C(O)C(C3=CC=C(O)C(O)=C3)=[O+]C2=C1,"2,4,6-Trihydroxybenzaldehyde",O=CC1=C(O)C=C(O)C=C1O,Unspecified gut bacterial enzyme,Anthocyanidin C-ring fission,0.12
Cyanidin,OC1=CC(O)=C2C=C(O)C(C3=CC=C(O)C(O)=C3)=[O+]C2=C1,"3,4-Dihydroxyphenylacetic acid",O=C(O)CC1=CC=C(O)C(O)=C1,Unspecified gut bacterial enzyme,Anthocyanidin C-ring fission,0.14
Genistein,O=C1C(C2=CC=C(O)C=C2)=COC2=CC(O)=CC(O)=C12,Dihydrogenistein,O=C1C2=C(O)C=C(O)C=C2OCC1C1=CC=C(O)C=C1,Unspecified bacterial isoflavone reductase,Reduction of isoflavone to isoflavanone,0.24
Dihydrogenistein,O=C1C2=C(O)C=C(O)C=C2OCC1C1=CC=C(O)C=C1,,C=C(C(=O)C1=C(O)C=C(O)C=C1O)C1=CC=C(O)C=C1,Unspecified gut bacterial enzyme,Isoflavanone C-ring fission,0.47
,C=C(C(=O)C1=C(O)C=C(O)C=C1O)C1=CC=C(O)C=C1,6'-Hydroxy-O-desmethylangolensin,CC(C(=O)C1=C(O)C=C(O)C=C1O)C1=CC=C(O)C=C1,EC 1.6.99.1,"Reduction of alpha,beta unsaturated carbon-carbon double bond adjacent to an electron withdrawing group",0.62
,C=C(C(=O)C1=C(O)C=C(O)C=C1O)C1=CC=C(O)C=C1,4-hydroxyphenyl-2-propenoic acid,C=C(C(=O)O)C1=CC=C(O)C=C1,Unspecified gut bacterial enzyme,Keto hydrolysis,0.37
,C=C(C(=O)C1=C(O)C=C(O)C=C1O)C1=CC=C(O)C=C1,Phloroglucinol,OC1=CC(O)=CC(O)=C1,Unspecified gut bacterial enzyme,Keto hydrolysis,0.11
Sudan I,OC1=CC=C2C=CC=CC2=C1N=NC1=CC=CC=C1,1-Amino-2-naphthol,NC1=C(O)C=CC2=CC=CC=C12,EC 1.7.1.6,Reduction of azobenzene,0.64
